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Oil-in-water nanoemulsions (NE), comprising of an oil dispersed in a water and stabilised 
by a surfactant, have been increasingly explored as vehicles for the delivery of poorly-
water soluble drugs. This interest stems from the ability of NE to increase the apparent 
aqueous solubility of such drugs. The aims of the current study were several fold and 
included the determination of the molecular architecture and physico-chemical properties 
of NE to determine their suitability as vehicles for the parenteral delivery of the 
hydrophobic drugs, testosterone propionate (TP), curcumin (CUR) and docetaxel (DTX) 
and establishing the cytotoxicity of NE towards CT26 and HeLa cancer cell lines. Finally 
a folate derived surfactant was synthesised to explore targeting of the NE. 
The study involved the preparation and physico-chemical characterisation of NE 
stabilised by a range of nonionic surfactants, sometimes in combination with another 
surfactant and/or cosurfactant. The systems studied included Brij O10 (B), Tween 80 (T), 
Tween 80 with the cosurfactant, Dermosoft GMCY (TD), and Tween 80 with Dermosoft 
GMCY and lecithin (TDL). The NE contained as oil, either one of a series of triglyceride 
oils (namely tripalmitin (hTPN), soybean oil (hSBO), triolein (hGTO), and tristearin 
(hGTS)) or one of a series of ethyl ester of fatty acid oils (namely ethyl oleate (hEO) and 
ethyl stearate (hES)). A range of physico-chemical techniques including the phase 
inversion temperature (PIT), photon correlation spectroscopy (PCS), small angle neutron 
scattering (SANS), and UV spectroscopy, were used to characterise the NE in terms of 
their size and shape and ability to solubilise drug.  
The Brij O10 NE containing hSBO (B20-hSBO), hTPN (B20-hTPN), hGTO (B20-
hGTO) and hEO (B20-hEO) exhibited a larger area of NE formation whereas those 
containing GTS (B20-hGTS) and ES (B20-hES) produced only a small area of NE 
existence. The TDL NE incorporated only small amounts of SBO (TDL25-hSBO), while 
in contrast TD-stabilised NE were found to incorporate high amounts of the oil, EO 
(TD25-98hEO). The PIT and PCS studies recorded an increase in the PIT and apparent 
hydrodynamic size upon the addition of oil, suggesting that large molecular volume oils 
formed a distinct oil core in the NE. A significant enhancement in TP solubilisation in 
B20 NE was seen with an increase in the amount of oil in the following clear or slightly 
hazy NE, namely B20-hSBO, B20-85hTPN, B20-99hTPN, B20-99hGTO and B20-
98hEO. However, there was a dramatic decrease in TP solubilisation when the B20-
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hSBO, B20-85hTPN and B20-99hTPN NE were either cloudy or milky. Interestingly the 
addition of oil to B20, TD25 and TDL25 micelles did not significantly improve the 
solubility of CUR and DTX. Solubilisation and PIT studies suggested that both CUR and 
DTX tended to sit in the surfactant shell. After fitting the SANS data for the all of the NE 
studied, it was clear that the model which consistently provided the best fit was that of an 
oblate ellipsoid in which the radius of core of the NE increased with oil content. In 
addition, the shape of the NE became considerably more elongated as the oil content 
increased, explaining the decrease in TP solubilisation observed in the cloudy or milky 
NE.  
The cytotoxicity of NE in HeLa and CT26 cell lines suggested that blank B20 NE were 
toxic while blank TD25 and TDL25 NE were far less toxic. TD25 NE containing 98hEO 
and TDL25 NE containing hSBO did not show any difference in toxicity in the absence 
and absence of CUR (a high-dose anticancer agent). As a consequence therefore, DTX (a 
low-dose anticancer drug) was selected for further study. TDL25 NE containing hSBO 
in the presence of DTX exhibited a significant different in cytotoxicity when compared 
to blank TDL25-hSBO NE. In order to selectively deliver DTX to solid tumours 
expressing folate receptor, folate derived BO10 was successfully synthesised and 
characterised.  
In conclusion, these results suggest that the NE containing a large molar volume oil are 
the most suitable for the parenteral administration of a poorly water-soluble drug. 
However, before use the morphology of the NE and the nature of the drug to be 
solubilised should be carefully examined as both have an effect on the level of 
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Recent advances in drug discovery such as combinatorial chemistry and high throughput 
screening have led to the identification of large numbers of compounds with good 
therapeutic potential, however many of these compounds have extremely poor water 
solubility and fall into class II or IV of the Biopharmaceutical Classification Scheme 
(BCS) (Lipinski et al., 2001). Poor-water solubility is one of the major obstacles for drugs 
attempting to reach the biological compartments. The definition of drug solubility is 
shown in Table 1.1.  
 
Table 1.1 The definition used in statements of approximate solubilities (British Pharmacopoeia, 
2013). 
 
Definitions Approximate volume of solvent in mL per gram of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000 
Practically insoluble More than 10000 
 
The poor aqueous solubility is a particular problem if the drug is intended for intravenous 
administration, and as such as might be the cause of failure in the treatment of cancers. 
In previous studies, a wide variety of techniques have been attempted to improve the 
aqueous solubility of drugs intended for intravenous administration including using 
water-soluble organic solvents, cyclodextrin complexation, micelle, microemulsions 
(ME), nanoemulsions (NE), nanoparticles, liposome, niosomes or nanosuspensions 
(Strickley, 2004; Gulati and Gupta, 2011; Hamman and Steenekamp, 2012; Savjani et al., 
2012). Nanoemulsions have attracted a lot of attention due to the number of potential 
benefits of nanoemulsions including improved stability, high optical clarity and the increased 
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bioavailability of any encapsulated lipophilic compounds and the less cytoxicity compared to 
micellce formulations (McClements, 2012; Warisnoicharoen et al., 2003). 
Another major obstacle in drugs reaching the biological compartment(s) in which they 
act, is their limited transport across a range of biological barriers. These biological 
barriers can include the reticulo-endothelial system, endothelial or epithelial membranes, 
a complex network of blood vessels and abnormal flow of blood. These barriers are 
particularly problematic for biomolecules where they represent limiting steps in the 
delivery of such molecules to their intended site of action (Figure 1.1). 
 
Figure 1.1: Obstacles or biological barriers that prevent injected chemicals, biomolecules, drug 
carriers and other foreign agents from reaching their intended site of action. (Copied from Sanhai 
et al., 2008) 
 
In this study, nanoemulsions intended for the delivery of poorly-water soluble drugs, such 
as testosterone propionate (TP), curcumin (CUR) and docetaxel (DTX) will be 
formulated. The formulations will be prepared from nonionic surfactants including 
polyoxyethylene surfactants, Brij O10 or Polysorbate surfactants, Tween 80 in the 
absence or presence of cosurfactant and triglyceride/ethyl ester in water. All materials 
used in the preparation of NE are pharmaceutically acceptable and safe for intravenous 
use (Strickley, 2004; Date and Nagarsenker, 2008). In order to develop and design NE 
suitable for delivering a drug to its intended site of action, it is essential to understand the 
morphology of the NE. The physico-chemical characterisation of the drug-free and drug-
containing formulations will also be examined using a range of techniques such as photon 
correlation spectroscopy (PCS), phase inversion temperature (PIT), small angle neutron 
scattering (SANS). The ability of NE to solubilise drugs is also important and will be 
performed using UV spectroscopy. The cytotoxicity of the resulting drug-containing 
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nanoemulsion formulations will be tested in vitro using HeLa (folate-expressing cervical-
tumour-derived cell line) and CT26 (murine colon carcinoma) cell lines. It is also possible 
to attach a targeting group to the surface of NE to directly target NE to its intended site 
of action in the body and achieve drug targeting. Therefore, folate derived Brij O10 in 
which folate is covalently attached to Brij O10 via a polyethyleneglycol (PEG) linker will 
be synthesised. It has been reported that the folate receptor (FR) is frequently elevated in 
epithelial, ovarian, cervical, lung, kidney, colorectal and breast cancer (Praveen Kumar 
and Divya, 2015). Therefore, this receptor-targeting strategy has been exploited in the 
present study in the delivery of anticancer agents, and can be used as an ideal receptor to 




Nanoemulsions (NE) are emulsions with an extremely small droplet size. In the current 
scientific literature, there is significant confusion about the use of the terms NE and 
“microemulsions” (ME) (Gutierrez et al., 2008; McClements, 2012) because of the 
prefixes used to describe them. The term of “micro-” means 10-6, while the term of “nano” 
means 10-9, which suggests that the particle size of ME is 1000 times larger on average 
than that of NE. However, the fact is the particle size of ME are smaller than that of the 
NE. The reason for this confusion is that the word ME was used before the particle size 
of the particles could be measured and had become well-established before the 
nanotechnology was introduced.  
In addition, there are many similarities between both types of colloidal dispersions. For 
example, both of them typically comprise of an oil phase, a water phase, a surfactant, and 
sometimes a cosurfactant. In terms of size, recent literature has stated that the upper 
particle size of NE droplets could be as large as 500 nm (Anton et al., 2008), although 
upper limits of 200 nm (Tadros et al., 2004; Solans et al., 2005; Huang et al., 2010) and 
100 nm (Rao et al., 2012) have all been widely quoted. Recently McClements (2012) has 
suggested that an upper limit of 100 nm would lead to a number of potential benefits of 
NE including improved stability, high optical clarity and the increased bioavailability of 
any encapsulated lipophilic compounds. Although there is some variability in the size 
range quoted for NE, a particle size range of 20-200 nm is most typically seen (Solans et 
al., 2005), in contrast to the widely quoted size range of 5-100 nm for ME. Normally, the 
physical appearance of a ME is clear, while that of a NE can be clear, translucent, or 
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cloudy. In this context it is worth noting that the appearance of a colloidal system is 
generally transparent or translucent when the dispersed particle size is less than 30 nm 
(Wooster et al., 2008). In addition to size and appearance, there is another major 
difference between ME and NE, that is ME are thermodynamically stable while NE are 
thermodynamically unstable, although they can be kinetically stable (Anton and 
Vandamme, 2011). As a result, ME are spontaneously formed by simply admixing the 
required ingredients, while NE need to be produced by adding energy. The difference 
between the property of microemulsion and nanoemulsion was shown in the Table 1.2. 
 
Table 1.2 The difference between nanoemulsion and microemulsion 
 
Property Nanoemulsion Microemulsion 
Size 20-200 nm 5-100 nm 
Appearance Clear, translucent, or cloudy Clear 
Stability  Thermodynamic unstable but kinetically 
stable 
Thermodynamic unstable 
Preparation Simply admixing Addition of energy 
 
1.2.2 Structure 
NE are typically composed of oil, water, surfactant and possibly a cosurfactant. Oil-in-
water (o/w) NE possess a disperse phase of oil which is separated from the aqueous phase 
by a monolayer of surfactant. The hydrophobic portion of surfactant is in contact with the 
disperse oil phase whereas the surfactant’s hydrophilic head groups are in contact the 
continuous aqueous phase. On the other hand, water-in-oil (w/o) NE similarly contain an 
interfacial surfactant monolayer but show a reversed configuration in which the surfactant 
head groups are the centre of the droplets containing the aqueous phase, while the 
hydrocarbon chains of the surfactant are expressed on the exterior and contact the non-
polar phase (Izquierdo et al., 2005; Morales et al., 2006; Sadtler et al., 2010,). 
In this study, only an o/w NE, i.e. a system suitable for encapsulating hydrophobic drug 
in an oil phase, are of interest. o/w NE, consisting of oil surrounded with surfactant 
molecules dispersed in an aqueous phase, were examined for their ability to solubilise 
poorly water-soluble drugs. As a NE possesses an oily core, they should be able to 
increase apparent aqueous solubility over the corresponding micelles, assuming the drug 
has a good solubility in the relevant oil. Figure 1.2 shows schematic diagram of NE 





Figure 1.2: Schematic diagram of nanoemulsions and microemulsions containing oil, water and 
surfactant (modified from McClements, 2012). 
 
1.2.3 Composition 
Nonionic surfactants are used in various pharmaceutical formulations including micelles, 
ME and NE (Matsuyama et al., 2006; Feng et al., 2009; Maali and Mosavian, 2013) since 
they exhibit better compatibility, improved stability, and reduced toxicity when compared 
to ionic, or amphoteric surfactants (Jiao, 2008). As surfactants poses a polar head group 
and nonpolar hydrocarbon chain they exhibit a wide range of interfacial activities and 
functions as emulsifiers (Kumar and Rajeshwarrao, 2011). Due to the uncharged head 
group present in nonionic surfactants, these surfactants are less sensitive than ionic 
surfactants to salt, changes in pH and ionic strength of the water phase, although they are 
quite sensitive to temperature changes (Li et al., 2009). The surface tension at the 
concentration that polyethoxylated nonionic surfactants can form aggregates (i.e. the 
critical micelle concentration) is usually higher than that of ionic surfactants (Jiao, 2008). 
This tends to make the nonionic surfactants less destructive towards cell membranes and 
therefore less toxic and less irritating. Moreover, as nonionic surfactants are usually more 
bulky in size, they tend to be less well adsorbed onto surfaces and are less polar, therefore 
they tend to associate together at a lower cmc to reduce the free energy of the system 
(Jiao, 2008).  
Polyoxyethylated nonionic surfactants are widely employed in various pharmaceutical 
applications. Examples of this class of surfactant are the polysorbates, polyoxyethylene 
sorbitan, Tyloxapol, poloxamers, Brij and Cremophor EL (Jiao, 2008). These surfactants 
are generally defined as polymeric ethers because all of them contain as their hydrophilic 
moiety, polyoxyethylene or polyethylene glycol. This polymer is a repeated structure of 
polyoxyethylene, (CH2CH2O)n where n is the number of polyoxyethylene groups. The 
most common polyoxyethylene nonionic surfactant is described as being an ethylene 
oxide alkyl ether type and is represented as CmEn, where m and n are the number of the 
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carbon atoms in the hydrocarbon chain, and the number of oxyethylene groups, 
respectively (Inoue and Yamakawa, 2011). The solubility of these nonionic surfactants 
in water depends on the length of alkyl chain and the number of oxyethylene groups in 
their structure. According to the HLB system, the higher percentage weight of the 
polyoxyethylene, the higher HLB value of the surfactant, the higher its solubility in water 
(Jiao, 2008). In the present study, the use of the polyoxyethylene nonionic surfactant, 
polyoxyethylene 10-oleyl ether (C18:1E10) to stabilise the NE is attractive because it is 
possible to use it to produce ME without recourse to a cosurfactant and, as well, it is 
possible to use it for the microemulsification of many oils (Malcolmson et al., 1997; Ko 
et al., 2003).  
When formulating a NE to deliver drug, it is very important to determine which oils can 
form NE with a given surfactant. The choice of the oil is crucial because the oil has an 
effect on both the area of nanoemulsion existence and the solubilisation capacity of the 
NE (Malcolmson et al., 1997; Warisnoicharoen et al., 2000a; Djekic and Primorac, 2008). 
Frequently, amphiphilic oils such as the medium- or long-chain triglyceride and the fatty 
acid ester are utilised in the pharmaceutical, food and cosmetic industries because they 
are compatible with biological systems and are more environmentally friendly compared 
to hydrocarbon oils. Medium-chain and long-chain triglycerides from vegetable oils are 
usually used in commercial applications because these oils can provide desirable physical 
and drug absorption properties (Hauss, 2007). For example lymphatic transport can be 
promoted by long-chain triglycerides to deliver drug into the lymph before entering the 
systemic circulation to avoid hepatic first-pass metabolism (Khoo et al., 2003). Note that 
triglycerides are made up of three fatty acids and a glycerol backbone. The length of their 
carbon atom chains and the number of double bonds can be varied by the fatty acids that 
compose the structure of the triglycerides. Long-chain triglycerides tend to be solubilised 
to a lower extent by PEG-8 caprylic/capric glycerides surfactant than their medium-chain 
triglycerides counterparts (Djekic and Primorac, 2008). On the other hand, previous 
studies have shown that Brij O10 containing NE can, surprisingly, solubilise more long-
chain triglycerides than medium- or short-chain triglycerides (Warisnoicharoen et al., 





1.2.4 Formation  
 
Figure 1.3: Differences in the free energy of NE systems compared with their phase separated 
state (bulk oil and water phases) (copied from McClements, 2012). 
 
Oil, water, surfactant and an in-put of energy are needed to prepare emulsions. Figure 
1.3 shows the differences in the free energy of NE systems compared with their phase 
separated states (i.e. bulk oil and water phases). Nanoemulsions have a higher free energy 
than the phase separated state. The free energy of emulsion formation (ΔGformation) is 
considered to depend on the interfacial free energy (ΔGI) and the configuration entropy 
term (-TΔS) which is illustrated by following equation (Tadros et al., 2004): 
ΔGformation =  ΔGI - T∆S 
where ∆S is the change in entropy of the system, effectively the dispersion entropy, and 
T is the temperature. The interfacial free energy (ΔGI) is equal to the increase in the 
interfacial area between the oil and the aqueous phases (∆A) multiplied by the interfacial 
tension (γ) at the oil-water interface at constant temperature, pressure and interfacial 
chemical potential: 
ΔGI  = ∆Aγ 
In addition, the interfacial free energy term (ΔGI) is usually positive as increasing the 
contact area and the interfacial tension both require the input of energy. Therefore, this 
term always opposes NE formation. The free energy of the preparation of an emulsion 
can be considered from the energy required to expand the interface, ΔAγ (where ΔA is 
the change of interfacial area upon emulsification when the bulk oil with area A1 produces 
a large number of oil droplets with area A2, and the value of A2 is much higher than that 
of A1). Since γ is positive, the energy to expand the interface is large and positive.  
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The configuration entropy (-TΔS) is dependent upon the number of different 
arrangements of the oil within the system. The configuration entropy is always negative 
because the number of possible arrangements of the oil phase in an emulsified state is 
much greater than in a non-emulsified state, and therefore the configuration energy 
always favours the formation of a colloidal (emulsified) dispersion. 
It was known that the interfacial tension of the system depends on the curvature of the 
surfactant monolayer. NE are formed when the interfacial tension at the oil-water 
boundary in the emulsified system is similar to the interfacial tension at a planar oil-water 
interface. However, upon decreasing particle size, the interfacial free energy becomes 
increasingly less negative or more positive (i.e. unfavourable to the formation of a 
colloidal dispersion) due to an increasing contact area, while the configuration free energy 
becomes more negative (i.e. favourable to the formation of a colloidal dispersion) as the 
oil droplets increase the number of different ways in which the oil can be organised. 
Overall, the total free energy change becomes increasingly positive because the interfacial 
free energy term dominates over the configuration entropy term. This results in NE 
formation which although is a thermodynamic unstable system, possess sufficient kinetic 
stability to be used as a drug delivery vehicle (Girard et al., 1997; Tadros et al., 2004).  
 
1.2.5 Preparation  
In terms of preparation, NE always require the input of external energy to convert the 
separated oil and water phases into a (thermodynamically unstable) colloidal dispersion. 
NE are usually prepared by the input of external energy, the power of which depends 
upon the physico-chemical mechanism of the droplet disruption. Generally, one of the 
techniques to produce NE are the high-energy emulsification procedures, such as 
microfluidizers, high-pressure homogenizers, sonicators and ultrasound generators 
(Schultz et al., 2004; Kentish et al., 2008; Gaikwad and Pandit, 2008; McClements, 2013). 
On the other hand, NE can be prepared by low-energy emulsification procedures such as 
phase inversion temperature (PIT), phase inversion composition and self-emulsifying 
methods (Izquierdo et al., 2005; Maestro et al., 2008; McClements, 2013). In these cases, 
smaller NE droplets are formed when the system undergoes a phase inversion in response 
to a change in either composition and/or temperature (Mason et al., 2006). Indeed, PIT is 
one of the low energy methods used to produce nanoemulsions (Forgiarini et al., 2001a; 




Phase inversion temperature (PIT)  
Nonionic surfactants of the polyethoxylene type used in the preparation of NE have been 
studied by Shinoda and co-workers (Shinoda et al., 1969). The behaviour of these 
surfactants is very dependent on the experimental temperature and they become 
hydrophobic with increasing temperature due to the dehydration of the polyoxyethylene 
head groups. In fact o/w NE, of very small and uniform droplet size, stabilised by 
nonionic surfactants are typically prepared by the PIT method (Morales et al., 2003; 
Izquierdo et al., 2004; Rao et al., 2010). When an o/w emulsion prepared using this type 
of surfactant is heated at a phase inversion temperature, the emulsion converts to a w/o 
emulsion. By rapid cooling of the emulsion that is prepared at a temperature near the PIT, 
the transition of w/o emulsion to o/w emulsion occurs. In addition, very stable and small 
emulsion droplets can be produced (Tadros et al., 2004). 
In the present study, NE will be prepared using the phase inversion temperature (PIT) 
method, which results in the formation of optically transparent colloidal dispersions by 
heating a mixture of oil, water and surfactant (and possibly cosurfactant or second 
surfactant) to just above the phase inversion temperature of the system and then cooling 
the mixture to ambient with continuous and vigorous stirring.  
 
1.2.6 Application of nanoemulsions in drug delivery  
The interest in NE in terms of their application in drug delivery application has increased 
in recent years, as evidenced by the many publications and the fact that some NE are 
commercialised and are on the market. Table 1.2 lists some commercially available NE 
formulations (Gulati and Gupta, 2011). The attraction of NE for pharmaceutical 
applications is increasing because their many beneficial properties including their 
transparency, their small droplet size, high surface area which makes them suitable for 
the efficient delivery of active ingredients, their ease of preparation, their highly 
kinetically stability and their ability to be sterilised by filtration as well as their 
solubilising capacity which can improve the apparent aqueous solubility of a wide range 
of drug molecules, especially poorly-water soluble drugs (Kentish et al., 2008; Maestro 
et al., 2008; Shah et al., 2010). Indeed the potential ability of NE to increase drug 
solubility and stability are among some of the most important reasons why NE are 
attractive drug delivery systems (Brime et al., 2002; Shafiq et al., 2007; Date and 
Nagarsenker, 2007). The ability of NE to increase drug solubilisation over the 
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corresponding micelles is considered to be a consequence of the fact that drug is soluble 
in the oil that comprises the micelle core.  
 
Table 1.3 Commercially available nanoemulsion formulations (Gulati and Gupta, 2011). 
 
Drug Brand Company Indication 
Propofol  Diprivan® Astra Zeneca Anesthetic 
Dexamethasone  Limethason® Mitsubishi Pharmaceuticals Steroid 
Flurbiprofen axetil  Ropion® Mitsubishi Pharmaceuticals Non-steroidal analgesic  
Vitamin A, D, E, K  Vitalipid® Fresenius Kabi Parenteral nutrition 
 
O/w NE have been widely employed for their ability to increase the solubilisation and 
bioavailability of hydrophobic drug molecules. NE have been shown to enhance the oral 
bioavailability of a wide range of drugs (Shafiq et al., 2007; Singh and Vingkar, 2008). 
There have been a number of studies into the application of NE as drug carriers for a 
whole range of administration routes including intravenous (Ahmed et al., 2008), 
transdermal (Dixit et al., 2008), and pulmonary (Bivas-Benita et al., 2004). In an o/w NE, 
it is widely considered that hydrophobic drug molecules are solubilised within the oil core 
while more hydrophilic drug molecules are located at a boundary between the 
hydrophobic chains of the surfactant and the surfactant head group depending on their 
hydrophilicity (Torchilin, 2001). The primary locus of drug solubilisation depends on 
drug hydrophobicity and its interaction with the oil, surfactant and/or cosurfactant.  
 
1.2.6.1 NE for parenteral administration 
NE are used as injectable drug delivery vehicles for a variety of purposes including the 
administration of nutrition (fats, carbohydrates or vitamins), for controlled drug release, 
targeting of drugs to specific sites in body and the delivery of vaccines or as gene carriers 
(Pan et al., 2003; Tamilvanan et al., 2004). The benefit of NE in the parenteral 
administration of drugs is partly due to the small droplet size of these formulations - a 
strict requirement of this route of administration. 
Oils used in the parenteral administration 
The choice of oils used in NE formulations is a crucial factor for the preparation of o/w 
NE as an oil with a maximum solubilising potential for the selected drug(s) can help to 
achieve the maximum drug loading in NE. In addition, the ability of the selected oil to 
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yield systems with a large NE existence region is also important. The oily components 
available for parenteral NE range from fixed oils (e.g. soybean oil, castor oil), medium 
chain triglycerides (e.g. triglycerides of capric/caprylic acids), fatty acid esters (e.g. ethyl 
oleate, isopropyl myristate, isopropyl palmitate) (Date and Nagarsenkar, 2008).  
Surfactants used in the parenteral administration 
The selection of surfactant is important for the formulation of NE. The surfactant or 
combination of surfactants used should favour nanoemulsification of the oil phase and 
possess good solubilizing potential for the selected drugs. It should be noted that no 
surfactant is completely harmless. For instance, PEG-35-castor oil, a surfactant with very 
good parenteral acceptability can cause a range of adverse effects including anaphylactic 
shock and histamine release (Tije et al., 2003). Such adverse effects must be considered 
when selecting a type and the concentration of surfactant to use. The choice of the 
surfactant is also governed by the type of the NE to be formulated. Low HLB surfactants 
such as the sorbitan monoesters (Span) are preferred for w/o NE whereas high HLB 
surfactants such as Tween 80 are preferred for o/w NE. In several cases, a mixture of 
lipophilic (low HLB) and hydrophilic (high HLB) surfactant may be required to formulate 
a NE or ME. The various class of surfactant that can be used for the parenteral ME range 
from the polysorbates (Tween 20, Tween 80), the sorbitan esters (e.g. Span 20), the PEO–
PPO-block copolymers (Poloxamer 188), the polyoxyethylene alkyl ethers (POE-10-
oleyl ether), POE castor oil (POE-35-castor oil), POE hydrogenated castor oil 
(Cremophore RH 40, Cremophore RH 60), POE-stearate (PEG-660-12-hydroxystearate) 
and phospholipids (soybean lecithin, egg lecithin, diolelyl phosphatidyl choline, 
distearoyl phosphatidyl glycerol, PEGylated phospholipids, dimyristoyl phosphatidyl 
choline). Among the various surfactants that are available for producing NE and ME, the 
lecithins, poloxamers and polysorbates are the most preferred (Strickley, 2004).  
 
1.3 Physico-chemical characterisation of micelles and 
nanoemulsions 
As NE have attracted attention as potential drug delivery systems, the relationship 
between their solubilisation capacity and physicochemical properties needs to be fully 
explored. There are a wide range of different techniques that can be used to characterise 
NE. NE have been characterised with respect to their composition by establishing the 
phase behaviour, the size and shape of the NE droplets (Yuan et al., 2008; Kuntsche et 
al., 2011, Sharma and Warr, 2012). An excellent understanding of the influence of the 
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physicochemical properties of the NE droplets is required for the best application and use 
of NE.  
1.3.1 Phase behaviour 
The study of phase behaviour is used to determine the types of NE formed and their area 
of existence, as well as stability, all of which is related to the composition of the three 
main components; oil, surfactants and water. Phase diagrams are prepared simply and can 
show a large amount of information relating to the phase behaviour of a NE system. Each 
apex of the triangle represents 100% of that component. The region can be separated into 
w/o or o/w NE by simply considering the amount of water and oil in the composition. 
Figure 1.4 illustrates some of the possible structures that are usually formed by a mixture 
of oil, surfactant and water including micelles, NE, ME and bilayers (Talegaonkar et al., 
2008).  
 
Figure 1.4: Schematic diagram illustrating the phase behaviour of oil/water/surfactant systems. 
(modified from Talegaonkar et al., 2008).  
 
1.3.2 Phase inversion temperature (PIT) 
In NE prepared using a nonionic surfactant, the transition from o/w to w/o NE typically 
occurs upon altering either the phase volume and/or temperature. It is known that most 
nonionic surfactants, especially the polyoxyethylene surfactants, form aqueous micellar 
solutions which exhibit a phase inversion temperature (PIT) when heated (Corti et al., 
2002). Once the temperature of o/w NE reaches the PIT, the NE turns from clear to cloudy 
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and vice versa, as the temperature is increased and decreased, respectively. However, note 
that it is not possible to observe the PIT of a cloudy NE. The PIT occurs because the 
interactions between the surfactant molecules in the aggregate change from repulsive to 
attractive forces at higher temperature. For example, increasing the temperature of 
polyoxyethylene ether surfactant solutions in water causes the dehydration of ethylene 
oxide head groups. These changes lead to a decrease in the area of the effective surfactant 
head group and the shape of the aggregate which may become elongated or bicontinuous. 
Finally, the formation of w/o structure occurs which depends on the surfactant: oil ratio 
(Tadros, 2005). The data obtained from the PIT experiments can be used to give indirect 
information of the location and arrangement of the oil within the surfactant aggregate. 
Typically, the changes in PIT are explained in terms of the way in which oils of different 
molecular volume/weight are solubilized within the droplets (Schubert and Kaler, 1996). 
When there is a decrease in PIT of NE compared to the cloud point (CP) of the 
corresponding micelle, it can be assumed that the aggregates of micelle are probably 
slightly asymmetric and have become even more asymmetric on the addition of oil, 
probably because of the oil chains mixing with the surfactant chains, in much the same 
way as a cosurfactant does (Wasutrasawat, 2011). In contrast, an increase in the PIT with 
an increasing amount of oil present, suggests that the oil is forming a core in the centre 
of the droplet and, as a consequence, more spherical NE aggregates (Aveyard et al., 1990; 
Malcolmson et al., 1998).  
 
1.3.3 Photon correlation spectroscopy (PCS) 
In a photon correlation spectroscopy (PCS) or dynamic light scattering (DLS) study, time-
dependent fluctuations of the light intensity from NE droplets are measured enabling the 
determination of a NE diffusion coefficient. It is generally assumed that the shape of 
particles are spherical and in doing so the diffusion coefficient of the NE can be used to 
calculate a hydrodynamic particle size (Aveyard et al., 1989). Due to the random motion 
of the colloidal aggregates in solution (Brownian motion), these fluctuations can be 
analysed in terms of the variation in the intensity of the scattered light with time. The 
motion of the colloidal particles in the solution is inversely proportional to their particle 
size. Large particles will move more slowly and as consequence cause lower intensity 
fluctuations. By measuring the fluctuations over period of time, it is possible to determine 
an autocorrelation function, and therefore the diffusion coefficient of the particles. The 
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information about the diffusion coefficient (D) can then be used to calculate size, 
hydrodynamic diameter (Dh) using the Stokes-Einstein equation (Tadros, 2005): 
 
where Dh is hydrodynamic diameter, k is Boltzmann constant, T is absolute temperature 
(K), D is diffusion coefficient and η is viscosity of the medium. PCS measures an 
‘equivalent particle diameter’ which is known as the apparent hydrodynamic diameter of 
the particles dispersed in solution. 
PCS is widely used to determine the size distribution of small particles and assess the 
stability profile of systems by measuring the variation in the diameter of the particles as 
a function of time. Its popularity is partly because it is a rapid measurement technique 
and requires only a small amount of sample (Anton et al., 2007; Nobbmann and Morfesis, 
2009). In addition, it is possible to measure particle size in a wide variety of suspending 
liquids. For example, in the study of Izquierdo et al. (2005) PCS was used to investigate 
the stability of o/w NE containing water, mixed nonionic surfactants and isohexadecane. 
The results in this study showed that Ostwald ripening led to an instability of the NE. 
Moreover, PCS measurement can illustrate the effect of varying the amounts of 
components present in the NE system of interest. For instance, Sadurni et al. (2005) 
reported that the NE droplet size increased from 14 to 39 nm when the oil/surfactant ratios 
were changed from 10/90 to 40/60, respectively. However, there are a few drawbacks to 
this technique. First, this technique does not provide the information about the shape of 
particles. In addition, a small amount of dust can make the measurements and their 
subsequent interpretation difficult (Tscharnuter, 2006), although the present of dust can 
be avoided by the use of filtered water to prepare the samples. 
 
1.3.4 Small angle neutron scattering (SANS) 
Small angle neutron scattering (SANS) is a diffraction technique that exploits the neutron 
wave and its unique nuclear properties to provide information on particle morphology 
including the size and shape of a molecule, such as a surfactant, and its assemblies, such 
as a micelle (King, 1999). SANS is one of the most important techniques used to 
determine the structure, interaction and phase transition in micellar and ME systems 
(Chen, 1986). Despite these significant advantages, this technique has a number of 
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disadvantages. For example, it is slow and expensive as the experiment takes several days 
and must be performed at large international facilities. 
However, SANS is probably the best technique to measure the internal architecture of 
small and colloidal particles. There are two ways to produce neutrons. Firstly, neutrons 
are produced by the nuclear fission of a heavy atom such as uranium-235 in a reactor, i.e. 
a continuous or steady-state source. The example neutron sources using the reactor source 
are the Institute Laue Langevin (ILL), Grenoble, France and the National Institute of 
Standard and Technology (NIST). The second way to produce neutrons is using a pulsed 
or spallation neutron source, where particle accelerators and synchrotrons are used to 
generate intense, high-energy, proton beams which are directed at a target composed of 
heavy nuclei to produce a beam of neutrons (King, 1999). After producing a beam of 
neutrons, the beam is moderated by passing through a material such as liquid hydrogen 
to decrease its velocity and to produce neutrons of the required wavelength for the 
experiment. An example of a pulsed neutron source is the ISIS facility, Rutherford-
Appleton Laboratory (RAL), Didcot, UK, which is used in the present study. At ISIS, 
time of flight techniques are used to obtain the energy and wavelength of each neutron, 
and allowing fixed scattering geometries to be used by recording the time neutron takes 
for travelling from the target to the detectors (Rogers et al., 2009). 
Light scattering and small angle X-ray scattering (SAXS) provide the same information 
for the sample as small angle neutron scattering. However, the difference between neutron 
and other scattering techniques is that neutrons are scattered by the nucleus and is not 
dependent upon atomic number, while light and X-ray are scattered by the electron cloud 
around the atom, and are therefore dependent upon atomic number and vary in intensity 
with atomic number of the atom. It is significant that neutrons are scattered differently by 
different isotopes of the same element due to the fact that an isotope’s neutron scattering 
ability is determined by its scattering length. For instance, H and D have very different 
coherent scattering lengths which are -3.741 x 10-15 and 6.671 x 10-15 Å-2, respectively. 
Due to this property, the part of a structure of interest can be highlighted by selective 
deuteration and thereby making part of the system invisible to neutrons, a technique 
known as contrast matching. 
Moreover, light scattering especially PCS is used widely to determine the particle size of 
a colloidal sample, however there are limitations to the technique because the wavelength 
of light (4000-8000 Å) restricts the ability of light scattering to determine the shape of 
small aggregates. Additionally, SAXS is limited in that the X-ray beam may irreversibly 
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damage the sample, especially for biological samples such as proteins and lipids (King, 
1999). 
In contrast, neutron scattering possess many advantages over light and X-ray scattering, 
such as the fact that neutrons can penetrate into a sample without damaging it and that it 
is possible to specifically highlight the part of the system of interest by altering the 
scattering length of the sample (i.e. contrast matching). As a consequence of these, and 
other advantages, small angle neutron scattering (SANS) was used in the present study to 
determine the size and morphology of the NE droplets in the absence and presence of 
drugs. 
 
1.3.4.1 Theory of small angle neutron scattering (SANS) 
The scattering vector 
 
Figure 1.5: Scattering of neutrons by a sample (King, 1999). 
 
The geometry of a SANS experiment is shown in Figure 1.5. Neutron waves are 
spherically symmetrically scattered by the nuclei of the sample. The fraction of the 
neutron scattered by the particles at a particular scattering angle are then recorded on a 2-
dimensional detector at a distance Lsd from the sample at a radial distance rdet. The 
momentum transfer or wave vector transfer is known as the scattering vector (Q). Q is 
described by the relationship between the incident (ki) and the scattered (ks) wave vectors. 
Q has dimensions of (length)-1 and is quoted in the units of either nm-1 (SI units) or, more 
typically Å-1.  The magnitude of scattering vector (Q) can be defined as: 








when n is “neutron” refractive index, θ is the scattering angle and λ is the incident neutron 
wavelength. In practise, n is found to be slightly less than unity. Neutrons of the right 
wavelength are totally externally reflected from an interface so that n can be 
approximated to ~1. By substituting the equation above into Bragg’s law of diffraction: 









where the d-spacing of plane (d) is obtained at a particular Q. This equation allows the 
ready determination of the molecular length scale (d) in a sample from the position of any 
diffraction peak in Q space (King, 1999). 
 
1.3.4.2 Scattering length density and contrast matching 
One of the important factors when determining particle size and morphology using light 
scattering technique is the difference in the refractive index of the solute and solvent. The 
same principle applies in SAXS, although the difference in this technique is due to the 
difference in electron density, while the difference in SANS is a consequence of the 
difference in scattering length density. The scattering length density (ρSLD) of a molecule 
with i atoms may be readily calculated from the simple expression:  




where bi is the coherent neutron scattering length of nucleus i, D is the bulk density of the 
molecule, NA is Avogadro’s constant and MW is molecular weight. The scattering length 
density normally has dimensions of (length)-2 and is expressed in units of 1010 cm-2 or  
10-6 Å-2. 
Contrast matching is a powerful tool and useful in neutron scattering studies containing 
multicomponent samples. In any experiment, the contrast term is described as the square 
of the difference in the scattering length density between the solute (ρ) and the 
surrounding medium (ρm), ((∆ρ)2 = (ρ-ρm)2). At the contrast match point which is the 
point that the difference in scattering length density is zero ((∆ρ)2 = (ρ-ρm)2 = 0), there is 
no neutron scattering observed from the part of the sample of interest, which becomes 
“invisible” to neutrons. In neutron scattering studies, the difference in scattering length 
density between a proton and a deuterium is widely exploited in contrast match studies. 
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For example, using a mixture of D2O (ρ = 6.39 x 10-6 Å-2) and H2O (ρ = -0.56 x 10-6 Å-2) 
is often possible to match the scattering length density of the medium to the scattering 
region of interest and therefore making it “invisible” as is illustrated in Figure 1.6. 
 
Figure 1.6: Schematic representation of a contrast variation experiment using different D2O/H2O 
mixtures to study core shell nanoparticles. The second row of figures schematically show the 
scattering length density profile across the core shell structure (Rübe et al., 2005). 
 
1.3.4.3 SANS data interpretation 
The differential scattering cross−section, (∂Σ/∂Ω) is the dependent variable measured in 
a SANS experiment and is often referred to as the intensity of scattering, I(Q). The 
absolute SANS intensity of scattering I(Q) is expressed by the form factor, P(Q) and the 
structure factor, S(Q); 
(∂Σ/ ∂Ω)  = I(Q) = NpP(Q)S(Q) 
where Np is the average number density of the scattering droplets. The form factor, P(Q) 
is also known as the shape factor, which is a dimensionless function which describes how 
(∂Σ/∂Ω) is modulated by interference effects between radiation scattered by different 
parts of the same scattering centres (King, 1999). As a consequence, the term of (∂Σ/∂Ω) 
depends on both the size and shape of the scattering centre in the absence of interference 
effects. The structure factor, S(Q) represents the effect of interference due to 
neighbouring scatterers and depends on their relative positions. In the diluted system, this 
S(Q) parameter is approximately 1 which suggests that the interaction between the 
droplets is negligible and the scattering intensity is mainly dependent on the form factor, 
P(Q). 
 
1.3.4.4 The form factor, P(Q) 
A core-shell model is widely used to describe the scattering data obtained from micelles 
or NE, where the core is considered to consist of the tails of the surfactant for micelles or 
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the oil core for NE, while the shell is composed of the surfactant head groups for micelle 
or whole surfactant molecule for NE. Pedersen (1997) found that micelles or ME could 
be well fitted by assuming one of two shapes, namely a sphere or an ellipsoid. The form 
factor is weighted by the relative volumes of the core and shell of the droplets as well as 
their scattering length densities. This form factor is described by (Chen, 1986): 




where F(Q) is the single particle form factor. 
The form factor for a core shell model of homogeneous spherical particle is: 















where,  ji(x) =
sinx−xcosx
x2
 is the first order spherical Bessel function, Rc and Rs are the 
radius of core and shell, ⍴c, ⍴s and ⍴solvent are the scattering length densities of core, shell 
and solvent. 
In addition, the form factor for ellipsoidal droplets is written as: 









where Vc and Vs are the volumes of core and shell, ⍴c, ⍴s and ⍴0 are the scattering length 
densities of core, shell, and solvent, Rc and Rs are the semi-axes of core and shell, and ɛc 
and ɛs are the axial ratios of core and shell. 
 
1.3.4.5 The structure factor, S(Q) 
The structure factor, S(Q), describes how (∂Σ/∂Ω) is modulated by interference effects 
between neutrons scattered by different scattering bodies (King, 1999). Consequently, it 
is dependent on the degree of local order in the sample and increases with the 
concentration of scattering bodies in the system.  
Many previous studies have found that a hard-sphere model can satisfactorily describe 
the structure factor for many NE and ME (Arleth et al., 2001; Preu et al., 1999) and in 
particular, when a nonionic surfactant is used to prepare the system (Nagao et al., 2005). 
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Therefore, in this present study, the structure factor derived by using the Percus-Yevick 
approximation was used for the analysis of the NE stabilised by nonionic surfactant. The 









































1.4 Aim of the current project 
The first aim of this present study was to formulate o/w NE stabilised by the nonionic 
surfactant, Brij O10 or Tween 80 in the absence and presence of cosurfactant: lecithin 
and Dermosoft GMCY and containing pharmaceutical acceptable oils either triglycerides 
or ethyl esters to study the effect of surfactant, cosurfactant and oil on the formation of 
NE. A study of the physicochemical properties of NE such as their phase behaviour, their 
phase inversion temperature, and particle size (as characterised by light scattering and 
small angle neutron scattering) was undertaken to examine the architecture of the NE. 
The ability of the NE to solubilise poorly water soluble drugs, testosterone propionate 
(TP), curcumin (CUR) and docetaxel (DTX) was determined by UV/vis spectroscopy and 
allowed the establishment of whether it is possible to solubilise poorly water soluble drug 
in NE in high loading.  
The second aim of this study was to investigate the cytotoxicity and efficacy of NE in the 
absence and presence of either CUR or DTX to deliver anticancer drug to HeLa and CT26 
cancer cell lines. Moreover, the ultimate purpose in cancer therapy was to deliver 
anticancer drugs to tumour tissue with reduced toxicity to normal cells. This resulted in 
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the synthesis of folate receptor-targeting surfactant in order to specifically increase the 
intracellular uptake of anticancer drugs encapsulated in NE within cancer cells. 
60 
Chapter 2                               
Experimental 
 
Part 1 The physicochemical properties of nanoemulsions 
2.1.1 Materials 
2.1.1.1 Surfactants and co-surfactants 
Brij O10 (polyoxyethylene-10-oleyl ether, C18:1E10, Brij 97, Brij 96), Brij 99 
(polyoxyethylene-20-oleyl ether, C18:1E20), Triton X-100, Tyloxapol were purchased from 
Sigma-Chemicals Ltd. (Dorset, UK). Lutrol F68 was supplied by BASF (New Jersey, USA) 
while Brij 35 (polyoxyethylene-23-dodecyl ether) was obtained from MP Biomedicals LLC 
(Ohio, USA). Tween 20, Tween 80, Span 20, Span 60 and Span 80 were purchased from 
Merck KGaA (Darmstadt, Germany). Tween 60 was purchased from Acros Organics (Geel, 
Belgium). Dermosoft GMCY (glyceryl caprylate) was a gift from Infinity Ingredients 
(Berkshire, UK). L-α-phosphatidylcholine from soy bean (lecithin) was purchased from 
Avanti Polar lipids (Alabama, USA). The structures of surfactants studied are shown in Table 
2.1. 
 
Table 2.1 Surfactants used in the preparation of the nanoemulsions. 
 
Surfactant Chemical Formula 
Brij O10 (C18:1E10, Brij 97,  
Brij 96 or polyoxyethylene-10-oleyl ether) 
 n = 10 
Brij 99 (C18:1E20  
or polyoxyethylene-20-oleyl ether) 
 n = 20 
Brij 35 (C12E23  








Table 2.1 Surfactants used in the preparation of nanoemulsions (cont.). 
 







w+x+y+z = 20 
Tween 60 
  
w+x+y+z = 20 
Tween 80 
 





Table 2.1 Surfactants used in the preparation of the nanoemulsions (cont.). 
 

















2.1.1.2 Oils  
The oils employed in this study include a range of triglyceride oils, ethyl esters of fatty acids 
and hydrocarbon oils (Table 2.2). (Protiated) soybean oil ((h-)SBO), a mixture of 
predominately (i.e. > 75 %) C18:1 and C18:2 triglycerides, was supplied by Alfa Aeser 
(Lancashire, UK). It is noted that the precise chemical structure of (h-)SBO varies due to the 
natural source of the material. (Protiated) tripalmitin of >85 % purity (85(h-)TPN) was 
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purchased from Sigma-Chemicals Ltd. (Dorset, UK) while (protiated) tripalmitin of purity 
99 % (99(h-)TPN), (protiated) triolein of 99% purity (99(h-)GTO) were obtained by Acros 
Organic (New Jersey, USA). (Protiated) triolein of purity 65 % (65(h-)GTO) and (protiated) 
tristearin of 99% purity (99(h-)GTS) were from Sigma-Chemicals Ltd. (Dorset, UK). 
(Protiated) tristearin of purity >60 % (60(h-)GTS), (protiated) ethyl oleate of purity >60 % 
(60(h-)EO), (protiated) ethyl oleate of 98% purity (98(h-)EO), (protiated) ethyl stearate of 
purity 99 %, (99(h-)ES), and (protiated) hexadecane of 99% purity were purchased from 
Aldrich Chemical (Dorset, UK). (Protiated) 1-hexadecene (purity 92%) was supplied by 
Merck KGaA (Darmstadt, Germany). The chemical structure of the various triglyceride oils 
(i.e. (h-)SBO, 65(h-)GTO, 99(h-)GTO, 85(h-)TPN, 99(h-)TPN, 60(h-)GTS, 99(h-)GTS) and 
ethyl ester oils (i.e. 60(h-)EO, 98(h-)EO and 99(h-)ES) was confirmed by dissolving the oil 
in chloroform-d (99.8 atom %D) and performing 1H NMR spectroscopy (Bruker Avance 
DRX 400 MHz NMR spectrometer) (Bruker, Coventry, UK). The fully deuterated form of 
tripalmitin (–d98, 98.6 atom%D) ((d-)TPN) was obtained from CDN Isotopes (Quebec, 
Canada) whereas the terminal chain deuterated form of triolein (–d51, 98 atom%D) (d-)GTO) 
























Table 2.2 Structure and melting point of the triglyceride, ethyl ester and hydrocarbon oils. 
 
Oil (and where available its purity) Structure Melting  
point (˚C) a 
Triglyceride 
Soybean oil (h-SBO) - < 0 
Triolein, purity >65 % (65h-GTO) 
 
< 0 
Triolein, purity 99 % (99h-GTO) < 0 
Triolein (d-GTO) < 0 
Tripalmitin, purity >85 %, (85h-TPN) 
 
66-67 
Tripalmitin, purity 99 %, (99h-TPN) 65-68 
Tripalmitin – d98 (d-TPN) 63-64 
Tristearin, purity >60 % (60h-GTS) 
 
72 
Tristearin, purity 99 % (99h-GTS) 72 
Ethyl ester oils 
Ethyl oleate, purity >60 % (60h-EO) 
 
-32 
Ethyl oleate, purity 98 % (98h-EO) -32 




Hexadecane  18 
1-hexadecene  2.2 
 




Ultrapure water (UPW), supplied by a well-seasoned, all glass still (D4000 Distinction, 
Sterling, UK) was used throughout. Sodium chloride, extra pure was purchased from Acros 
Organics (Geel, Belgium) and used to prepare a 0.9 %w/v NaCl solution in water. 
Isopropanol was obtained from Fisher Scientific (Leicestershire, UK). D2O (99.9 atom %D) 
was supplied by from Aldrich Chemical Company (Dorset, UK) while chloroform-d (99.8 
atom %D) containing 0.03 %v/v TMS was from Acros Organics (Geel, Belgium). 
 
2.1.1.4 Drugs 
Testosterone propionate (TP) was purchased from Sigma-Chemicals Ltd. (Dorset, UK). 
Curcumin, purity 98 % (CUR) was obtained from Alfa Aeser (Lancashire, UK). Docetaxel 
(DTX) was supplied by Apollo Scientific Ltd (UK). The chemical structures of testosterone 
propionate (TP), curcumin (CUR) and docetaxel (DTX) are given in Table 2.3. 
 
Table 2.3 Structure of drugs used in this study. 
 
Drug Structure 








2.1.2 Sample nomenclature 
In order to make it easier to know the composition of the sample under the study, a sample 
nomenclature has been devised (Figure 2.1). The first letter (A in Figure 2.1) is used to 
denote the surfactant used. This is immediately followed some numbers (B in Figure 2.1) 
denoting the concentration of surfactant used in its preparation (in %w/w). Thus far the code 
is the same for micelles and nanoemulsions (NE). In the case of NE, the letters A/B are 
followed by C/D, which are the codes for the nature and amount (in %w/w) of oil present, 
respectively. C/D are obviously omitted in the case of micelles. Finally, if a drug is present 
in either the micelles or NE, the code used to indicate the drug follows, either C/D in the case 
of a NE or A/B in the case of micelles. The full code used to denote the micelles and NE is 
shown in Figure 2.1. Note that in the final code a hyphen separates A/B from C/D and C/D 
from E. The codes used for the various surfactants, oils and drugs are tabulated in Table 2.4. 




















Table 2.4 Code of surfactants, oils and drugs used in the preparation of the micelles and 
nanoemulsions. 
 
Chemicals (and where available purity) Code 
Surfactants (A) 
Brij O10 B 
Tween 80 T 
Dermosoft GMCY D 
Lecithin L 
Oils (B) 
Soybean oil hSBO 
Triolein, purity >65 % (65h-GTO) 65hGTO 
Triolein, purity 99 % (99h-GTO) 99hGTO 
Triolein (d-GTO) 98dGTO 
Tripalmitin, purity >85 %, (85h-TPN) 85hTPN 
Tripalmitin, purity 99 %, (99h-TPN) 99hTPN 
Tripalmitin – d98 (d-TPN) 98.6dTPN 
Tristearin, purity >60 % (60h-GTS) 60hGTS 
Tristearin, purity 99 % (99h-GTS) 99hGTS 
Ethyl oleate, purity >60 % (60h-EO) 60hEO 
Ethyl oleate, purity 98 % (98h-EO) 98hEO 
Ethyl stearate, purity 99 % (99h-ES)) 99hES 
Drugs (E) 
Testosterone propionate TP 





2.1.3.1 Preparation of nanoemulsions by phase inversion temperature method 
Nanoemulsions (NE) were individually prepared by the phase inversion temperature (PIT) 
method using H2O or an aqueous solution of 0.9 %w/v NaCl. The required amounts of oil, 
surfactant and water or aqueous 0.9 %w/v NaCl solution making a total of 2 g of sample were 
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weighed. The list of all formulations studied is shown in Appendix A, Table A.1 which 
illustrates the amount of material in the unit of %w/w. To illustrate the example of 
measurement for the preparation of NE, B20-SBO2 NE containing 2 %w/w SBO, 20 %w/w 
Brij O10 and 78 %w/w water was weighed 0.4 g of SBO, 0.04 g of Brij O10 and 1.56 g of 
water to prepare 2 g of sample. The order of materials weighed was oil, 
surfactant/cosurfactant and water, respectively. A magnetic stirrer was added to the sample 
and the sample heated for 10 min at 70 - 80 ˚C and then cooled to room temperature with 
vigorous stirring throughout. Micellar solutions were prepared in the same method but with 
no added oil. After preparation, all the samples were placed in tightly sealed glass bottles and 
stored at room temperature unless otherwise stated. 
 
2.1.3.2 Determination of phase diagrams 
The area of existence for the NE were determined by individually preparing a large number 
of compositions. Samples were routinely visually (including through cross polars) inspected 
for stability immediately after preparation, after one day, one week, and one month. 
Specifically, the samples were visually examined for any physical changes such as the 
changing from clear to cloudy or undergoing a phase separation. Those samples which 
remained completely clear, non-birefringent (isotropic) when observed through crossed 
polars, one-phase and fluid after one month were denoted as a NE and included within the 
NE area of existence. Samples that were clear (or indeed turbid), non-birefringent but did not 
change their meniscus after tilting to an angle of 90° were classified as gels and were not 
studied further. Samples that were fluid and exhibited phase separation or birefringence were 
denoted to lie outside the NE area. 
Each area of NE existence was determined using triplicate samples to ensure an accuracy of 
the boundary to better than ± 1 %w/w for each component. The composition of stable NE 
formulations was plotted as a partial triangular phase diagram. Each apex of the triangular 
plot in 3-component systems represents 100 % of one of the components (Figure 2.2). In the 
present study, the 3 components are oil (triglyceride or ethyl ester), surfactant and water. 
Each point within the triangle represents a different composition of the three components. 
The point shown in Figure 2.2a has a composition of 20 %w/w surfactant, 5 %w/w oil, and 
75 %w/w water. 
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In the present study, stable, clear NE are described as Region A NE, while bluish or 
translucent NE as Region B NE and cloudy or milky NE as Region C NE. The boundaries of 
each of the resulting areas of NE existence were drawn. The partial triangular diagram in 
Figure 2.2b represents an example of a NE that contains Regions A, B and C.  
(a)         (b)  
Figure 2.2: a) Tertiary phase diagram for a 3-component system and b) partial tertiary phase diagram 
showing Region A nanoemulsions (i.e. clear nanoemulsions), Region B nanoemulsions (bluish or 
translucent nanoemulsions) and Region C nanoemulsions (cloudy or milky nanoemulsions). 
 
2.1.3.3 Dilutability of nonionic o/w nanoemulsions 
Nanoemulsion was diluted with water from a range of surfactant concentrations, namely 20-
25 %w/w, down to 1-2 %w/w surfactant. The diluted NE samples were kept at room 
temperature and visually inspected for stability immediately after dilution, after one day, one 
week, and one month.  
 
2.1.3.4 Cloud point and phase inversion temperature determination 
The phase inversion temperatures (PIT) of the clear Region A NE, and the cloud point (CP) 
of the corresponding micelles were determined by placing a thermometer inside a glass bottle 
which contained the sample, which was itself placed in a water bath on a hot plate. The 
samples were heated until they became turbid and thereafter cooled to ambient, both heating 
and cooling at a rate of about 1 ˚C/min with constant, vigorous throughout stirring. The 
temperatures at which the onset of turbidity (upon heating) and the appearance of clarity 
(upon cooling) occurred were recorded. The reported PIT of the NE, and the CP of the 
corresponding micellar solutions, are the average of 3 temperature and cooling cycles, i.e. 





2.1.3.5 Particle size measurement by photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) was employed to investigate the apparent 
hydrodynamic size of micelles and oil-in-water (o/w) NE samples. Specifically, either a 
Brookhaven ZetaPlus particle sizer v2.29 (Brookhaven Instruments Corporation, UK) or a 
Malvern Nano ZS Zetasizer (Worcestershire, UK) was used. The former instrument used a 
scattering angle of 90° while the latter exploited a scattering angle of 173°, both instruments 
used a red laser of wavelength 633 nm and a temperature of 25 ± 0.1 °C. The PCS 
measurement used a value of refractive index of 1.33 and a viscosity of 0.89 cP or 1.10 cP 
for water and deuterium oxide, respectively. The water used to dilute the samples under study 
was clarified by filtration through a 0.2 µm polyethersulfone (PES) filter (Jet biofil, 
Guangzhou, China).  All samples were stored in the concentrated form and freshly diluted to 
a surfactant concentration of 1 %w/w immediately before the PCS measurement in order to 
avoid the effects of multiple scattering, likely to be present at higher surfactant 
concentrations. Unless otherwise stated, all diluted samples were stable for at least a month. 
The diluted samples were filtered through a 0.45 µm polyethersulfone (PES) filter (Jet biofil, 
Guangzhou, China) immediately before examination by PCS to avoid the presence of dust. 
The diluted samples were allowed to equilibrate at the experimental temperature for 10 
minutes before measuring by PCS. In order to determine sample stability over 1 month, 
samples were measured immediately after their preparation, after 1 day, 1 week and 1 month 
storage at room temperature, unless otherwise stated. The particle size of three individual 
samples was measured and the results expressed as the average and standard deviation of the 
mean apparent hydrodynamic size. The apparent hydrodynamic size and polydispersity of 
each sample were determined assuming that the particles were spherical. The relationship 
between the visual appearance of the sample and the results of the light scattering study were 
noted. The variation, if any, in the apparent hydrodynamic size of the micelles and NE with 
surfactant concentration for samples in different NE Regions of the phase diagram was 
determined. 
 
2.1.3.6 Solubilisation of the hydrophobic drugs 
The incorporation of testosterone propionate (TP) was determined in both the micelles and 
the NE in Regions A, B, and C, while that of curcumin (CUR) and docetaxel (DTX) were 
determined only in the micelles and in Region A NE. Samples for solubilisation studies were 
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prepared in the absence of drug as described in section 2.1.3.1 and a known excess of drug 
added to 3 x 1 mL aliquots of the micelles and the NE contained in eppendorf tubes, which 
were tightly closed and covered in foil to protect the samples they contained from light. The 
samples were equilibrated at room temperature on a circular rotating wheel for 5 or 7, 10, 
and 14 days to ensure that the drugs have reached their maximum solubility. Excess drug was 
removed by centrifugation (6500 rpm Biofuge pico, Heraeus, Osterode, Germany) for 20 
minutes. A blank sample (i.e. either the corresponding micelles or the NE without drug) was 
treated in the same way.  
The solubility of drug in the micelles and NE samples was assessed by diluting an aliquot of 
the supernatant obtained by centrifugation in isopropanol. Only the 85hTPN and 99hTPN 
NE containing TP and their corresponding blanks needed sonication in order to help the TPN 
dissolve in isopropanol. After dilution of each sample, the drug concentration in the resulting 
clear isopropanol solutions was determined by UV analysis, subtracting the absorbance of 
the isopropanol diluted blank containing the equivalent concentration of surfactant and oil, 
and comparing the resultant absorbance with the corresponding calibration curves for that 
drug. The levels of drug incorporation obtained in the micelles and the o/w NE were 
compared. CUR solubility also was similarly determined in the various bulk oils and distilled 
water, in this case excess CUR was removed from the samples by filtration through 0.2 µm 
polyethersulfone (PES) filters (Jet biofil, Guangzhou, China). Filtration was used to separate 
excess CUR from the solvent under tested (either an oil or water) due to the fact that 
centrifugation could not separate the CUR from oil because of the high viscosity of the oils. 
 
2.1.3.6.1 Calibration curve of testosterone propionate in isopropanol 
A calibration curve for TP was obtained by dissolving a precisely known quantity of TP 
(approximately 40 mg) in 20 mL isopropanol. This stock solution was then serially diluted 
by taking 50, 100, 150, 200, 250 and 300 µL aliquots and making up to 20 mL with 
isopropanol. Dilutions were performed in triplicate. The UV spectra of the TP containing 
standard solutions in a 1-cm path length cuvette was then measured and the value at a lambda 
max of 240 nm determined (UV/Vis Spectrophotometer LAMBDA 35, Perkin-Elmer, USA). 




2.1.3.6.2 Calibration curve of curcumin in isopropanol 
A calibration curve for CUR was obtained by dissolving a precisely known quantity of CUR 
(approximately 5 mg) in 10 mL isopropanol. This stock solution was then serially diluted by 
taking 7, 14, 28, 42, 56 and 70 µL aliquots and making up to 5 mL with isopropanol. The 
dilutions were performed in triplicate. The UV spectra of the CUR containing standard 
solutions in 1-cm path length cuvette was then measured and the value at a lambda max of 
428 nm determined (UV/Vis Spectrophotometer LAMBDA 35, Perkin-Elmer, USA). The 
blank was isopropanol.  
 
2.1.3.6.3 Calibration curve of docetaxel in isopropanol 
A calibration curve for DTX was obtained by dissolving an accurately known quantity of 
DTX (approximately 2 mg) in 2 mL isopropanol. This stock solution was then serially diluted 
by taking 25, 75, 125, 175 and 225 µL aliquots and making up to 5 mL with isopropanol. 
The dilutions were performed in triplicate. The UV spectra of the DTX containing standard 
solutions in 1-cm path length cuvette was then measured and the value at a lambda max of 
229 nm determined (UV/Vis Spectrophotometer LAMBDA 35, Perkin-Elmer, USA). The 
blank was isopropanol. 
 
2.1.3.7 Characterization of drug-loaded nanoemulsions 
The effect of the incorporation of the maximum amount of drug on the stability, size, and 
PIT of the NE droplets was determined by visual observation, light scattering (PCS), heating 
and cooling of the NE to determine PIT, as well as by small angle neutron scattering (SANS).  
 
2.1.3.8 Small-angle neutron scattering  
Small angle neutron scattering (SANS) studies were performed on the SANS2d small-angle 
diffractometer at the ISIS Pulsed Neutron Source (STFC Rutherford-Appleton Laboratory, 
Didcot, Oxford) (Heenan, 2011). Neutrons of wavelengths from 2 to 14 Å were used for 
SANS2d and were separated by time-of-flight technique. The SANS2d instrument gives a 
scattering vector, Q, where Q = (4π/λ) sin (θ/2), in the range of 0.0045 to 0.8 Å-1. SANS 
measurements were performed at 25 ± 0.1 or 37 ± 0.1 ºC using a 12-mm diameter neutron 
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beam. The pattern of scattering of neutrons after passage through the sample were recorded 
on two 3He-CF4 filled ORDELA 96.5 x 96.5 cm
2, two-dimensional detectors of resolution of 
5 mm, and rear detector was positioned at either 4 m from the clear micelle and NE samples 
and typically 8 m from the bluish/translucent and cloudy/milky NE samples because of their 
larger size and therefore greater scattering.  
Wavelength dependent corrections were made to allow for the incident spectrum, detector 
efficiencies and measured sample transmissions in order to create a composite SANS pattern. 
Comparisons with scattering from a partially deuterated polystyrene standard allowed the 
absolute scattering cross section to be determined, with an error of ~ ± 2 %. All the samples 
were contained in 1 or 2 mm path length Hellma quartz cuvettes, depending on whether the 
solvent of the sample was predominately H2O or D2O, respectively. The transmission and 
scattering runs of sample and solvents were simultaneously measured and accumulated. An 
empty cell was used as direct beam. 
Each raw scattering data set was corrected for detector efficiencies, sample transmission and 
background scattering and converted to the scattering cross-section (∂Σ/∂Ω) as a function of 
Q using the instrument-specific software, Mantid, before being converted into “scattered 
intensity” (I(Q)) as a function of Q. These data were placed on an absolute scale (cm−1) using 
the scattering from a standard sample (a solid blend of hydrogenous and perdeuterated 
polystyrene) in accordance with established procedures. 
 
2.1.3.8.1 Preparation of samples for SANS studies 
As a rule all NE and micellar samples studied by SANS were individually prepared by 
weighing the required amount of h- or d-triglyceride or ethyl ester, h-surfactant and either 
ultrapure water (H2O) or deuterated water (D2O) at room temperature, depending upon the 
contrast required (Appendix A.1a)-A.1h)). For each sample, a total of 1 g was prepared. A 
small magnetic stirrer was placed into the sample vial and the sample heated to 70-80 ºC for 
10 minutes before cooling to room temperature with vigorous stirring throughout. 
Due to the small amount of dGTO that was synthesised, the core and shell contrasts of the 
B20-98dGTO NE were individually prepared only at the highest concentration of oil. NE 
containing lower amounts of oil were then prepared by taking a small amount of the NE 
containing the highest concentration oil and diluting with surfactant solution. The resulting 
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mixture was re-heated for 10 min and then stirred at room temperature until cool to prepare 
the NE containing lower concentration of oil. In all experiments that necessitated the use of 
deuterated material, the weight of the deuterated material to be added was corrected for the 
difference in density compared to its protiated counterpart to ensure the same volume/number 
of molecules of each component was present in the final samples. It is worth noting that NE 
containing hSBO, 98hEO, hGTS could be prepared only as drop contrasts as there was no 
commercially available deuterated form of hSBO.  
Once prepared, the samples were stored in tightly sealed containers after flushing with 
nitrogen in an attempt to reduce D to H exchange. Typically, both deuterated and protiated 
triglycerides and water were used, along with the normal (protiated) surfactant, as d-oil/h-
surfactant/H2O (D/H/H), d-oil/h-surfactant/D2O (D/H/D) and h-oil/h-surfactant/D2O 
(H/H/D) combinations of triglyceride oil or ethyl ester oil/surfactant/water for the core, shell 
and drop contrast, respectively (Table 2.5). The protiated and deuterated chemicals used 
were selected to highlight specific parts of the NE droplets when studying using SANS. 
 
Table 2.5 Composition of protiated and deuterated chemicals for contrast matching. 
 
Composition Drop Core Shell 
Protiated 
   
Deuterated 
Oil h-oil d-oil d-oil 
Surfactant h-surfactant h-surfactant h-surfactant 
Solvent D2O H2O D2O 
 
 
In order to avoid the existence of strong interactions between the micelles and NE droplets 
when examining by SANS, a stock solution was diluted to the required surfactant 
concentration immediately prior to its measurement. It was necessary to produce a stock 
solution as it was often not possible to prepare the required (low concentration surfactant) 
NE compositions directly. The list of sample nomenclature for SANS contrast matching 





were diluted to 2 %w/w surfactant concentration. Note that when a stock solution had been 
diluted 10 times for the Brij O10 NE and 12.5 times for the TD and TDL NE. “B2-hSBO0.2” 
means that the stock “B20-hSBO2” (which contains 20 %w/w Brij O10 and 2 %w/w SBO) 
had been diluted 10 times. Testosterone propionate (TP) or/and curcumin (CUR) saturated 
NE were prepared by adding an excess of TP or/and CUR to the concentrated NE which were 
then left to rotate on a wheel, generally for 1 week, following which time any excess TP or 
CUR was removed by centrifugation. When a sample was saturated with drug in this manner, 
a -TP was added to the end of the code such that B2-hSBO0.2-TP means a diluted stock NE 
which contains 2 %w/w Brij O10 and 0.2 %w/w hSBO and is saturated with TP. 
In order to study the effect of temperature on the physico-chemical properties of micelles/ 
NE, B2-hSBO NE, TD2-98hEO NE and TDL2-hSBO NE was performed at 25 ºC and 37 ºC. 
When a sample was measured at 37 ºC overtime, a -37C was added to the end of the code 
such that B2-hSBO0.6-37C means that the measurement was performed at 37 ºC. 
The drop contrast of B2-hSBO NE, TD2-98hEO NE was prepared by PIT method and the 
SANS experiments were performed at 37 ºC in the presence of complete media by dilution 
the sample with an equal volume of complete media to order to investigate if there was any 
interaction of the micelles or NE with complete media. When the sample under study was 
mixed with complete media and measured using SANS, the scattering intensity was 
determined overtime, namely immediately (t0), 2.5 hours (2.5h)/3 hours (3h)/3.5 hours 
(3.5h), 6 hours (6h), and 11 hours (11h)/12 hours (12h). In this case after mixing, a –DM and 
time point were added to the middle and end of the sample code such that B2-hSBO0.6-DM-





Table 2.6 List of sample nomenclature for SANS contrast matching experiments in the absence and presence of drug (TP, CUR, CUR-TP). 
2.6a) Brij O10 micelles (B micelles) in the absence and presence of drug. 
Contrast B0.1 B0.2 B0.5 B1 B1.5 B2 B5 B10 B15 B20 
Droplet B0.1d B0.2d B0.5d B1d B1.5d B2d B5d B10d B15d B20d 
Droplet with drug - - - - - B2d-TP - - - - 
- - - - - B2d-CUR - - - - 
- - - - - B2d-CUR-TP - - - - 
 
2.6b) Brij O10 and soybean oil nanoemulsions (B-SBO NE) in the absence and presence of drug. 
Contrast B2-SBO0.2 B2-SBO0.4 B2-SBO0.6 B2-SBO0.8 
Droplet B2-hSBO0.2d B2-hSBO0.4d B2-hSBO0.6d B2-hSBO0.8d 
Droplet with drug B2-hSBO0.2d-TP B2-hSBO0.4d-TP B2-hSBO0.6d-TP B2-hSBO0.8d-TP 
B2-hSBO0.2d-CUR B2-hSBO0.4d-CUR B2-hSBO0.6d-CUR B2-hSBO0.8d-CUR 
B2-hSBO0.2d-CUR-TP - - B2-hSBO0.8d-CUR-TP 
 
2.6b) Brij O10 and soybean oil nanoemulsions (B-SBO NE) in the absence and presence of drug (cont.). 
Contrast B2-SBO0.9 B2-SBO1.0 B2-SBO1.2 B2-SBO1.4 B2-SBO1.6 
Droplet B2-hSBO0.9d B2-hSBO1.0d B2-hSBO1.2d B2-hSBO1.4d B2-hSBO1.6d 
Droplet with drug B2-hSBO0.9d-TP B2-hSBO1.0d-TP B2-hSBO1.2d-TP B2-hSBO1.4d-TP B2-hSBO1.6d-TP 
B2-hSBO0.9d-CUR - - - - 





2.6c) Brij O10 and triolein nanoemulsions (B-GTO NE) in the absence and presence of drug. 
Contrast B2-GTO0.05 B2-GTO0.1 B2-GTO0.2 B2-GTO0.4 B2-GTO0.6 
Core B2-98dGTO0.05c B2-98dGTO0.1c B2-98dGTO0.2c B2-98dGTO0.4c B2-98dGTO0.6c 
Shell B2-98dGTO0.05s B2-98dGTO0.1s B2-98dGTO0.2s B2-98dGTO0.4s B2-98dGTO0.6s 
Droplet B2-65hGTO0.05d B2-65hGTO0.1d B2-65hGTO0.2d - - 
B2-99hGTO0.05d B2-99hGTO0.1d B2-99hGTO0.2d B2-99hGTO0.4d B2-99hGTO0.6d 
Droplet with drug B2-65hGTO0.05d-TP B2-65hGTO0.1d-TP B2-65hGTO0.2d-TP - - 
B2-99hGTO0.05d-TP B2-99hGTO0.1d-TP B2-99hGTO0.2d-TP B2-99hGTO0.4d-TP B2-99hGTO0.6d-TP 
 
2.6c) Brij O10 and triolein nanoemulsions (B-GTO NE) in the absence and presence of drug (cont.). 
Contrast B2-GTO0.8 B2-GTO1.0 B2-GTO1.2 B2-GTO1.5 
Core B2-98dGTO0.8c B2-98dGTO1.0c B2-98dGTO1.2c B2-98dGTO1.5c 
Shell B2-98dGTO0.8s B2-98dGTO1.0s B2-98dGTO1.2s B2-98dGTO1.5s 
Droplet - - - - 
B2-99hGTO0.8d B2-99hGTO1.0d B2-99hGTO1.2d B2-99hGTO1.5d 
Droplet with drug - - - - 








2.6d) Brij O10 and tripalmitin nanoemulsions (B-TPN NE) in the absence and presence of drug. 
Contrast B2-TPN0.2 B2-TPN0.4 B2-TPN0.6 B2-TPN0.8 
Core B2-98.6dTPN0.2c B2-98.6dTPN0.4c B2-98.6dTPN0.6c B2-98.6dTPN0.8c 
Shell B2-98.6dTPN0.2s B2-98.6dTPN0.4s B2-98.6dTPN0.6s B2-98.6dTPN0.8s 
Droplet B2-85hTPN0.2d B2-85hTPN0.4d B2-85hTPN0.6d B2-85hTPN0.8d 
B2-99hTPN0.2d B2-99hTPN0.4d B2-99hTPN0.6d B2-99hTPN0.8d 
Core with drug B2-98.6dTPN0.2c-TP B2-98.6dTPN0.4c-TP B2-98.6dTPN0.6c-TP B2-98.6dTPN0.8c-TP 
Shell with drug B2-98.6dTPN0.2s-TP B2-98.6dTPN0.4s-TP B2-98.6dTPN0.6s-TP B2-98.6dTPN0.8s-TP 
Droplet with drug B2-85hTPN0.2d-TP B2-85hTPN0.4d-TP B2-85hTPN0.6d-TP B2-85hTPN0.8d-TP 
B2-99hTPN0.2d-TP B2-99hTPN0.4d-TP B2-99hTPN0.6d-TP B2-99hTPN0.8d-TP 
 
2.6d) Brij O10 and tripalmitin nanoemulsions (B-TPN NE) in the absence and presence of drug (cont.). 
Contrast B2-TPN1.0 B2-TPN1.2 B2-TPN1.4 B2-TPN1.6 
Core B2-98.6dTPN1.0c B2-98.6dTPN1.2c B2-98.6dTPN1.4c B2-98.6dTPN1.6c 
Shell B2-98.6dTPN1.0s B2-98.6dTPN1.2s B2-98.6dTPN1.4s B2-98.6dTPN1.6s 
Droplet B2-85hTPN1.0d B2-85hTPN1.2d B2-85hTPN1.4d B2-85hTPN1.6d 
B2-99hTPN1.0d B2-99hTPN1.2d B2-99hTPN1.4d B2-99hTPN1.6d 
Core with drug B2-98.6dTPN1.0c-TP B2-98.6dTPN1.2c-TP B2-98.6dTPN1.4c-TP B2-98.6dTPN1.6c-TP 
Shell with drug B2-98.6dTPN1.0s-TP B2-98.6dTPN1.2s-TP B2-98.6dTPN1.4s-TP B2-98.6dTPN1.6s-TP 
Droplet with drug B2-85hTPN1.0d-TP B2-85hTPN1.2d-TP B2-85hTPN1.4d-TP B2-85hTPN1.6d-TP 




2.6e) Brij O10 and tristearin nanoemulsions (B-GTS NE) in the absence and presence of drug. 
Contrast B2-GTS0.1 B2-GTS0.2 B2-GTS0.4 B2-GTS0.6 B2-GTS0.8 B2-GTS1.0 B2-GTS1.2 B2-GTS1.3 
Droplet B2-99hGTS0.1d B2-99hGTS0.2d B2-99hGTS0.4d B2-99hGTS0.6d B2-99hGTS0.8d B2-99hGTS1.0d B2-99hGTS1.2d B2-99hGTS1.3d 
 
2.6f) Brij O10 and ethyl oleate nanoemulsions (B-EO NE) in the absence and presence of drug. 
Contrast B2-EO0.2 B2-EO0.4 B2-EO0.6 B2-EO0.8 
Droplet B2-98hEO0.2d B2-98hEO0.4d B2-98hEO0.6d B2-98hEO0.8d 
Droplet with drug B2-98hEO0.2d-TP B2-98hEO0.4d-TP B2-98hEO0.6d-TP B2-98hEO0.8d-TP 
 
2.6g) Tween 80 (T micelle), Tween 80:Dermosoft GMCY (weight ratio 3:1) (TD micelles) and Tween 80:Dermosoft GMCY: lecithin (weight ratio 
7.5:2.5:1) micelles (TDL micelle) in the absence and presence of drug. 
Contrast T2 TD2 TDL2 
Droplet T2d TD2d TDL2d 
Droplet with drug - TD2d-CUR TDL2d-CUR 
- TD2d-CUR-TP TDL2d-CUR-TP 
 
2.6h) Tween 80:Dermosoft GMCY (weight ratio 3:1) micelles and ethyl oleate nanoemulsions (TD-EO NE) in the absence and presence of drug. 
Contrast TD2-EO0.64 TD2-EO0.72 
Droplet TD2-98hEO0.64d TD2-98hEO0.72d 





2.6i) Tween 80:Dermosoft GMCY (weight ratio 3:1) micelles and soybean oil nanoemulsions (TD-SBO NE) and Tween 80:Dermosoft GMCY: lecithin 
(weight ratio 7.5:2.5:1) micelles and soybean oil nanoemulsions (TDL-SBO NE) in the absence and presence of drug (cont.). 
Contrast TD2-EO0.8 TDL2-SBO0.24 
Droplet TD2-98hEO0.8d TDL2-hSBO0.24d 





2.1.3.8.2 Analysis of SANS data 
The FISH and SASView program were used to analyse the SANS data (Heenan, 1989; 
www.sasview.org). Before fitting the SANS data, the SLD of the various ingredients was 
calculated from Equation 2.1: 
 
SLD = (∑nibi)/Vm    Equation 2.1 
 
where bi is the bound coherent scattering length of ni atoms in a molecule with molecular 
volume, Vm. In addition, the volume fraction of NE’s was calculated. For SLD of mixture of 
solvent or surfactant, SLD of mixture was calculated by Equation 2.2: 
 
SLD of mixture = ((nxbx)+(nyby))/((nxVmx)+(nyVmy))  Equation 2.2 
 
where nx is the mole fraction of chemical x, bx is the bound coherent scattering length of 
chemical x while ny is the mole fraction of chemical y, by is the bound coherent scattering 
length of chemical y. Vmx and Vmy are the molar volume of chemical x and y, respectively. 
The SLD of the various ingredients is tabulated in Table 2.7 and 2.8. 
The data was analysed using solid-body models which allow for the ready construction of 
various possible models of the micelles and NE including spherical, oblate, prolate or triaxial 
ellipsoid and rod-shaped. In particular, the modelling of the micelles and NE using a 
core/shell model was explored. Here it was assumed that micelle core contained the 
surfactant tails and shell contained the surfactant head group and associated water of 
hydration while in the case of NE, the core consisted of oil while the shell consisted of the 











Table 2.7 Scattering length densities (SLDs) and related physicochemical parameters of the solvents 













(Å-2)          
x 10-6 
Solvent H2O 18.01 1.00 29.99 -0.561 
D2O 20.03 1.107 29.99 6.393 
H2O:D2O (1:1) - - 29.99 2.916 b 
hBrij O10 whole C38H76O11 708.94 1 1143.34 0.273 
hBrij O10 tail C18H35 251.47 0.75 556.97 -0.20 
hBrij O10 head C20H41O11 457.47 1.30 586.38 0.74 
hTween 80 whole C64H124O26 1309.65 1.07 2031.79 0.554 
hTween 80 tail C17H33 237.44 0.77 513 -0.204 
hTween 80 head C47H91O26 1072.21 1.17 1518.79 0.808 
hDermosoft GMCY whole C11H22O4 218.29 1.0 362.36 0.405 
hDermosoft GMCY tail C7H15 99.19 0.759 217 -0.441 
hDermosoft GMCY head C4H7O4 119.10 1.36 145.36 1.625 
hLecithin whole C42H80NO8P 758.06 1.012 1244 0.329 
hLecithin tail C32H62 446.83 0.824 900 -0.213 
hLecithin head C10H18NO8P 311.23 1.502 344 1.75 
hTween 80: hDermosoft GMCY  (weight 
ratio3:1) whole 
- - - 918.28 0.510 
hTween 80: hDermosoft GMCY  (weight 
ratio3:1) tail 
- - - 315.57 -0.415 
hTween 80: hDermosoft GMCY  (weight ratio 
3:1) head 
- - - 602.71 0.941 
hTween 80: hDermosoft GMCY: hLecithin 
(weight ratio 7.5: 2.5: 1) whole 
- - - 942.48 0.493 
hTween 80: hDermosoft GMCY: hLecithin 
(weigh ratio 7.5: 2.5: 1) tail 
- - - 357.25 -0.370 
hTween 80: hDermosoft GMCY: hLecithin 
(weight ratio 7.5: 2.5: 1) head 
- - - 585.23 0.974 
 
a from manufacturer 


















Volume       
(Å3) 
SLD 
(Å-2)                 
x 10-6 
hSBO - 885.5 0.924 1563 0.154 
65hGTO C57H104O6 885.43 0.91 1609.91 0.153 
99hGTO C57H104O6 885.43 0.913 1609.91 0.154 
98dGTO b C57D52.92H51.08O6 938.78 1.060 1609.91 3.916 
85hTPN C51H98O6 807.29 0.92 1457.62 0.050 
99hTPN C51H98O6 807.32 0.92 1457.62 0.050 
98.6dTPN c C51D96.63H1.37O6 905.93 1.03 1457.62 6.951 
99hGTS  C57H110O6 891.48 0.856 1728.8 0.013 
98hEO C20H38O2 310.52 0.87 600 0.041 
 
a from manufacturer 
b Deuterated assumes 51% replacement of H for GTO. 
c Deuterated assumes 98.6 % replacement of H for TPN.  
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Part 2 Study of nanoemulsion cytotoxicity 
2.2.1 Materials 
Advanced RPMI-1640 media (Roswell Park Memorial Institute), fetal bovine serum (FBS), 
penicillin-streptomycin (100X), trypsin-EDTA (0.05%, 1X) with phenol red, GlutamaxTM 
supplement and phosphate buffered saline (PBS, 10X, pH 7.4) were all obtained from Gibco, 
Invitrogen (UK). Trypan blue solution (0.4 %w/v), dimethylsulphoxide (DMSO) and 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were purchased from 
Sigma-Chemical Co. Ltd. (Dorset, UK). Double distilled water were used to prepare 
autoclaved water and dilute PBS (10X) to prepare PBS (1X). 
 
2.2.2 Methods 
The determination of the cytotoxicity of the micelles and NE was performed using the MTT 
assay. The experiment was performed in a Howorth Airtech safety cabinet (Model SC II, 
class 2, Farnworth, UK). 
 
2.2.2.1 Cell culture 
The cervical-tumour-derived cell line, HeLa (HeLa; ATCC, CCL-2) and the murine colon 
carcinoma cell line, CT26, (CT26; ATCC, CRL-2638TM), were cultured in a complete 
media (i.e. advanced RPMI-1640 media supplemented with 10 % FBS, 50 U/mL penicillin, 
50 μg/mL streptomycin, and 1 %v/v of 200 mM L–glutamine) in a humidified atmosphere at 
37 °C in 5 % CO2 and 95 % air. Cells were routinely grown in 75 cm
2 canted-neck tissue 
culture flask. The cells were passaged twice weekly when they had reached ~80 % 
confluency by removing the growth medium, washing the cell monolayer with PBS (1x), 
which prepared from PBS (10x) diluted 10 times using DI water, in order to remove any 
traces of serum which would inhibit the action of trypsin, while completely covering the 
monolayer of cells with trypsin-EDTA (0.05 %) and incubating the cells for approximately 
2 minutes until more than 90% of cells had detached from the flask. After the incubation 
period, growth medium was added to inhibit any further activity of trypsin and cells were re-
suspended by gently pipetting the cell suspension in and out of a Stripette Serological Pipette 
to break up any clumps of cells. The cell suspension was then divided between 75 cm2 canted-
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neck tissue culture flasks containing growth medium for further culturing or used in the MTT 
assay as described below. 
 
2.2.2.2 Preparation of the cells for MTT assay 
After the cells were washed with PBS (1x) which was prepared from PBS (10x) diluted 10 
times using DI water and trypsinised, they were re-suspended in growth medium to obtain a 
known volume (Vsp) of cell suspension, normally 10 mL. Typically a 20 uL aliquot of this 
cell suspension was removed and 20 uL of trypan blue (0.4 %w/v) added to stain any dead 
cells dark blue. The hemocytometer and cover slip was cleaned and dried. Once the coverslip 
was fixed in the position, 20 uL of cells was added to the hemocytometer. The number of 
living, clear cells within 4 squares of the hemocytometer was then determined and the volume 
of growth medium required to re-suspend the cells (Vmed) at the desired cell count per mL 
(Ccell) calculated as Equation 2.3. 
 
Vmed  = (total cell count/4) x 2 x (104/Ccell) x Vsp  Equation 2.3 
 
where the factor 2 accounts for the dilution of 20 uL of cell suspension with 20 uL trypan 
blue solution. Dividing the total cell count by 4 gives the average number of cells in a single 
square of the hemocytometer since the volume contained in each square is 0.1 mm3 or 10-4 
mL, a multiplication factor of 104 is used. 
Once diluted using advanced RPMI-1640 media to the required cell count, the cell suspension 
was then dispensed into a 96-well flat bottom tissue culture plate (0.2 mL per well) using a 
multichannel pipette. The 96-well tissue culture plate was then incubated overnight in a 
humidified incubator at 37 ˚C and 5 % CO2, 95 % air. 
 
2.2.2.3 Sample preparation for the MTT assay 
The HeLa and CT26 cells was seeded in 96-well plates at 5 x 103 cells/ well in a complete 
media for 24 or 72 hours in a humidified incubator at 37 ˚C and 5 % CO2, 95 % air. The outer 
wells of the plate were not used to avoid any edge effects and filled with PBS. The cells were 
then incubated with 200 uL of different concentration surfactant micelles or NE dispersions 
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in the presence or absence of different concentrations of CUR or DTX. The autoclaved water 
and DMSO were the negative and positive controls, respectively, achieved by incubating the 
cells with 20 uL of either autoclaved water or DMSO and 180 uL of complete media. 
The 5 mg/mL of MTT solution was prepared by reconstituting the MTT powder in 1x sterile 
PBS and subsequently filtered to sterilise this solution using a 0.22-um sterile filter. The 
MTT solution was stored at −20°C and protected from light until use. Before using, the MTT 
solution was diluted with complete media at a volume ratio of 1:6. At the end of the 
incubation period, the complete media was removed at the required time and replaced with 
120 μL of the mixture of complete media and MTT solution. Cells were incubated for 3 hours 
at 37 °C and 5 % CO2. At the end of the incubation period, formazan was dissolved in 200 
μL of DMSO and the wells in the plate were read at 570 nm (A570nm) using a FLUO star 
OPTIMA plate reader (BMG Labtech). The results were expressed as percentage cell survival 
(mean ± SD), calculated using Equation 2.4 and expressed as mean ± S.D., (n=5): 















Part 3 Synthesis 
2.3.1 Materials 
Brij O10, hydrochloric acid 37 % (HCl), poly(ethylene glycol) bis(3-aminopropyl) 
terminated (bis(3-aminopropyl) terminated PEG), dicyclohexylcarbodiimide (DCC), 
HEPES, ninhydrin, Sephadex G-25 and pyridine were all obtained from Sigma-Aldrich 
(Dorset, UK). Folic acid, crystalline was purchased from Alfa Aesar (Lancashire, UK), while 
2, 2, 2-trifluoroethanesulfonyl chloride (tresyl chloride) was supplied by Acros organics 
(Geel, Belgium). Absolute ethanol was from VWR international (Leicestershire, UK). 
Dimethylsulfoxide, anhydrous dimethylsulfoxide (DMSO), dichloromethane and anhydrous 
dimethylformamide (DMF) was purchased from Fisher Scientific (Loughborough, UK). 
Deuterium oxide was supplied by Goss Scientific Instruments (Cheshire, UK). 
Dimethylsulfoxide (–d6) was obtained from Cambridge Isotope Laboratories (Massachusetts, 
USA). Ultrapure water (MilliQ, Millipore, Spain) and double distilled water were used 
throughout all experiments. 
 
2.3.2 Methods 
2.3.2.1 Synthesis of PEG bis(3-aminopropyl) terminated-folate 
2.3.2.1.1 Preparation of PEG bis(3-aminopropyl) terminated-folate  
2.250 mg (1.5 mmol) bis(3-aminopropyl) terminated PEG was reacted with 661.5 mg (1.5 
mmol) folic acid in DMSO (50 mL) containing one molar equivalent of DCC and 100 uL of 
pyridine. The reaction mixture was stirred 2 days in the dark at room temperature. Water 
(100 mL) was added and the insoluble by-product, dicyclohexylurea, removed by filtration 
through Whatman glass microfiber filter, grade GF/F. The filtrate was then evaporated and 
kept in the fridge until use. The filtrate was dissolved in water and then passed through a 
Sephadex G-25 column, previously equilibrated with water. The filtrate was eluted with 
water at a flow rate of 2 mL/min, and 10-mL fractions were collected from first yellow elute 
was eluted. This collection was repeated until all of the yellow eluates had been eluted, 
typically 15 x 10-mL fractions. Each fraction was analysed for folate content by determining 
its absorbance at 364 nm and for -NH2 content by the ninhydrin assay as described below. 




Figure 2.3: Synthesis of PEG bis(3-aminopropyl) terminated-folate 
 
2.3.2.1.2 Analysis of PEG bis(3-aminopropyl) terminated-folate  
The diagram of analysis of PEG bis(3-aminopropyl) terminated-folate was shown in Figure 
2.4. 
 
Figure 2.4: Diagram shown the process of synthesis and analysis of PEG bis(3-aminopropyl) 
terminated-folate. 
 
Analysis of PEG bis(3-aminopropyl) terminated-folate using UV-vis spectroscopy 
A calibration curve of folate was prepared by first making a stock folic acid solution by 
dissolving folic acid in ethanol at a concentration of 0.13 mg/mL. The stock solution was 
diluted with ethanol to prepare a number of solutions of folic acid concentration ranging from 





Analysis of PEG bis(3-aminopropyl) terminated-folate using ninhydrin reaction 
To qualitatively analyse the amount of –NH2 present in each fraction, a 2 %w/v ninhydrin 
stock solution was prepared by dissolving 2 g ninhydrin in ethanol and adjusting volume to 
100 mL with ethanol. For the assay, 200 uL of ninhydrin solution was added to 100 uL of 
each fraction in glass vial. This mixture was heated by a heat gun for 5 minutes and the 
change in colour of mixture was examined by eye. In this test, bis(3-aminopropyl) terminated 
PEG and folic acid were positive and negative controls, respectively. 100 uL of the positive 
control was reacted with 200 uL of ninhydrin and a purple colour was detected. On the other 
hand, 100 uL of negative control was reacted with 200 uL of ninhydrin and a colour of the 
mixture remained yellow. 
 
Analysis of PEG bis(3-aminopropyl) terminated-folate using proton nuclear magnetic 
resonance spectroscopy (1H NMR) 
After each fraction was analysed for its folate and –NH2 content, the fractions which showed 
same results for the ninhydrin reaction and the folate analysis were pooled together and 
evaporated using a rotary evaporator. 
The chemical structure of dry product of the various pooled fractions, i.e. the first fractions 
which are positive to folate only, the fractions which are positive for both folate and 
ninhydrin and finally the last group fractions of fractions which are positive to folate, was 
determined using 1H NMR spectroscopy (Bruker Avance DRX 400 MHz NMR 
spectrometer) (Bruker, Coventry, UK). Each dry product was dissolved in a D2O or DMSO 
system prior to analysis by 1H NMR spectroscopy. The chemical shifts (δ) were expressed 
as parts per million (ppm). Data from synthetic procedures was analysed using MestReNova 
software (Mestrelab Research SL, Spain). 
 
Analysis of PEG bis(3-aminopropyl) terminated-folate for folate and –NH2 ratio 
To quantitatively determine the folate content in the final product, the dry product of fractions 
that contained PEG bis(3-aminopropyl) terminated-folate was diluted in HEPES buffer to 
prepare a solution at a concentration of 0.368 mg/mL and the absorbance at 364 nm measured 




In order to quantitatively determine -NH2 content, 10 mg of bis(3-aminopropyl) terminated 
PEG was weighed and water added up to 10 mL to obtain a stock solution. Solutions were 
prepared as illustrated in Table 2.9. Both standard and samples were gently mixed and heated 
in boiling water for 15 min, after which time the samples were cooled to room temperature 
and 5 mL of 50 %v/v ethanol was added. The UV absorbance of each sample was measured 
at 570 nm (LAMBDA 2 UV/Vis Spectrophotometer, Perkin-Elmer, USA). The blank in this 
study was the mixture of 1 mL of water, 1 mL of 2 %w/v ninhydrin solution and 5 mL of 50 
%v/v ethanol, heated in the same way as the sample. 
 
Table 2.9 Composition of samples used to prepare the calibration curve. 
 
Chemical 
Amount of chemicals (mL) 
1 2 3 4 5 6 
bis(3-aminopropyl) terminated PEG stock solution 0.3 0.4 0.6 0.7 0.9 1.0 
water 0.7 0.6 0.4 0.3 0.1 0 
2 %w/v  ninhydrin solution 1 1 1 1 1 1 
50 %v/v ethanol 5 5 5 5 5 5 
 
 
Consequently the folate and -NH2 content of the PEG bis(3-aminopropyl) terminated-folate 
was determined from the calibration curve obtained for both of the chemicals using the 
absorbance measured for both chemicals. 
 
2.3.2.2 Synthesis of tresylated Brij O10  
2.3.2.2.1 Preparation of tresylated Brij O10  
The synthesis of tresylated Brij O10 is shown in Figure 2.5. 
 




The method used for tresylation of Brij O10 was a modification of the method used to 
tresylate Brij 78 (Jain et al., 2010). In brief, Brij O10 (2.84 g, 4mmol) was dissolved in 10 
mL dichloromethane and incubated at 0 ˚C. Tresyl chloride (480 uL, 8 mmol) and 1 mL 
pyridine were then added dropwise to the Brij O10 solution with stirring. Once the addition 
was complete, the reaction was allowed to continue at room temperature with constant 
stirring for 2 days under nitrogen atmosphere. After which time the solution was rotary 
evaporated under reduced pressure and the resultant precipitate re-dissolved in 240 mL 
ethanol with 1 mL HCl. The solution was kept overnight at −20 ˚ C and the precipitate formed 
centrifuged at 3000 rpm for 2 min. The supernatant was discarded and the resultant pellet 
was re-suspended in 50 mL ethanol acidified with 50 uL HCl. The centrifugation and the re-
suspension in a mixture of ethanol and HCl were repeated until pyridine was removed as 
verified by a minimum and constant absorbance (around 0.1) at 255 nm. The solid tresylated 
Brij O10 was stored at -20 ˚C under nitrogen. 
 
2.3.2.3 Synthesis of folate derived Brij O10 
2.3.2.3.1 Preparation of folate derived Brij O10 
 
Figure 2.6: Synthesis of folate derived Brij O10. 
 
PEG bis(3-aminopropyl) terminated-folate (0.165 mmol, 1.63 mL of a 194.39 mg/mL in 
anhydrous dimethylformamide) was added to tresylated Brij O10 (424.9 mg, 0.495 mmol) 
and the mixture allowed to react overnight at room temperature. The reaction mixture was 
then evaporated using the rotary evaporator to remove dimethylformamide and the resulting 
product dissolved in 15 mL of DI water and subjected to chromatography using a Sephadex 
G-25 column previously equilibrated with water. The sample was eluted with water at a flow 
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rate of 2 mL/min, and 10-mL fractions were collected from the first yellow elute. This 
collection was repeated until all of the yellow material had been eluted, typically this needed 
16 x 10-mL fractions. Each fraction was analysed for folate content by determining its 
absorbance at 364 nm and for -NH2 content using the ninhydrin assay described below. The 
synthesis of the folate derived Brij O10 is shown in Figure 2.6. 
 
2.3.2.3.2 Analysis of folate derived Brij O10  
The diagram of analysis of PEG bis(3-aminopropyl) terminated-folate is shown in Figure 
2.7.  
  
Figure 2.7: The diagram of analysis of folate derived Brij O10. 
 
Analysis of folate derived Brij O10 using UV-vis spectroscopy 
In order to determine the folate content of the final product, each fraction was analysed for 
folate content by measuring its absorbance at 364 nm. Blank was ethanol (LAMBDA 2 






Analysis of folate derived Brij O10 using ninhydrin reaction  
To examine the presence of –NH2 in the product, 2 %w/v ninhydrin solution was prepared 
by dissolving 2 g ninhydrin in ethanol and adjusting its volume to 100 mL with ethanol. For 
the assay, 200 uL of ninhydrin solution was added to 100 uL of each fraction in a glass vial. 
This mixture was heated and the colour of the mixture examined. In this test, bis(3-
aminopropyl) terminated PEG and folic acid were the positive and negative controls, 
respectively. 100 uL of the positive control was reacted with 200 uL of ninhydrin and a purple 
colour was detected. Reacting 100 uL of the negative control with 200 uL of ninhydrin 
resulted in the mixture remaining yellow. 
 
Analysis of folate derived Brij O10 using proton nuclear magnetic resonance 
spectroscopy (1H NMR) 
The chemical structure of folate derived Brij O10 after elution through Sephadex G-25 
column was obtained using 1H NMR spectroscopy (Bruker Avance DRX 400 MHz NMR 
spectrometer) (Bruker, Coventry, UK). Each dry sample was dissolved in a D2O or DMSO 





Chapter 3                                    




Over the last two decades, many researchers have attempted to develop improved delivery 
systems for challenging drug candidates, in particular those candidates belonging to either 
Class II or IV of the biopharmaceutical classification system (BCS) (Table 3.1) (Amidon et 
al., 1995, Lobenberg and Amidon, 2000). Drug substances presenting with very poor 
aqueous solubility generally fall into Class II or IV of the BCS as a consequence of their 
low solubility, which results in a very poor in vivo absorption. In order to overcome the 
problem of the very poor water solubility of many drugs and drug candidates, new delivery 
systems are urgently required.  
 
Table 3.1 Biopharmaceutical classification system (Amidon et al., 1995). 
 
Class Solubility Permeability Description 
I High High Well absorbed, absorption rate is usually higher than excretion rate. 
II Low High 
Bioavailability is limited by solvation rate. A correlation can be found 
between the in vivo bioavailability and the in vitro solvation rate. 
III High Low 
Although the drug is solvated quickly, absorption is limited by 
permeation rate. 
IV Low Low 
Those compounds have a poor bioavailability. Usually they are not 
well absorbed across the intestinal mucosa and thus a high variability 
is expected. 
 
Over the last decade, there has been considerable interest in the use of nanoemulsions (NE) 
as drug delivery vehicles for poorly-water soluble drugs. This interest stems largely from 
the potential of NE to increase drug solubility, particularly in comparison to the 
corresponding micelles (Shafiq et al., 2007; Date and Nagarsenker, 2007). The ability of 
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NE to increase drug solubilisation is a consequence of the core of oil present in the NE, 
always assuming that is the drug is soluble in the oil. Despite the fact that NE have 
considerable potential as drug delivery vehicles, they have not been widely commercialised 
to date. This lack of exploitation is most probably a consequence of the requirement for 
advanced physico-chemical techniques such as laser light and neutron scattering, to both 
characterise and determine their stability, although almost all papers on NE suggest that it 
is possible to formulate them with stability lasting many years (Malcolmson, 1993; Solan et 
al., 2005; Maruno and Rocha-Filho, 2009).   
An understanding of the detailed internal structure of a NE is important because of the 
correlation between structure, drug solubilisation capacity and ultimately drug 
bioavailability. The increase in bioavailability achievable with a NE is attributed to their 
small droplet size, which provides a large surface area for drug release (Charman et al., 
1992, Shah et al., 1994). In addition, the amount and nature of the oil present in the NE 
have been shown to effect the physico-chemical properties of the NE, including the ability 
of the NE to solubilise drug. A previous study within our group has shown that NE 
containing the polyoxyethylated nonionic surfactant, C18:1E10 (Brij O10), and very low 
levels of the triglyceride soybean oil can significantly increase the apparent aqueous 
solubility of the hydrophobic drug, testosterone propionate, when compared to the 
corresponding Brij O10 micelles (Malcolmson et al., 1998). This increase in solubility was 
attributed to the large molecular volume of the soybean oil which resulted in the oil 
forming a core in the centre of the microemulsion (ME) droplets, thereby creating an extra 
locus of solubilisation of the testosterone propionate.  
The present study examines the formation and detailed physico-chemical characterisation 
of oil-in-water (o/w) nanoemulsions (NE) prepared using the nonionic surfactant, Brij O10 
in either water or an aqueous solution of 0.9 %w/v NaCl at room temperature. The 
polyoxyethylene nonionic surfactant, Brij O10 (C18:1E10), was chosen for this study because 
it has been shown in many studies to form NE without the need for cosurfactant 
(Malcolmson and Lawrence, 1995, Warisnoicharoen et al., 2000a; Wasutrasawat et al., 
2013). Moreover, it is currently used in a range of pharmaceutical and cosmetic 
preparations (Porter, 1991). Furthermore, all oils used in this study are pharmaceutically 
acceptable. The phase inversion temperature of the polyoxyethylene nonionic surfactant, 
Brij O10, was determined in order to ensure the absence of any phase change around the 
Preparation of Brij O10 nanoemulsions 
96 
temperatures of interest, namely 25 and 37°C. In addition, the particle size of the NE was 
examined to ensure the stability of the NE over time. 
 
3.1.2 Aim of the study 
The aim of the study was to investigate the detailed molecular architecture and the physico-
chemical properties of the NE in order to establish their capacity for two poorly-water 
soluble drugs, namely testosterone propionate (TP) and curcumin (CUR), alone or in 
combination. A range of physico-chemical techniques have been employed to achieve this 
aim. 
 
3.2 Micelle and nanoemulsion without drug 
3.2.1 The area of existence of Brij O10 nanoemulsions 
Three component o/w NE were prepared and examined for their ability to remain stable at 
room temperature using a commercially available triglyceride or ethyl ester, the nonionic 
surfactant Brij O10 (C18:1E10) and either distilled water or an aqueous solution of 0.9 %w/v 
NaCl. In previous studies, it was found that both triglyceride and ethyl ester oils, possessing 
a high molar volume, could produce a large area of existence of NE using Brij O10 in water 
(Malcolmson et al., 1998; Warisnoicharoen et al., 2000a; Wasutrasawat et al., 2013). As a 
consequence triglyceride and ethyl ester oils with high molar volumes were chosen for the 
present study. The triglycerides used were selected from either the liquid triglycerides, 
soybean oil (hSBO) or triolein (two purities studied - 65hGTO and 99hGTO) or the solid 
triglycerides, tripalmitin (two purities studied - 85hTPN and 99hTPN) or tristearin (two 
purities studied - 60hGTS and 99hGTS). The high molar volume ethyl ester oils studied 
were either the liquid ethyl ester, ethyl oleate (two purities tested - 60hEO and 98hEO) or 
the solid ethyl ester, ethyl stearate (99hES). The area of NE existence was determined by 
varying the composition of each sample and plotting the results, on a weight basis, on a 
partial ternary phase diagram in order to understand the phase behaviour of the NE 
formulations (Figures 3.1, 3.2 and 3.3).  
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Figure 3.1: Partial ternary phase diagrams obtained for the oil-in-water nanoemulsions prepared 
using hSBO, Brij O10 and water or an aqueous solution of 0.9 %w/v NaCl after 1 month storage at 
room temperature. Clear NE are described as Region A NE, while bluish or translucent NE are 
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Figure 3.2: Partial ternary phase diagrams of the oil-in-water nanoemulsions prepared using 
triglyceride, Brij O10 and water after 1 month storage at room temperature. Clear NE are described 
as Region A NE, while bluish or translucent NE are called Region B NE and the cloudy or milky 
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ES  Low purity ES was not available commercially. 





















Figure 3.3: Partial ternary phase diagrams for the oil-in-water nanoemulsions prepared using ethyl 
ester, Brij O10 and water after 1 month storage at room temperature. Clear NE are described as 
Region A NE, while bluish or translucent NE are called Region B NE and the cloudy or milky NE 
were denoted as Region C NE. 
 
On the abscissa, surfactant concentration (in %w/w) increases from left to right while on 
the ordinate, oil concentration (in %w/w) increases from bottom to top. A (partial) phase 
diagram is used regularly to observe the NE formation (Djekic et al., 2011; Lawrence and 
Rees, 2012). In the present study, only the region of the phase diagram at lower and 
intermediate surfactant concentrations of up to ~ 50 %w/w surfactant was determined. In 
previous studies the appearance of the individual NE after one month storage at room 
temperature was plotted on the phase diagrams. The present study focused on the one phase 
o/w NE region immediately, 1 day, 1 week and 1 month after preparation when stored at 
room temperature. Figure 3.4 shows the appearance of 1 month old, stable NE. It can be 
seen that the appearance of these NE samples altered from transparent samples in Region 
A, the bluish/translucent samples of Region B, to the cloudy/milky samples of Region C as 
oil concentration increased.  
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Figure 3.4: The appearance of oil-in-water nanoemulsions in Region A (clear), Region B 
(bluish/translucent) and Region C (cloudy/milky). 
 
As can be seen in Figures 3.1, 3.2 and 3.3, the Brij O10 concentrations that formed NE 
ranged from 5-30 %w/w. Furthermore, when using hSBO, 85hTPN and 99hGTO, NE of all 
types of NE, i.e. Regions A, B and C NE, could be formed, with largest region of NE 
existence being Region A. In addition, the maximum level of oil incorporation observed 
occurred in the 20-25 %w/w range of surfactant. The formation of gels was observed at Brij 
O10 concentrations above 30 %w/w and when high amounts of oil were present. (Note that 
gels do not fall under the definition of a NE.) Indeed, many samples containing oils at a 
level greater than those recorded in Region C were gels or else they formed two phase 
systems and were therefore not studied any further. For comparative purposes, the upper 
limit of the amount of oil (%w/w) incorporated into stable, NE in Regions A, B and C are 
shown in Table 3.2. 
 
 
Preparation of Brij O10 nanoemulsions 
101 
Table 3.2 Upper limit of the amount of oil (%w/w) incorporated into Brij O10 containing oil-in-water nanoemulsions in Regions A, B and C which were stable for 1 
month. 
 
Type Appearance of  
oil 
Sample 5% Brij O10 10% Brij O10 15% Brij O10 20% Brij O10 25% Brij O10 30% Brij O10 
A B C A B C A B C A B C A B C A B C 
Triglyceride Liquid hSBO, H2O 1.4 2 4 2.3 7 8 5 12 15 9 14 16 7.5 10 11 - 0.5 1 
hSBO, 0.9 %w/v NaCl 1.4 N N 2.3 N N 5 N N 9 N N 7.5 N N - N N 
65hGTO, H2O 0.5 - 1 0.5 1 - 1 - - 1 2 - 2 3 - - 0.5 2 
99hGTO, H2O 1 3 4 3 7 8 5 8 - 8 15 - 6 8 15 - 2 5 
Solid 85hTPN, H2O 1 3 5 3 5 9 3 10 14 6 11 18 10 12 16 - - 1 
99hTPN, H2O 0.5 2 5 0.5 2 9 0.5 1 14 0.5 1 18 1 - 16 - - 1 
60hGTS, H2O - 3 - - 1 - - - - - 1 - - - - - - 1 
99hGTS, H2O - - - - - - - - - - 11 1, 
 12-13  
- 11 1-2,  
12-13 
- - 1 
Ethyl ester Liquid 60hEO, H2O 1 2 8 3 4 12 5 - - 7 - 8 5 6 - - - 2 
98hEO, H2O 1 - 8 2 3 - 5 - - 6 8 - 4 5 - - 2 - 
Solid 99hES,  H2O - - - - - - - - - 1 - - 1 - - - - 2 
 
- means the NE was not formed. 
N  means the experiment was not performed. 
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The area existence of clear Region A NE formed by hSBO, shown in Figure 3.1, 
occurred between 5-30 %w/w Brij O10, with a maximum oil incorporation of 9 %w/w 
hSBO, which occurred at ~ 20 %w/w Brij O10. The highest hSBO concentration 
obtainable in the bluish/translucent Region B NE was 14 %w/w which occurred at a 
Brij O10 concentration of 20 %w/w. In comparison the highest hSBO concentration 
achievable in the NE formed in cloudy/milky, Region C was 16 %w/w, which again 
occurred at 20 %w/w Brij O10.  
The presence of electrolytes in the aqueous phase of micellar or NE formulations has 
been known to affect, generally reduce, the extent of hydration of the polyoxyethylene 
head group and may, as a consequence, reduce the extent of the area of NE existence 
(Schott and Royce, 1984). In the present study, the effect of electrolytes on the level of 
oil incorporation in NE at 22 °C was examined by the use of an aqueous solution 
containing 0.9 %w/v NaCl solution in place of water. A 0.9 %w/v aqueous NaCl 
solution was selected for study because it is isotonic and is commonly used in 
pharmaceutical preparations intended for intravenous administration. It was clear from 
Figure 3.1 that the phase behaviour of NE prepared using Brij O10 and the aqueous 0.9 
%w/v NaCl solution at 22 °C was very similar to that seen when water was used as 
solvent, suggesting that at this experimental temperature, the phase behaviour of the 
surfactants is not very sensitive to the presence of this concentration of electrolyte. 
Based on previous work it was anticipated that NE prepared using a large molar volume 
oil would produce a large area of NE existence in the phase diagramm. However, some 
of NE prepared using the same oil but of differing purity did not produce NE of 
comparable area existence. Specifically, the area existence of NE containing 65hGTO, 
99hTPN and 60hGTS were much smaller than those obtained using the corresponding 
oils of differing purity, namely 99hGTO, 85hTPN and 99hGTS, respectively (Figure 
3.2), although interestingly, in all cases, the maximum level of oil incorporation 
occurred at approximately 20 %w/w Brij O10. For example, the maximum amount of 
oil incorporated into the area existence of clear, Region A and bluish/translucent, 
Region B, NE containing 65hGTO was 1 and 2 %w/w, respectively, while in contrast 
the maximum level of incorporation of GTO of 99% purity (99hGTO) in the 
corresponding regions was much higher at 8 and 15 %w/w, respectively. The maximum 
level of incorporation of 85hTPN in the clear, Region A and bluish/translucent, Region 
B NE was 6 and 11 %w/w, respectively while only 0.5 and 1 %w/w of the higher purity 
TPN, namely 99hTPN, respectively was incorporated into the corresponding A and B 
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Regions. Differences were also observed in the cloudy/milky Region C NE. For 
example a maximum oil incorporation of 13 %w/w 99hGTS was observed in this region 
while NE containing 60hGTS did not exhibit the formation of any cloudy/milky NE. On 
the other hand, the area existence of Region C NE obtained using 60hEO as oil was not 
significantly different from that prepared using 98hEO.  
While, the differences observed in the extent of NE formation was clearly a 
consequence of the purity of the various oils, there was no obvious correlation between 
purity and the extent of NE formation. The purity of the oils used in the present study 
was assessed by determining their 1H NMR spectra in chloroform-d (Appendix B.1-
B.10). It was established that the 1H NMR spectra obtained was broadly in agreement 
with the reported composition of the oil, although there was the presence of some 
impurities which could potentially affect the formation of NE. The 1H NMR spectra of 
both 85hTPN and 99hGTS exhibited a signal at δ = 3.5 ppm, which Joyce et al. (2016) 
have proposed is due to the presence of a glyceryl group of monoglyceride or 
diglycerol. In contrast the corresponding oils, 99hTPN and 60hGTS, did not exhibit the 
same signal at δ = 3.5 ppm. It has been established that the presence of Imwitor 308, i.e. 
glyceryl caprylate, can increase the area of ME existence as a consequence of Imwitor 
308 penetrating into the interfacial surfactant region, acting as a cosurfactant (Zargar-
Shoshtari et al., 2010). Further, the higher amount of Imwitor 308 contained in ME, the 
greater the area of ME existence (Zargar-Shoshtari et al., 2010). Considering this 
information, it would be expected therefore that the presence of a monoglyceride and/or 
a diglycerol in 85hTPN and 99hGTS NE would be the reason why these oils exhibited a 
larger area of NE existence than was seen when the oils, 99hTPN and 60hGTS, were 
used. In addition, the level of saturation of a fatty acid has been also found to have an 
effect on the formation of NE (Almeida et al., 2010). Almeida et al. (2010) illustrateed 
that the particle size of NE containing cholesteryl stearate (C18:0) exhibited the greatest 
particle size and greater size variation than NE containing either cholesteryl oleate, 
C18:1, or cholesteryl linoleate, C18:2, respectively. In the present study, 65hGTO 
contained a lower amount of unsaturated fatty acid than 99hGTO, resulting in a smaller 
area of NE formation in the 65hGTO-containing systems. However, clear NE stabilised 
by 20 %w/w Brij 96 NE showed a maximum incorporation of tributyrin (C4:0) at 4 
%w/w (Warisnoicharoen et al., 2000a) while a maximum incorporation of 10 %w/w 
trilaurin (C12:0) occured at the same concentration of surfactant (Wasutrasawat et al., 
2013). Consequently, the degree of saturation of a fatty acid did not show the clear 
relationship with the area existence of NE. Interestingly, while 60hEO exhibited a 
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signal at δ = 2.8 ppm, suggesting that 60hEO contained the impurity CH=CH-CH2*-
CH=CH (Miyake et al., 1998; Knothe and Kenar, 2004), 98hEO contained a 
monoglyceride/glycerol impurity. As a consequence of both oils containing impurities, 
the effect of which balanced each other out, lead to a similarity in the area of NE 
existence of the 60hEO and 98hEO containing systems.  
As expected, NE prepared using either triglyceride or ethyl ester possessing long, (C18) 
saturated chains, namely 60hGTS, 99hGTS and 99hES formed only very small areas of 
NE existence. Both 60hGTS and 99hGTS could not form clear, Region A, NE while 
99hES formed a clear Region A NE containing only 1% oil. This observation can be 
explained by the fact that 60hGTS, 99hGTS and 99hES are expected to be 
crystallisation at room temperature, and hence it may be inferred that at higher 
concentrations of oil, the formation of fat crystals might disturb surfactant formation of 
the NE. Calligaris et al. (2016) reported that systems containing hGTS and 30 %w/w 
Tween 80 in 0.8 M NaCl only formed transparent ME (diameter ~25 nm) at or below 5 
%w/w oil content; whereas turbid dispersions were generated at hGTS concentrations of 
7.5 %w/w or above. Lyon et al. (1990) have also reported the formation of opalescent 
systems (which the authors termed ME) containing ES and the surfactant, Teric X10 or 
Triton X100, at oil:surfactant ratios of 0.8:1, 1:1 and 1.6:1. These systems become 
milkier is appearance over several hours before creaming and finally separating into 
oily layers and transparent aqueous layers. Interestingly, the 99hGTS containing 
systems formed cloudy NE at an oil concentration of only 1%, while at the higher oil 
concentrations of 2-11%, the NE became bluish/translucent (Region B) and at 12-13% 
oil content appeared cloudy. This result suggested that the shape and size of NE 
changed at each boundary. In order to confirm this hypothesis, it was necessary to use 
SANS to establish the presence of shape changes in the 99hGTS-containing systems as 
a function of oil concentration.  
The results obtained in the present studies of the formation of a clear NE area at low 
surfactant concentrations (Figures 3.1, 3.2 and 3.3) are in contrast to those reported by 
Kale and Allen (1989) who determined that it was not possible to produce ME using 
light mineral oil, Brij 96 and water without the presence of a cosurfactant. 
Encouragingly however, the area existence of Brij O10 NE found in the present study 
covered a similar range of concentrations to those reported by Gradzielski et al. (1990) 
for the formation of isotropic, water-continuous phase (L1 phase) by paraffin/Brij 
96/water. Although, in contrast to the studies of Gradzielski et al. (1990) the area of NE 
observed in this study does not extend to the water apex. This difference could be 
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explained by the greater number of compositions prepared at low surfactant 
concentrations in the present study, allowing the extent of NE existence in this region to 
be more closely defined. It was also observed that the NE compositions individually 
produced within the Region A of the three-phase diagram shown in Figures 3.1, 3.2 
and 3.3 could be diluted with water to produce compositions closer to the water apex 
which, although outside the experimentally determined NE region, remained clear for at 
least a month.  
Compositions outside the Region A towards the water apex, exhibited varying degrees 
of turbidity, eventually separating into two phases. The boundary of NE with higher 
surfactant concentrations was not as easy to define. Clear and fluid NE systems tended 
to increase in viscosity with increasing Brij O10 content until gels were formed. These 
gels, although initially clear, fluid systems could also form some time after preparation. 
The gels sometimes produced a ring upon tapping, and frequently exhibited 
birefringence. A region of a clear gel directly adjacent to the NE region, at a minimum 
Brij O10 concentration of approximately 30%, has also been reported by other 
researchers (Provost and Kinget, 1988; Gradzielski et al., 1990).  
Due to the large size of the oil molecules and the long alkyl chains of the triglyceride or 
ethyl ester studied, it is not expected that oil will significantly penetrate into the 
hydrophobic chain region of the interfacial surfactant monolayer (Aveyard and Lawless, 
1986). Therefore, it is expected that the core of the o/w NE droplet will consist of only 
oil and that this core is surrounded by the oleyl chains of the interfacial Brij O10 
monolayer. The outer region of the NE is composed of ethylene oxide chains, the 
hydration of which increases as the distance from the core increases. In addition, 
previous studies (Malcolmson et al., 1998; Warisnoicharoen et al., 2000a; 
Wasutrasawat et al., 2013) have reported that NE prepared using large molecular 
volume triglycerides and stabilised by Brij O10 tend to form the large o/w NE region. 
The reason for this may be due to the fluid, long hydrophobic chain of the surfactant 
which assist in the incorporation of both long-chained oils and large volume triglyceride 
oils into the o/w NE droplets. These earlier studies (Malcolmson et al., 1998; 
Warisnoicharoen et al., 2000a; Wasutrasawat et al., 2013) reported the preparation of 
o/w NE using hSBO, 85hTPN and 98hEO using the same surfactant, C18:1E10 as studied 
here. It should be noted that Brij 96 and Brij 97 are the oldest and the previous version, 
respectively of Brij O10 (C18:1E10) and are no longer commercially produced.  
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At 20 %w/w surfactant, Brij O10 NE could incorporate 9 %w/w hSBO while Brij 96 
and Brij 97 NE incorporated slightly lower levels of SBO, namely 6.5 and 7 %w/w 
hSBO, respectively (Malcolmson et al., 1995; Warisnoicharoen et al., 2000a). 
Obviously, the phase behaviour of the three versions of C18:1E10 was slightly different 
and this showed that the commercially polyoxyethylene surfactants contain a 
polydispersity of head group that has an effect on a variation of the phase diagram 
between different batches of surfactant. Besides the oil molecular volume, NE 
formation also depends on other factors such as chemical structure of the oils, the 
hydrophilic-lipophilic balance of surfactants and oils used, the surfactant molecular 
structure, the shape of micellar solution, etc.   
 
3.2.2 Dilutability of nonionic o/w nanoemulsions containing Brij O10 
The ability of NE to be diluted is essential for their use as drug delivery vehicle, 
particularly for oral delivery, because they will be diluted by body fluids after 
administration. The dilutability of NE also allows their physicochemical properties to 
be investigated with no change of the integrity of the system; which assures that the 
appearance of the clear NE remains clear, fluid and non-birefringent upon dilution. It 
should be noted that the ratio of oil to surfactant of the o/w NE stabilised by nonionic 
surfactant is expected to remain constant upon dilution (Attwood, 1994). 
Dilutability experiments on Brij O10 NE showed that the NE stabilised by Brij O10 and 
prepared in water could be readily diluted from a range of surfactant concentrations, 
namely 15-25 %w/w, down to 1-2 %w/w surfactant, and that these diluted NE remained 
stable for at least a month at room temperature. These results suggest that the ability of 
the nonionic o/w NE prepared (without a cosurfactant) in the present study, to be 
readily diluted offers advantage for pharmaceutical purposes. In contrast, it has been 
established that ME containing cosurfactants cannot be diluted without altering the ME 
and in many cases, destroying them (Attwood, 1994). ME containing cosurfactant 
(typically a short chain alcohol) are frequently destroyed upon dilution due to the 
cosurfactant partitioning out from the interfacial monolayer of the ME droplet into the 
continuous phase (Lawrence, 1994).  
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3.2.3 Cloud point and phase inversion temperature 
One of the characteristic properties of nonionic surfactants is their cloud point (CP). In 
general, the phase behaviour of nonionic surfactant micellar solutions especially of the 
polyoxyethylene surfactants depends on the experimental temperature. For example, 
increasing the temperature of a solution containing a water soluble nonionic surfactant 
frequently results in a phase separation of the micelles into surfactant-rich and 
surfactant-lean phases at a temperature known as the cloud point (CP) (Aveyard et al., 
1989, Strey, 1996).  
The phase inversion temperature (PIT) is defined as the temperature below which a 
surfactant preferentially partitions into water, and at which an o/w NE is transformed 
into a w/o NE. The PIT also corresponds to the temperature of the minimum value in 
o/w interfacial tension (Ruckenstein, 1997) and the temperature at which the uptake of 
oil and water into the surfactant-rich phase is equal (Billman and Kaler, 1991). The 
presence of a CP or a PIT in a surfactant system, especially if their temperature is close 
to that at which the micellar solution and NE will be used, can cause problems with 
their exploitation as a drug delivery vehicle because of the changes in physical 
behaviour and appearance that may occur upon routine temperature fluctuations. As a 
consequence it is therefore necessary to determine the CP and PIT of the Brij O10-
containing micelles and NE.  
 
3.2.3.1 The effect of micelle concentration on cloud point 
The CP of Brij O10 micellar solutions was determined over a 1 – 20 %w/w 
concentration range of Brij O10 (Figure 3.5). The results show that the CP increases 
slowly with increasing nonionic surfactant concentration at concentrations above the 
critical micelle concentration (CMC). Similar trends in the variation of CP have been 
reported for the nonionic surfactant, Triton X-100 (Sadaghiania and Khan, 1991). The 
CP of 15, 20 and 25 %w/w Brij O10 micellar solutions were recorded in the present 
study as 67.4 ± 0.5, 69.3 ± 0.8, and 73.3 ± 0.7 °C respectively. Similar trends in the 
variation of the CP with Brij O10 concentration have been reported previously 
(Malcolmson et al., 1998; Warisnoicharoen et al., 2000a). However, the CP (and PIT) 
measured in this study were lower than those recorded for Brij 96, the oldest version of 
Brij O10, (Malcolmson et al., 1998) and higher than those recorded for Brij 97, the 
previous version of Brij O10, (Warisnoicharoen et al., 2000a). This observation might 
suggest that while Brij O10 was a less hydrophilic surfactant than Brij 96, it was more 
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hydrophilic surfactant than Brij 97. It is worth noting that the commercially 
polyoxyethylene surfactants contain a polydisperse head group. Any variation in the 
polydispersity of the head group has an effect on the CP leading to potential differences 
between different batches of surfactant. It has been suggested that the CP is more 
sensitive to impurities than the area of NE existence (Malcolmson et al., 1998; 
Warisnoicharoen et al., 2000a). 
The CP of a nonionic surfactant system is the temperature at which the total effective 
forces between micelles changes from being repulsive to attractive (Mukherjee et al., 
2011). This change results from either an increase in the attractive forces due to van der 
Waals forces of attraction and hydrophobic interactions between hydrophobic surfaces, 
or a decrease in repulsive forces because of a reduction in hydration forces at higher 
temperature and/or electrostatic double-layer forces, or a combination of both effects 
(Sadaghiania and Khan, 1991), in addition to related changes in micelle size and shape 
(Aveyard et al., 1990). With ethylene oxide surfactants such as Brij O10, an increase in 
experimental temperature results in a dehydration of the ethylene oxide head groups 
causing a reduction of the cross-sectional area of a polyoxyethylene head group (ao). 
This dehydration results in an increase in the critical packing parameter (CPP) of the 
surfactant, and the formation of more elongated aggregates such as rods or discs of 
decreased curvature, all possessing higher aggregation numbers (Kjellander, 1982; 
Aveyard et al., 1990; Shigeta et al., 2001). However, this change is reversible when the 
system is cooled to a temperature below the CP with the system becoming a clear, 
single phase solution once again.  
 
 
Figure 3.5: The cloud point of Brij O10 micellar solutions as a function of surfactant 
concentration (%w/w). 
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3.2.3.2 The effect of oil on the phase inversion temperature (PIT) 
The CP of a micellar surfactant solution can be altered by the presence of additives such 
as oils. Note that the corresponding temperature of a NE is termed a phase inversion 
temperature (PIT) (Shinoda and Arai, 1964). The results of the CP experiments for the 
Brij O10/water systems and of the PIT experiments for the NE containing various 
triglycerides or ethyl esters as a function of oil concentration are shown in Figures 3.6, 
and 3.7. 




Figure 3.6: The phase inversion temperature of the oil-in-water nanoemulsions containing 
triglyceride (a) hSBO, (b) hGTO, and (c) hTPN and containing 20 %w/w Brij O10 in H2O 
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(a)   (b)  
 
Figure 3.7: The phase inversion temperature of the oil-in-water nanoemulsions containing ethyl 
ester, (a) hEO and (b) hES, and containing 20 %w/w Brij O10 in H2O (mean ± S.D.). Error bars 
in some cases contained within symbols. 
 
The values determined for the PIT illustrated the complex and concentration-dependent 
way in which PIT varies with the nature and the amount of oil incorporated. According 
to the results obtained in the present study, the PIT of the Brij O10 NE containing the 
larger molecular volume oils first decreased and then increased as the concentration of 
oil increased. For example, NE systems containing more than 4 %w/w hSBO and 20 
%w/w Brij O10 showed an increased PIT compared to the corresponding NE containing 
2 %w/w hSBO. The decrease and then increase in PIT as the amount of oil increases 
suggests that the micellar aggregates were originally asymmetric in shape and became 
more spherical with oil concentration.  
In order to interpret the results of the PIT studies, it is proposed that Brij O10 forms 
asymmetric rather than spherical micelles in the absence of oil. When a low level of oil 
is incorporated, it is proposed that the oil penetrates the interfacial surfactant 
monolayer, encouraging the formation of even more asymmetric micelles resulting in a 
PIT of the NE that is below the CP of the micelle. When an even higher content of oil is 
added, an increase in the PIT of the NE is observed. This increase can be explained by 
the fact that the oil can cause a transformation of asymmetric into spherical aggregates 
and the formation of a core of oil. It is clear from the PIT studies that only low level of 
triglyceride, namely 2 %w/w hSBO, 2 %w/w 99hGTO and, 1 %w/w 85hTPN was 
required to promote the transformation of the aggregates from asymmetric to spherical 
droplets, while larger amount of ethyl ester, namely 4 %w/w 60hEO and 4 %w/w 
98hEO, was needed to effect the same transformation. This result is not surprising when 
considering the relative molecular volume of oils, shown in Table 2.8. The results of an 
earlier light scattering study (Warisnoicharoen et al., 2000b) support the hypothesis 
proposed here, and show that the asymmetric Brij 97 aggregates became more spherical 
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upon the addition of oil, with the oil forming a core. The hypothesis that the presence of 
a sufficient amount of a large molecular volume oil will cause a change in the shape can 
ideally be studied using small angle neutron scattering (SANS) in combination with 
contrast variation to determine the size and shape of the NE. 
As the reduction of PIT was greatest for the smallest molecular volume oils, hEO and 
hES, it is likely that the smaller molecular volume oil penetrated the interfacial 
surfactant monolayer furthest forming the most asymmetric droplets. Indeed, the 
behaviour of small molecular volume oils may reasonably be likened to cosurfactant, 
sitting alongside the surfactant in the interfacial monolayer as opposed to forming a 
core of oil. On the other hand, the larger the molecular volume of the oil, the lower the 
extent of its penetration into the interfacial surfactant monolayer, the more symmetric 
the droplet becomes and the greater the increase in PIT. The order of the PIT measured 
in the present study was 99hGTO > 85hTPN > hSBO > 65hGTO >> 98hEO = 60hEO = 
99hES. Based on the similarity in the value of the molecular volume (Vm) of the 
following oils, it would be anticipated that the PIT of NE containing either of the three 
triglycerides, namely hGTO (Vm = 1610 Å
3), hSBO (Vm = 1563 Å
3) or hTPN (Vm = 
1458 Å3), and the two ethyl esters, namely hEO (Vm = 600 Å
3) or hES (Vm = 596 Å
3) 
would be comparable. Correspondingly, the PIT of NE containing hGTO, hSBO or 
hTPN was expected to be higher than those containing hEO or hES. The PIT of 
65hGTO is also much lower than that of 99hGTO which suggests that 65hGTO 
contained smaller molecular volume impurities than 99hGTO. 
Moreover, the changes in PIT are typically explained in terms of the solubilisation of 
the oils of differing volume into the NE droplets. For example, oils with a large 
molecular volume are expected to form a core in the centre of the droplet. (Evans et al., 
1986). A large core of oil in the centre of a NE droplet can provide an additional site to 
solubilise poorly-water soluble drug. It was therefore expected that the higher the molar 
volume of oil-contained in the NE, the greater the solubilisation of drug. 
 
3.2.4 Light scattering investigations by photon correlation spectroscopy 
Calculation of the hydrodynamic radius of a particle from the measured value of the 
diffusion coefficient obtained from photon correlation spectroscopy (PCS) only gives a 
true assessment of size at infinite dilution. The measurement of highly concentrated 
particles leads to problems with the interpretation of the data due to the presence of 
inter-particulate forces and/or the presence of multiple scattering of the laser beam 
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(Muller and Muller, 1984). The consequence of these effects is typically a higher 
diffusion coefficient, and a correspondingly smaller particle radius (Muller and Muller, 
1984; Cheung, 1987). As a consequence therefore, all micelles and NE examined in the 
present study by PCS were diluted in order to increase the distance between droplets 
and decrease the interaction between individual particles (Ganz and Boeger, 1985). 
However, it is worth noting that dilution in (some) NE may change the interfacial 
composition of droplets, leading to a change in the structure or stability of the system 
(Siano et al., 1987) and the possible disappearance of the NE (Hermansky and Mackay, 
1979; Richtening et al., 1988). This was not thought to be a problem in the present 
study due to the absence of a cosurfactant, coupled with the fact that the Brij O10 
surfactant used could prepare the NE exhibited a low cmc. Due to the fact that the 
micelles and NE were not being measured at infinite dilution, the measured Z mean 
diameter is therefore referred to as the apparent hydrodynamic size or diameter (Dh).  
 
3.2.4.1 Effect of Brij O10 concentration on particle size of micelle 
The variation in the Dh of the Brij O10 micellar solutions at different concentrations of 
Brij O10, diluted to 1 %w/w Brij O10, without any added oil were examined by PCS 
(Figure 3.8). For Brij O10 surfactant solutions, the size of the micelles were found to 
be fairly constant at about between 13 – 15 nm. This constant size would be expected if 
the diluted micelles were acting as non-interacting aggregates. In all following studies, 
samples were diluted to 1 %w/w Brij O10 for determination of particle size, unless 
otherwise stated.  
 
 
Figure 3.8: The mean hydrodynamic droplet size of the Brij O10 micellar solution without SBO 
(mean ± S.D.) at 25 °C. All samples were diluted to 1 %w/w Brij O10 for measurement. 
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3.2.4.2 Stability of nanoemulsions 
A range of compositions within the NE area of existence were examined visually for 
any physical change immediately after preparation and after storage for periods of up to 
a month at room temperature. The NE were also examined by PCS for periods of up to 
1 month. The apparent hydrodynamic size showed a good correlation between with NE 
appearance.  
Figures 3.9 and 3.10 give graphs of the variation in the apparent hydrodynamic size 
measured at 25 ºC with varying oil concentration with time after preparation. The PCS 
measurements indicated that, because Dh did not exhibit any significant change, most of 
the samples were stable for at least 1 month. The only exceptions were 85hTPN NE 
containing greater than 12 %w/w oil, 99hTPN NE containing 2 %w/w oil and 99hGTS 
NE containing 1 %w/w oil, where there was a big increase in the apparent 
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Triglyceride Triglyceride purity 
Low purity High purity 
SBO 








d)  e)  
GTS Low purity GTS was not examined. 
f)  
 
Figure 3.9: The mean apparent hydrodynamic droplet size of the oil-in-water nanoemulsions 
containing 20 %w/w Brij O10 and containing either (a) hSBO, (b) 65hGTO, (c) 98hGTO, (d) 
85hTPN, (e) 99hTPN, or (f) 99hGTS at different triglyceride concentrations over a period of up 
to a month (mean ± S.D.) at 25 °C. Samples were diluted to 1 %w/w Brij O10 for measurement. 
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Ethyl ester Ethyl ester purity 
Low purity High purity 
EO Low purity EO was not examined. 
 
 
Figure 3.10: The mean apparent hydrodynamic droplet size of the oil-in-water nanoemulsions 
containing 20 %w/w Brij O10 and containing 98hEO (diluted to 1 %w/w Brij O10 for 
measurement) at different triglyceride concentrations over a period of up to a month (mean ± 
S.D.) at 25 °C. Samples were diluted to 1 %w/w Brij O10 for measurement. Error bars in some 
cases contained within the symbols. 
 
Note that while the appearance and apparent hydrodynamic size of NE containing 8 
%w/w 98hEO changed over time - becoming translucent (from bluish) and larger in size 
- this composition is on the phase boundary between Regions B and C. NE with greater 
than 8 %w/w were not stable and exhibited a phase separation over time. 
 
3.2.4.3 Effect of oil on the particle size of nanoemulsions  
The apparent hydrodynamic droplet size (Dh) of the NE with increasing oil 
concentration was examined at a Brij O10 concentration of 20 %w/w and a temperature 
of 25ºC (diluted to 1 %w/w for measurement). Regardless of the nature and amount of 
oil present, the Dh of the NE droplets fell well within the size range quoted for a NE 
(i.e. an upper limit of 200 nm) with sizes of up to a 100 nm being recorded for NE with 
an oil content within the upper boundary of Region C (Figures 3.11 and 3.12) (Solan et 
al. 2005; Gutierrez et al., 2008). More, however that NE containing 1 %w/w 99hGTS 
and prepared using 20 %w/w Brij O10 exhibited a Dh of 325 nm.  
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(c)  (d) 99hGTS concentration (%w/w)






































Figure 3.11: The mean hydrodynamic droplet size of the 1-month old oil-in-water nano 
emulsions containing 20 %w/w Brij O10 and containing triglyceride either (a) hSBO, (b) 
hGTO, (c) hTPN, or (d) 99hGTS at different triglyceride concentrations (mean ± S.D.) at 25 °C. 
All samples were diluted to 1 %w/w Brij O10 for measurement. Error bars in some cases 




Figure 3.12: The mean hydrodynamic droplet size of the 1-month old oil-in-water 
nanoemulsions stabilised by 20 %w/w Brij O10 and containing ethyl ester, 98hEO at different 
concentrations (mean ± S.D.) at 25 °C. All samples were diluted to 1 %w/w Brij O10 for 
measurement. Error bars in some cases contained within the symbols. 
 
It is of note that, regardless of the oil, NE droplets in Region A tended to be less than 25 
nm in size while those that were in Region B were either bluish or transparent and 
exhibited a size in the range of 25 – 60 nm. For example, the Dh of one-month-old 
samples measured by PCS and prepared using 20 %w/w Brij O10 and containing the 
highest amount of oil in Region A were 19.6  0.9 nm (at 9 %w/w hSBO), 11.1  0.3 
Preparation of Brij O10 nanoemulsions 
117 
nm (at 1 %w/w 65hGTO), 18.1  0.6 nm (at 8 %w/w 99hGTO), 22.8  2.9 nm (at 10 
%w/w 85hTPN) and 14.5  0.1 nm (at 6 %w/w 98hEO).  
The corresponding NE, prepared using the same concentration of Brij O10, and 
containing the highest amount of oil in Region B were 27.2  0.6 nm (at 12 %w/w 
hSBO), 11.0  0.1 nm (at 2 %w/w 65hGTO), 54.0  3.7 nm (at 15 %w/w 99hGTO), 
22.8  2.9 nm (at 10 %w/w 85hTPN), 21.2  0.1 nm (at 4 %w/w 99hGTS) and 96.4  
9.7 nm (at 8 %w/w 98hEO) in size. The corresponding NE containing the highest 
amount of oil in Region C were 50.1  1.3 nm (at 15 %w/w hSBO), 37.7  4.0 nm (at 
16 %w/w 85hTPN), 34.6  3.1 nm (at 16 %w/w 99hTPN) and 72.7  11.2 nm (at 13 
%w/w 99hGTS). 
It is clear that the particle size of NE containing a triglyceride of large molecular 
volume and ethyl ester exhibited first a decrease in apparent hydrodynamic size 
followed by an increase in apparent hydrodynamic size as the level of oil increased 
(Figures 3.11 and 3.12). This fall and subsequent rise in apparent hydrodynamic size 
upon increasing oil concentration is indicative of a change in the shape of the surfactant 
aggregates from ellipsoidal aggregates at low oil concentrations to increasingly 
spherical at higher oil concentrations. The transformation of asymmetric or ellipsoid 
aggregates at low oil concentrations to spherical ones at higher oil concentrations has 
been observed with ME formed by both nonionic and ionic surfactants (Hoffmann and 
Ulbright, 1989).  
The apparent hydrodynamic size of the NE varied approximately linearly with 
triglyceride or ethyl ester concentration in Region A suggesting that a bigger oil core 
was formed upon increasing oil concentration. Interestingly, for NE in Region B and C, 
the apparent hydrodynamic size either slightly increased or sharply increased. For 
example, the apparent hydrodynamic size increased from ~ 20 to 60 nm for NE 
containing either hSBO, 98hGTO, 85hTPN or 99hTPN while the size changed from 20 
to ~ 100 nm for NE containing 99hGTS and 98hEO. This dramatic change in the size of 
the NE between Region B and Region C is indicative of a change in the structure of the 
NE found in Region A, most probably as a consequence of a larger amount of oil being 
present. It is thought that the higher amount of oil in Region B and C leads either to the 
formation of a larger oil core in the centre of NE droplet compared to the NE in Region 
A and/or the formation of a totally different NE structure from the structure of NE in 
Region A. It might reasonably be expected that in the larger sized NE, the interfacial 
surfactant monolayer represents a smaller portion of the NE volume, and as a 
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consequence the oil is more likely to behave a bulk oil. Interestingly, the particle size of 
NE in Region C containing either hSBO or 85hTPN and prepared using 20 %w/w Brij 
O10 were smaller than the corresponding NE examined in an earlier study 
(Wasutrasawat et al., 2013). This result suggested that the batch-to-batch variation of 
the Brij O10 surfactant had an effect on particle size. 
 
3.3 Micelle and nanoemulsion in the presence of hydrophobic 
drugs 
In order to examine the advantage of a NE as a delivery system, two hydrophobic drugs, 
testosterone propionate (TP) and curcumin (CUR), were chosen as drugs. In the present 
study, it is hoped not only to increase the apparent aqueous solubility of both drugs by 
formulating them as o/w NE but also to increase their bioavailability. 
It is worth noting that NE are not inert vehicles for drug because the presence of drug 
may alter NE size, shape and/or stability. This is particularly true if the drug is surface 
active and sits in the interfacial surfactant region as it may disrupt the packing of 
surfactant in this region (Narang et al., 2007). 
 
3.3.1 The incorporation of testosterone propionate 
To investigate the incorporation of hydrophobic drug into a NE, the water-insoluble 
steroid, testosterone propionate (aqueous solubility of 0.0009 ± 0.002 %w/w), of log 
Poct 4.78 was selected as drug (Malcolmson et al., 1998; Craig, 1990). Earlier studies 
reported that Brij 96 ME containing SBO were unaffected by the presence of an excess 
of TP (Malcolmson, 1993). In contrast, however, the presence of the drug, Tacrolimus, 
has an effect on NE particle (Borhade et al., 2008). In the present study, the effect of the 
addition of TP on NE stability was investigated by saturating the NE prepared using 20 
%w/w Brij O10 containing varying amounts of oil with excess TP. After 7, 10 and 14 
days incubation, excess TP was removed from the NE by centrifugation. TP was 
selected for study here as our group have shown that it is possible to prepare ME in 
which its apparent aqueous solubility was increased by careful selection of the 
components used to make the ME (Satra et al., 1995; Malcolmson et al., 1998). 
Example of licensed pharmaceutical formulation for TP include testosterone propionate 
ointment (2 %w/w) and testosterone propionate (50 mg/ml) in ethyl ester for 
intramuscular use (Virormone ®) (Lund W., 1994), both of which were prepared as oil-
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based formulations. The solubility of TP in Brij O10 micelles and 3-component o/w NE 
were compared, and the effect of the drugs on the area of NE existence, apparent 
hydrodynamic size and phase inversion temperature of the NE droplets determined. The 
solubilisation of TP was determined in a range of oil types - namely triglycerides, ethyl esters 
and hydrocarbon oils (Table 3.3). The results of this study suggested that TP is preferentially 
solubilised in the triglycerides or ethyl esters of relatively high polarity in comparison to the 
hydrocarbon oils with relatively low polarity in which the TP is poorly soluble. 
 
Table 3.3 The solubilisation of testosterone propionate in water and various oils (Malcolmson 
et al, 1998).   
 
Sample Drug solubilisation (%w/v) 
DI water 0.0009 ± 0.0002 
Triglycerides 
tributryin 8.78 ± 0.51 
Miglyol 812 6.20 ± 0.44 
Soybean oil 3.42 ± 0.29 
Ethyl esters 
Ethyl butyrate 18.64 ± 0.45 
Ethyl caprylate 12.17 ± 0.68 
Ethyl oleate 5.79 ± 0.40 
Hydrocarbon oils Hexadecane 1.70 ± 0.10 
 Hexadecane 1.74 ± 0.13 
 1-octadecene 1.51 ± 0.01 
 
3.3.1.1 Effect of testosterone propionate on the area of NE existence 
A large number of samples were prepared using Brij O10 and containing varying 
amounts of either triglyceride or ethyl ester. The samples were all within the o/w NE 
region as shown in Figures 3.1, 3.2 and 3.3. When the samples were saturated with the 
drug, their physical appearance did not appear to be affected by the presence of TP, this 
was particularly true for samples in Region A. Furthermore, in no case did the presence 
of TP cause the NE to become cloudy/milky if the NE was initially bluish/translucent or 
to become bluish/translucent if the NE was initially clear. 
It is important to note that, from visual observation, there was no evidence of the 
centrifugation resulting in the precipitation in any NE, either in the presence and 
absence of TP. Stability studies showed that the TP saturated NE prepared with either 
hSBO, 65hGTO, 99hGTO or 98hEO were stable for at least 2 months. In contrast, when 
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TP was added to NE samples containing 85hTPN and 99hTPN they became unstable. 
For example TP-loaded NE containing 14-16 %w/w of either 85hTPN or 99hTPN were 
precipitated within three weeks after preparation, while those containing 8-12 %w/w oil 
were unstable within four weeks and those containing 4-6 %w/w oil within six weeks. 
Significantly, the TP-loaded NE containing either 85hTPN or 99hTPN manifested their 
instability more quickly than the corresponding TP-free NE. The only exceptions to this 
were the TP-loaded NE containing relatively small amounts of TPN, namely 1-2 %w/w, 
which remained stable for at least 2 months, suggesting that the NE containing the 
lower concentrations of triglyceride were more stable. On the other hand, the NE 
containing the higher triglyceride concentrations might not be able to re-arrange to 
accommodate both the TP and triglyceride within their structure. Previous PCS results 
suggested that the 85hTPN incorporated into NE containing 20 %w/w Brij O10 and 
between 2-3 %w/w oil were in a ‘liquid-like’ state (Wasutrasawat et al., 2013). 
Wasutrasawat et al. (2013) showed that NE containing either fluid triglycerides 
exhibited a better long term stability, both in the absence and presence of the lipophilic 
TP drug, when compared to NE containing ‘solid-like’ triglycerides particularly when a 
high amount of solid triglyceride was present and the NE loaded with TP. The high 
stability of NE containing either hSBO, 99hGTO or 98hEO NE, coupled with the 
relatively large NE region exhibited by the NE containing these oils, suggests that these 
NE offer considerable potential as drug delivery vehicles. 
 
3.3.1.2 Effect of testosterone propionate on cloud point and phase inversion 
temperature 
The cloud points (CP) and the variation in the phase inversion temperature (PIT) of 
drug-loaded micellar solutions and NE followed the trend of the corresponding samples 
prepared in the absence of TP (Figures 3.13 and 3.14) suggesting that (some of) TP 
was probably located at the boundary between the hydrophobic and hydrophilic regions 
of the interfacial surfactant monolayer. The differences in the PIT of NE containing 
either hSBO, 65hGTO or 98hEO NE with and without TP was around 5 ºC (p < 0.05). 
A similar difference was also seen between the CP of TP-free micellar solutions and the 
CP of TP-loaded micellar solutions (p < 0.05). On the basis of these results, it is 
proposed therefore that TP was solubilised in the surfactant micelles in a similar way to 
NE containing the oils, hSBO, 65hGTO or 98hEO NE. 
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High purity TPN was not examined. 
 
Figure 3.13: The phase inversion temperature of oil-in-water nanoemulsions containing 
triglyceride, (a) hSBO, (b) 65hGTO, (c) 99hGTO and (d) 85hTPN and stabilised by 20 %w/w 
Brij O10 in H2O and in the absence and presence of testosterone propionate (TP) (mean ± S.D.). 
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Figure 3.14: The phase inversion temperature of oil-in-water nanoemulsions containing ethyl 
ester, 98hEO, and stabilised by 20 %w/w Brij O10 in H2O and in the absence and presence of 
testosterone propionate (TP) (mean ± S.D.). Error bars in some cases contained within the 
symbols. 
 
The decrease in PIT of 99hGTO containing NE loaded with TP compared with the 
corresponding NE in the absence of TP was greater than the difference between the 
measured CP for the TP-free and TP-loaded micellar solutions. This result suggested 
that the amount of TP solubilised in the interfacial surfactant monolayer of 99hGTO 
containing NE was higher than the amount of TP solubilised in the same region in the 
drug-free micelles, possibly as a consequence of the solubility of TP in GTO being so 
low such that more TP tended to sit in the interfacial surfactant monolayer of the NE 
(Wasutrasawat et al, 2013). 
In the case of 85hTPN containing NE, the difference in PIT in NE with and without TP 
was ~ 5 ºC, suggesting that again TP was solubilised at the boundary between the 
hydrophobic and hydrophilic portions of the surfactant monolayer in the TPN-NE. The 
difference between PIT with and without TP increased with increasing content of 
85hTPN (4-6 %w/w 85hTPN). Hence the core of NE containing a higher amount of 
85hTPN were more solid as evidenced by the results of DSC experiments 
(Wasutrasawat et al., 2013). Consequently, the ability of TP to solubilise in the oil core 
were decreased as the amount of 85hTPN increased and thus more TP tends to sit at the 
boundary between the hydrophobic and hydrophilic region of the interfacial surfactant 
monolayer (Wasutrasawat et al, 2013). 
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3.3.1.3 Effect of testosterone propionate on the particle size of Brij O10 micelle and 
nanoemulsions 
Light scattering investigations by photon correlation spectroscopy (PCS) were carried 
out on six NE systems in which a saturation amount of TP had been added in order to 
examine the effect of the TP on the apparent hydrodynamic size of NE containing either 
hSBO, 65hGTO, 99hGTO, 85hTPN, 99hTPN or 98hEO. PCS investigations of the 
equivalent drug-free NE have been previously reported (Figures 3.15 and 3.16). Light 
scattering analysis of the TP saturated NE prepared using 20 %w/w Brij O10 and 
containing the six oils were performed 7 days after the addition of TP, with the excess 
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Triglyceride Triglyceride purity 
 Low purity High purity 
SBO 




b)  c)  
TPN 
d)  e)  
 
Figure 3.15: The mean hydrodynamic droplet size of the 1-month old oil-in-water 
nanoemulsions stabilised by 20 %w/w Brij O10 and containing triglyceride either (a) hSBO, (b) 
65hGTO, (c) 99hGTO, (d) 85hTPN, or (e) 99hTPN at different concentrations in the absence 
and presence of testosterone propionate (TP) (mean ± S.D.) at 25 °C. Samples were diluted to 1 
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Ethyl ester Ethyl ester purity 
Low purity High purity 
EO Low purity EO was not performed. 
 
 
Figure 3.16: The mean hydrodynamic droplet size of the 1-month old oil-in-water 
nanoemulsions stabilised by 20 %w/w Brij O10 and containing ethyl ester, (a) 98hEO at 
different concentrations in the absence and presence of testosterone propionate (TP) (mean ± 
S.D.) at 25 °C. Samples were diluted to 1 %w/w Brij O10 for measurement. Error bar in some 
cases contained within the symbols. 
 
Results of the PCS investigations are shown in Figures 3.15 and 3.16. The apparent 
hydrodynamic size of the NE with and without TP, are plotted as a function of oil 
concentration. In all Region A NE, the apparent hydrodynamic size (Dh) of NE 
containing a saturation amount of TP were slightly larger in those prepared in its 
absence. In region B the only exception was the measured Dh of 99hGTO and 98hEO 
containing NE where there was a significant increase in particle size of TP-saturated NE 
(p < 0.05). In Region C, NE containing either hSBO, 85hTPN or 99hTPN NE were 
significantly larger in the presence of TP (p < 0.05).  This increase in size was 
anticipated due to the presence of drug within the NE droplet. However, it must also be 
noted that (because the added TP had replaced an equivalent weight of water found in 
the drug-free compositions) the volume fraction of the TP-loaded NE droplets was 
larger than the corresponding TP-free compositions increasing the possibility of a 
greater degree of interaction between NE droplets.  
However, the increase in NE size observed in this study was much less than the 
dramatic increase reported by Wasutrasawat et al. (2013) who stated that the Dh of TP 
saturated 85hTPN NE containing 16 %w/w oil was 183.3 ± 3.8 nm compared to the 
71.8 ± 0.3 nm size determined for the corresponding TP-free 85hTPN NE. This result 
showed the effect of batch-to-batch variation of surfactant. 
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3.3.1.4 The solubility of testosterone propionate in micelle and nanoemulsions 
The level of TP incorporation after saturation was investigated in Brij O10 micelles and 
o/w NE containing six oils, namely hSBO, 85hTPN, 99hTPN, 65hGTO, 99hGTO and 
98hEO (Figures 3.17 and 3.18). It can be seen that saturation solubilisation of TP was 
achieved by 7 days. In addition, the results clearly showed that there was a significant 
increase in the amount of TP solubilised in the hSBO, 99hGTO, 85hTPN or 99hTPN 
containing NE system prepared using 20 %w/w Brij O10 compared to corresponding 
micellar systems. It has been reported that the differences in the location of solubilised 
steroid molecules in surfactant micelles depend upon the polarity of the drug (Tomida et 
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Triglyceride Triglyceride purity 
Low purity High purity 
SBO 
Low purity SBO was not available 
commercially. 
a) hSBO concentration (%w/w)
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d) 85hTPN concentration (%w/w)
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Figure 3.17: The solubilisation of testosterone propionate in micelles and oil-in-water 
nanoemulsions stabilised using 20 %w/w Brij O10 and containing triglyceride either (a) hSBO, 
(b) 65hGTO, (c) 99hGTO, (d) 85hTPN or (e) 99hTPN at different concentrations (mean ± S.D.) 
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Low purity High purity 
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Figure 3.18: The solubilisation of testosterone propionate in micelles and oil-in-water 
nanoemulsions stabilised using 20 %w/w Brij O10 and containing ethyl ester, 98hEO at 
different concentrations (mean ± S.D.) at 25 °C. Error bars in some cases contained within the 
symbols. 
 
As can be seen, a significant increase in TP solubilisation was observed with increasing 
triglyceride or ethyl ester concentration in Region A NE. In NE containing 2 %w/w 
triglyceride or ethyl ester, the solubility of TP in the oil phase was deemed insufficient 
to affect any significant increase in TP loading. The only NE containing 2 %w/w oil 
that exhibited a much higher level of incorporation of TP was the NE containing 
99hTPN. In contrast the solubility of TP in NE containing higher amount of oil was 
large enough to allow a significant increase in the amount of TP in the NE when 
compared to the parent micelles. The increase in TP continued with oil concentration 
until Region B, where solubilisation levelled off, whereas in Region C solubilisation 
dramatically decreased (Figures 3.17a, 3.17d and 3.17e). The levelling off in Region B 
and decrease in TP solubilisation in the Region C was unexpected. It had been 
anticipated that NE in these regions would exhibit an increase in TP solubilisation due 
to the high solubility of TP in the oil coupled with the large apparent hydrodynamic size 
of the NE. Possible changes in the structure of the NE at higher triglyceride/ethyl ester 
concentrations maybe responsible for this observation. In particular the results may 
indicate a significant change in the internal structure of the NE resulting in it becoming 
a less favourable environment for TP solubilisation. Small angle neutron scattering 
therefore was used to probe the internal structure of the NE. 
In the PIT experiments, it was seen that the oil with the higher molecular volume 
caused the greatest increase in the PIT, ultimately forming a large oil core in the centre 
of the NE providing an additional locus to solubilise TP. On the basis of these results, it 
was anticipated that the high molar volume oil containing NE would exhibit a greater 
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level of TP solubilisation. The results obtained for TP solubilisation agree with this 
assumption; TP solubilisation was greater in 99hGTO containing NE, which in turn 
were greater than hSBO containing NE, which in turn are greater than the 85hTPN 
containing NE. However, it was unexpected that TP solubilisation in 98hEO containing 
NE was higher than that seen in 85hTPN containing NE. 
Table 3.4 gives a comparison of the experimentally measured TP solubilisation with 
that calculated from the solubilisation of TP in the Brij O10 micelles coupled with the 
amount of oil incorporated in the NE. This comparison shows that the experimentally 
measured TP solubilisation in the NE was higher than the calculated solubilisation, 
which shows the advantage of NE over micelles in improving the apparent TP 
solubilisation. This observation suggests that oil was incorporated in the NE in such a 
way as to improve the solubilisation of TP. 
 







B20 - 0.48 ± 0.03 - 
B20-hSBO1 
A 
0.50 ± 0.05 0.51 
B20-hSBO2 0.72 ± 0.04 0.55 
B20-hSBO4 0.88 ± 0.04 0.62 
B20-hSBO6 0.90 ± 0.08 0.69 
B20-hSBO8 1.10 ± 0.11 0.75 
B20-hSBO9 1.17 ± 0.08 0.79 
B20-hSBO10 
B 
1.08 ± 0.10 0.82 
B20-hSBO12 1.12 ± 0.08 0.89 
B20-hSBO14 1.07 ± 0.07 0.96 
B20-hSBO16 C 0.74 ± 0.08 1.03 
B20-98hEO1 
A 
0.55 ± 0.04 0.54 
B20-98hEO2 0.65 ± 0.03 0.60 
B20-98hEO4 0.79 ± 0.04 0.71 
B20-98hEO6 0.92 ± 0.05 0.83 
B20-98hEO8 B 1.09 ± 0.06 0.94 
 
a calculated from the experimental TP solubilisation in micelle and oil according to amount of oil and surfactant in 
the samples. The solubility of TP in 20 %w/w Brij O10 was 0.48 ± 0.03 %w/v at 25 ⁰C while the solubility of TP in 
hSBO and 98hEO was 3.42 ± 0.29 and 5.79 ± 0.40 %w/v at 25 ⁰C (Malcolmson et al., 1993; Malcolmson et al., 
1998). 
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3.3.2 The incorporation of curcumin 
In order to investigate the incorporation of hydrophobic drug into the NE, the water 
insoluble drug, curcumin was selected. The solubilisation of CUR was determined in a 
range of oils - namely triglycerides, ethyl esters and hydrocarbon oils (Table 3.5). The 
results suggest, that even though CUR is water-insoluble drug, it does not dissolve at 
high levels in the various oils studied. The results indicate that CUR was preferentially 
solubilised in the triglycerides or ethyl esters (i.e. oils with relatively high polarity) in 
comparison to the hydrocarbon oils (i.e. oils with relatively low polarity). Moreover, the 
limited results available suggests that the purity of material had an effect on CUR 
solubilisation in the oil as CUR solubilisation in 60hGTO was higher than that in 
99hGTO. Because the triglycerides and ethyl esters, hSBO and 98hEO respectively, 
exhibited the highest level of CUR solubilisation, both oils were selected for further 
study. 
 
Table 3.5 The solubilisation of curcumin in water and various oils (mean ± S.D.), n = 3. 
 
Sample Drug solubilisation (%w/v) 
 7 days 10 days 14 days 
DI water < 0.0007 - - 
Triglycerides hSBO 0.18 ± 0.03 0.19 ± 0.01 0.20 ± 0.02 
60hGTO 0.12 ± 0.00 - - 
99hGTO 0.07 ± 0.02 - - 
Ethyl ester 60hEO 0.14 ± 0.01 - - 
98hEO 0.14 ± 0.03 - - 
Hydrocarbon oils Hexadecane < 0.0007 - - 
Hexadecene < 0.0007 - - 
 
The effect of the addition of CUR on the stability of the NE containing varying amounts 
of oil was investigated by saturating Brij O10 micelles and NE with an excess of CUR. 
The excess CUR was removed from contact with either micelles or NE after either 7, 10 
or 14 days by centrifugation. The effect of the presence of a saturation amount of CUR 
on the area of NE existence, the phase inversion temperature, and the apparent 
hydrodynamic size was determined. In addition, the solubility of CUR in Brij O10 
micelles and 3-component o/w NE were established. 
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3.3.2.1 Effect of curcumin on the area of NE existence 
A large number of samples of varying hSBO or 98hEO content, all from within Region 
A of the o/w NE area of existence, were prepared in the presence of a saturation amount 
of CUR (Figures 3.1 and 3.3). It is worth commenting that, from visual observation, 
there was no evidence of instability in any of the CUR containing micelles or NE, 
before or after removal of excess CUR. Most of the CUR-containing Brij O10 NE were 
completely clear in Region A (Figure 3.19). Furthermore, most of the CUR saturated 
NE prepared using hSBO or 98hEO were stable for at least 1 month. However, in the 
presence of CUR all the Brij O10 micelles, regardless of surfactant concentration, as 
well as B20-hSBO9-CUR, B20-98hEO1-CUR and B20-98hEO2-CUR NE transformed, 
within 2 weeks of preparation, from clear to turbid. This observation suggests that the 
physical appearance of Brij O10 micelles and Region A, 3-component o/w NE 
produced from hSBO or 98hEO and Brij O10, were affected by the presence of CUR, 
possibly by affecting/disrupting the packing of surfactant and the long term stability of 
the micelles and NE.  
a) b)  
Figure 3.19: The appearance of a) clear nanoemulsions and b) cloudy nanoemulsions in the 
presence of curcumin. 
 
3.3.2.2 Effect of curcumin on cloud point and phase inversion temperature 
The cloud point of B20-CUR micelles at different concentrations of surfactant is 
reported in Figure 3.20. The micelles saturated with CUR showed a decrease in the 
measured cloud point, the precise depression being dependent upon the surfactant 
concentration - in general the difference between the CUR containing and the CUR free 
micelles was around 10 ºC (p < 0.05). These observations suggest that CUR was 
solubilised at the boundary between the hydrophobic and hydrophilic portions of the 
Brij O10 surfactant. Indeed it has been reported, based on 1H NMR spectroscopy and 
confirmed by using transmission electron microscopy (TEM), that the location of CUR 
molecules in the cationic and nonionic mixed surfactant aggregates was predominately 
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in the head region of mixed surfactant system, particularly when compared to core of 
mixed micelle (Kumar et al., 2016). 
 
Figure 3.20: The cloud point of Brij O10 micelles at different surfactant concentrations in the 
absence and presence of CUR (mean ± S.D.), n=3. 
 
The differences in PIT between the SBO-containing NE, B20-hSBO-CUR NE, and 
ethyl oleate-containing NE, B20-98hEO-CUR NE, are shown in Figure 3.21. The PIT 
of B20-hSBO-CUR exhibited a small increase in the PIT upon the increasing amount of 
oil, although surprisingly any increase was extremely small or non-existent when 
compared to the PIT recorded for the drug-free NE, B20-hSBO NE (p > 0.05) (Figure 
3.21a). The absence of any effect of CUR on the PIT of B20-hSBO-CUR suggested that 
CUR might not sit at the boundary between the NE core and head group region and it 
may instead sit in the NE core due to its solubility in SBO. This result was in 
contradiction to that seen for CUR in Brij O10 micelles where the drug was believed to 
sit at the boundary of the core and head group region in the NE. Upon the addition of 
more oil, an increase in the PIT of the CUR-containing NE was observed, which is most 
likely due to the oil resulting in the formation of less ellipsoidal/more spherical 
aggregates. 
The PIT of B20-98hEO-CUR first decreased and then increased upon the increasing the 
amount of EO present. Overall, while the data obtained for the CUR-containing NE 
followed the trend in the variation in PIT with EO content observed for the CUR-free 
NE, there was a small decrease in PIT, of around 2-3 ºC (p < 0.05) (Figure 3.21b). 
These observations suggest that CUR is solubilised in the surfactant boundary of B20-
98hEO, in agreement with the results obtained for the Brij O10 micelles. However, it is 
likely that the amount of CUR present in the core/head group boundary of the NE is 
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lower than that of CUR in the Brij O10 micelles. The decrease and then increase in the 
PIT of the various NE implies that the micellar aggregates were asymmetrical shape. In 
fact, when a low level of oil was incorporated, it is likely that it penetrated the 
interfacial surfactant monolayer, encouraging the formation of asymmetric aggregates, 
which lower the PIT of the NE below that of the corresponding micelle. Upon the 
addition of a further amount of oil, an increase in the PIT of the NE was observed, due 
to the added oil resulting the transformation of asymmetric to spherical aggregates. 
a) b)  
Figure 3.21: The variation in the phase inversion temperature of nanoemulsions stabilised by 
20 %w/w Brij O10 and containing varying amounts of either hSBO or 98hEO and in the 
absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in some cases contained in 
symbol. 
 
3.3.2.3 Effect of curcumin on the particle size of Brij O10 micelle and 
nanoemulsions 
The apparent hydrodynamic size (Dh) of micelles with varying Brij O10 concentrations 
and B20-hSBO and B20-98hEO NE in the presence and absence of CUR was obtained 
using Brookhaven ZetaPlus particle sizer (Figure 3.22). Unexpectedly, the Dh of Brij 
O10 micelles as well as B20-hSBO and B20-98hEO NE exhibited a significant increase 
in Dh in the presence of CUR as assessed using the Brookhaven ZetaPlus particle sizer, 
even though the diluted samples containing CUR were completely clear by eye. The 
measured Dh of B20-CUR was 8 to 9 times larger than that of the corresponding B20 
micelles (Figure 3.22a). Moreover, the measured increase in Dh of both B20-hSBO-
CUR and B20-98hEO-CUR NE did not follow the expected trend of exhibiting an 
increase in size with increasing oil concentration, instead Dh exhibited an irregular 
fluctuation with increasing oil (Figure 3.22b and 3.22c). 
To explore the origin of this unexpected result, the diluted samples were re-filtered 
through a 0.45 um polyethersulfone (PES) filter (Jet biofil, Guangzhou, China) before 
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re-examination by PCS to ensure the absence of dust in the samples, however the Dh of 
micelles or NE samples still exhibited an irregular variation in size (data was not 
shown). As the Brookhaven nanosizer was fitted with a red laser, it was necessary to 
ensure that the yellow, CUR-containing samples were not absorbing the beam by 
checking that the beam remained as a thin red line as it passed through the NE. In 
addition, the clear, 4-sided, 10-mm path length disposable polystyrene cuvette typically 
used for PCS measurements was replaced by a 4-sided, 1-cm path length quartz cuvette, 
normally used for fluorescence spectroscopy, to ensure that a chemical reaction was not 
occurring between the samples and the container which might affect particle size. 
`however, none was seen and the measured Dh varied in an irregular manner as before. 
Finally, size measurement of the samples was performed using the Malvern Nano ZS 
Zetasizer, which exploited a scattering angle of 173° while the Brookhaven ZetaPlus 
particle sizer used a scattering angle of 90°. 
a) b)  
c)  
Figure 3.22: The mean hydrodynamic droplet size measured using a Brookhaven ZetaPlus 
particle sizer of a) Brij O10 micelles prepared using different surfactant concentrations and 
nanoemulsions prepared using 20 %w/w Brij O10 and different concentrations of either b) 
hSBO or c) 98hEO in the absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in 
some cases contained in symbol. 
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The apparent hydrodynamic size (Dh) of Brij O10 micelles with varying surfactant 
concentration as well as B20-hSBO, and B20-98hEO NE prepared in the absence and 
presence of curcumin using Malvern Nano ZS Zetasizer is shown in Figure 3.23. 
While, the Dh of the Brij O10 micelles, and B20-hSBO and B20-98hEO NE containing 
CUR still exhibited a fluctuation in the value Dh, these fluctuations were less than those 
seen with the Brookhaven nanosizer. This observation might suggest that CUR could 
interact with Brij O10 resulting in an increase in the size of the micelles and NE. An 
alternative explanation is that CUR might be incorporated into and link 2 micelle or 2 
NE droplets leading to a miss-interpretation of the PCS data leading to a larger apparent 
size. As a consequence of these results it was decided to perform small-angle neutron 
scattering (SANS) studies on the systems to try and understand these randomly variable 
results. 
 
a) b)  
c)  
Figure 3.23: The mean hydrodynamic droplet size measured using a Malvern Nano ZS 
Zetasizer of a) Brij O10 micelles prepared using different surfactant concentrations and 
nanoemulsions prepared using 20 %w/w Brij O10 and different concentrations of either b) 
hSBO or c) 98hEO in the absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in 
some cases contained in symbol. 
 
Note that the Dh of B20-hSBO-CUR is 
not shown because by 7 days there was 
not enough of the sample to be measured 
using the Malvern instrument. 
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3.3.2.4 The solubility of curcumin in micelle and nanoemulsions 
The solubilisation of curcumin (CUR) in micelles prepared using different surfactant 
concentrations is shown in Figure 3.24. It is clear that the CUR reached saturation level 
in the micelles by 7 days, solubilisation at earlier times were not measured. 
Furthermore, the solubility of CUR increased, in an approximately linear fashion, with 
increasing Brij O10 concentration up to 20 %w/w.  
 
Figure 3.24: Variation in the level of solubilisation of curcumin in Brij O10 micelles of 
different surfactant concentration (mean ± S.D.). Error bars in some cases contained within 
symbol. 
 
The variation in the solubilisation of CUR in different concentrations of Brij O10 
micelles, B20-hSBO and B20-98hEO NE is shown in Figure 3.25. Again the results 
indicated that CUR saturated the samples within 7 days, shorter time courses were not 
measured. Surprisingly, the solubilisation of CUR in the NE did not increase 
significantly, over the corresponding micelles suggesting that the presence of oil did not 
have positive effect on the solubilisation of CUR. This observation can be explained by 
the low level of CUR solubility in both of the oils, hSBO and 98hEO, meaning that 
there was no benefit in the addition of oil, in terms of solubilisation.  
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a) b)  
Figure 3.25: Variation in the solubilisation of curcumin in 20 %w/w Brij O10 micelles and 
nanoemulsions prepared using 20 %w/w Brij O10 and containing varying amounts of either a) 
hSBO or b) 98hEO (mean ± S.D.). Error bars in some cases contained in symbol. 
 
Table 3.6 Comparison of experimentally obtained and predicted curcumin (CUR) solubilisation  
 
Sample Region Experimentally measured CUR 
solubilisation in B20-hSBO-CUR (%w/v) 
Predicted CUR solubilisation in 
B20-hSBO-CUR (%w/v) a 
B20 - 0.58 ± 0.02 - 
B20-hSBO1 
A 
0.49 ± 0.03 0.58 
B20-hSBO2 0.53 ± 0.02 0.58 
B20-hSBO4 0.54 ± 0.02 0.59 
B20-hSBO6 0.55 ± 0.02 0.59 
B20-hSBO8 0.58 ± 0.03 0.59 
B20-hSBO9 0.60 ± 0.03 0.60 
B20-98hEO1 
A 
0.54 ± 0.02 0.58 
B20-98hEO2 0.57 ± 0.02 0.58 
B20-98hEO4 0.58 ± 0.03 0.59 
B20-98hEO6 0.59 ± 0.03 0.59 
a
 calculated from the experimental CUR solubilisation in the Brij O10 micelles and oil according to amount of oil 
and surfactant contained in the samples. The solubility of CUR in 20 %w/w Brij O10 was 0.58 ± 0.02 %w/v at 25 °C 
while the solubility of CUR in hSBO and 98hEO was 0.18 ± 0.03 and 0.14 ± 0.03 %w/v at 25 °C.   
 
As it was possible to predict the expected level of CUR solubilisation in the NE from a 
knowledge of the level of solubilisation of CUR in B20-CUR and its solubility in the 
oils of interest, here SBO and EO (Table 3.6) it is possible to compare the predicted 
solubilisation with that experimentally measured. This comparison showed that the 
experimental CUR solubilisation in NE containing a small amount of oil was less than 
the predicted solubilisation. This result indicated that formulation of CUR in NE did not 
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yield the anticipated advantages, most probably because the oil was incorporated in NE 
in a manner that did not lead to an improved solubilisation of CUR. It is therefore useful 
to perform small angle neutron scattering studies to establish the internal structure of 
the NE. 
 
3.3.3 The incorporation of curcumin and testosterone propionate 
To investigate the behaviour of two hydrophobic drugs when incorporated into the same 
NE, curcumin (CUR) and testosterone propionate (TP) were selected as drugs. The 
effect of the addition of CUR and TP on the stability of the NE containing varying 
amounts of hSBO as a representative oil, was investigated by saturating B20-hSBO 
with CUR and TP. Excess drug was removed from the NE after 7, 10 and 14 days by 
centrifugation allowing the solubility of CUR and TP in Brij O10 micelles solutions and 
B20hSBO-CUR-TP to be established. The effect of the presence of both drugs on the 
area of NE existence, phase inversion temperature and particle size of the NE were also 
determined. 
 
3.3.3.1 Effect of curcumin and testosterone propionate on the area of NE existence 
A large number of NE of varying hSBO content within Region A were produced 
containing saturation amounts of both CUR and TP (Figures 3.1). It is important to 
note that, from visual observation, there was no evidence of the precipitation in any of 
the NE, either in the presence and absence of CUR and TP, after centrifugation 
suggesting that presence of both drugs did not immediately de-stabilise the NE. In 
addition, the physical appearance of the B20hSBO-CUR-TP NE did not appear to be 
detrimentally affected by the presence of CUR and TP as they were stable for at least 1 
month. The NE in Region A containing as saturation amount of CUR and TP were 
completely clear systems, suggesting that it was possible to incorporate a saturation 
amount of CUR and TP without any visible effect the area of NE existence. The high 
stability of the B20-hSBO-CUR-TP NE and the relatively large NE region they 
exhibited supports the potential of B20-hSBO NE as drug delivery vehicles. 
Interestingly, while B20-hSBO-CUR-TP NE exhibited good stability of NE, the B20-
hSBO-CUR NE did not, suggesting that the presence of TP stabilised the NE. 
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3.3.3.2 Effect of curcumin and testosterone propionate on cloud point and phase 
inversion temperature 
The CP of B20-CUR-TP micelles and the PIT of B20-hSBO-CUR-TP NE at various 
hSBO concentrations are shown in Figure 3.26. The B20-CUR-TP NE exhibited a 
decrease in cloud point, in comparison with the corresponding CUR-TP-free micelles 
which was around 13 ºC less than the CP of CUR-TP-free micelles and indeed the 
solution and CUR-TP-saturated micelles (p < 0.05).. This finding indicates that CUR 
and possibly TP were solubilised at the boundary between the hydrophobic and 
hydrophilic portions of the Brij O10 surfactant micelle.  
The differences in PIT of B20-hSBO-CUR-TP NE are shown in Figure 3.26. The PIT 
of B20-hSBO-CUR-TP NE containing hSBO concentrations of 2 %w/w and above, was 
only slightly less than the PIT recorded for the CUR-TP-free samples (p < 0.05). As 
with the micelles, this result suggests that CUR and possibly, TP might sit at the 
hydrophilic and hydrophobic boundary of the surfactant monolayer. Finally, the 
observed increase in the PIT suggested that more spherical aggregates of NE were 
formed as the amount of oil increased. 
 
 
Figure 3.26: Cloud point of 20 %w/w Brij O10 micelles and phase inversion temperature of 
corresponding nanoemulsions containing varying amounts of hSBO in the absence and presence 
of curcumin (CUR) and testosterone propionate (mean ± S.D.). Error bars in some cases 
contained in symbol. 
 
3.3.3.3 Effect of curcumin and testosterone propionate on the particle size of Brij 
O10 micelles and nanoemulsions 
The apparent hydrodynamic size (Dh) of micelles of varying Brij O10 concentration as 
well as B20-hSBO NE in the absence and presence of CUR and TP measured using 
Brookhaven ZetaPlus particle sizer and Malvern Nano ZS Zetasizer is shown in Figure 
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3.27. The Dh of the hSBO-containing NE measured using the Brookhaven ZetaPlus 
particle sizer demonstrated a significant increase in the Dh measured for CUR-
containing samples at low oil concentrations, namely 4-6 %w/w hSBO. At higher oil 
concentrations, the Dh of CUR-containing samples started to decrease (i.e. size 
increased), even though the diluted samples containing CUR were completely clear. 
Indeed the Dh of the B20-hSBO4-CUR-TP and B20-hSBO6-CUR-TP NE was 6 to 8 
time larger than that of the micelles in the absence of the two drugs (Figure 3.27a).  
a) b)  
Figure 3.27: The variation in the mean hydrodynamic droplet size with the surfactant 
concentration of the Brij O10 micelles and nanoemulsions prepared using 20 %w/w Brij O10 
and containing different concentrations of hSBO in the absence and presence of curcumin and 
testosterone propionate (mean ± S.D.) using a) Brookhaven ZetaPlus particle sizer and b) 
Malvern Nano ZS Zetasizer. Error bars in some cases contained in symbol. 
 
As before, the diluted samples were re-filtered through a 0.45 um polyethersulfone 
(PES) filter (Jet biofil, Guangzhou, China) to ensure the absence of dust in the samples 
before their re-examination by PCS. However, the Dh of micelles or NE stills showed 
the significant increase (data not shown). As before, the laser was checked to ensure 
that it remained thin and red upon passage through the yellow coloured NE. 
Additionally, the clear, 4-sided, 10-mm path length disposable polystyrene cuvette 
generally used for PCS measurement was exchanged with a 4-sided clear 1-cm path 
length quartz cuvette used for fluorescence spectroscopy measurements, to ensure that 
there was no chemical reaction occurring between the NE and the container which 
would have affected the measurement of NE size. The Dh of the NE remained high and 
variable suggesting that the plastic nature of the measurement cells was not the reason 
for the irreproducible size measurements. Once again, NE size was measured using the 
Malvern Nano ZS Zetasizer, which exploited a scattering angle of 173° as opposed to 
the usual Brookhaven ZetaPlus particle sizer which utilised a scattering angle of 90°. 
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The apparent hydrodynamic size (Dh) of the B20 micelles and B20-hSBO NE in the 
absence and presence of CUR and TP, measured using a Malvern Nano ZS Zetasizer is 
shown in Figure 3.27b. As was seen when using the Brookhaven particle sizer, the Dh 
of the drug containing micelles, B20-CUR-TP and drug containing B20-hSBO-CUR-TP 
NE exhibited an increase when measured using a Malvern Nano ZS Zetasizer. In order 
to gain a fuller understanding of these unpredictable size effects, the size of B20-hSBO-
CUR-TP NE will be assessed using small-angle neutron scattering (SANS). 
 
3.3.3.4 The solubility of curcumin and testosterone propionate in micelle and 
nanoemulsions 
The ultra-violet (UV) absorbance spectra of CUR and TP in isopropanol is shown in 
Figure 3.28. It was clear that both CUR and TP absorbed UV light at 240 nm while in 
contrast only CUR absorbed UV light at 428 nm. Here UV-vis spectroscopy was used 
to analyse the amount of CUR and TP in the micelle and NE in the presence of CUR 
and TP.  
a) wavelength (nm)





















































Figure 3.28: Ultra-violet absorbance spectra of a) curcumin (CUR) and b) testosterone 
propionate (TP) in isopropanol (n = 9 at each concentration studied). 
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Figure 3.29 shows the variation in absorbance of curcumin over the concentration 
range of 0.00007-0.00070 %w/v in isopropanol at wavelengths of 240 nm (Figure 
3.29a) and 428 nm (Figure 3.29b). The calculated extinction coefficient for CUR in 
isopropanol at wavelengths of 240 and 428 nm were 13509 and 54445 M-1 cm-1, 
respectively. The extinction coefficient of CUR in isopropanol obtained in this study of 
55445 M-1 cm-1 at wavelength of 428 nm was similar to the extinction coefficient 
reported in previous studies (Waranyoupalin et al., 2009; Zsila et al., 2003; Jasim and 
Ali, 1989). Specifically an extinction coefficient of 49,370 M-1cm-1 for CUR in in 
methanol/H2O (1:1 v/v) of at wavelength of 428 nm have been reported by 
Waranyoupalin et al. (2009). Zsila et al (2003) noted an extinction coefficient of 55,000 
M-1 cm-1for CUR in ethanol at wavelength of 429 nm while Jasim and Ali (1989) 
quoted values of 67,680 and 54,954 M-1 cm-1 in methanol and ethanol, respectively at 
428 nm. Figure 3.30 shows the variation in the absorbance of testosterone propionate 
over the concentration range of 0.0005-0.0030 %w/v in isopropanol at wavelength of 
240 nm. The extinction coefficient of 16722 M-1 cm-1 determined in this study for TP in 
isopropanol at wavelength of 240 nm, was reassuring similar to an extinction coefficient 
of 17400 M-1 cm-1 reported for TP in ethanol by Sigma Aldrich. 
In order to determine the solubilisation of CUR and TP in samples containing both 
drugs, the absorbance of CUR at 428 nm was used to estimate the incorporation of CUR 
in the B20-hSBO-CUR-TP NE after which the absorbance of TP at 240 nm was 
estimated by subtracting from the total absorbance at this wavelength, the predicted 
absorbance for CUR at 240 nm, calculated using the ratio of 0.25 for the absorbance of 
CUR at 240:428 nm. A ratio of 0.25 was calculated by dividing the extinction 
coefficient of CUR at a wavelength of 240 nm by the extinction coefficient of CUR at 
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a) CUR concentration (%w/v)
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R2 = 0.9999 
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Figure 3.29: The absorbance of curcumin concentration in isopropanol at 0.00007-0.00070 
%w/v at the wavelength of a) 240 nm and b) 428 nm, respectively (n = 9 at each 
concentration studied). Extinction coefficient of curcumin at 240 and 428 nm were 13509 and 
54445 M-1 cm-1, respectively. Error bars in some cases contained within the symbols. 
 
a) TP concentration (%w/v)


















y = 485.39 + 0.0011
R2 = 1
 
Figure 3.30: The absorbance of testosterone propionate concentration in isopropanol at 
0.0005-0.0030 %w/v at the wavelength of a) 240 nm (n = 9 at each concentration studied). 
Extinction coefficient of testosterone propionate at 240 nm was 16722 M-1 cm-1. Note that TP 
does not absorb UV light at 428 nm. Error bars in some cases contained within the symbols. 
 
The solubilisation of CUR and TP in B20-hSBO after saturation with both drugs for 7, 
10 and 14 days are shown in Figure 3.31. The results showed that the CUR could 
saturate in all samples within 7 days (shorter time periods not measured), while TP 
could reach the saturation between 10-14 days. Figure 3.32 shows the solubility of (a) 
CUR measured in the absence and presence of TP and (b) TP measured in the absence 
and presence of CUR in B20-hSBO NE saturation with drug for 7 days. It was clear that 
B20-hSBO NE containing saturation amounts of both CUR and TP could incorporate 
more CUR than could be incorporated in B20-hSBO NE in the absence of TP. Similarly 
much less TP was solubilised in B20-hSBO NE containing CUR compared to those in 
which CUR was absent. Taken together these results suggest that the presence of TP 
had a positive effect on the solubilisation of CUR in NE. 
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a) b)  
Figure 3.31: Solubilisation over time of a) curcumin (CUR) and b) testosterone propionate (TP) 
in hSBO-containing NE prepared using 20 %w/w Brij O10 and containing varying amounts of 
hSBO and saturated with both curcumin and testosterone propionate (mean ± S.D.). Error bars 
in some cases contained within symbol. 
a) b)   
Figure 3.32: Solubilisation at 7 days of a) curcumin (CUR) and b) testosterone propionate (TP) 
in hSBO-containing NE prepared using 20 %w/w Brij O10 and containing varying amounts of 
hSBO and saturated with both curcumin and testosterone propionate (mean ± S.D.). Error bars 
in some cases contained within the symbol. 
 
Table 3.7 shows the comparison between the experimentally measured TP and CUR 
solubilisation with the expected level of solubilisation of TP and CUR. The expected 
level of TP or CUR solubilisation was calculated from the level of TP and CUR 
solubilisation in B20 and their solubility in the oils that comprise the NE is shown in 
Table 3.7. This comparison showed that the experimentally measured TP solubilisation 
in B20-hSBO NE containing both saturated amount of CUR and TP and containing low 
levels of hSBO (2-4 %w/w) was greater than that predicted. These results show that 
CUR-containing NE improve the solubilisation of TP. At higher hSBO concentrations, 
namely 6-9 %w/w, the experimentally determined TP solubilisation in NE was lower 
than that predicted, which showed that the presence of CUR could affect the amount of 
TP solubilised in the NE. 
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On the other hand, the experimentally measured level of CUR solubilisation in B20-
hSBO NE saturated with both CUR and TP and containing a low level of oil 
incorporated was similar to that level predicted for CUR solubilisation in NE. This 
observation indicated that formulation in a NE did not an advantageous effect on the 
solubilisation of CUR in NE and that the presence of hSBO did not improve the 
solubilisation of CUR. Interestingly, however, the level of CUR solubilisation in B20-
hSBO NE containing saturation amounts of both CUR and TP was higher than in the 
corresponding NE containing only CUR, indicating that the presence of TP could 
improve the solubility of CUR in the NE. On the basis of these solubilisation studies, it 
is likely that performing SANS studies would be beneficial in that they would enable 
the internal structure of the NE to be probed. 
 
Table 3.7 Comparison of the experimentally determined and predicted testosterone propionate 





















hSBO-CUR-TP   
(%w/v) a 
0 0.48 ± 0.08 - 0.61 ± 0.03 - 
2 0.66 ± 0.11 0.51 0.58 ± 0.04 0.58 
4 0.90 ± 0.08 0.55 0.65 ± 0.03 0.59 
6 0.59 ± 0.08 0.62 0.61 ± 0.05 0.59 
8 0.59 ± 0.03 0.69 0.62 ± 0.03 0.59 
9 0.53 ± 0.08 0.75 0.61 ± 0.04 0.60 
a calculated from the experimentally determined solubilisation of CUR in a micelle and the bulk oil according to 
amount of oil and surfactant in the NE. The solubility of CUR in 20 %w/w Brij O10 was 0.58 ± 0.02 %w/v at 25 ⁰C 
while the solubility of CUR in hSBO was 0.18 ± 0.03 %w/v at 25 ⁰C.   
b calculated from the experimentally determined TP solubilisation in a micelle and the bulk oil according to amount 
of oil and surfactant in the NE. The solubility of TP in 20 %w/w Brij O10 was 0.48 ± 0.03 %w/v at 25 ⁰C while the 
solubility of TP in hSBO was 3.42 ± 0.29 %w/v at 25 ⁰C (Malcolmson et al., 1993; Malcolmson et al., 1998). 
 
 
3.3.4 Comparison of physico-chemical properties of NE in the absence and 
presence of hydrophobic drugs 
The cloud point of B20 micelles and the phase inversion temperature of B20-hSBO NE, 
both dispersed in H2O, in the absence and presence of TP, CUR and both TP and CUR 
are shown in Figure 3.33. Table 3.8 gives the solubility of TP and CUR in B20 
micelles and B20-hSBO NE containing different amounts of hSBO. It was found that 
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the CP of the micelles increased in the order of B20-CUR-TP < B20-CUR < B20-TP < 
B20, whereas the level of drug solubility in micelles was CUR solubility (0.61 %w/v) 
and TP solubility (0.48 %w/v) in B20-CUR-TP > CUR solubility (0.58 %w/v) in B20-
CUR > TP solubility (0.48 %w/v) in B20-TP > B20. The decrease in the cloud point of 
the micelles was due to the incorporation of hydrophobic drugs, most likely at the 
boundary between the micelle core and its head group. The results of the CP and drug 
solubilisation studies indicated that the presence of both CUR and TP had an effect on 
the CP of the micelle. 
In contrast, the order of the PIT of the NE was B20-hSBO-TP < B20-hSBO-CUR-TP < 
B20-hSBO-CUR = B20-hSBO. The PIT studies indicated that only TP in NE decreased 
the PIT of NE while in contrast the presence of CUR in NE had little or no effect on the 
PIT of NE. The order of drug solubility in the NE was CUR solubility (0.58 %w/v) and 
TP solubility (0.66 %w/v) in B20-hSBO2-CUR-TP > TP solubility (0.72 %w/v) in B20-
hSBO2-TP NE > CUR solubility (0.53 %w/v) in B20-hSBO2-CUR > B20-hSBO2. 
Taken together the PIT and drug solubilisation studies imply that the site of 
incorporation of CUR and TP in micelles might result in differences in the phase 
behaviour of NE. 
 
Figure 3.33: The cloud point of 20 %w/w Brij O10 micelles and phase inversion temperature of 
nanoemulsions containing hSBO and prepared using 20 %w/w Brij O10 and in the absence and 
presence of testosterone propionate (TP), curcumin (CUR), and both testosterone propionate 
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Table 3.8 The solubility of testosterone propionate and curcumin in micelles and 
nanoemulsions prepared using 20 %w/w Brij O10 and containing different amounts of hSBO 
(mean ± S.D). 
 
Oil concentration  
(%w/w) 
The solubilisation  
of TP in  
B20-hSBO-TP  
(%w/v) 
The solubilisation  
of CUR in  
B20-hSBO-CUR  
(%w/v) 
The solubilisation  
of TP in  
B20-hSBO-CUR-TP  
(%w/v) 
The solubilisation  
of CUR in 
B20-hSBO-CUR-TP  
(%w/v) 
0 0.48 ± 0.03 0.58 ± 0.02 0.48 ± 0.08 0.61 ± 0.03 
2 0.72 ± 0.04 0.53 ± 0.02 0.66 ± 0.11 0.58 ± 0.04 
4 0.88 ± 0.04 0.54 ± 0.02 0.90 ± 0.08 0.65 ± 0.03 
6 0.90 ± 0.08 0.55 ± 0.02 0.59 ± 0.08 0.61 ± 0.05 
8 1.10 ± 0.11 0.58 ± 0.03 0.59 ± 0.03 0.62 ± 0.03 
9 1.17 ± 0.08 0.60 ± 0.03 0.53 ± 0.08 0.61 ± 0.04 
 
3.4 Effect of deuterated materials on the physico-chemical 
properties of Brij O10 micelles and nanoemulsions 
It has been reported that there is a significant isotope effect observed on the cloud point 
and phase boundary when H2O is replaced with D2O in a solution containing a mixed 
alkylglucoside surfactant (Whiddon and Soderman, 2001). Subsequent to the exchange 
of H for D on the hydroxyl groups of the surfactant’s glucose head groups, the 
combination of the increased hydrophobicity of the surfactant in D2O and changes in 
the hydrogen bond strength and length result in an isotope effect. In case a similar effect 
was occurring in the micelles and NE under examination here, a series of studies on the 
physico-chemical properties of micelles and NE in D2O was performed and the results 
compared to those obtained in NE in H2O. These studies included determining the area 
of NE existence, the cloud point/phase inversion temperature and particle size. It was 
important that these isotope studies were performed prior to the small angle neutron 
scattering experiments. 
 
3.4.1 Effect of deuterated water on the area of existence of Brij O10 nanoemulsion 
Three component NE systems were prepared using commercially available protiated 
triglyceride/ethyl ester and Brij O10 (C18:1E10) in D2O and their stability examined at 
room temperature. The area of NE existence was determined by varying the amount of 
each component and plotting the results on a weight basis on a ternary phase diagram in 
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order to understand the phase behaviour of the NE formulations in D2O (Figures 3.34-
3.35 and Table 3.9). On the abscissa, surfactant concentration (in %w/w) increases 
from left to right while on the ordinate, oil concentration (in %w/w) increases from 
bottom to top. It can be seen that the appearance of NE samples prepared in D2O is the 
same area of NE existence as that of NE prepared in H2O, suggesting that under the 













Figure 3.34: Partial ternary phase diagrams for o/w nanoemulsions formed using protiated 
triglyceride and Brij O10 in either D2O or H2O after 1 month storage at room temperature. Clear 
NE are described as Region A NE, while bluish or translucent NE as Region B NE and cloudy 
or milky NE as Region C NE. 
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Figure 3.35: Partial ternary phase diagrams for o/w nanoemulsion formed with ethyl ester and 
Brij O10 in either D2O or H2O after 1-month storage at room temperature. Clear NE are 
described as Region A NE, while bluish or translucent NE are called Region B NE, and the 
cloudy or milky NE were denoted as Region C NE. 
 
Table 3.9 The upper limit of oil (%w/w) incorporation into nanoemulsions prepared using Brij 
O10 and D2O in Regions A, B and C which were stable for 1 month 
 
Type Sample 5% Brij  
O10 
10% Brij  
O10 
15% Brij  
O10 
20% Brij  
O10 
25% Brij  
O10 
30% Brij  
O10 
A B C A B C A B C A B C A B C A B C 
Triglyceride hSBO, D2O 1.4 2 4 2.3 7 8 5 12 15 9 14 16 7.5 10 11 - - - 
65hGTO, 
D2O 
- 0.5 1 0.5 1 - 1 - - 1 2 - 2 3 - - 0.5 2 
99hGTO, 
D2O 
1 3 4 3 7 8 5 8 - 8 15 - 6 8 15 - 2 5 
85hTPN, D2O 1 3 5 3 5 9 3 10 14 6 11 18 10 12 16 - - 1 
Ethyl ester 98hEO, D2O 1 - 8 2 3 - 5 - - 6 8 - 4 5 - - 2 - 
 
- means the NE was not formed. 
 
3.4.2 Effect of deuterated water on the cloud point and phase inversion 
temperature 
Pandit and Caronia studied the effect on the cloud point of Triton X-100 of replacing 
H2O with D2O (Pandit and Caronia, 1987) and reported that while the trend of the cloud 
points measured in H2O and D2O were similar, the value of the cloud points determined 
in D2O were consistently ~ 4 °C lower than those measured in H2O. These results were 
in agreement with those reported by other workers who found that replacing H2O with 
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D2O leads to a widening of the miscibility gap, i.e. the region of composition or 
temperature in which a composition of mixtures form two phases (Schon et al., 1986).  
The same phenomena of a widening miscibility gap is exhibited by many 
polyoxyethylated nonionic surfactant systems. For example the CP of the C12E5 in D2O 
was 2 K lower than the same surfactant in H2O (Martin et al., 1996). In addition, a 
similar effect of deuteration on clouding temperature was exhibited by the zwitterionic 
surfactant, 2-decyldimethylammonioethane sulphate (DES), where it was found that the 
CP of DES in D2O was 8 °C higher than that measured in H2O (Nilsson et al., 2004). 
Note that zwitterionic surfactants cloud upon decreasing temperature as opposed to 
increasing temperature as recorded for nonionic surfactants. This observation suggests 
that H2O and D2O have a different effect on the conformation of the self-assembled 
surfactant structures. As a consequence, it is necessary to study the effect of H2O and 
D2O on the CP of the micelles and the phase inversion temperature of NE prior to 
SANS measurements.  
 
Figure 3.36: The cloud point of Brij O10 micelles as a function of concentration (%w/w) in 
D2O. 
 
The CP of different concentrations of Brij O10 micelles prepared in D2O is shown in 
Figure 3.36. As anticipated the same variation in the trend in the cloud point was seen 
when replacing H2O with D2O in that the CP of Brij O10 micelle in D2O increases with 
the increasing surfactant concentration (Figure 3.5). Furthermore, in agreement with 
the results of Pandit and Caronia (Pandit and Caronia, 1987), the value of the CP 
recorded for D2O and H2O were different, with the CP of the surfactant in D2O being ~ 
3 °C lower than that recorded in H2O (p < 0.05). 
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The phase inversion temperature (PIT) of 20 %w/w Brij O10 NE containing different 
amounts of either hSBO, 65hGTO, 99hGTO, 85hTPN, or 98hEO are shown in Figures 
3.37 and 3.38. Again the trend in the variation of the PIT of the NE prepared in D2O 
was comparable with that of the corresponding NE prepared in H2O (Figures 3.6 and 
3.7). The PIT of Brij O10 NE in D2O first decreased with increasing oil concentration 
and then increased upon the addition of further oil. Again, as anticipated there was a 
difference in the value of the PIT reported for the NE prepared in D2O and H2O, with 
the NE dispersed in D2O exhibiting the lower cloud point (p < 0.05). However, the use 
of D2O in place of H2O is not thought to affect the morphology of the NE which was 
important for the SANS experiments, which were predominately performed at 25 °C, 
although a few NE containing hSBO, were measured at 37 °C, because the CP of the 
micelle and the PIT of NE is significantly higher than the experimental temperature 
used.  
a) b)
c) d)   
Figure 3.37: The variation in the phase inversion temperature of nanoemulsion  prepared using 
20 %w/w Brij O10 and containing a triglyceride, (a) hSBO, (b) 65hGTO, (c) 99hGTO and (d) 
hTPN and in either D2O or H2O (mean ± S.D.). Error bars in some cases contained within the 
symbol. 
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Figure 3.38: The variation in the phase inversion temperature of nanoemulsion prepared using 
20 %w/w Brij O10 and containing the ethyl ester oil, 98hEO in either D2O or H2O (mean ± 
S.D.). Error bars in some cases contained within the symbol. 
 
3.4.3 Effect of deuterated water on the particle size determined by photon 
correlation spectroscopy (PCS) 
In order to ensure that D2O does not grossly change the morphology of the micelle and 
NE, the size of the micelles and NE by PCS at 25 °C. Such measurements were 
important because it has been reported that substitution of H2O by D2O can affect 
micelle size, such as was reported for micelles formed by the alkyl glycoside surfactant, 
n-nonyl-β-D-glucoside (β-C9G1) (Ericsson et al., 2004). The same research group also 
studied the aggregation of the related sugar surfactant, n-tetradecyl-β-D-maltoside 
(C14G2), determining particle size using photon correlation spectroscopy (PCS), and 
again found that the particle size of the micelles in D2O were larger than those in H2O 
(Ericson et al., 2005). 
Therefore, to evaluate the effect of D2O on the particle size of the aggregates prepared 
in the present study, PCS was employed to measure the particle size of all micelles and 
NE prior to their study by SANS. Figures 3.39 and 3.40 shows the apparent 
hydrodynamic size of the NE in D2O at 25 °C after 1-month storage and compares their 
size to that obtained for the samples prepared in H2O and measured under the same 
conditions. It was clear that replacing the H2O with D2O did not significantly affect the 
particle size, or indeed stability, of micelles and NE as determined by PCS. 
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a) b)
c) d)  
Figure 3.39: The variation in the mean apparent hydrodynamic droplet size of 1 month old 
nanoemulsions prepared using 20 %w/w Brij O10 and containing a triglyceride, (a) hSBO, (b) 
65hGTO, (c) 99hGTO and (d) hTPN and in either D2O or H2O (mean ± S.D.). Error bars in 
some cases contained within the symbol. 
 
 
Figure 3.40: The variation in the mean apparent hydrodynamic droplet size of 1 month old 
nanoemulsions prepared using 20 %w/w Brij O10 and containing the ethyl ester, 98hEO and in 
either D2O or H2O (mean ± S.D.). Error bars in some cases contained within the symbol. 
 
3.5 Small angle neutron scattering data 
The first step in the analysis of SANS data is an initial estimation of the shape of the 
NE particles. The SANS data were therefore analysed using a range of different form 
factors, P(Q), in order to determine the shape of the aggregates. The different form 
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factors selected to fit that SANS data for the micelles and NE where a sphere, an oblate 
or a prolate ellipsoid (Figure 3.41). In all these models, the interparticulate structure 
factor, S(Q), used was the Percus-Yevick approximation to account for hard-sphere 
interactions present in the system. In order to analyse the SANS data, the micelles and 
NE were assumed to be monodisperse and of a uniform scattering length density (SLD). 
 
Figure 3.41: Schematic representation of a) a sphere, b) an oblate ellipsoid and c) a prolate 
ellipsoid. 
 
The model used for the micelles examined in this study assumes the existence of a core-
shell particle, with the core containing the hydrocarbon chains of the surfactant only 
and a shell composed of the surfactants polar head groups together with some solvent 
molecules. In contrast, the model used for the NEs, where more than one contrast was 
frequently available, was slightly different in that it was assumed that the core of the 
NE consisted only of oil, while the shell consisted of the whole surfactant molecule 
along with any associated solvent. In this case each contrast was fitted separately but 
the parameters used had to be consistent with the other models. 
Clearly, the SANS data could not be satisfactorily fitted using simple form factors such 
as spheres, while in contrast, the data could be reasonably well fitted using prolate 
ellipsoids for the Brij O10 micelles and oblate ellipsoids for the Brij O10 NEs. It is 
clear from this preliminary study that the particles were not spherical but rather were 
ellipsoidal in nature. As a consequence of these preliminary results, a core-shell 
ellipsoid model was chosen as standard to analyse this SANS data in the present study 
as it appeared to be the most appropriate way to describe the SANS data, yielding 
statistically better results in comparison to the spherical model. 
 
3.5.1 SANS studies of Brij O10 micelle in the presence and absence of drug 
A series of the best fits to the data were obtained using the core-shell ellipsoidal model 
for the Brij O10 micelles at various concentration, as shown in Figure 3.42. Note that Q 
Preparation of Brij O10 nanoemulsions 
155 
and I(Q) are scattering vector and the intensity of the scattered neutron radiation, 
respectively. As can be seen, the scattering intensity increased with the increasing 
surfactant concentration. Furthermore the shape of the curve maintained a similar shape 
at a surfactant concentration up to 5 %w/w. Above this concentration, a peak appears in 
the scattering curve at a Q value of 0.06 Å-1, which is indicative of the presence of 
strong inter-particulate interactions. In addition the apparent volume of the micelles 
decreased as the Brij O10 concentration increased. However, the structure factor, S(Q), 
obtained from samples at Brij O10 concentration above 2 %w/w was not equal to 1, 
which further indicates the presence of inter-particulate interactions at higher 
concentrations. Taken together this information suggests that, at concentrations above 2 
%w/w, the interactions were too strong and too long range to be described by the simple 
hard-sphere model, and/or also possibly because of an elongation of the micelles, the 
model fails to describe the interactions present in the elongated micelles present at the 
higher surfactant concentrations. As a consequence therefore, a Brij O10 concentration 
of 2 %w/w was used to prepare NE for the remaining part of the SANS study.  
a) b)  
Figure 3.42: Drop contrast of SANS data and the ‘best’ fits for Brij O10 micelle droplets with 
increasing surfactant concentration from a) 0.1 to 5 %w/w and b) 10 to 20 %w/w at 25 ˚C using 
a core-shell ellipsoid model together with a hard sphere model for interactions. 
 
The dimensions obtained from the best fits to the SANS data for the Brij O10 micelles, 
namely, the core equatorial radius, the minor radius, the major radius and the shell 
thickness are listed in Table 3.10. It is noteworthy that there was no remarkable 
difference result observed between the different surfactant concentrations, in that the 
micelles remained the same size and shape between Brij O10 concentrations of 0.1-5 
%w/w Brij O10 when the core equatorial radius was around 22.5-23.0 Å and the core 
axial ratio of ~ 3.0, suggesting that the Brij O10 micelles were prolate ellipsoid in 
shape. The shell thickness obtained from these fits was 10.5-11.0 Å with 30 % of the 
shell being D2O, while the minor and major radii were 33.0-33.5 Å and 76.0-83.0 Å, 
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respectively. Overall, the size of the Brij O10 micelles at concentrations of between 1-5 
%w/w remained similar with the trend seen upon increasing surfactant concentration 
being the same as that seen with the variation in apparent hydrodynamic size of the 
micelles determined using PCS. The aggregation number of Brij O10 micelles were in 
the range 254-276, while the equivalent hard sphere (SPH) radius was 82.0-93.0 Å. A 
schematic representation of the ellipsoidal Brij O10 micelles seen at a concentration of 
2 %w/w is shown in Figure 3.43. At Brij O10 concentrations of above 10 %w/w, where 
the inter-particulate interactions where greatest, the micelles surprisingly became more 
spherical, while the core equatorial radius remained the same, the core axial ratio 
decreased to 1.6. 
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Table 3.10 Parameters obtained for the best fit to the SANS data for 0.1, 0.2, 0.5, 1, 1.5, 2, 5, 10, 15, 20 %w/w Brij O10 micelles in the absence of drugs using a 
core-shell ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore, along with 
the percentage of solvent in shell at 30%. 
 








































B0.1d 22.6 2.9 66.2 10.5 33.1 76.6 2.3 350701 83.3 30 254 61 526 
B0.2d 22.7 3.0 67.8 10.6 33.3 78.4 2.4 364972 83.8 30 262 60 1440 
B0.5d 23.0 2.9 65.5 10.6 33.6 76.2 2.3 361059 87.7 30 261 60 8552 
B1d 22.8 3.0 69.0 10.9 33.7 79.9 2.4 379742 87.9 30 270 60 22917 
B1.5d 22.7 3.1 70.7 11.0 33.7 81.8 2.4 389705 81.7 30 274 60 35868 
B2d 22.6 3.2 72.0 11.0 33.6 83.0 2.5 393141 92.7 30 276 60 43473 
B5d 22.1 3.3 73.0 10.9 33.0 83.8 2.5 382361 86.8 30 269 61 35316 
B10d 23.0 2.1 48.5 10.3 33.3 58.8 1.8 272491 65.0 30 192 62 42416 
B15d 23.3 1.7 39.7 9.9 33.2 49.5 1.5 228472 51.5 30 162 63 24440 
B20d 22.7 1.6 35.6 9.7 32.4 45.3 1.4 199171 47.9 30 138 65 72778 
 
 
Estimated uncertainty for R1 and x were ± 0.2 and ± 0.05, respectively. 
 
Figure 3.43: Schematic representation of the ellipsoidal 2 %w/w Brij O10 micelles. 
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Surprisingly, the prolate ellipsoid shape of Brij O10 micelles determined in the present 
study was in direct contrast to the oblate ellipsoids previously reported by Wasutrasawat 
(2011). This observation might be the result of batch-to-batch variations in the C18:1E10 
surfactant. However, the volume of one Brij O10 micelle at 25 °C was calculated to be 
~ 350-393 nm3, which was a little bigger than the volume of 271-302 nm3 at 25 °C 
calculated by Wasutrasawat (2011) and 324 nm3 at 20 °C reported by Prak et al. (2011). 
This observation showed that even though the shape of Brij O10 micelles were different 
in each study, but the volume of micelles were comparable. 
The SANS data and the best fits for 2 %w/w Brij O10 micelles in the presence of a 
saturated amount of drug, namely testosterone propionate (TP), curcumin (CUR), and 
curcumin in combination with testosterone propionate (CUR-TP) are shown in Figure 
3.44 and Table 3.11. A schematic representation of the ellipsoidal Brij O10 micelles 
together with either TP, CUR, or CUR-TP is shown in Figure 3.45. It is found that the 
presence of TP and CUR-TP slightly affected the size and shape of the micelles. 
According to the best fits, the core radius increased from 22.6 ± 0.2 Å for the micelles 
(B2d) to 23.0 ± 0.4 Å for the micelles containing a saturation amount of TP (B2d-TP) 
and 23.4 ± 0.4 Å for micelles containing a saturation amount of CUR and TP (B2d-
CUR-TP), while the minor radius very slightly changed from 33.6 Å for B2d to 34.3 Å 
for B2d-TP and 34.6 Å for B2d-CUR-TP, the major radius increased from 83.0 Å for 
B2d to 87.0 Å for B2d-TP and 88.0 Å for B2d-CUR-TP. The very small change in the 
axial ratio (x) from 3.2 ± 0.05 for B2d to 3.3 ± 0.05 for B2d-TP and 3.3 ± 0.05 for B2d-
CUR-TP shows that the shape of micelle was not greatly affected by the addition of TP 
or CUR-TP. In addition, the shell thickness remained relatively constant at ~ 11.0 Å for 
B2d, B2d-TP and B2d-CUR-TP. Interestingly, the small increase in size of B2d-CUR-
TP as determined by SANS is not in good agreement with the large increase in size 
observed for the CUR and TP containing B2d micelles determined by PCS. This 
apparent discrepancy may suggest a limitation of PCS to measure particle size and/or 
the absence of any correction for inter particulate interactions. 
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a) b)  
Figure 3.44: SANS curves obtained for drop contrast of 2 %w/w Brij O10 micelles a) in the 
absence and presence of TP, b) in the presence of either CUR or CUR-TP, along with the ‘best’ 
fits to the data.  
 
In contrast, the presence of CUR alone significantly affected the shape of B2 micelles 
according to the SANS measurements. According to the best fits to the SANS data, 
there was a large change in the axial ratio of the micelles from 3.2 ± 0.05 to 3.7 ± 0.05 
in the presence of CUR, while the core radius remained approximately the same at 22.5 
Å for B2d micelles to 22.7 ± 0.2 Å for B2d-CUR micelles as did the shell thickness, 
which was ~ constant at 11.0 Å for both B2d and B2d-CUR micelles. In addition, the 
minor radius stayed constant at ~ 33.5 Å for B2d and B2d-CUR micelles, although the 
major radius increased from 83.0 Å for B2d micelles to 94.5 Å for B2d-CUR micelles. 
Taken together these results suggest that the presence of CUR affects the shape of the 
B2 micelles. The change in shape of the B2d micelles in the presence of CUR measured 
with SANS might suggest the reason why the measured PCS indicated an increase in 
the size of the micelles containing CUR. This result might be a consequence of the fact 
that the PCS measurements assumed the presence of spherical micelles, while the SANS 
measurements clearly indicated that the shape of the B2d-CUR micelles were oblate 
ellipsoid. 
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Table 3.11 Parameters obtained for the best fit to the SANS data for 2 %w/w Brij O10 micelles in the presence of drugs using a core-shell ellipsoid model together 
with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore, along with the percentage of solvent in shell at 
30%. 
 








































B2d-TP 23.0 3.3 75.7 11.3 34.3 87.0 2.5 428894 92.8 30 302 59 51192 
B2d-CUR 22.7 3.7 83.6 11.1 33.7 94.7 2.8 450887 98.2 30 323 59 25903 
B2d-CUR-TP 23.4 3.3 76.8 11.2 34.6 88.0 2.5 441479 98.4 30 317 58 59207 
 
Estimated uncertainty for R1 and x were ± 0.4 and ± 0.05, respectively. 
 
a) b) c)  
Figure 3.45: Schematic representation of the ellipsoidal 2 %w/w Brij O10 micelles containing with either a) TP, b) CUR or c) CUR and TP. 
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The parameters obtained for the best fit to the SANS data for NE in the absence and presence of 
drugs are shown in Tables 3.12-3.15 for the SBO NE, Tables 3.17-3.18 for the GTO NE, Table 
3.20-3.21 for the TPN NE, Table 3.23 for the GTS NE and Table 3.24-3.25 for the EO NE. The 
parameters obtained for the best fit to the SANS data for the NE performed at 37 °C are shown 
in Table 3.27, while those for NE incubation in the presence of cell culture media at 37 °C are 
shown in Table 3.28-3.29. 
 
3.5.2 SANS studies of Brij O10 nanoemulsions  
3.5.2.1 SANS studies of Brij O10 nanoemulsions containing soybean and drug 
A range of models (form factors) were used to fit the drop contrasts of the B2-hSBO NE 
(prepared using hSBO, hBrij O10, D2O) at different concentration of hSBO in Regions 
A, B and C. It was clear from the preliminary modelling that the best fit to the SANS 
data was an ellipsoid, with an axial ratio of the core of less than 1, suggesting the 
presence of an oblate ellipsoid, the same shape as reported for SBO NE in an earlier 
study (Wasutrasawat, 2011). The SANS data and the ‘best’ fits of the B2-hSBO NE 
obtained using the core-shell ellipsoid model are shown in Figure 3.46 while Table 
3.12 shows the parameters obtained from the ‘best’ fits of the SANS data.  
a) b)  
c)  
Figure 3.46: SANS data and ‘best’ fits using the oblate ellipsoid model for the drop contrast of 
NE prepared using 2 %w/w Brij O10 and containing various concentration of hSBO from a) 0.2 
- 0.6 %w/w, b) 0.8 - 1.0 %w/w and c) 1.2-1.6 %w/w in the absence of drug. SANS data of NE 
performed on SANS2D with the rear detector positioned at 8 m showed a wider Q range than 
that of NE performed on SANS2D with the rear detector positioned at 4 m. 
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Table 3.12 Parameters obtained for the ‘best’ fit of the SANS data to 2 %w/w Brij O10 and hSBO nanoemulsions in the absence of drug using a core-shell ellipsoid 
model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant  
(Å2) 






27.0 0.4 10.5 24.8 51.8 35.3 0.7 397912 55.7 20 256 74 5347 
B2-hSBO0.4d 36.1 0.4 16.1 22.6 58.7 38.7 0.7 559854 58.5 15 351 78 13950 
B2-hSBO0.6d 46.7 0.5 21.9 22.2 68.9 44.1 0.6 878496 73.0 10 534 73 3816 
B2-hSBO0.8d 60.4 0.4 25.0 22.3 82.7 47.3 0.6 1353642 82.7 10 764 71 7301 
B2-hSBO0.9d 66.9 0.4 26.1 22.0 88.9 48.1 0.5 1591197 95.9 10 868 72 9978 
B2-hSBO1.0d 
B 
71.8 0.4 28.1 21.9 93.7 50.0 0.5 1839135 91.9 10 970 72 4689 
B2-hSBO1.2d 91.1 0.3 29.0 21.8 112.9 50.8 0.5 2712089 116.1 10 1342 72 15191 
B2-hSBO1.4d 124.6 0.2 28.1 21.8 146.3 49.9 0.3 4475604 150.4 10 2085 73 42635 
B2-hSBO1.6d C 165.5 0.2 27.2 21.3 186.7 48.5 0.3 7089159 192.5 10 3134 76 84407 
 
Estimated uncertainty for R1 was ± 0.2 for B2-hSBO0.2d to B2-hSBO0.8d and then increased to ± 1.5 for B2-hSBO1.6d in the absence of drug.  
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The results obtained suggest that no significant interactions occurred between the 
diluted NE droplets as expected. As can be seen the core equatorial radius of the NE 
increased with hSBO content, a trend which was similar to that seen with dynamic light 
scattering. The shell thickness obtained from the ‘best’ fits were in the range 21.5-25.0 
Å. After attempting to fit the SANS data using various levels of hydration of the B2-
hSBO NE, the best value of shell hydration for the various hSBO-containing NE was 
found to decrease with an increase in SBO from 20 % for hSBO1 NE to 10 % for 
hSBO0.5 NE and higher SBO concentrations. Surprisingly, the shape of the NE became 
more elongated as the oil content increased. Figure 3.47 gives a schematic 
representation of the NE containing the upper limit possible of hSBO in a) Regions A, 
b) Region B and c) Region C in the absence of drug. 
 
a)  b)   
c)  
Figure 3.47: Schematic representation of ellipsoidal 2 %w/w Brij O10 NE containing the upper 
limit possible of hSBO incorporated in a) Regions A, b) Region B and c) Region C in the 
absence of drug. 
 
The major radius of B2-hSBO NE in Region A NE increased from 35.5 Å for B2-
hSBO0.2d NE to 48.0 Å for B2-hSBO0.9d NE, while the minor radius of B2-hSBO NE 
in Region A NE increased with increasing hSBO concentration from 52.0 Å for B2-
hSBO0.2d NE to 89.0 Å for B2-hSBO0.9d NE. However, the major radius of B2-hSBO 
NE in Regions B and C NE stayed constant at around 50 Å, while the minor radius of 
B2-hSBO NE in Region B and C NE increased with the increasing hSBO concentration 
from 93.5 Å for the B2-hSBO1.0d NE to 187.0 Å for the B2-hSBO1.6d NE.  
After using a range of form factors to try to individually fit the drop contrast of B2-
hSBO-TP, B2-hSBO-CUR and B2-hSBO-CUR-TP NE containing different 
concentrations of hSBO in Regions A, B and C for B2-hSBO-TP NE and in Region A 
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for B2-hSBO-CUR and B2-hSBO-CUR-TP NE, it was clear that there was no 
difference in the shape and size of the NE in the absence and presence of drug. The 
SANS data and ‘best’ fits of the NE with the upper limit of amount of hSBO 
incorporated into NE denoted in Regions A, B and C are shown in Figure 3.48. 
 
a)  b)  
c)  
Figure 3.48: SANS data together with the ‘best’ fits using oblate ellipsoid model obtained for 
the drop contrast of 2 %w/w Brij O10 NE containing the upper limit of hSBO incorporated in a) 
Region A, b) Region B, and c) Region C in the absence and presence of drug.  
 
The SANS data and ‘best’ fits obtained for B2-hSBO-TP, B2-hSBO-CUR and B2-
hSBO-CUR-TP NE using the core-shell ellipsoid model are shown in Figures 3.49, 
3.50 and 3.51, respectively. The parameters obtained for the ‘best’ fits to the B2-hSBO-
TP, B2-hSBO-CUR and B2-hSBO-CUR-TP NE are shown in Tables 3.13, 3.14 and 
3.15. The results suggest that no significant interaction occurred between droplets as 
was expected in the diluted NE system.   
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a)  b)  
c)  
Figure 3.49: SANS data and corresponding ‘best’ fits to the drop contrast of 2 %w/w Brij O10 
and hSBO nanoemulsions with increasing hSBO content from a) 0.2 - 0.6 %w/w, b) 0.8 - 1.0 
%w/w and b) 1.2 - 1.6 %w/w in the presence of TP.  
 
 
Figure 3.50: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 
O10 and hSBO nanoemulsions with increasing hSBO content from 0.2 - 0.9 %w/w in the 
presence of CUR.  
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Figure 3.51: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 
O10 and hSBO nanoemulsions with increasing hSBO content from 0.2 - 0.9 %w/w in the 
presence of CUR and TP. 
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Table 3.13 Parameters obtained for the ‘best’ fit of the SANS data to 2 %w/w Brij O10 and hSBO nanoemulsions in the presence of TP using a core-shell ellipsoid 
model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore.  
 










































26.9 0.4 10.4 24.5 51.1 34.8 0.7 401462 56.6 20 245 75 4521 
B2-hSBO0.4d-TP 38.2 0.4 15.5 23.0 61.1 38.4 0.6 601965 71.9 15 377 76 1644 
B2-hSBO0.6d-TP 48.5 0.4 21.4 22.4 70.9 43.8 0.6 923486 75.5 10 561 72 2720 
B2-hSBO0.8d-TP 59.7 0.4 25.9 22.5 82.2 48.4 0.6 1370239 90.6 10 774 70 1631 
B2-hSBO0.9d-TP 68.5 0.4 26.1 22.3 90.9 48.4 0.5 1675591 95.3 10 914 70 9594 
B2-hSBO1.0d-TP 
B 
71.8 0.4 29.0 22.5 94.3 51.5 0.5 1918142 98.5 10 1016 69 6200 
B2-hSBO1.2d-TP 93.6 0.3 29.8 22.4 116.0 52.2 0.5 2943671 115.9 10 1456 69 14861 
B2-hSBO1.4d-TP 129.1 0.2 29.0 22.5 151.6 51.5 0.3 4961346 151.7 10 2312 70 38118 
B2-hSBO1.6d-TP C 169.4 0.2 27.9 21.8 191.2 49.7 0.3 7615899 198.7 10 3353 74 78879 
 
Estimated uncertainty for R1 remained at ± 0.2 for B2-hSBO0.2d-TP to B2-hSBO0.8d-TP and then increased to ± 1.5 for B2-hSBO1.6d-TP.  
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Table 3.14 Parameters obtained for the ‘best’ fit of the SANS data to 2 %w/w Brij O10 and hSBO nanoemulsions in the presence of CUR using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant  
(Å2) 






26.0 0.4 10.8 24.6 50.6 35.3 0.7 379227 56.1 20 244 75 2825 
B2-hSBO0.4d-CUR  37.9 0.4 15.9 23.2 61.1 39.1 0.6 610497 67.2 15 383 75 1601 
B2-hSBO0.6d-CUR  49.0 0.4 20.9 22.3 71.3 43.2 0.6 920774 73.5 10 559 72 1684 
B2-hSBO0.8d-CUR 60.9 0.4 24.4 22.1 83.0 46.4 0.6 1340070 83.8 10 757 72 6812 
B2-hSBO0.9d-CUR 67.5 0.4 25.3 21.8 89.3 47.1 0.5 1573771 95.0 10 858 73 11073 
 
Estimated uncertainty for R1 and x were ± 0.3 and ± 0.01, respectively. 
 
Table 3.15 Parameters obtained for the ‘best’ fits of the SANS data to 2 %w/w Brij O10 and hSBO nanoemulsions in the presence of CUR and TP using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant  
(Å2) 






26.7 0.4 10.7 24.9 51.6 35.6 0.7 396259 55.8 20 255 73 4282 
B2-hSBO0.8d-CUR-TP 62.1 0.4 23.8 22.0 84.1 45.8 0.5 1358766 87.4 10 767 72 7648 
B2-hSBO0.9d-CUR-TP 69.1 0.4 24.8 21.8 91.0 46.6 0.5 1615925 97.6 10 881 73 10969 
 
Estimated uncertainty for R1 and x were ± 0.3 and ± 0.01, respectively. 
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As can be seen from the ‘best’ fit parameters obtained using an oblate ellipsoid, the 
SANS results showed a slight difference in the size and shape of the NE in the presence 
and absence of TP (Table 3.13). As expected, the equatorial core radius of the B2-
hSBO-TP NE increased with hSBO content, exhibiting a similar trend to that seen in the 
B2-hSBO NE. After fitting the SANS data with varying levels of shell hydration, the 
shell hydration of the hSBO NE was found to decrease from 20 % at B2-hSBO0.2d-TP 
NE to 10 % at B2-hSBO0.6d-TP NE and remained at 10 % for higher hSBO 
concentrations. The shell thickness obtained from the ‘best’ fits was in the range 21-
24.5 Å.  
As the concentration of hSBO increased within Regions A and B, the solubilisation of 
TP in the B2-hSBO-TP NE also increased, no doubt because of the larger equatorial 
core radius and the high solubility of TP in the hSBO comprising the core. The shape of 
the Region C NE containing TP and a high amount of hSBO was unexpected as it 
became more elongated as the content of hSBO increased as it was anticipated that NE 
would be more spherical in shape due to their high hSBO loading and the anticipated 
low penetration of the large molecular volume oil, SBO, into the interfacial surfactant 
monolayer. Interestingly, however, this change in morphology explains the decrease in 
observed TP solubilisation in Region C - because in this Region there is less of a 
distinct core of oil in which TP can be solubilised.  
Within Region A, the major radius of B2-hSBO-TP NE increased upon increasing 
hSBO concentration from 35.0 Å for B2-hSBO0.2d-TP NE to 48.5 Å for B2-
hSBO0.9d-TP NE, while the minor radius of B2-hSBO-TP NE changed from 51.0 Å for 
B2-hSBO0.2d-TP NE to 91.0 Å for B2-hSBO0.9d-TP NE for the same increase in 
hSBO concentration. In Regions B and C, the major radius of B2-hSBO-TP NE was 
unaltered by the amount of hSBO present, staying constant at ~ 50 Å while the minor 
radius increased with increasing hSBO content from 94.5 Å for B2-hSBO1.0d-TP NE to 
191.0 Å for B2-hSBO1.6d-TP NE. When comparing the SANS data there was no 
difference in shape and/or size of TP-free and TP-containing NE, a result that was in 
direct contrast to the results obtained from PCS experiments. It is worth noting, that in 
this context, the analysis used for the PCS measurements assumed that the NE droplets 
were spherical, although from the SANS data the shape of B2-hSBO-TP NE were not 
spherical.  The assumption of sphericity in the case of PCS, might explain the 
discrepancy between the two techniques, in particular the apparently larger size of the 
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B2-hSBO-TP NE in Regions B and C when compared with the size of the B2-hSBO NE 
when assessed by PCS. 
In order to illustrate the change in shape reduces the capacity of NE to solubilise 
hydrophobic drug, the volume and the surface area of the equivalent ellipsoid and 
sphere are shown in Table 3.16. In this study it was reasonably assumed that TP would 
sit in the oil core and at the surfactant interface. As a consequence therefore the volume 
in which TP could be solubilised is the volume of the oil core and the volume of the 
surfactant hydrocarbon tails. Figure 3.52 shows the schematic representation of an 
ellipsoidal SBO NE droplet.  
 
Figure 3.52: The schematic representation of ellipsoidal nanoemulsion containing soybean oil 
with the equatorial radius of the core (R1), major radius of ellipsoid core (xR1) and the length of 
the surfactant hydrocarbon tail (lc) 
 
The minor radius of equivalent ellipsoid is the sum of the length of the equatorial radius 
of the core (R1) and the length of the surfactant hydrocarbon tail (lc) calculated to be 
17.3 Å by Malcolmson et al. (1995), i.e. R1+lc. The major radius of ellipsoid is the 
length of the axial radius of the core (xR1) and the length of surfactant hydrocarbon tail 
(xR1 + lc). Both of these values were used to calculate the volume of oblate ellipsoid in 
which the drug was solubilised. The volume and surface area of ellipsoid were 
calculated using the following formula: 
 
 
The radius of the equivalent sphere is the equatorial radius of the core (R1) obtained 
from the fitting of the SANS data for NE and the length of the surfactant hydrocarbon 
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tail (lc) calculated to be 17.3 Å by Malcolmson et al. (1995), i.e. R1+lc. The volume and 
surface area of sphere were calculated using the following formula: 
 
 
It is clear from the volume and surface area of the equivalent ellipsoid were much lower 
than those of the corresponding sphere, suggesting that a change in the shape of the NE 
from sphere to ellipsoid would affect the drug solubilisation capacity of NE (Table 
3.16). 
 
Table 3.16 The comparison of the volume and the surface area of ellipsoid and sphere of 2 
%w/w Brij O10 and hSBO nanoemulsions in the presence of TP 
 
sample region ellipsoid sphere 
 volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
ellipsoid 
(Å3) 
volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
sphere 
(Å3) 















































As can be seen from the parameters obtained for the best fit, the SANS results showed a 
slight difference in size and shape of NE droplets in the presence and absence of CUR 
(Table 3.14). As expected, the core equatorial radius of the B2-hSBO-CUR NE 
increased with hSBO content - a trend which was similar to that seen for the 
corresponding B2-hSBO NE in the absence of CUR. The shell thickness obtained from 
the fits decreases from 24.5 to 22.0 Å with hSBO concentration. After attempting to fit 
the SANS data using a range of hydration levels, the best fits to the data yielded a shell 
hydration for hSBO-CUR NE which decreased from 20 % for B2-hSBO0.2d-CUR NE 
to 10 % for B2-hSBO0.6d-CUR NE whereafter it remained at 10 % regardless of any 
Preparation of Brij O10 nanoemulsions 
172 
increase in hSBO concentration. Again the model which provided the best fit to the 
SANS data was an ellipsoid. The axial ratio of the core suggested that the shape of B2-
hSBO NE was an oblate ellipsoid. In Region A NE, the major radius of B2-hSBO-CUR 
NE increased from 35.5 Å for B2-hSBO0.2d-CUR NE to 47.0 Å for B2-hSBO0.9d-
CUR NE, while the minor radius of B2-hSBO-CUR NE changed from 51.0 Å for B2-
hSBO0.2d-CUR NE upon increasing hSBO concentration to 89.5 Å for B2-hSBO0.9d-
CUR.   
Interestingly, although the equatorial radius of the core of B2-hSBO-CUR NE increased 
with increasing hSBO content, the solubilisation of CUR in B2-hSBO-CUR remained 
unaltered. This observation may be explained by the poor solubility of CUR in hSBO, 
particularly when compared to the very much higher solubility of TP in hSBO. 
Moreover, the shape and size of the B2-hSBO-CUR NE obtained from the SANS 
experiments was not significantly different from that of B2-hSBO NE. On the other 
hand, using PCS the size of B2-hSBO-CUR NE were significantly larger and exhibited 
a fluctuation with increasing hSBO content. This observation suggests again that there 
is a limitation using PCS for the size measurement of CUR-containing hSBO NE. 
As can be seen from the fitting parameters, the SANS results showed a slight difference 
in size and shape of NE droplets in the presence and absence of CUR-TP (Table 3.15). 
As expected, the core equatorial radius of the B2-hSBO-CUR-TP NE increased with 
hSBO content, a trend which was similar to B2-hSBO NE. After fitting SANS data with 
varying levels of the hydration in shell for each NE sample, the shell hydration of 
hSBO-CUR-TP NE was found to decrease from 20 % for B2-hSBO0.2d-CUR-TP NE 
and remained at 10 % at other higher hSBO concentrations. The shell thickness 
obtained from the fits stayed the same at about 25.0 Å to 22.0 Å. It was clear that the 
model that provided the best fit to the SANS data was an ellipsoid. The axial ratio of the 
core suggested that the shape of B2-hSBO-CUR-TP NE was an oblate ellipsoid. In 
Region A NE, the major radius of B2-hSBO-CUR-TP NE changed from 35.5 Å for B2-
hSBO0.2d-CUR-TP NE to 46.5 Å for B2-hSBO0.9d-CUR-TP NE and the minor radius 
of B2-hSBO-CUR-TP NE increased from 51.5 Å for B2-hSBO0.2d-CUR-TP NE to 
91.0 Å for B2-hSBO0.9d-CUR-TP NE with the increasing hSBO.   
Even though the core equatorial radius of B2-hSBO-CUR-TP NE increased with 
increasing hSBO content, the level of CUR solubilisation in B2-hSBO-CUR-TP NE 
was little higher than that in B2-hSBO-CUR NE while the solubilisation of TP in B2-
hSBO-CUR-TP NE was less than that that of TP in B2-hSBO-TP NE. The small 
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increase in CUR solubilisation could be explained by the low CUR solubility in hSBO 
while the presence of CUR could result in a decrease of TP solubilisation in B2-hSBO-
CUR-TP NE. Moreover, the shape and size of B2-hSBO-CUR-TP NE obtained from 
SANS was not any larger than that of B2-hSBO NE. This observation suggests that 
there is a limitation of PCS in the measurement of the particle size of CUR and TP-
containing hSBO NE. 
 
3.5.2.2 SANS studies of Brij O10 nanoemulsions containing triolein in the absence 
and presence of drug 
The use of a range of models to individually fit the three contrasts of B2-GTO NE at 
different concentration of GTO in Region A and B was explored. The SANS data and 
best fits to the SANS data for B2-GTO NE when fitted with a core-shell ellipsoid model 
are shown in Figures 3.53-3.54, while Table 3.17 shows the parameters obtained from 
the best fits. The results indicated that no significant interaction occurred between the 
droplets as was expected in the diluted NE. As anticipated the core equatorial radius of 
the NE increased with GTO content, a trend which was similar to that seen with PCS. 
Fitting the SANS data for GTO NE using various levels of shell hydration, showed that 
shell hydration decreased from 35 % for GTO0.05 to 30 % for GTO0.2 to 20 % for 
GTO0.4 then to 15 % for GTO0.6 and remained at 10 % for GTO1.0 and higher GTO 
concentrations. The thickness of the shell determined for GTO NE from the best fit 
ranged from ~ 25.0-26.0 Å for B2-65hGTOd NE, 22.0-27.0 Å for B2-99hGTOd NE, 
27.0-32.0 Å for B2-98dGTOc NE to 18.0-27.0 Å for B2-98dGTOs NE.        
a) b)  
Figure 3.53: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing the 
maximum amount of 65hGTO, in the absence of drug in a) Region A and b) Region B. Shell 
contrast for 2 %w/w Brij O10 NE containing 98dGTO was multiplied by the factor of 10. 
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a) b)
Figure 3.54: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing the 
maximum amount of 99hGTO, in the absence of drug in a) Region A and b) Region B. Shell 
contrast for 2 %w/w Brij O10 NE containing 98dGTO was multiplied by the factor of 10. Note 
that best fits to shell contrast for 2 %w/w Brij O10 NE containing 0.8 %w/w 98dGTO and 
higher concentrations of 98dGTO were not well fitted to the SANS data. 
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Table 3.17 Parameters used to obtain the individual ‘best fits’ to the SANS results for 2 %w/w Brij O10 and GTO nanoemulsions in the absence of drug using a 
core-shell ellipsoid model in combination with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
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surfactant 
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25.0 0.1 2.1 25.8 50.7 27.8 0.5 300052 51.5 35 168 90 75874 
B2-99hGTO0.05d 20.6 0.1 2.8 26.8 47.4 29.6 0.6 278353 50.7 35 155 82 2142 
B2-98dGTO0.05c 19.3 0.2 4.0 30.9 50.3 34.9 0.7 369888 56.8 35 207 60 209 
B2-98dGTO0.05s 19.5 0.1 2.8 26.6 46.1 29.4 0.6 262135 47.3 35 146 83 11450 
B2-65hGTO0.1d 24.5 0.2 4.5 25.7 50.3 30.2 0.6 320548 51.9 35 176 88 6360 
B2-99hGTO0.1d 20.2 0.3 6.2 26.6. 46.8 32.8 0.7 300820 50.7 35 165 82 1804 
B2-98dGTO0.1c 22.9 0.3 7.1 31.0 53.9 38.1 0.7 464469 58.0 35 255 60 132 
B2-98dGTO0.1s 20.8 0.3 5.5 26.4 47.1 31.8 0.7 296451 55.4 35 163 83 14653 
B2-65hGTO0.2d B 24.8 0.4 10.5 25.0 49.9 35.6 0.7 370308 55.8 30 210 83 1917 
B2-99hGTO0.2d 
A 
26.2 0.4 10.5 25.9 52.0 36.4 0.7 412941 53.6 30 234 78 16260 
B2-98dGTO0.2c 28.8 0.4 11.8 29.7 58.5 41.5 0.7 595487 61.7 30 339 60 231 
B2-98dGTO0.2s 26.4 0.4 9.3 25.5 51.9 34.8 0.7 392682 63.7 30 224 81 17698 
B2-99hGTO0.4d 36.7 0.5 17.3 24.1 60.8 41.4 0.7 640235 66.3 20 380 75 16587 
B2-98dGTO0.4c 38.5 0.6 21.4 27.9 66.4 49.3 0.7 911350 72.2 20 545 58 312 
B2-98dGTO0.4s 38.0 0.4 15.2 24.0 62.1 39.3 0.6 633915 71.3 20 379 75 35068 
 
Estimated uncertainty for R1 for B2-65hGTOd decreased from ± 0.9 for B2-65hGTO0.05d to ± 0.3 for B2-65hGTO0.2d, while those for B2-99hGTOd decreased from ± 0.4 for B2-99hGTO0.05d to ± 
0.2 for B2-99hGTO0.8d and then increased to ± 1.5 for B2-99hGTO1.5d. Estimated uncertainty for R1 for B2-98dGTOc decreased from ± 4 for B2-98dGTO0.05c to ± 0.3 for B2-98dGTO0.8c and then 
increased to ± 2.2 for B2-98dGTO1.5c, whereas those for B2-98dGTOs increased from ± 0.4 for B2-98dGTO0.05s to ± 2.6 for B2-98dGTO1.5s.   
Estimated uncertainty for x of all B2-GTO NE were ± 0.01. 
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Table 3.17 Parameters used to obtain the individual ‘best fits’ to the SANS results for 2 %w/w Brij O10 and GTO nanoemulsions in the absence of drug using a 
core-shell ellipsoid model in combination with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore (cont.).  
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46.9 0.5 22.1 22.8 69.7 44.9 0.6 913182 70.8 15 527 74 16572 
B2-98dGTO0.6c 48.9 0.6 28.1 26.8 75.7 54.9 0.7 1318925 76.9 15 771 57 268 
B2-98dGTO0.6s 47.9 0.4 20.0 22.9 70.8 42.9 0.6 900730 84.7 15 527 74 83862 
B2-99hGTO0.8d 57.0 0.5 25.8 22.3 79.3 48.1 0.6 1265395 82.3 15 680 75 14762 
B2-98dGTO0.8c 62.1 0.5 32.3 26.9 89.0 59.2 0.7 1965715 90.6 15 1073 56 397 
B2-98dGTO0.8s 61.4 0.4 21.9 22.4 83.9 44.4 0.5 1307297 91.9 15 714 75 119540 
B2-99hGTO1.0d 
B 
75.1 0.4 30.1 22.7 97.8 52.7 0.5 2111980 105.5 10 1103 68 4830 
B2-98dGTO1.0c 80.9 0.4 35.7 26.7 107.5 62.3 0.6 3018350 115.5 10 1607 54 1250 
B2-98dGTO1.0s 80.5 0.2 19.8 19.7 100.3 39.6 0.4 1666482 117.0 10 887 85 137340 
B2-99hGTO1.2d 94.9 0.3 30.5 22.3 117.2 52.8 0.5 3034349 120.2 10 1485 69 12355 
B2-98dGTO1.2c 120.0 0.3 35.5 28.3 148.2 63.8 0.4 5876954 160.6 10 2939 51 6336 
B2-98dGTO1.2s 101.3 0.2 20.4 19.1 120.4 39.5 0.3 2400822 132.1 10 1201 88 203830 
B2-99hGTO1.5d 167.3 0.2 27.1 21.9 189.3 49.1 0.3 7367770 198.0 10 3293 74 96526 
B2-98dGTO1.5c 256.0 0.1 35.8 31.9 288.0 67.8 0.2 23553358 296.2 10 10793 48 11259 
B2-98dGTO1.5s 142.9 0.1 19.9 17.8 160.6 37.7 0.2 4070528 163.6 10 1865 97 345400 
 
Estimated uncertainty for R1 for B2-65hGTOd decreased from ± 0.9 for B2-65hGTO0.05d to ± 0.3 for B2-65hGTO0.2d, while those for B2-99hGTOd decreased from ± 0.4 for B2-99hGTO0.05d to ± 
0.2 for B2-99hGTO0.8d and then increased to ± 1.5 for B2-99hGTO1.5d. Estimated uncertainty for R1 for B2-98dGTOc decreased from ± 4 for B2-98dGTO0.05c to ± 0.3 for B2-98dGTO0.8c and then 
increased to ± 2.2 for B2-98dGTO1.5c, whereas those for B2-98dGTOs increased from ± 0.4 for B2-98dGTO0.05s to ± 2.6 for B2-98dGTO1.5s.   
Estimated uncertainty for x of all B2-GTO NE was ± 0.01. 
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It is clear that the model that provided the best fit to the SANS data was an ellipsoid. 
The axial ratio of the core suggested that the shape of B2-GTO NE aggregates was an 
oblate ellipsoid because the axial ratio was less than 1. Interestingly, the core of the 
GTO NE became less ellipsoidal/more spherical in Region A as the GTO concentration 
increased as indicated by the increase in the core axial ratio from 0.1-0.5 - a result in 
agreement with the PIT study. Surprisingly, therefore the shape of the particles in 
Region B become more elongated as the oil content increases, as indicated by a change 
in the axial ratio obtained for the NE from the best fit data from 0.4 for drop and core 
contrasts and 0.2 for shell contrast to 0.2 for drop contrast and 0.1 for core and shell 
contrasts. Imaging of lipid NE droplets, composed of sphingomyelin/cholesterol/triolein 
in the molar ratio of either 1:1:4.7 or 4:1:11.7 revealed a rounded structure, similar to 
that of large unilamellar lipid vesicles (Vezocnik et al., 2015). 
In Region A upon increasing GTO concentration, the major radius of the B2-GTO NE 
increased from 28.0 Å to 59.0 Å, while the minor radius increased from 46.0 to 89.0 Å. 
However, in Region B upon increasing GTO concentration, the major radius of B2-
GTO NE stayed constant at around 40-60 Å while, in contrast, the minor radius of B2-
GTO NE increased from 98.0 to 288.0 Å. Schematic representations of ellipsoid 2 
%w/w Brij O10 NE containing the upper limit of either 65hGTO and 99hGTO, in both 
Regions A and B, in the absence of drug are shown in Figures 3.55 and 3.56, 
respectively. 
a)  b)   
Figure 3.55: Schematic representation of the ellipsoidal 2 %w/w Brij O10 NE containing the 
maximum amount of 65hGTO in Region A for a) B2-65hGTO0.1d and in Region B for b) B2-
65hGTO0.2d in the absence of drug. 
 
a)  b)  
Figure 3.56: Schematic representation of the ellipsoidal 2 %w/w Brij O10 NE containing the 
maximum amount of 99hGTO in Region A for a) B2-99hGTO0.8d and in Region B for b) B2-
99hGTO1.6d in the absence of drug. 
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When compared with the particle size of B2-65hGTO and B2-99hGTO NE obtained 
from SANS experiment, it was found that the core equatorial radius of B2-
65hGTO0.05d NE was larger than that of B2-99hGTO0.05d NE, despite its possession 
of a comparable axial ratio. Although the radius of the core of B2-65hGTO0.1d NE was 
larger than that of B2-99hGTO0.1d NE, its core axial ratio was smaller, however the 
parameters obtained from the best fit to the SANS data resulted in particles of similar 
size. The trends in particle size of B2-65hGTO and B2-99hGTO NE obtained from the 
SANS experiments were reassuringly in agreement with those obtained from PCS, as 
well as being in line with the trends seen in the PIT experiments. 
It was worth noting that there was the difference in parameters obtained for the three 
contrasts of the same NE. In Region A, the difference in the fit parameters were small, 
while in Region B, the thickness of the shell obtained from the core contrast was 
significantly larger than that the corresponding value obtained for the other contrasts. 
Furthermore, the fits to the shell contrast were not ideal and yielded smaller axial ratios 
that were obtained with the other fits. Due to the fact that many of the B2-GTO NE 
were run on multiple occasions and exhibited the same scattering, we are confident 
therefore that the SANS data were reproducible. In order to find out which factors were 
affecting the fitting, the level of deuteration of 98dGTO was first varied when fitting the 
SANS data using the core-shell ellipsoid model. However, the change in level of 
deuteration of 98dGTO did not improve the quality of the fitting. Next, another model 
contained in the program SASview, namely the triaxial ellipsoid model, was used to 
‘fit’ the SANS data obtained for GTO. Again, however, no improvement was seen in 
the ‘best fits’ to the GTO SANS data. The triaxial ellipsoid model used in the present 
study is shown in Figure 3.57. As a consequence of this study it is proposed that the 
models currently available to analyse the SANS data might not be the most appropriate 
for B2-GTO NE.  
 
Figure 3.57: Triaxial ellipsoid model in SASview 
 
Due to the small amount of 98dGTO synthesised, the drop contrast prepared using 
protiated GTO and surfactant, dispersed in D2O was chosen to study the effect of the 
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drug, TP, on the size and shape of B2-GTO NE. As can be seen from the fitting 
parameters used to model the SANS2D data shown in Figures 3.58-3.59 and given in 
Table 3.18, there was a slight difference in size and shape of NE droplets in the 
presence of TP. As expected, the equatorial core radius of the B2-GTO-TP NE 
increased with an increase in GTO content, a trend which was similar to that seen in the 
corresponding, drug-free B2-GTO NE. The hydration of the shell of the hGTO NE was 
found to decrease from 35 % in hGTO0.05d-TP NE to 10 % in hGTO1.0d-TP NE 
whereafter it remains at 10 % despite an increase in hGTO concentration. In all cases, 
the thickness of the fitted shell was in the range 22-27 Å. As with the drug-free TP NE, 
the model that provided the best fit to the SANS data was that an ellipsoid, with the 
axial ratio of the core suggesting that the shape of B2-hGTO-TP NE was an oblate 
ellipsoid.  
a) b)  
Figure 3.58: SANS data and best fits to drop contrast for 2 %w/w Brij O10 NE containing the 
maximum amount of 65hGTO in a) Region A and b) Region B in the absence and presence of 
TP. 
 
a) b)  
Figure 3.59: SANS data and best fits to drop contrast for 2 %w/w Brij O10 NE containing the 
maximum amount of 99hGTO in a) Region A and b) Region B in the absence and presence of 
TP. 
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Table 3.18 Parameters used to obtain the individual ‘best fits’ to the SANS results for 2 %w/w Brij O10 and GTO nanoemulsions in the presence of TP using a core-
shell ellipsoid model in combination with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant 
 (Å2) 






29.2 0.1 1.8 25.7 54.9 27.5 0.5 347559 56.0 35 194 90 37727 
B2-99hGTO0.05d-TP 22.1 0.1 2.5 26.6 48.7 29.1 0.6 289427 48.8 35 162 84 4808 
B2-65hGTO0.1d-TP 23.6 0.2 5.0 26.5 50.1 31.5 0.6 331886 52.6 35 182 83 10037 
B2-99hGTO0.1d-TP 19.8 0.3 6.6 26.8 46.6 33.4 0.7 304478 52.7 35 167 80 2848 
B2-65hGTO0.2d-TP B 24.7 0.4 10.8 25.2 49.9 36.0 0.7 376655 53.0 30 214 82 2743 
B2-99hGTO0.2d-TP 
A 
26.1 0.4 10.6 25.9 52.1 36.5 0.7 414979 56.8 30 235 78 3863 
B2-99hGTO0.4d-TP 36.9 0.5 16.8 23.8 60.7 40.7 0.7 629042 69.6 20 373 76 4729 
B2-99hGTO0.6d-TP 47.6 0.5 22.6 23.2 70.8 45.8 0.6 963278 75.2 15 556 72 4742 
B2-99hGTO0.8d-TP 58.1 0.5 26.3 22.7 80.9 49.0 0.6 1343449 87.1 15 722 73 1682 
B2-99hGTO1.0d-TP 
B 
76.2 0.4 29.8 22.7 98.9 52.6 0.5 2156393 108.9 10 1126 68 5953 
B2-99hGTO1.2d-TP 95.3 0.3 30.3 22.3 117.6 52.6 0.4 3052169 134.8 10 1493 69 13239 
B2-99hGTO1.5d-TP 168.1 0.2 27.3 22.1 190.1 49.4 0.3 7482387 207.4 10 3345 73 94599 
 
Estimated uncertainty for R1 for B2-65hGTOd-TP decreased from ± 1.7 for B2-65hGTO0.05d-TP to ± 0.3 for B2-65hGTO0.2d-TP, while those for B2-99hGTOd-TP decreased from ± 0.5 for B2-
99hGTO0.05d-TP to ± 0.2 for B2-99hGTO0.8d-TP and then increased to ± 1.5 for B2-99hGTO1.5d-TP.  
Estimated uncertainty for x of all B2-GTO-TP NE was ± 0.01. 
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Within Region A, the solubilisation of TP in B2-GTO-TP increased with GTO content 
because of the larger core equatorial radius. However, the TP-containing NE particles in 
Region B, became much more elongated with oil content. This change in morphology 
was unexpected as it had been anticipated that NE would become more spherical upon 
increasing GTO loading. This change in morphology can explain the plateau in TP 
solubilisation observed in Region B as there is less of an oil core in which the TP can be 
solubilised.  
In Region A, the major radius of B2-hGTO-TP changed from 27.5 Å for B2-
65hGTO0.05d-TP NE to 31.5 Å for B2-65hGTO0.1d-TP NE and 29 Å for B2-
99hGTO0.05d-TP NE to 49 Å for B2-99hGTO0.8d-TP NE while the minor radius of 
B2-hGTO-TP NE changed from 55 Å for B2-65hGTO0.05d-TP NE to 50 Å for B2-
65hGTO0.1d-TP NE and 49 Å for B2-65hGTO0.05d-TP NE to 81 Å for B2-
99hGTO0.8d-TP NE. In Region B NE, the major radius of B2-99hGTO-TP NE 
remained approximately the same at ~ 50 Å, while the minor radius dramatically 
increased in size from ~ 99 Å for B2-99hGTO1.0d-TP NE to 190.0 Å for B2-
99hGTO1.5d-TP NE. In contradiction to the results of the PCS experiments, the SANS 
data did not exhibit any difference in shape and size of the TP-free and TP-containing 
NE. It is of note that the analysis of the PCS data assumed that the NE were spherical, 
however it was clear from the SANS analysis that the shape of the B2-hGTO-TP NE in 
Region B was not spherical and may be the origin of the discrepancy between the SANS 
and PCS experiments as PCS indicated that the particle size of the B2-99hGTO-TP NE 
in Region B was much larger than that of B2-99hGTO NE. 
The volume and the surface area of ellipsoid and sphere are shown in Table 3.19 to 
illustrate the change in shape reduces the capacity of NE to solubilise hydrophobic drug. 
The PIT and TP solubility results suggested that TP would sit in oil core and surfactant 
interface, therefore the volume that TP could be solubilised is the volume of oil core 
and surfactant hydrocarbon tail. The schematic representation of ellipsoidal GTO NE is 
shown in Figure 3.60.  
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Figure 3.60: The schematic representation of ellipsoidal triolein nanoemulsion with the 
equatorial radius of the core (R1), major radius of ellipsoid core (xR1) and the length of the 
surfactant hydrocarbon tail (lc) 
 
The minor radius of ellipsoid is the length of the core equatorial radius (R1) and the 
length of surfactant hydrocarbon tail (lc) i.e. 17.3 Å (Malcolmson et al., 1995) (R1+lc), 
and the major radius of ellipsoid is the length of core axial radius (xR1) and the length 
of surfactant hydrocarbon tail (xR1+lc) were used to calculate the volume of oblate 
ellipsoid, while the radius of the equivalent sphere is the equatorial radius of the core 
(R1) obtained from the fitting of the SANS data for NE and the length of the surfactant 
hydrocarbon tail (lc) calculated to be 17.3 Å by Malcolmson et al. (1995), i.e. R1+lc. The 





It is clear from the volume and surface area of the equivalent ellipsoid were much lower 
than those of the corresponding sphere, suggesting that a change in the shape of the NE 
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Table 3.19 The comparison of the volume and the surface area of ellipsoid and sphere of 2 
%w/w Brij O10 and hGTO nanoemulsions in the presence of TP 
 
sample region ellipsoid sphere 
 volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
ellipsoid 
(Å3) 
volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
sphere 
(Å3) 
B2-65hGTO0.05d-TP A 172077 17441 419696 27112 
B2-99hGTO0.05d-TP 128994 13520 256557 19528 
B2-65hGTO0.1d-TP 156484 15067 287015 21045 
B2-99hGTO0.1d-TP 137273 13350 213494 17277 
B2-65hGTO0.2d-TP B 207446 17467 310075 22157 
B2-99hGTO0.2d-TP A 220251 18301 342937 23697 
B2-99hGTO0.4d-TP 419841 28233 666791 36915 
B2-99hGTO0.6d-TP 704624 40051 1146706 52988 
B2-99hGTO0.8d-TP 1038279 52511 1797144 71493 
B2-99hGTO1.0d-TP B 1724884 76108 3420830 109807 
B2-99hGTO1.2d-TP 2529929 103589 5984011 159418 
B2-99hGTO1.5d-TP 6419664 244421 26675108 431797 
 
3.5.2.3 SANS studies of Brij O10 nanoemulsions containing tripalmitin in the 
absence and presence of drug 
A range of models were used to individually fit the three SANS contrasts obtained for 
B2-TPN NE containing different concentrations of TPN in Regions A, B and C. The 
SANS data and the ‘best fits’ for B2-TPN NE were obtained using a core-shell ellipsoid 
model, shown in Figures 3.61-3.62 while Table 3.20 gives the parameters used to 
obtain the best fits. The results suggested that no strong interactions occurred between 
droplets, as would be expected with a diluted NE system. Furthermore, upon increasing 
TPN content, there was an increase in the dimensions of the core equatorial radius of 
the NE - a similar increase in size with TPN content was seen with the dynamic light 
scattering results. The SANS data for the various NE was fitted using varying levels of 
shell hydration - the hydration was found to decrease from 30 % at TPN0.2 to 25 % at 
TPN0.4 and 20 % at TPN0.6 and 15 % at TPN1.0 whereafter it became at 10 % at 
TPN1.4 and remained at this level at higher TPN concentrations. The thickness obtained 
for the shell of TPN NE from the ‘best fits’ to the data were 19.0-25.5 Å for B2-
85hTPNd NE, 19.5-25.5 Å for B2-99hTPNd NE, 23.0-29.5 Å for B2-98.6dTPNc NE 
and 20.0-25.5 Å for B2-98.6dTPNs NE.          
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a) b)  
c)  
Figure 3.61: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing the 
maximum amount of 85hTPN in the absence of drug in a) Region A, b) Region B and c) Region 
C. Shell contrast for NE containing 98.6dTPN was multiplied by the factor of 10. Note that the 
best fits to shell contrast for 2 %w/w Brij O10 NE containing 0.4 %w/w 98.6dTPN and higher 
concentrations of 98.6dTPN were not well fitted to SANS data and the best fits to core contrast 
for 2 %w/w Brij O10 NE containing 0.8 %w/w 98.6dTPN and higher concentrations of 




Figure 3.62: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing the 
maximum amount of 99hTPN in the absence of drug in a) Region C. Shell contrast for NE 
containing 98.6dTPN was multiplied by the factor of 10. Note that the best fits to shell contrast 
for 2 %w/w Brij O10 NE containing 0.4 %w/w 98.6dTPN and higher concentrations of 
98.6dTPN were not well fitted to SANS data and the best fits to core contrast for 2 %w/w Brij 
O10 NE containing 0.8 %w/w 98.6dTPN and higher concentrations of 98.6dTPN were not fitted 
to SANS data. 
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Table 3.20 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and TPN nanoemulsions in the absence of drug using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant  
(Å2) 




B2-85hTPN0.2d A 25.4 0.4 10.7 25.6 51.0 36.3 0.7 395174 59.1 30 224 79 14542 
B2-99hTPN0.2d C 25.1 0.4 10.5 25.3 50.4 35.8 0.7 380802 58.8 30 216 81 11991 
B2-98.6dTPN0.2c 
A 27.1 0.4 11.8 29.6 56.6 41.4 0.7 555767 59.1 30 318 61 339 
B2-98.6dTPN0.2s 24.6 0.4 9.4 25.5 50.1 34.9 0.7 367056 58.9 30 210 81 53029 
B2-85hTPN0.4d A 36.1 0.5 16.6 24.4 60.5 41.0 0.7 629622 64.0 25 354 78 13604 
B2-99hTPN0.4d C 36.0 0.5 16.6 24.4 60.4 40.9 0.7 625413 65.3 25 351 78 13293 
B2-98.6dTPN0.4c 
A 38.9 0.5 18.6 28.7 67.6 47.3 0.7 905073 74.9 25 516 59 2510 
B2-98.6dTPN0.4s 35.6 0.4 14.9 24.8 60.4 39.7 0.7 607642 71.7 25 347 76 99268 
B2-85hTPN0.6d A 46.5 0.5 21.4 23.4 69.9 44.8 0.6 917022 80.3 20 506 76 3136 
B2-99hTPN0.6d C 48.3 0.4 21.0 23.7 71.9 44.6 0.6 967639 75.2 20 534 75 3850 
B2-98.6dTPN0.6c 
A 49.2 0.5 22.9 26.8 76.0 49.7 0.7 1204333 78.3 20 680 61 1711 
B2-98.6dTPN0.6s 46.1 0.4 19.8 24.2 70.4 44.0 0.6 913540 80.6 20 516 72 28584 
B2-85hTPN0.8d B 58.9 0.4 23.2 22.7 81.6 45.9 0.6 1280144 90.5 20 659 78 5659 
B2-99hTPN0.8d C 59.8 0.4 22.9 22.7 82.6 45.6 0.6 1302971 84.9 20 671 78 5775 
B2-98.6dTPN0.8c 
B 63.9 0.4 27.1 27.5 91.5 54.6 0.6 1914576 92.9 20 1015 58 6733 
B2-98.6dTPN0.8s 57.6 0.4 21.7 23.5 81.1 45.1 0.6 1243223 88.4 20 659 75 56191 
 
Estimated uncertainty for R1 for B2-TPNd increased from ± 0.2 for B2-TPN0.2d to ± 1.2 for B2-TPN1.6d, those for B2-98.6dTPNc decreased from ± 1.0 for B2-98.6dTPN0.2c to ± 0.3 for B2-
98.6dTPN0.6c and then increased to ± 7.8 for B2-98.6dTPN1.6c, and those for B2-98.6dTPNs increased from ± 0.4 for B2-98.6dTPN0.2s to ± 4.5 for B2-98.6TPN1.6s.  
Estimated uncertainty for x of all B2-TPN NE was ± 0.01. 
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Table 3.20 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and TPN nanoemulsions in the absence of drug using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore (cont.). 
 
































Nagg surfaces  
area of  
surfactant 
 (Å2) 




B2-85hTPN1.0d B 73.5 0.3 25.4 21.6 95.2 47.0 0.5 1783419 106.8 15 898 78 16836 
B2-99hTPN1.0d C 72.2 0.3 25.0 21.3 93.5 46.3 0.5 1694898 103.8 15 854 80 10540 
B2-98.6dTPN1.0c  
B 78.7 0.4 28.9 26.0 104.7 54.9 0.5 2520604 115.4 15 1316 60 23710 
B2-98.6dTPN1.0s  71.3 0.3 22.7 21.9 93.2 44.7 0.5 1627702 102.1 15 850 77 93182 
B2-85hTPN1.2d 
C 
91.2 0.3 25.3 20.8 112.1 46.1 0.4 2425502 119.2 15 1148 82 31099 
B2-99hTPN1.2d 87.9 0.3 26.1 20.8 108.7 46.9 0.4 2319561 113.8 15 1098 82 21132 
B2-98.6dTPN1.2c 96.4 0.3 29.5 25.3 121.7 54.8 0.5 3401401                                                                                                                                                                       127.5 15 1676 62 123050
B2-98.6dTPN1.2s 87.5 0.3 24.6 22.0 109.5 46.6 0.4 2340426 123.7 15 1153 76 154100 
B2-85hTPN1.4d 
C 
111.1 0.2 27.2 20.0 131.1 47.2 0.4 3401268 136.8 10 1570 81 73631 
B2-99hTPN1.4d 107.5 0.3 27.2 19.7 127.2 46.9 0.4 3183783 133.7 10 1470 82 43050 
B2-98.6dTPN1.4c 119.9 0.2 28.1 23.1 143.0 51.1 0.4 4379461 153.0 10 2116 68 756760 
B2-98.6dTPN1.4s 96.8 0.3 25.5 19.9 116.7 45.4 0.4 2592750 123.2 10 1253 82 198790 
B2-85hTPN1.6d 
C 
122.7 0.2 27.8 18.9 141.7 46.7 0.3 3929056 145.4 10 1713 86 135460 
B2-99hTPN1.6d 132.2 0.2 27.3 19.3 151.5 46.7 0.3 4487618 157.9 10 1956 85 106340 
B2-98.6dTPN1.6c 135.3 0.2 31.6 23.4 158.7 54.9 0.3 5795257 160.7 10 2654 66 31355000 
B2-98.6dTPN1.6s 124.8 0.2 25.9 20.1 144.8 46.0 0.3 4041126 153.2 10 1851 81 396990 
 
Estimated uncertainty for R1 for B2-TPNd increased from ± 0.2 for B2-TPN0.2d to ± 1.2 for B2-TPN1.6d, those for B2-98.6dTPNc decreased from ± 1.0 for B2-98.6dTPN0.2c to ± 0.3 for B2-
98.6dTPN0.6c and then increased to ± 7.8 for B2-98.6dTPN1.6c, and those for B2-98.6dTPNs increased from ± 0.4 for B2-98.6dTPN0.2s to ± 4.5 for B2-98.6TPN1.6s.  
Estimated uncertainty for x of all B2-TPN NE was ± 0.01. 
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As with the other systems tested, it was clear that the model that best fit the SANS data 
was an ellipsoid. Furthermore, the axial ratio of the core obtained for B2-TPN NE was 
less than 1 indicating that these NE were oblate ellipsoids. However, as the 
concentration of TPN increased, the core of the NE became more spherical as indicated 
by the change in the axial ratio of the core from 0.4-0.5 in Region A of either B2-
85hTPN, B2-98.6dTPNc or B2-98.6dTPNs and Region C of B2-99hTPN0.2d to B2-
99hTPN0.8d - an observation in agreement with the PIT study. Surprisingly, however, 
the shape of the NE droplets in Region C become more elongated as the oil content 
increased as indicated by a change in the droplet axial ratio from 0.3 (for the drop and 
shell contrasts) and 0.4 (for the core contrast) to 0.2 for all contrasts at 1.6 % TPN. In 
Region A, the major and minor radii of B2-TPN NE increased from 35.0 to 50.0 Å and 
50.0 to 76.0 Å, respectively upon increasing TPN concentration. However, in Regions 
B and C, the major radius of the B2-TPN NE remained constant at ~ 45.0-55.0 Å, while 
the minor radius increased from 45.0 to 159.0 Å with increasing TPN concentration. A 
schematic representation of ellipsoidal 2 %w/w Brij O10 NE containing the maximum 
amount of either 85hTPN or 99hTPN incorporated into the NE in Regions A, B or C in 
the absence of TP is given in Figures 3.63–3.64.  
 
a) b)  
c)   
 
Figure 3.63: Schematic representation of the ellipsoidal 2 %w/w Brij O10 NE containing the 
maximum amount of 85hTPN incorporated into NE in a) Region A B2-85hTPN0.6d, b) Region 
B B2-85hTPN1.0d and c) Region C B2-85hTPN1.6d. 
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a)  
Figure 3.64: Schematic representation of the ellipsoidal 2 %w/w Brij O10 NE containing the 
maximum amount of 99hTPN incorporated into NE in a) Region C B2-99hTPN1.6d. 
 
It has been reported that TPN suspensions stabilised by either purified soybean lecithin 
(S100), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), or 1,2-dilauroyl-sn-
glycero-3-phosphocholine (DLPC) formed individual, polydisperse, platelet-like 
particles with diameters ranging between 50 and 400 nm with some of the particles 
appearing to possess a rather elongated elliptic shape. The platelet-like shape of the 
particles are characteristic for the β-crystalline platelet form of tripalmitin which 
supports the findings from the WAXS measurement and TEM micrographs (Schmiele, 
2013, Schmiele, 2014a and Schmiele, 2014b). No spherical tripalmitin nanoparticles in 
their α-crystal form were observed in the micrographs. At TPN concentrations above 4 
%, the particles started to self-assemble in stacks as observed using cryo-TEM and 
freeze-fracture electron microscopy (Schmiele, 2013, Schmiele, 2014a and Schmiele, 
2014b). 
The size obtained from the SANS study for the core equatorial radius and the axial ratio 
of B2-85hTPN and B2-99hTPN NE were similar. This observation was in contrast to 
the results obtained from the PCS study where the particle size of B20-99hTPN4 NE 
were found to be larger than that of B20-85hTPN4 NE.  
It was worth noting that there were the differences in the parameters used to fit the 
SANS data obtained for three contrasts. At low concentrations of TPN (i.e. below 0.6 
%w/w) any differences in the parameters used for fitting the SANS data from all 
contrasts was small. Yet when the amount of TPN was 0.8% or higher, the thicknesses 
of the shell obtained from the core contrasts were significantly thicker than obtained 
from the other contrasts. Furthermore, it was not possible to obtain a good fit to the 
SANS data obtained for the core and shell contrasts, suggesting that the model did not 
perfectly describe the structure of the NE. Repeat SANS experiments confirmed that the 
data for these samples were reproducible as when the B2-TPN samples were run several 
different occasions, virtually identical scattering was obtained. To establish which 
factors affected the fitting, the level of deuteration of 98.6dTPN was varied when fitting 
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data using the core-shell ellipsoid model. Yet any change in the level of deuteration of 
98.6dTPN did not improve the fitting of the data. Similarly any change in the hydration 
of the head group (manifested as a change in the SLD of the surfactant shell) did not 
improve the fitting. In addition, the use of different models, i.e. the triaxial, elliptical 
cylinder and core shell cylinder (illustrated in Figure 3.65), available in SASview, did 
not improve the fit to the SANS data. It is proposed here therefore that the models used 
to analyse data might not be the most appropriate for B2-TPN.  
a) b)  c)  
Figure 3.65: Triaxial ellipsoid, elliptical cylinder and core shell cylinder models from 
SASview. 
 
As can be seen from the fitting parameters reported in Table 3.21 and from Figures 
3.66-3.69, the SANS results obtained for TPN NE droplets in the presence and absence 
of TP indicate that there were slight differences in the size and shape of the three 
contrasts. As expected, the core equatorial radius of the B2-TPN-TP NE increased with 
TPN content, a trend similar to that seen with TP-free B2-TPN NE. The shell hydration 
of TPN NE was found to decrease from 30 % for TPN0.2-TP NE to 10 % for TPN1.4-
TP NE and thereafter remained at 10 % for all higher TPN concentrations, regardless of 
contrasts. The thickness of the shell obtained from the fits decreased from ~ 25 to 22 Å. 
It was clear from the axial ratio of the core that the model that provided the best fit to 
the SANS data was an oblate ellipsoid.  
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Table 3.21 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and TPN nanoemulsions in the presence of TP using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant 
(Å2) 




B2-85hTPN0.2d-TP A 24.5 0.5 11.4 25.8 50.3 37.1 0.7 393793 61.4 30 224 78 3830 
B2-99hTPN0.2d-TP C 24.8 0.4 10.8 25.4 50.2 36.2 0.7 382523 58.4 30 217 81 3045 
B2-98.6dTPN0.2c-TP 
A 26.9 0.4 11.8 29.4 56.3 41.2 0.7 547596 59.5 30 313 61 109 
B2-98.6dTPN0.2s-TP 24.9 0.4 9.8 26.1 51.0 35.9 0.7 391082 58.3 30 224 77 8312 
B2-85hTPN0.4d-TP A 37.6 0.4 15.3 24.2 61.8 39.5 0.6 632267 70.1 25 355 79 3136 
B2-99hTPN0.4d-TP C 36.2 0.4 16.3 24.3 60.5 40.6 0.7 621819 69.1 25 349 79 4392 
B2-98.6dTPN0.4c-TP 
A 39.4 0.5 18.6 28.9 68.3 47.5 0.7 928839 70.3 25 530 58 475 
B2-98.6dTPN0.4s-TP 36.0 0.4 14.5 24.7 60.7 39.2 0.6 605405 72.0 25 345 77 14021 
B2-85hTPN0.6d-TP A 47.1 0.4 21.1 23.4 70.5 44.5 0.6 928390 79.4 20 512 76 3080 
B2-99hTPN0.6d-TP C 48.5 0.4 19.9 23.1 71.6 43.0 0.6 922868 74.1 20 509 78 2995 
B2-98.6dTPN0.6c-TP 
A 51.6 0.5 23.2 27.7 79.3 50.9 0.6 1342679 83.4 20 758 58 1873 
B2-98.6dTPN0.6s-TP 46.3 0.4 19.3 24.0 70.3 43.3 0.6 895047 79.6 20 505 74 30867 
B2-85hTPN0.8d-TP B 57.7 0.4 24.0 22.8 80.5 46.7 0.6 1267448 91.3 20 653 78 5173 
B2-99hTPN0.8d-TP C 61.0 0.4 22.3 22.7 83.7 45.0 0.5 1320183 84.5 20 680 79 2611 
B2-98.6dTPN0.8c-TP 
B 65.1 0.4 28.3 28.4 93.5 56.7 0.6 2076860 96.0 20 1101 56 4424 
B2-98.6dTPN0.8s-TP 60.5 0.3 20.2 23.3 83.8 43.5 0.5 1280947 91.7 20 679 76 52387 
 
Estimated uncertainty for R1 for B2-TPNd-TP increased from ± 0.2 for B2-TPN0.2d-TP to ± 1.3 for B2-TPN1.6d-TP, those for B2-98.6dTPNc-TP decreased from ± 2.0 for B2-98.6dTPN0.2c-TP to ± 
0.4 for B2-98.6dTPN0.6c-TP and then increased to ± 7.5 for B2-98.6dTPN1.6c-TP, and those for B2-98.6dTPNs-TP increased from ± 0.4 for B2-98.6dTPN0.2s-TP to ± 4.0 for B2-98.6TPN1.6s-TP.  
Estimated uncertainty for x of all B2-TPN-TP NE was ± 0.01. 
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Table 3.21 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and TPN nanoemulsions in the presence of TP using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore (cont.). 
 
































Nagg surfaces  
area of  
surfactant 
(Å2) 




B2-85hTPN1.0d-TP B 76.7 0.3 24.6 21.7 98.4 46.3 0.5 1879483 98.6 15 947 78 14654 
B2-99hTPN1.0d-TP C 74.0 0.3 25.1 21.6 95.5 46.6 0.5 1784438 101.0 15 899 78 11185 
B2-98.6dTPN1.0c-TP 
B 78.4 0.4 28.4 25.7 104.1 54.1 0.5 2457085 116.3 15 1283 61 31503 
B2-98.6dTPN1.0s-TP  72.7 0.3 22.8 22.1 94.8 44.9 0.5 1691260 100.4 15 883 76 92300 
B2-85hTPN1.2d-TP 
C 
90.8 0.3 25.7 21.0 111.7 46.7 0.4 2442626 125.6 15 1156 81 27897 
B2-99hTPN1.2d-TP 88.2 0.3 26.2 20.9 109.1 47.0 0.4 2345035 115.8 15 1110 81 19227 
B2-98.6dTPN1.2c-TP 95.2 0.3 31.0 25.8 121.0 56.8 0.5 3487027 127.9 15 1718 60 142690 
B2-98.6dTPN1.2s-TP 89.1 0.3 23.5 21.6 110.8 45.1 0.4 2317995 124.0 15 1142 79 139620 
B2-85hTPN1.4d-TP 112.3 0.2 26.3 19.7 132.0 45.9 0.3 3352375 142.3 10 1547 83 67425 
B2-99hTPN1.4d-TP 120.0 0.2 26.7 20.5 140.4 47.2 0.3 3899776 145.7 10 1800 79 37915 
B2-98.6dTPN1.4c-TP 112.7 0.2 27.0 22.0 134.7 49.0 0.4 3725813 139.4 10 1800 72 1572900 
B2-98.6dTPN1.4s-TP 104.2 0.3 26.2 20.9 125.1 47.1 0.4 3089149 132.4 10 1493 77 218590 
B2-85hTPN1.6d-TP 126.4 0.2 28.2 19.3 145.8 47.5 0.3 4229117 150.9 10 1843 84 136710 
B2-99hTPN1.6d-TP 134.4 0.2 28.1 19.7 154.2 47.8 0.3 4761054 163.8 10 2075 82 98724 
B2-98.6dTPN1.6c-TP 135.3 0.2 31.6 23.4 158.7 55.0 0.3 5799001 165.8 10 2656 66 24667000 
B2-98.6dTPN1.6s-TP 120.3 0.2 22.8 18.3 138.6 41.1 0.3 3309804 141.4 10 1516 92 264600 
 
Estimated uncertainty for R1 for B2-TPNd-TP increased from ± 0.2 for B2-TPN0.2d-TP to ± 1.3 for B2-TPN1.6d-TP, those for B2-98.6dTPNc-TP decreased from ± 2.0 for B2-98.6dTPN0.2c-TP to ± 
0.4 for B2-98.6dTPN0.6c-TP and then increased to ± 7.5 for B2-98.6dTPN1.6c-TP, and those for B2-98.6dTPNs-TP increased from ± 0.4 for B2-98.6dTPN0.2s-TP to ± 4.0 for B2-98.6TPN1.6s-TP.  
Estimated uncertainty for x of all B2-TPN-TP NE was ± 0.01. 
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a) b)  
c)  
Figure 3.66: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
the maximum amount of 85hTPN in the presence and absence of TP in a) Region A, b) Region 
B and c) Region C.  
 
Figure 3.67: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
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a) b)  
c)   
Figure 3.68: SANS data and best fits to the core contrast for 2 %w/w Brij O10 NE containing 
the maximum amount of 98.6dTPN in the presence and absence of TP in a) Region A, b) 
Region B and c) Region C. The best fits to core contrast for 2 %w/w Brij O10 NE containing 
0.8 %w/w 98.6dTPN and higher concentrations of 98.6dTPN were not well fitted to SANS data. 
 
a) b)  
c)  
Figure 3.69: SANS data and best fits to the shell contrast for 2 %w/w Brij O10 NE containing 
the maximum amount of 98.6dTPN in the presence and absence of TP in a) Region A, b) 
Region B and c) Region C. Shell contrast for NE containing 98.6dTPN was multiplied by the 
factor of 10. Note that the best fits to shell contrast for 2 %w/w Brij O10 NE containing 0.4 
%w/w 98.6dTPN and higher concentrations of 98.6dTPN were not well fitted to SANS data. 
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At low amounts of TPN, in Regions A and B, the solubilisation of TP in B2-TPN-TP 
NE resulted in an increase in the size of the core equatorial radius. Surprisingly, within 
Region C, a further increase in the amount of TPN present resulted in the production of 
elongated TP-containing particles. This change in morphology was unexpected as it had 
been anticipated that the NE would become more spherical upon increasing TPN 
content. This change in morphology and reduction in the size of the oil core could 
explain the decrease in TP solubilisation observed in Region C.  
Upon increasing hTPN concentration in Region A, the major radius of B2-85hTPN-TP 
NE changed from 37.0 Å for B2-85hTPN0.2d-TP NE to 44.5 Å for B2-85hTPN0.6d-TP 
NE while the minor radius increased from 50.5 Å for B2-85hTPN0.2d-TP NE to 70.5 Å 
for B2-85hTPN0.6d-TP NE. In contrast, in Regions B and C, the major radius of the 
B2-85hTPN-TP NE remained constant at around 45-55 Å while the minor radius 
dramatically increased from 80.5 Å for B2-85hTPN0.8d-TP NE to 146.0 Å for B2-
85hTPN1.6d-TP NE. In 99hTPN containing NE, within Region C, the major radius was 
36.0 Å for B2-99hTPN0.2d-TP NE and increased to 45.0 Å for B2-99hTPN0.8d-TP 
NE, and then remained at 45-50 Å up to the limit of 99hTPN (i.e. B2-99hTPN1.6-TP 
NE) while the minor radius dramatically increased from 50.0 Å for B2-99hTPN0.2d-TP 
NE to 154.0 Å for B2-99hTPN1.6d-TP NE. In contrast to the PCS data, the SANS data 
did not show any difference in the size and shape of TP-free and TP-containing NE. 
This discrepancy may be due in part to the fact that analysis of the PCS assumed that 
the NE were spherical, however the shape of B2-hTPN-TP NE in Region C were clearly 
not spherical. 
The volume and the surface area of ellipsoid and sphere are shown in Table 3.22. The 
PIT and TP solubility results suggested that TP would sit in oil core and surfactant 
interface, therefore the volume that TP could be solubilised is the volume of oil core 
and surfactant hydrocarbon tail. Figure 3.70 shows the schematic representation of 
ellipsoidal TPN NE.  
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Figure 3.70: The schematic representation of ellipsoidal tripalmitin nanoemulsion with the 
equatorial radius of the core (R1), major radius of ellipsoid core (xR1) and the length of the 
surfactant hydrocarbon tail (lc) 
 
The minor radius of ellipsoid is the length of the core equatorial radius (R1) and the 
length of surfactant hydrocarbon tail (lc) i.e. 17.3 Å (Malcolmson et al., 1995) (R1+lc), 
and the major radius of ellipsoid is the length of core axial radius (xR1) and the length 
of surfactant hydrocarbon tail (xR1+lc) were used to calculate the volume of oblate 
ellipsoid.  
The radius of sphere is the sum of core equatorial radius (R1) obtained from the fitting 
of NE and the length of surfactant hydrocarbon tail (lc) i.e. 17.3 Å (Malcolmson et al., 




The radius of the equivalent sphere is the equatorial radius of the core (R1) obtained 
from the fitting of the SANS data for NE and the length of the surfactant hydrocarbon 
tail (lc) calculated to be 17.3 Å by Malcolmson et al. (1995), i.e. R1+lc. The volume and 
surface area of sphere were calculated using the following formula: 
 
 
It can be seen that the volume and surface area of ellipsoid were much lower than those 
of sphere which suggested that the change in NE shape from sphere to ellipsoid have an 
effect on the TP solubilisation in TPN NE (Table 3.22).  
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Table 3.22 The comparison of the volume and the surface area of ellipsoid and sphere of 2 
%w/w Brij O10 and hTPN nanoemulsions in the presence of TP 
 
sample region ellipsoid sphere 
 volume of oil 
core and tail of 
surfactant (Å3) 
surface area of 
ellipsoid 
(Å3) 
volume of oil 
core and tail of 
surfactant (Å3) 
surface area of 
sphere 
(Å3) 
B2-85hTPN0.2d-TP A 209695 17531.2 306131 21969 
B2-99hTPN0.2d-TP C 208107 17506.6 311304 22216 
B2-98.6dTPN0.2c-TP 
A 
237864 19187.7 361685 24553 
B2-98.6dTPN0.2s-TP 202206 17287.6 314923 22388 
B2-85hTPN0.4d-TP A 411890 28189.7 693751 37903 
B2-99hTPN0.4d-TP C 402256 27456.4 641164 35963 
B2-98.6dTPN0.4c-TP 
A 
482856 30955 761827 40344 
B2-98.6dTPN0.4s-TP 378137 26593.0 632775 35649 
B2-85hTPN0.6d-TP A 667586 38861.1 1119397 52143 
B2-99hTPN0.6d-TP C 672604 39505 1190446 54327 
B2-98.6dTPN0.6c-TP 
A 
806050 44186 1370085 59663 
B2-98.6dTPN0.6s-TP 618800 37222 1075667 50776 
B2-85hTPN0.8d-TP B 971564 50790 1766158 70669 
B2-99hTPN0.8d-TP C 1017396 53498 2013479 77121 
B2-98.6dTPN0.8c-TP 
B 
1296462 61462 2340587 85263 
B2-98.6dTPN0.8s-TP 950525 51784 1970335 76016 
B2-85hTPN1.0d-TP B 1548901 73416 3473779 110937 
B2-99hTPN1.0d-TP C 1478564 70307 3185646 104715 
B2-98.6dTPN1.0c-TP 
B 
1752957 78092 3669256 115061 
B2-98.6dTPN1.0s-TP  1357754 67275 3049501 101710 
B2-85hTPN1.2d-TP 
C 
2103314 93520 5286392 146774 
B2-99hTPN1.2d-TP 2024360 90073 4914962 139816 
B2-98.6dTPN1.2c-TP 2558040 103829 5958550 158965 
B2-98.6dTPN1.2s-TP 1934750 89677 5051448 142392 
B2-85hTPN1.4d-TP 3061360 128121 9110167 210973 
B2-99hTPN1.4d-TP 3475315 142175 10838671 236879 
B2-98.6dTPN1.4c-TP 3136286 129407 9193586 212259 
B2-98.6dTPN1.4s-TP 2690299 114645 7520586 185657 
B2-85hTPN1.6d-TP 3934197 155330 12438600 259651 
B2-99hTPN1.6d-TP 4373122 170867 14636968 289408 
B2-98.6dTPN1.6c-TP 4769943 175638 14885721 292677 
B2-98.6dTPN1.6s-TP 3181565 139788 10921409 238083 
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3.5.2.4 SANS studies of Brij O10 nanoemulsions containing tristearin in the 
absence of drug 
A range of models were used in order to try and individually fit the drop contrast of B2-
99hGTS NE at different 99hGTS concentrations within Regions B and C. The SANS 
data for the B2-99hGTS NE along with the best fits to the data, which was obtained 
using the core-shell ellipsoid model, are shown in Figure 3.71 while Table 3.23 shows 
the parameters obtained from the best fits to the SANS data.  
a) b)  
Figure 3.71: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 
increasing concentration of 99hGTS from a) 0.1-0.6 %w/w and b) 0.8-1.3 %w/w. 
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Table 3.23 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and 99hGTS nanoemulsions in the absence of drug using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore (cont.). 
 








































B2-99hGTS0.1d C 21.5 0.3 5.8 25.9 47.4 31.7 0.7 297661 50.0 35 163 86 18202 
B2-99hGTS0.2d 
B 
65.6 0.1 4.2 24.6 90.2 28.9 0.3 984760 93.4 30 556 89 410200 
B2-99hGTS0.4d 42.3 0.4 16.2 23.4 65.7 39.6 0.6 715844 73.5 15 442 73 19238 
B2-99hGTS0.6d 50.3 0.4 21.2 22.2 72.5 43.4 0.6 956006 83.2 15 544 77 16335 
B2-99hGTS0.8d 64.6 0.4 23.5 21.8 86.3 45.2 0.5 1411995 91.4 15 745 78 60184 
B2-99hGTS1.0d 81.2 0.3 24.5 20.2 101.5 44.8 0.4 1932429 108.1 10 987 80 168260 
B2-99hGTS1.2d 
C 97.4 0.3 25.1 19.3 116.7 44.4 0.4 2535455 126.2 10 1210 85 333480 
B2-99hGTS1.3d 111.4 0.2 25.2 19.2 130.6 44.4 0.3 3169667 136.9 10 1465 86 488930 
 
Estimated uncertainty for the radius of the R1 for either B2-99hGTS0.1d, B2-99hGTS0.4d, B2-99hGTS0.6d or B2-99hGTS0.8d were ± 0.3, that for either B2-99hGTS1.0d, B2-99hGTS1.2d or B2-
99hGTS1.3d were ± 1.0 and that for B2-99hGTS0.2d were ± 0.3.  
Estimated uncertainty for x of all B2-99hGTS NE was ± 0.01. 
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The results obtained indicate that there was no strong interaction occurring between 
droplets, as would be expected from a diluted NE. After attempting to fit the SANS data 
for each NE using various levels of hydration for the shell, the best levels of shell 
hydration for the 99hGTS NE were found to decrease from 35 % for 99hGTS0.1 to 10 
% for hGTS1.0d whereafter it remained constant for all higher 99hGTS concentrations. 
The optimal value of the shell thickness was found to be in the range 19.2-25.9 Å. The 
axial ratio of the core, which was less than 1, suggested that the shape of B2-99hGTS 
NE were oblate ellipsoids. Surprisingly, the core equatorial radius of the NE varied 
irregularly with oil concentration, first increasing at low oil concentrations from 21.5 Å 
for B2-99hGTS0.1d to 65.6 Å for B2-99hGTS0.2d and finally decreasing to 42.3 Å for 
B2-99hGTS0.4d. This unusual variation could explain the change in the appearance of 
the 99hGTS NE from cloudy at B20-99hGTS1 to translucent at B20-99hGTS2. At 
99hGTS concentrations of above 0.4 %w/w, the core equatorial radius of the NE 
increased with increasing 99hGTS content. The shape of the B2-99hGTS0.1d NE 
changed from an oblate ellipsoid to more elongated ellipsoids after the addition of 1 
%w/w 99hGTS.  After adding more 99hGTS, the shape of NE become more spherical 
in Region B and then surprisingly changed to become more elongated in Region C as 
indicated by the droplet axial ratio. A schematic representation of the ellipsoidal 2 
%w/w Brij O10 NE containing the different amount of 99hGTS at the upper boundary 
of each Region in the absence of drug is shown in Figure 3.72. 
 
a) b)  
c) d)  
 
Figure 3.72: Schematic representation of the ellipsoidal 99hGTS NE a) B2-99hGTS0.1d in 
Region C, b) B2-99hGTS0.2d in Region B, c) B2-99hGTS1.0d NE in Region B and d) B20-
99hGTS1.3d in Region C. 
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The major radius of B2-99hGTS NE only slightly changed for B2-99hGTS0.1d NE 
(31.7 Å) and B2-99hGTS0.2d NE (28.9 Å) while the minor radius increased from 47.4 
Å to 90.2 Å for B2-99hGTS0.1d NE and B2-99hGTS0.2dNE, respectively. After the 
addition of more 99hGTS, the major radius of B2-99hGTS NE in Regions B and C NE 
increased from 39.6 Å for B2-99hGTS0.4d to 45 Å for B2-99hGTS1.3d while the minor 
radius of B2-99hGTS NE increased upon increasing 99hGTS concentrations from 65.7 
Å for B2-99hGTS0.4d to 130.6 Å for B2-99hGTS1.3d. 
 
3.5.2.5 SANS studies of Brij O10 nanoemulsions containing ethyl oleate in the 
absence and presence of drug 
A range of models were used to individually fit the drop contrast of B2-98hEO NE at a 
range of different 98hEO concentrations of 98hEO in Regions A and B. The SANS data 
and best fits to B2-98hEO NE were obtained using a core-shell ellipsoid model and are 
shown in Figure 3.73 while Table 3.24 gives the parameters used to obtain the best fits. 
As expected the results indicated that there was no strong interaction between the 
diluted NE. Again as expected, the core equatorial radius of the NE increased with 
98hEO content, a trend which was similar to that seen with dynamic light scattering.  
 
Figure 3.73: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 
increasing concentration of 98hEO from 0.2-0.8 %w/w. 
 
Preparation of Brij O10 nanoemulsions 
201 
Table 3.24 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and 98hEO nanoemulsions in the absence of drug using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 






























Nagg surfaces  
area of  
surfactant 
 (Å2) 






27.3 0.4 10.6 23.9 51.2 34.4 0.7 378186 52.8 20 241 79 21207 
B2-98hEO0.4d 34.8 0.5 17.5 22.6 57.4 40.0 0.7 552902 64.7 20 325 83 12030 
B2-98hEO0.6d 43.8 0.5 23.1 22.3 66.1 45.5 0.7 832499 67.4 20 452 81 12454 
B2-98hEO0.8d B 53.3 0.6 29.4 21.8 75.0 51.2 0.7 1208160 79.1 15 638 77 3026 
 
Estimated uncertainty for the radius of the R1 and x were ± 0.3 and ± 0.01, respectively. 
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After attempting to fit the SANS data using a range of shell hydrations, the best fit for 
the shell hydration of 98hEO NE was found to decreased from 20 % at 98hEO0.2 to 15 
% at 98hEO0.8. The thickness of the shell obtained from the fits were in the range 21.8-
23.9 Å. It was clear that the model that provided the best fit to the SANS data was that 
of an oblate ellipsoid as the axial ratio was less than 1. Furthermore, the shape of the NE 
became more spherical as the oil content increased as suggested by the droplet axial 
ratio. A schematic representation of the oblate ellipsoids of 2 %w/w Brij O10 NE 
containing the maximum amount of 98hEO incorporated in a) Region A and b) Region 
B in the absence of drug is shown in Figure 3.74. The major radius of B2-98hEO NE in 
Regions A and B NE increased from 34.4 Å for B2-98hEO0.2d NE to 51.2 Å for B2-
98hEO0.8d NE, while the minor radius increased from 51.2 Å for B2-98hEO0.2d NE to 
75.0 Å for B2-98hEO0.8d NE upon increasing 98hEO concentration.  
 
a) b)  
Figure 3.74: Schematic representation of the oblate ellipsoids of 98hEO NE for a) B2-
98hEO0.6d in Region B and for b) B2-98hEO0.8d in Region B in the absence of drug. 
 
A range of form factors were used to obtain individually the best fit to the SANS data 
obtained for the drop contrast of TP containing NE, namely B2-98hEO-TP, at different 
98hEO concentrations in Region A. The upper limit of the amount of 98hEO 
incorporated into NE denoted in Regions A and B are shown in Figure 3.75. It is clear 
that there was no difference in the size and shape of the NE in the absence and presence 
of TP. The SANS data and best fits to TP-containing NE of B2-98hEO-TP were 
obtained using the core-shell ellipsoid model as shown in Figure 3.76. Table 3.25 gives 
the values of the parameters used to obtain the best fits to the SANS data. As anticipated 
the results suggested that there was no significant interaction between the NE as 
anticipated with dilute NE.   
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a) b)  
Figure 3.75: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE at the limit 




Figure 3.76: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 
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Table 3.25 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and 98hEO nanoemulsions in the presence of TP using a core-shell 
ellipsoid model together with a hard sphere structure factor S(Q). The modelling of the SANS was constrained using Vshell(dry)/Vcore. 
 






























Nagg surfaces  
area of  
surfactant 
 (Å2) 






26.6 0.4 11.2 24.0 50.7 35.2 0.7 378691 51.7 20 242 78 3211 
B2-98hEO0.4d-TP 35.2 0.5 17.9 22.9 58.1 40.9 0.7 578292 60.5 20 340 80 5305 
B2-98hEO0.6d-TP 43.6 0.6 24.2 22.7 66.3 46.8 0.7 862471 71.8 20 469 70 4368 
B2-98hEO0.8d-TP B 53.7 0.6 29.8 22.0 75.7 51.8 0.7 1241806 78.4 15 656 76 5256 
 
Estimated uncertainty for the radius of the R1 and x were ± 0.3 and ± 0.01, respectively. 
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As can be seen from the parameters used for the fitting, the SANS results showed only a 
slight difference in size and shape of NE droplets in the presence and absence of TP. As 
expected, the core equatorial radius of the drug-containing NE, B2-98hEO-TP, 
increased with 98hEO content - a trend that was seen with B2-98hEO also. Attempts 
were made to fit the SANS data with varying levels of shell hydration, and it was found 
that the shell hydration of hEO NE decreased from 20 % in B20-98hEO0.2d-TP NE to 
15 % in B20-98hEO0.8d-TP, while the thickness of the shell varied from 24 Å to 21 Å. 
It was clear that the model that provided the best fit to the SANS data was that of an 
oblate ellipsoid.  
In Regions A and B, the solubilisation of TP in B2-98hEO-TP increased, most likely 
because of the bigger core equatorial radius together with the high solubility of TP in 
98hEO. As anticipated that NE became less oblate/more spherical upon increasing their 
98hEO loading, the change in morphology explaining the increase in TP solubilisation 
in both Region A and B. 
In Regions A and B upon increasing 98hEO concentration, the major radius of the TP-
containing NE, B2-98hEO-TP NE, increased from 35.2 Å for B2-98hEO0.2d-TP NE to 
51.8 Å for B2-98hEO0.8d-TP NE while the minor radius of B2-98hEO-TP NE changed 
from 50.7 Å for B2-98hEO0.2d-TP NE to 75.7 Å for B2-98hEO0.8d-TP NE. The 
SANS data did not exhibit any difference in the size and shape of the TP-containing and 
TP-free NE - a result in contradiction to that obtained from the PCS experiment. The 
fact that PCS assumed that the NE were spherical, when clearly the SANS experiments 
indicated that the shape of the TP-containing NE, B2-98hEOd-TP NE, were not 
spherical, might be the reason why the PCS results suggested that the size of the TP-
containing NE, B2-98hEO0.8d-TP NE, were larger than the drug-free, B2-98hEO0.8d 
NE. 
Table 3.26 shows the volume and the surface area of ellipsoid and sphere. The PIT and 
TP solubilisation results of 98hEO NE suggested that TP would sit in oil core and 
surfactant interface, therefore the volume that TP could be solubilised is the volume of 
oil core and surfactant hydrocarrbon tail. The schematic representation of ellipsoidal EO 
NE is shown in Figure 3.77.  
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Figure 3.77: The schematic representation of ellipsoidal ethyl oleate nanoemulsion with the 
equatorial radius of the core (R1), major radius of ellipsoid core (xR1) and the length of the 
surfactant hydrocarbon tail (lc) 
 
The minor radius of ellipsoid is the length of the core equatorial radius (R1) and the 
length of surfactant hydrocarbon tail (lc) i.e. 17.3 Å (Malcolmson et al., 1995) (R1+lc), 
and the major radius of ellipsoid is the length of core axial radius (R1x) and the length 
of surfactant hydrocarbon tail (R1x+lc) were used to calculate the volume of oblate 
ellipsoid, whereas the radius of sphere is the length of core equatorial radius (R1) 
obtained from the fitting of the SANS data for NE and the length of the surfactant 
hydrocarbon tail (lc) calculated to be 17.3 Å by Malcolmson et al. (1995), i.e. R1+lc. The 





Clearly, the volume and surface area of ellipsoid were much lower than those of sphere 
which suggested that the change in NE shape from sphere to ellipsoid resulted in the TP 
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Table 3.26 The comparison of the volume and the surface area of ellipsoid and sphere of 2 
%w/w Brij O10 and 98hEO nanoemulsions in the presence of TP 
 
sample region ellipsoid sphere 
 volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
ellipsoid 
(Å3) 
volume of oil core 
and tail of 
surfactant (Å3) 
surface area of 
sphere 
(Å3) 
B2-98hEO0.2d-TP A 229599 18786 354290 24217 
B2-98hEO0.4d-TP 406156 27324 605152 34603 
B2-98hEO0.6d-TP 644029 37079 946627 46630 
B2-98hEO0.8d-TP B 992711 49673 1497202 63299 
 
3.5.3 Effect of temperature on Brij O10 nanoemulsions in the absence and 
presence of drug 
In order to use Brij O10 NE as vehicles for the delivery of anticancer agents and to test 
their cytotoxicity using cell culture, it is essential to understand the effect of 
temperature, namely 37 °C (i.e. body temperature and the temperature used for 
cytotoxicity experiments) on the structure of the NE. It has been reported previously 
that the structure of the nonionic surfactant micelles formed by C12E6 did not change 
over a temperature of 25 and 31 °C when assessed using SANS (Zielinski wt al, 1995).  
Another SANS study over the wider temperature range of 30 to 75 °C showed that sizes 
of anionic, SDS micelles of 10 wt% decreased in size with an increase in temperature, 
while in contrast the size of micelles formed by the non-ionic surfactant, C12E10 at 10 
%w/w increased in size. The SANS data of C12E10 exhibited a weak correlation peak, 
which shifted to smaller Q values with an increase in temperature, while there was an 
increase in the scattering cross-section on raising temperature (Aswal and Wagh, 2008). 
The present SANS study will therefore determine the effect of temperature on the 
properties of the Brij O10 NE. The oil selected for further study was SBO. The insight 
provided by this study should provide a better understanding of the potential of NE as 
vehicles for drug delivery. 
A range of models were used to individually obtain the best fit to the drop contrast 
SANS data for B2-hSBO NE at either 0.6, 0.8 or 0.9 %w/w hSBO at 37 °C. The best fit 
model was obtained using core-shell ellipsoid model and are shown in Figures 3.77-
3.80. Table 3.27 gives the parameters used to obtain the best fits to the SANS data. As 
can be seen from the fitting parameters, the SANS results showed a small difference in 
size and shape of NE droplets at 25 and 37 °C, both in drug-free and drug-containing 
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NE. As expected, the core equatorial radius of the B2-hSBO-37C increased with hSBO 
content, a trend which was similar to that seen in the same NE at 25 °C. After fitting the 
SANS data with varying levels of shell hydration, the shell hydration of hSBO-CUR-TP 
was found to remain at 10 % for NE containing 0.6, 0.8 or 0.9 %w/w hSBO, regardless 
of the presence of drug. The thickness of the shell obtained from the fits remained 
constant at about 22.0-23.0 Å. The model that provided the best fit to the SANS data 
was an oblate ellipsoid.  
a) b)  
Figure 3.78: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
0.6 %w/w hSBO with and without the presence of drug at 25 and 37 °C. 
 
a) b)  
c)   
Figure 3.79: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
0.8 %w/w hSBO with and without the presence of drug at 25 and 37 °C. 
Preparation of Brij O10 nanoemulsions 
209 
a) b)  
c)   
Figure 3.80: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
0.9 %w/w hSBO with and without the presence of drug at 25 and 37 °C. 
 
The fact that there was no change in the size and shape of hSBO NE at the higher 
temperature of 37 °C was in agreement with the PIT studies on hSBO NE - the PIT is 
much higher than 37 °C. A similar result was seen in previous studies, using nonionic 
micelles (Degiorgio and Corti, 1984) and other nonionic ME systems (Aveyard et al., 
1989), which concluded that at temperatures below the PIT the intensity of the scattered 
neutron radiation varies little with temperature and that only fairly weak interactions 
between NE exist. 
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Table 3.27 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and hSBO nanoemulsions in the absence and presence of drug using a 
core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 ˚C. The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  
area of  
surfactant  
(Å2) 






49.0 0.5 22.1 22.9 71.9 45.0 0.6 974078 70.7 10 592 69 6552 
B2-hSBO0.6d-CUR-37C 49.8 0.4 21.2 22.7 72.4 43.9 0.6 964522 74.0 10 586 71 7017 
B2-hSBO0.6d-CUR-TP-37C 50.4 0.4 21.1 22.8 73.2 43.9 0.6 986382 74.2 10 599 70 8112 
B2-hSBO0.8d-37C 61.0 0.4 25.7 22.7 83.7 48.4 0.6 1419746 84.4 10 802 69 19603 
B2-hSBO0.8d-CUR-37C 62.1 0.4 24.4 22.3 84.5 46.8 0.6 1399786 88.4 10 790 71 14794 
B2-hSBO0.8d-CUR-TP-37C 62.1 0.4 24.3 22.3 84.4 46.6 0.6 1389929 88.3 10 785 71 6510 
B2-hSBO0.9d-37C 68.6 0.4 26.0 22.2 90.8 48.2 0.5 1667050 97.5 10 909 71 12891 
B2-hSBO0.9d-CUR-37C 69.2 0.4 25.5 22.1 91.3 47.6 0.5 1664286 97.4 10 908 71 13436 
B2-hSBO0.9d-CUR-TP-37C 71.6 0.4 25.1 22.4 93.9 47.4 0.5 1754382 100.3 10 957 70 15300 
 
Estimated uncertainty for R1 and x were ± 0.3 and ± 0.01, respectively. 
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3.5.4 Effect of cell culture media on Brij O10 nanoemulsions in the absence and 
presence of drug 
In order to use Brij O10 NE as vehicles for the delivery of anticancer agents and to test 
their cytotoxicity in cell culture, it is essential to understand the effect of plasma 
proteins, which are present in the bloodstream and in cell culture media, on the structure 
of the NE. It has been reported previously that the addition of either the anionic 
surfactant, SDS, or the cationic surfactant, CTAB, to protein bovine serum albumin 
(BSA) exhibits a binding to the protein which leads to a change in the size and structure 
of protein (Chodankar et al., 2007; Gull et al., 2008; Gull et al., 2009).   
Although it is theoretically possible to use light scattering to observe any changes in the 
physical properties of the NE in the presence of electrolyte and/or plasma proteins, the 
wavelength of light (~ 500 nm) compared to the size (< 20 nm) of the NE droplets 
means that it will only be possible to detect gross changes in the NE without being able 
to attribute these changes to changes in the size and/or shape of the NE. Furthermore, 
such light scattering experiments are further complicated by the fact that the presence of 
plasma proteins, which themselves scatter light, and therefore complicate the analysis. 
Despite these problems, it is essential to determine the effect of serum on the NE if they 
are to be used as delivery vehicles intended for the intravenous administration. The aim 
of this part of the project is therefore to use SANS to determine the influence of the 
presence of plasma proteins on the physico-chemical properties of the Brij O10 NE and 
in particular their size and/or shape. Such a study should provide a better understanding 
of the potential of NE as vehicles for drug delivery. 
A range of models were used to establish the best fit to the drop contrast of B2-hSBO 
NE at either 0.6 or 0.9 %w/w hSBO in the presence of cell culture media at 37 °C 
overtime. The SANS data and the best fits to B2-hSBO-DM-37C using the core-shell 
ellipsoid model are shown in Figures 3.81-3.82 while Tables 3.28-3.29 show the 
parameters used to obtain the best fits to the SANS data. As can be seen from the fitting 
parameters, the SANS results of B2-hSBO-DM-37C exhibited a lower scattering 
intensity due to the fact that these samples contained H2O which has lower scattering 
density than D2O and therefore resulted in lowering the overall SLD difference between 
the NE samples and the solvent which comprised of a 1:1 mixture of D2O and cell 
culture media (DM). The parameters used to obtain the best fits to the data indicated 
that there were slight differences in the size and the shape of hSBO NE droplets at the 
temperature of 37 °C in the presence of cell culture media, regardless of the presence of 
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drug over 11 hours compared to size and shape of the corresponding hSBO NE at 25 
°C. As anticipated the core equatorial radius of the B2-hSBO-37C NE increased with 
hSBO content, a trend which was similar to that seen for B2-hSBO NE at 25 °C. 
Attempts at fitting the SANS data using varying levels of shell hydration. The shell 
hydration of B2-hSBO-DM-37C was found to be 10 % for all NE containing either 0.6 
or 0.9 %w/w hSBO, regardless of the presence of drugs. The thickness of the shell 
obtained from the fits remained constant at about 22.0-22.9 Å. It was clear that the 
model that provided the best fit to the SANS data was an oblate ellipsoid. 
 
 
Figure 3.81: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
0.6 %w/w hSBO with and without drugs in the absence and presence of cell culture media (1:1 










Figure 3.82: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
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Table 3.28 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and 0.6 %w/w hSBO nanoemulsions in the absence or presence of 
drugs and cell culture media using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 ºC. The modelling of the SANS data was 


































Nagg surfaces  
area of  
surfactant 
 (Å2) 




B2-hSBO0.6-DM-37C-t0 49.4 0.4 21.3 22.6 72.0 43.9 0.6 954604 75.3 10 580 71 150 
B2-hSBO0.6-DM-37C-3h 48.7 0.5 22.0 22.8 71.5 44.8 0.6 959652 77.3 10 583 70 138 
B2-hSBO0.6-DM-37C-6h 49.2 0.4 21.9 22.9 72.1 44.8 0.6 975300 73.6 10 593 70 117 
B2-hSBO0.6-DM-37C-11h 49.1 0.4 21.7 22.7 71.9 44.4 0.6 962490 78.7 10 585 70 122 
B2-hSBO0.6-CUR-DM-37C-t0 49.6 0.4 20.7 22.4 71.9 43.0 0.6 933581 75.3 10 567 72 265 
B2-hSBO0.6-CUR-DM-37C-3h 49.5 0.4 20.8 22.4 71.9 43.2 0.6 934733 80.9 10 568 72 273 
B2-hSBO0.6-CUR-DM-37C-6h 48.8 0.4 21.2 22.4 71.2 43.6 0.6 927440 84.4 10 564 72 225 
B2-hSBO0.6-CUR-DM-37C-11h 49.2 0.4 20.9 22.4 71.6 43.2 0.6 928161 83.4 10 564 72 210 
B2-hSBO0.6-CUR-TP-DM-37C-t0 50.1 0.4 20.8 22.6 72.6 43.4 0.6 959085 78.9 10 583 71 355 
B2-hSBO0.6-CUR-TP -DM-37C-3h 49.5 0.4 21.1 22.5 72.1 43.6 0.6 949914 76.3 10 577 71 428 
B2-hSBO0.6-CUR-TP -DM-37C-6h 49.4 0.4 21.1 22.6 72.0 43.7 0.6 949459 77.9 10 577 71 355 
B2-hSBO0.6-CUR-TP -DM-37C-11h 51.3 0.4 20.3 22.6 73.9 42.9 0.6 981588 77.7 10 596 71 250 
 




Preparation of Brij O10 nanoemulsions 
215 
Table 3.29 Parameters used for the best fits to the individual SANS data for 2 %w/w Brij O10 and 0.9 %w/w hSBO nanoemulsions in the absence or presence of 
drugs and cell culture media using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 ºC. The modelling of the SANS data was 










































B2-hSBO0.9-DM-37C-t0 68.4 0.4 26.1 22.2 90.6 48.3 0.5 1661527 92.6 10 906 71 519 
B2-hSBO0.9-DM-37C-3h 69.2 0.4 25.8 22.3 91.4 48.1 0.5 1684786 98.5 10 919 71 543 
B2-hSBO0.9-DM-37C-6h 68.8 0.4 26.1 22.3 91.1 48.5 0.5 1687578 98.9 10 920 70 528 
B2-hSBO0.9-DM-37C-11h 68.7 0.4 26.3 22.4 91.1 48.8 0.5 1697234 93.7 10 926 70 347 
B2-hSBO0.9d-CUR-DM-37C-t0 69.1 0.4 25.3 22.0 91.1 47.4 0.5 1646932 95.8 10 898 72 633 
B2-hSBO0.9d-CUR-DM-37C-3h 68.8 0.4 25.6 22.1 90.9 47.7 0.5 1652925 93.6 10 902 71 479 
B2-hSBO0.9d-CUR-DM-37C-6h 68.4 0.4 25.8 22.2 90.5 48.0 0.5 1647580 96.9 10 899 71 507 
B2-hSBO0.9d-CUR-DM-37C-11h 68.8 0.4 25.6 22.1 90.9 47.7 0.5 1652389 96.3 10 901 71 514 
B2-hSBO0.9-CUR-TP-DM-37C-t0 69.5 0.4 25.2 22.1 91.6 47.3 0.5 1661729 100.1 10 906 72 610 
B2-hSBO0.9-CUR-TP-DM-37C-3h 70.3 0.4 25.4 22.3 92.6 47.6 0.5 1710677 95.3 10 933 71 466 
B2-hSBO0.9-CUR-TP-DM-37C-6h 70.2 0.4 25.3 22.2 92.5 47.6 0.5 1705551 99.7 10 930 71 394 
B2-hSBO0.9-CUR-TP-DM-37C-11h 71.2 0.3 24.9 22.2 93.4 47.1 0.5 1721092 94.2 10 939 71 479 
 
Estimated uncertainty for R1 and x were ± 0.4 and ± 0.01, respectively. 
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To sum up, the effect of amount of oils and the presence of drug on the SANS results of 
all micelles and NE are shown in Table 3.30, while the effect of temperature and the 
presence of cell culture media on the SANS results of B2-hSBO NE are shown in Table 
3.34. 
 
Table 3.30 SANS results of micelles and NE in the absence and presence of drugs at 25 °C. 
 
Sample Appearance of droplet 
B2d Prolate ellipsoid 
B2d-TP Prolate ellipsoid 
B2d-TP showed the slight difference in shape and size to drug-free 
B2d. 
B2d-CUR Prolate ellipsoid 
B2d-CUR showed the change in shape to drug-free B2d due to the 
increased axial ratio. 
B2d-CUR-TP Prolate ellipsoid 
B2d-CUR-TP showed the slight difference in shape and size to 
drug-free B2d. 
B2-hSBOd Oblate ellipsoid 
As the oil content increased, the shape of NE became more 
elongated with the increasing major radius in Region A and with the 
constant major radius in Region B and C. 
B2-hSBOd-TP Oblate ellipsoid 
The slight difference in the size and shape of NE droplets in the 
presence of drug. B2-hSBOd-CUR 
B2-hSBOd-CUR-TP 
B2-65hGTOd Oblate ellipsoid 
As the oil content increased, the shape of NE became more 
spherical in  Region A and B. 
B2-99hGTOd Oblate ellipsoid 
As the oil content increased, the shape of NE became more 
spherical in Region A and more elongated with the constant major 
radius in Region B. 
Note that the best fits for shell contrast at some concentrations of oil 





The slight difference in the size and shape of NE droplets in the 
presence of drug. 
Note that the best fits for shell contrast at some concentrations of 
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Table 3.30: SANS results of micelles and NE in the absence and presence of drugs at 25 °C.  
 
Sample Appearance of droplet 
B2-85hTPNd Oblate ellipsoid 
As the oil content increased, the shape of NE became more 
spherical in Region A and more elongated with the constant major 
radius in Region B. 
Note that the best fits for core and shell contrasts at some 




B2-85hTPNd-TP Oblate ellipsoid 
The slight difference in the size and shape of NE droplets in the 
presence of drug. 
Note that the best fits for core and shell contrasts at some 




B2-99hGTSd Oblate ellipsoid 
B2-98hEO 
Oblate ellipsoid 
As the oil content increased, the shape of NE became more 
spherical in  Region A and B. 
B2-98hEO-TP 
Oblate ellipsoid 
The slight difference in the size and shape of NE droplets in the 
presence of drug. 
 
Table 3.31 SANS results of micelles and NE at 37 °C and in the absence and presence of cell 
culture media.  
 
Sample Appearance of droplet 
B2-hSBOd-37C 
Oblate ellipsoid 





The slight difference in the size and shape of NE droplets at 37 °C 
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3.6 Chapter summary 
Brij O10 NE stabilised by 20 %w/w Brij O10, non-ionic surfactant, and containing 
either a triglyceride or an ethyl ester of different but high molar volume and of different 
levels of oil purity were prepared by the phase inversion temperature (PIT) method. 
Clearly, the level of saturation of fatty acid in oils and the purity of oils have an effect 
on the extent of the area of NE existence. PIT experiments, particle size determination 
and SANS studies suggest that Brij O10 NE forms a distinct core of oil in the NE 
droplets. 
In order to study the suitability of Brij O10 NE as drug delivery vehicles, two poorly 
water soluble drugs, TP and CUR, were selected as model drugs. The level of TP 
solubilisation obtained suggested that Brij O10 NE were suitable as drug delivery 
vehicles for TP in both the clear/transparent, Region A and bluish/translucent, Region B 
NE. In addition, the SANS studies explained the decrease in TP solubility observed in 
cloudy/milky, Region C NE which was due to their transformation in morphology, 
changing the shape of the aggregate from an oblate ellipsoid to more elongated ellipsoid 
as the oil content increased. On the other hand, CUR solubilisation suggested that Brij 
O10 NE are suitable to deliver CUR as they exhibit a high level of CUR solubilisation. 
However, the solubilisation of CUR did not show an increase upon increasing the 
amount of oil in the B20-hSBO and B20-98hEO NE. This is due to a small amount of 
CUR solubilised in both oils. While the solubilisation of CUR and TP in B20-hSBO NE 
exhibited an increase in CUR solubilisation, solubilisation of TP decreased compared to 
NE containing only one drug, which suggested that the presence of CUR affected TP 
solubilisation in the NE. 
In the chapter 5, to determine the efficacy of NE as a delivery vehicle for anticancer 
drug, CUR, B20 micelle, B20-hSBO and B20-98hEO NE in the absence and presence 






Chapter 4                                             
The preparation of nanoemulsions with 
other nonionic surfactants in the 
absence and presence of cosurfactant 
 
4.1 Introduction 
4.1.1 Background  
The method of formation of nanoemulsions (NE) from ternary mixtures of oil, 
surfactant and water used in the present project involves the input of a low amount of 
energy in an approach known as the phase inversion temperature (PIT) method. In this 
method of NE preparation, which is only applicable to NE prepared using a POE-
containing nonionic surfactant, the NE components are first heated to a temperature 
above the PIT of the system and then cooled back down to their original temperature 
with constant agitation generally required to produce the NE. Mostly, nonionic 
surfactants are chosen to achieve this goal because of their safety and pharmaceutical 
acceptability and the fact that they exhibit a PIT. Within this surfactant class, 
ethoxylated surfactants are mainly chosen because of their inherent ability to become 
more hydrophobic with increasing temperature over a reasonable temperature range 
(Izquierdo et al., 2004; Anton and Vandemme, 2011).  
Factors affecting the area of nanoemulsion existence include the presence of 
cosurfactants, the relative proportion of each component, the chemical nature of 
surfactant, the molecular volume of the oil, and the experimental temperature. Recently, 
the addition of medium chain monoglycerides (MCM) into oil-in-water (o/w) NE 
formation has been studied. MCM are pharmaceutically acceptable and are used 
extensively in cosmetic products and in the pharmaceutical industry (Cornwell et al., 
1998). 
In this chapter, the phase behaviour (area of existence) of NE is studied and the results 
obtained are discussed. The area of NE existence is represented using ternary phase 
diagrams. When a mixture of surfactant and cosurfactant was examined in the present 
study, the resulting data were plotted on pseudoternary phase diagrams using a constant 
weight ratio of the surfactant:cosurfactant. Nonionic surfactants were investigated here 
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because of their low toxicity which makes them suitable for use in parenteral 
microemulsions (ME) (Strickley, 2004; Date and Nagarsenker, 2008). Monocaprylate 
(Dermosoft GMCY), a monoglyceride, and lecithin were used as cosurfactants in the 
NE formulations studied here, with the view of investigating the effect of added 
monoglyceride and/or lecithin on the phase behaviour of the nonionic surfactant NE. 
Oils, either the triglyceride, hSBO, or the ethyl ester, 98hEO, were added to the 
surfactant or the mixture of surfactant and cosurfactant. Both oils used in this study are 
pharmaceutically acceptable, being frequently used in parenteral formulations 
(Strickley, 2004; Date and Nagarsenker, 2008). The area of isotropic o/w NE existence 
and a range of the physico-chemical properties of the o/w NE; namely PIT and particle 
size were investigated. The PIT of the polyoxyethylene nonionic surfactants were 
studied in order to ensure the absence of any phase change at around the experimental 
temperature of 25 °C and to ensure that the particle size of the NE remained constant 
over time. The NE were finally studied using small angle neutron scattering to probe 
their internal structure at 25 and 37 °C to determine the effect of temperature on the 
shape and size of NE and in the presence of cell culture media to determine the effect of 
protein on the size and structure of the NE. 
 
4.1.2 Aim of the study 
The aim of the present study was to investigate the possibility of formulating o/w NE 
using pharmaceutical acceptable ingredients and to understand their molecular 
architecture and their physico-chemical properties in order to improve their capacity for 
poorly-water soluble drugs such as testosterone propionate (TP), curcumin (CUR) or 
docetaxel (DTX). A range of physico-chemical techniques have been employed to 
achieve this aim. 
 
4.2 Micelle and nanoemulsion without drug 
4.2.1 The area of existence of nanoemulsions 
Formation of nonionic surfactant nanoemulsions 
The phase behaviour of a number of pharmaceutically acceptable, POE-containing 
nonionic surfactants; namely the polyoxyethylene (POE) alkyl ethers, Brij 35 and Brij 
99; the aryl alkyl polyoxyethylene ethers, Triton X-100 and Tyloxapol; the POE 
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sorbitan fatty acid, Tween 20, 60 and 80; and the POE-polyoxypropylene (POP) 
surfactants, Lutrol F68 in the presence of either the triglyceride, hSBO, or the ethyl 
ester, 98hEO, and water has been investigated. The appearance of the resulting one-
phase NE ranged from transparent, where the samples were described as Region A, 
through bluish/translucent, when the samples were denoted as Region B, to 
cloudy/milky samples, which were termed Region C when plotted on the ternary phase 
diagram. The upper limits of the amount of oil incorporated into the NE prepared using 
the nonionic surfactants, denoted as Regions A, B and C, are shown in Table 4.1. Note 
that if NE did not form clear NE using 20 %w/w surfactant concentration or alternately 
formed NE containing only a very small amount of oil, no attempt was made to examine 
oil solubilisation levels for other concentrations of surfactants. 
 
Table 4.1 Upper limit of the amount of oil (%w/w) incorporated into Regions A, B and C of 
nonionic nanoemulsions containing a single surfactant at room temperature. 
 




15 %w/w  
surfactant 
20 %w/w  
surfactant 




A B C A B C A B C A B C A B C A B C 
Brij 35 
 
hSBO N N N N N N N N N - - - N N N N N N 
98hEO N N N N N N N N N - - - N N N N N N 
Brij 99 
 
hSBO N N N N N N N N N - - - N N N N N N 
98hEO N N N N N N - - - 1 - - 1 - - - 1 - 
Lutrol F68 
 
hSBO N N N N N N N N N - - - N N N N N N 




hSBO N N N N N N - - - 1 - - 1 - - - 1 - 
98hEO N N N - 2 - 2 4 - 4 - - 4 5 - 2 3 - 
Tyloxapol 
 
hSBO N N N N N N N N N - - - N N N N N N 
98hEO N N N N N N N N N - - - N N N N N N 
Tween 20 
 
hSBO N N N N N N N N N - - - N N N N N N 
98hEO N N N N N N N N N - - - N N N N N N 
Tween 60 
 
hSBO N N N N N N N N N - - - N N N N N N 
98hEO N N N N N N N N N - - - N N N N N N 
Tween 80 hSBO N N N - 1 2 1 - - 2 4 5 3 4 - 1 2 - 
98hEO N N N 1 - - 1 - - 1 3 - 1 2 - 2 3 - 
 
- means the NE was not formed. 
N  means the experiment was not performed. 
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As seen in Table 4.1, NE could not be formed using when using either Brij 35, Lutrol 
F68, Tyloxapol, Tween 20, or Tween 60 as surfactant and containing either hSBO or 
98hEO as oil. Triton X-100 could form NE containing only a small amount of either 
hSBO or 98hEO. Similarly Brij 99 could form NE containing only a limited amount of 
98hEO. It has previously been reported that, while Brij 99 could form clear o/w ME 
containing either heptane or 1-heptene, it formed only a very small ME area when using 
IPM as oil, and no ME when using oils possessing a longer chain hydrocarbon such as 
hSBO, hexadecane, 1-hexadecene, octadecane or 1-octadecene (Malcolmson et al., 
1995), which suggested that Brij 99 NE could only form ME containing smaller molar 
volume oils at room temperature. This observation could be explained by the fact that 
when the smaller molecular volume oil molecules were used, they penetrated into 
hydrocarbon chains of the interfacial surfactant, acting in much the same was as a 
cosurfactant, increasing the effective CPP of the surfactants.  
In contrast, out of the additional surfactants studied, only Tween 80 formed a reasonable 
size area of NE existence when using either hSBO or 98hEO as oil. Yet, in comparison 
to the NE formed by Brij O10, the NE formed by Tween 80 could only incorporate 
small amounts of oil. It was anticipated that, amongst the Tween surfactants tested, 
Tween 80 would be able to incorporate the highest amount of oil due to its possession 
of the longest of hydrophobic alkyl chain of all of the Tween surfactants and its 
subsequent ability to form the largest sized micellar aggregates (Tanford et al., 1977). 
Figures 4.1a-4.1b show the partial ternary phase diagrams for o/w Tween 80 NE 
formed using either 98hEO or hSBO in water. In fact, Tween 80 is already used as an 
emulsifying agent in the intravenous infusions, injections and oral formulations (Wade 
and Weller, 1994; Strickley, 2004; Date and Nagarsenker, 2008). For example, Cho et 
al. (2008) studied the formation of cosurfactant-free, o/w ME prepared using nonionic 
surfactants and showed that the transparent, liquid o/w Tween 80 ME could be formed 
using 20 %w/w Tween 80 and incorporating only 3 %w/w of the long chain triglyceride 
oil, canola. It has also been reported that the type of oil incorporated into the Tween 80 
NE had an effect on particle size (Ostertag et al., 2012). For example, medium chain 
triglycerides formed NE with droplet small sizes while mineral or long chain 
triglyceride oils formed NE containing relatively large sized particles. This observation 
suggests that the long hydrocarbon chain oils make it difficult to incorporated into 
Tween 80-based NE. The addition of cosurfactants into the NE formulations was 
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therefore studied as it was hoped that the cosurfactant might alter the structure of the 
NE and encourage the formation of a larger area of NE existence.  
Formation of nonionic surfactant nanoemulsions containing cosurfactant 
In the following study, either Dermosoft GMCY (monocaprylate, C8) and/or lecithin 
were added to the nonionic surfactant-based NE in order to study the effect of 
cosurfactants on their formation. 
Firstly, Dermosoft GMCY was mixed at a constant weight ratio of surfactant (either 
Tween 20 or Tween 80) to cosurfactant (Km). 98hEO was chosen as the model oil 
because it is a single chain oil with a high molar volume and is pharmaceutically 
acceptable. Furthermore, 98hEO is similar in structure to isopropyl myristate (IPM), 
which has been reported to form ME with either Tween 20 or Tween 80 in the presence 
of the monocaprylate, Imwittor 308 as cosurfactant (Jawhari, 1999). Moreover, the 
areas of ME existence obtained for cosurfactant-containing, lecithin-based ME 
incorporating either EO or IPM were very comparable, allowing the use of EO in place 
of IPM (Aboofazeli et al., 1993; Aboofazeli et al., 1995).  
The upper limit of the amount of oil incorporated into Regions A, B and C NE prepared 
using a nonionic surfactant in the presence of Dermosoft GMCY are shown in Table 
4.2. Figure 4.1c shows the partial ternary phase diagrams obtained for o/w NE prepared 
from Tween 80:Dermosoft GMCY and containing 98hEO. Clearly, it can be seen that a 
significantly higher level of oil incorporation was obtained in the Dermosoft GMCY-
containing NE compared to the Dermosoft GMCY-free NE. Encouragingly, the amount 
of 98hEO incorporated either Tween 20 or Tween 80 NE containing Dermosoft GMCY 
at a range of Km was similar to that reported for the Imwittor 308-containing NE by 
Jawhari (1999). The small differences reported in the level of oil incorporation between 
this and Jawhari’s earlier study could be the result of one or more of a number of 
effects, including the polydispersity of either POE surfactants or the Dermosoft GMCY. 
Indeed Jawhari (1999) previously reported that there were effects on phase behaviour 
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a)     b)  
c) d)  
Figure 4.1: Partial ternary phase diagrams for o/w nanoemulsions prepared using a) Tween 80 
and 98hEO; b) Tween 80 and hSBO; c) Tween 80:Dermosoft GMCY (Km 3:1) and 98hEO; d) 
Tween 80:Dermosoft GMCY:lecithin (Km 7.5:2.5:1) and hSBO after 1 months storage at room 
temperature. Clear NE are described as Region A NE, while bluish or translucent NE are called 
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Table 4.2 Upper limit of the amount of oil (%w/w) incorporated into Regions A, B and C of nonionic nanoemulsions containing either single surfactant 
or the mixture of surfactant and cosurfactant at room temperature. 
 
Surfactant with cosurfactant Weight ratio  
(Km) 
Oil 5% surfactant 10% surfactant 15% surfactant 20% surfactant 25% surfactant 30% surfactant 35% surfactant 
A B C A B C A B C A B C A B C A B C A B C 
Tween 20 without cosurfactant - 98hEO N N N N N N N N N - - - N N N N N N N N N 
Tween 20:Dermosoft GMCY  2:1 N N N N N N N N N N N N 8 9 - N N N N N N 
3:1 N N N N N N N N N N N N 6 7 - N N N N N N 
4:1 N N N N N N N N N N N N 3 4 - N N N N N N 
5:1 N N N N N N N N N N N N 3 - - N N N N N N 
Tween 80 without cosurfactant - 98hEO N N N 1 - - 1 - - 1 3 - 1 2 - 2 3 - N N N 
Tween 80:Dermosoft GMCY  2:1 N N N N N N N N N N N N 2 8 - N N N N N N 
3:1 1 - 2 2 3 - 3 5 - 6 7 - 10 - - 17 - - 23 - - 
4:1 N N N N N N N N N N N N 7 8 - N N N N N N 
5:1 N N N N N N N N N N N N 6 7 - N N N N N N 
 
- means the NE was not formed. 
N  means the experiment was not performed. 




The phase behaviour of NE could be explained by considering the action of Dermosoft 
GMCY as a cosurfactant within the interfacial surfactant region. Due to its low 
solubility in water, it is reasonable to assume that Dermosoft GMCY resides 
predominantly in the surfactant interfacial region and will act to increase the fluidity of 
the interfacial amphiphilic region, allowing more oil to penetrate the surfactant chains. 
It is anticipated that the incorporation of the hydrophobic amphiphile, Dermosoft 
GMCY into surfactant aggregates will result in an increase in the size of the aggregates, 
which in turn may increase the drug solubilising capacity of the NE (Saito and Shinoda, 
1967). The increase in the size of NE is likely to depend on how much of the 
cosurfactant, Dermosoft GMCY is incorporated.  
When using the saturated C12 surfactant, Tween 20, significant amounts of 98hEO were 
incorporated into NE when the Tween 20 was mixed with Dermosoft GMCY, the 
precise amount depending upon the mixing ratio (Km). The highest levels of 98hEO 
incorporation occurred at a Tween 20:Dermosoft GMCY weight mixing ratio of 2:1 - a 
result in agreement with previous studies (Jawhari, 1999). These observations are most 
likely related to the oil’s preferred site(s) of solubilisation. As a result of its relatively 
long hydrocarbon chain and its low polarity, when compared to Dermosoft GMCY 
(Malcolmson et al., 1998), 98hEO is considered to exhibit a low degree of penetration 
into the hydrocarbon chains of the interfacial surfactant monolayer, acting more like an 
oil than a cosurfactant, particularly at high concentrations of added 98hEO. As a 
consequence more 98hEO was solubilised when low weight mixing ratios were used, 
i.e. when there was a relatively high amount of cosurfactant present. When Tween 20 
was used as surfactant, no gel phase was found. At a total of 25 %w/w Tween 
20:Dermosoft GMCY and a Km of 2:1, the highest amount of 98hEO incorporation was 
recorded, with an upper limit of 8 %w/w 98hEO being seen in the clear, Region A NE 
and 9 %w/w being recorded in the bluish/translucent Region B NE. 
When the unsaturated C18:1 chain surfactant, Tween 80, was used significant amounts of 
98hEO were incorporated when it was mixed with Dermosoft GMCY, the precise 
amount being dependent upon the surfactant:cosurfactant weight mixing ratio (Km). The 
highest levels of 98hEO incorporation were seen to occur at a Tween 80:Dermosoft 
GMCY weight mixing ratio of 3:1. It is significant that a large clear (Region A) NE was 
formed when using 98hEO as oil and Tween 80:Dermosoft GMCY, most probably 




because the bulky C18:1 chain in 98hEO was matched with the surfactant chains Tween 
80, while the presence of the Dermosoft GMCY increases the fluidity of this region. 
Lecithin was selected as a surfactant for the study because of its non-toxicity and 
biocompatibility. In this study, lecithin was added to the surfactant, Tween 80, at a 
range of surfactant:cosurfactant weight ratios of Km. 98hEO and hSBO were chosen as 
the oils for study because they possess a high molar volume and are pharmaceutically 
acceptable. The appearance of the resultant samples varied from the clear/transparent, 
Region A, samples through bluish/translucent Region B samples to cloudy/milky 
(Region) samples, all of which were plotted on a ternary phase diagram. The maximum 
amount of oil incorporated into Regions A, B and C NE, prepared using the nonionic 
and lecithin surfactants, is shown in Table 4.3. Note, that if a composition did not form 
clear NE when using a total of 25 %w/w surfactant and incorporating a small amount 
(1-2 %w/w) of oil, no further attempt was made to examine higher levels of oil 
incorporation and/or other surfactant concentrations. 
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Table 4.3 Upper limit of the amount of oil (%w/w) incorporated into Regions A, B and C of nonionic nanoemulsions containing the mixture of surfactant and 
cosurfactant at room temperature. 
 
Surfactant with cosurfactant Weight ratio 
(Km) 
Oil 5% surfactant 10% surfactant 15% surfactant 20% surfactant 25% surfactant 30% surfactant 35% surfactant 
A B C A B C A B C A B C A B C A B C A B C 
Tween 80:lecithin 1:1 hSBO N N N - - - N N N N N N - - - N N N N N N 
98hEO N N N - - - N N N N N N - - 1 - - - N N N 
5:1 hSBO N N N - - - N N N N N N - 2 - N N N N N N 
98hEO N N N N N N N N N N N N - - 1 N N N N N N 
10:1 hSBO N N N - - - N N N N N N 1 - - N N N N N N 
98hEO N N N N N N N N N N N N 1 - - N N N N N N 
20:1 hSBO N N N - - - N N N N N N 1 - - N N N N N N 
98hEO N N N N N N N N N N N N 1 - - N N N N N N 
24:1 hSBO N N N - - - N N N N N N 1 - - N N N N N N 
98hEO N N N N N N N N N N N N 1 - - N N N N N N 
 
- means the NE was not formed. 
N  means the experiment was not performed. 




It was clear that Tween 80 in the presence of lecithin, at a range of different Km, could 
form NE but only containing 1 %w/w of hSBO or 98hEO, which is less than the amount 
of oil incorporated in NE formed by Brij O10 and Tween 80 when used as sole 
surfactants. It was well known that lecithin is too lipophilic and its molecular geometry 
is not well suited to form the highly curved surfaces required to form an o/w NE, when 
it is used as sole surfactant. In order to form stable lecithin-containing NE, it is 
therefore necessary to adjust its effective HLB/modify its critical packing parameter 
(Klang, and Valenta, 2011). In the system containing both lecithin and Tween 80, it is 
expected that the effective CPP of lecithin will be reduced by the addition of the more 
hydrophilic, Tween 80 surfactant which consequently allows the interfacial surfactant 
film to be more flexible resulting in it taking up the curvature necessary for the 
formation of o/w NE (Trotta et al., 2002). Indeed, additional POE surfactants such as 
Tween 80 are frequently added to surfactants such as lecithin, not only for modification 
of the critical packing parameter of lecithin, but also to provide steric stabilisation 
(Yilmaz and Borchert, 2005; Hoellar et al., 2009). However, as the mixture of Tween 
80 and lecithin in fact worsened the formation of NE, Dermosoft GMCY was added to 
the mixture to see if it can aid NE formation. 
The formation of NE using Tween 80, Dermosoft GMCY and lecithin was then 
explored using a mixture of Tween 80:Dermosoft GMCY at a constant weight ratio of 
Km 3:1 and adding to a 3:1 weight ratio of Tween 80:Dermosoft GMCY, lecithin in 
varying amounts from 5:1 to 24:1, which resulted in final weight ratios of Tween 
80:Dermosoft GMCY:lecithin of 3.75:1.25:1 to 18:6:1. As before, hSBO and 98hEO 
were selected as oils for this study. The appearance of resultant samples varied from 
clear/transparent (Region A) samples through bluish/translucent (Region B) samples, to 
cloudy/milky (Region C) samples which were plotted on a ternary phase diagram. The 
maximum of amount of oil incorporated into Regions A, B and C NE containing the 
nonionic surfactant, Tween 80, lecithin and Dermosoft GMCY is shown in Table 4.4. 
Note, that if a composition of Tween 80, lecithin and Dermosoft GMCY at 25 %w/w 
total surfactant mixture did not form a clear NE when using a small amount (1-2 %w/w) 
of oil, no further attempt was made to examine either higher levels of oil solubilisation 
levels or different surfactant concentrations. 
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Table 4.4 Upper limit of the amount of oil (%w/w) incorporated into Regions A, B and C of nonionic nanoemulsions containing either single surfactant or the 
mixture of surfactant and cosurfactants at room temperature. 
 
Surfactant with cosurfactant Weight ratio of Tween 80: 
Dermosoft GMCY: soybean 
lecithin 
Oil 5% surfactant 10% surfactant 15% surfactant 20% surfactant 25% surfactant 30% surfactant 35% surfactant 
A B C A B C A B C A B C A B C A B C A B C 
Tween 80:Dermosoft GMCY:lecithin 3.75:1.25:1 hSBO N N N N N N N N N - - - - - 1 N N N N N N 
98hEO N N N N N N N N N N N N - - - N N N N N N 
6:2:1 hSBO N N N N N N N N N - - - - - 1 N N N N N N 
98hEO N N N N N N N N N N N N N N N N N N N N N 
6.75:2.25:1 hSBO N N N N N N N N N N N N - - 1 N N N N N N 
98hEO N N N N N N N N N N N N N N N N N N N N N 
7.5:2.5:1 hSBO - - 1 - 1 2 - - - 2 3 - 4 - - 2 3 - 1 - - 
98hEO N N N N N N N N N N N N - - - N N N N N N 
9.75:3.25:1 hSBO N N N N N N N N N - - - 4 - - N N N N N N 
98hEO N N N N N N N N N N N N N N N N N N N N N 
11.25:3.75:1 hSBO N N N N N N N N N - - - 3 - - N N N N N N 
98hEO N N N N N N N N N N N N 1 - 2 N N N N N N 
13.5:4.5:1 hSBO N N N N N N N N N - - - N N N N N N N N N 
98hEO N N N N N N N N N N N N N N N N N N N N N 
14.25:4.75:1 hSBO N N N N N N N N N N N N 3 - - N N N N N N 
98hEO N N N N N N N N N N N N 1 - - N N N N N N 
 
- means the NE was not formed. 
N  means the experiment was not performed. 
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Table 4.4 Upper limit of the amount of oil (%w/w) incorporated into Regions A, B and C of nonionic nanoemulsions containing the mixture of surfactant and 
cosurfactants at room temperature (cont.). 
 
Surfactant with cosurfactant Weight ratio of Tween 80: 
Dermosoft GMCY:soybean 
lecithin 
Oil 5% surfactant 10% surfactant 15% surfactant 20% surfactant 25% surfactant 30% surfactant 35% surfactant 
A B C A B C A B C A B C A B C A B C A B C 
Tween 80:Dermosoft GMCY:lecithin 15:5:1 hSBO N N N N N N N N N 2 - - N N N N N N N N N 
98hEO N N N N N N N N N N N N N N N N N N N N N 
18:6:1 hSBO N N N N N N N N N 2 - - 3 - - N N N N N N 
98hEO N N N N N N N N N N N N 2 - - N N N N N N 
 
- means the NE was not formed. 
N  means the experiment was not performed. 
 




Overall, a higher amount of oil was incorporated in the NE stabilised by Tween 80, 
Dermosoft GMCY and lecithin compared to NE stabilised by Tween 80 and lecithin. 
This suggested that Dermosoft GMCY could encourage the formation of NE, an 
observation which can be explained by the reduction in the effective CPP of lecithin (a 
CPP = 1/2 - 1 suggests the formation of a vesicle or bilayer) upon the addition of a short 
chain cosurfactant. A short chain cosurfactant can reduce the effective CPP of a 
surfactant to (a CPP = 1/3 – 1/2 suggests the formation of a cylindrical aggregate, while 
a CPP <1/3 suggests the formation of a spherical aggregate) by its incorporation into the 
interfacial film or by increasing the fluidity of the interfacial layer of lecithin, thereby 
reducing the tendency of lecithin to form a highly rigid film (Bink et al., 1989) and 
allowing the interfacial film sufficient flexibility to form a highly curved NE droplet. 
Interestingly, this particular combination of surfactant/cosurfactant prefers 
incorporating hSBO to 98hEO. The highest amount of hSBO incorporated occurred at a 
weight ratio of Tween 80:Dermosoft GMCY:lecithin of between 7.5:2.5:1 and 
9.75:3.25:1. The weight ratio of 7.5:2.5:1 was chosen for further study because this ratio 
contained more lecithin and as a consequence it was anticipated to be less toxic towards 
cell lines (Figure 4.1d). 
 
4.2.2 Dilutability of nonionic o/w nanoemulsions  
The possibility of diluting a NE is important if it is to be used as a drug delivery 
vehicle. If a NE is to be administrated by intravenous injection then it will be subject to 
dilution by blood. The results obtained in this study show that the NE stabilised by 20 
%w/w Tween 80 (T20) in the absence of cosurfactant could be readily diluted down to 
at least 1 %w/w surfactant, and that these diluted samples remained stable for at least 
four weeks when stored at room temperature. These results suggest that the use of 
nonionic o/w NE in the absence of cosurfactant offers an important benefit if they are to 
be used for drug delivery purposes because the NE stabilised solely by nonionic 
surfactants prepared in this study were able to be diluted without any change in their 
appearance.  
In contrast, it is well established that the dilution of microemulsions (ME) containing 
cosurfactants can alter or destroy ME (Attwood, 1994). The ability of a NE containing a 
cosurfactant to be diluted is dependent on the nature of cosurfactant. For example, ME 
containing sorbitol, a hydrophilic cosurfactant, which resides predominantly in the 




aqueous phase, cannot be infinitely diluted without undergoing a phase separation 
(Attwood et al., 1992). In addition, cosurfactant-containing ME, are frequently 
destroyed upon dilution due to a cosurfactant partitioning out from the interfacial 
monolayer of the ME droplet to the continuous phase (Lawrence, 1994). In contrast, 
however, it has been observed that ME stabilised by the mixture of lecithin and N,N-
dimethyl alkyl amine N-oxides could be readily diluted (Satra, 1998). Taken together 
these results suggest that a suitable cosurfactant for incorporation into a NE intended for 
dilution would be one which will reside in the interfacial surfactant region, and which 
exhibits extremely low solubility in water, resulting in the ability to dilute the NE.  
The monoglyceride used in the present study is well established to be water insoluble 
and therefore micelles prepared with a Tween surfactant in combination with Dermosoft 
GMCY should be dilutable. For all NE, containing Dermosoft GMCY, it proved 
possible to dilute the NE with water, however the duration for which the diluted NE 
remained stable varied and was dependent upon the composition of the NE. In the case 
of NE prepared from Tween 20:Dermosoft GMCY at a Km of 2:1 and containing 
98hEO, the diluted NE became cloudy within 2 hours and therefore, Tween 
20:Dermosoft GMCY at a Km of 2:1 NE containing 98hEO were not suitable for further 
investigation in the present study. In contrast, the same dilution (i.e. 1:25) of NE 
containing either 98hEO and 25 %w/w Tween 80:Dermosoft GMCY at a Km of 3:1 
(TD25) or containing hSBO and 25 %w/w Tween 80:Dermosoft GMCY:lecithin at a 
Km of 7.5:2.5:1 (TDL25) were more stable than the Tween 20 NE containing Dermosoft 
GMCY, although the situation is complicated by the amount of oil incorporated into the 
NE, particularly true in the case of NE prepared in the absence of lecithin (Table 4.5).  
 
Table 4.5 Stability (as assessed in days) of 25 %w/w Tween 80:Dermosoft GMCY at a Km of 
3:1 (TD) NE containing 98hEO and 25 %w/w Tween 80:Dermosoft GMCY:lecithin at a Km  of 
7.5:2.5:1 (TDL) NE containing hSBO in the absence and presence of drug remained clear after 
diluted to 1 %w/w surfactant using water at room temperature. 
 











Compared to NE prepared with T20, it was clear from the results that the presence of 
Dermosoft GMCY or Dermosoft GMCY and lecithin in TD25 and TDL25 NE, 
respectively affected the appearance of diluted NE in that the diluted (i.e. Dermosoft 
GMCY and Dermosoft GMCY/lecithin free) T20 NE remained clear for longer than 
either of the diluted TD25 and TDL25 NE. Interestingly, dilution of the NE was 
associated with a dramatic decrease in the PIT for the TD25 and TDL25 NE (which 
contain, respectively around 17.1 and 18.8 %w/w Tween 80) by about ~ 30 °C from the 
CP of the Tween 80 micelles containing 20 %w/w (Table 4.6). Furthermore, the diluted 
TDL25 NE were more stable than the diluted TD25 NE, which indicates a difference in 
the phase behaviour of Tween 80 and Dermosoft GMCY in the presence of lecithin.  
In case of the TD25-98hEO NE, dilution with water was complicated by the oil 
penetrating into the hydrophobic chain region of the surfactant:cosurfactant monolayer, 
resulting in a depression of the PIT. It was considered that there were two reasons for 
the turbidity observed in these compositions, namely they are at the limit of the possible 
oil solubilisation and the depression of the PIT due to the presence of an increasing 
amount of 98hEO. The PIT of IPM-containing NE, prepared using Tween 80:Imwittor 
308 at a surfactant:cosurfactant weight ratio of Km 5:1 was determined by Jawhari 
(1999) who reported that dilution of a composition at the upper phase boundary, 
produced an unstable diluted NE, while dilution of a composition far from the phase 
boundary resulted in more stable NE. This behaviour is analogous to that observed in 
the present study and explains why the TD25-98hEO9 and TD25-98hEO10 became 
cloudier quicker than TD25-98hEO8.  
In conclusion, the ability to dilute a Tween 20:Dermosoft GMCY containing NE was 
limited while that of the Dermosoft GMCY containing Tween 80 NE in the absence and 
presence of lecithin (TD25 and TDL25) was less restricted. The most readily diluted NE 
where those prepared solely with Tween 80 (T20). As a consequence therefore, only 
three systems of Tween 80-containing NE systems, namely T20, TD25 and TDL25 NE 








4.2.3 Cloud point and phase inversion temperature 
When nonionic surfactants containing a hydrophilic POE head group are dispersed in 
water they exhibit a temperature-dependent behaviour, which leads to their separation 
into surfactant-rich and surfactant-poor phases upon heating. The temperature at which 
the phase separation occurs is called the cloud point (CP) (Corti et al., 1984). The phase 
inversion temperature (PIT) is the corresponding temperature in oil/nonionic 
surfactant/water systems below which the surfactant partitions preferably into water, 
thus preferring to form o/w NE, and above which, the surfactant partitions preferably 
into oil, supporting the formation of w/o NE (Ruckenstein, 1997).  
According to Conroy et al. (1990), the clouding of a solution of POE nonionic 
surfactant occurs upon increasing temperature as the result of dehydration of the POE 
head group. This dehydration is due to a decrease interaction between the hydrogen of 
water and the ether linkages of the POE head group, which reduce the area per 
surfactant head group, leading to an increase in the CPP (Corti et al., 1984; Lindman et 
al., 1989). Consequently, the intermicellar forces are changed from repulsive (hydration 
force) to attractive (Van der Waals and hydrophobic interactions), which allows a phase 
inversion to occur (Sadaghiania and Khan, 1991). Alternatively, raising the temperature 
of a surfactant solution has been linked to the transformation of a spherical micelle to a 
rod/disc shaped micelle (Conroy et al., 1990) eventually leading to the formation of 
liquid crystalline phase at a temperature above the PIT. Therefore, the type of NE 
formed and their stability is related to the PIT of the system, while the value and 
variations of the PIT can provide important information on the stability of the NE 
(Becher, 1984). The CP and PIT of T20, TD25 and TDL25 micelles and NE containing 












Table 4.6 Variation in cloud point of micelles of 20 %w/w Tween 80, 25 %w/w Tween 
80:Dermosoft GMCY at a Km of 3:1 and 25 %w/w Tween 80:Dermosoft GMCY:lecithin at a 
Km of 7.5:2.5:1 and the phase inversion temperature of their corresponding NE either various 
amounts of hSBO or 98hEO. 
 









- means that samples were not performed the PIT measurement. 
 
It is well established that the presence of a cosurfactant in a micelle can have an effect 
on the micelle’s CP. The CP of 20 %w/w Tween 80 (T20) was ~ 90 °C, whereas the CP 
of TD25 and TDL25, which contain 17.1 and 18.8 %w/w Tween 80, respectively, 
exhibited a CP of ~ 60 °C. Clearly, the CP of cosurfactant-containing micellar solution 
was significantly lower than that of cosurfactant-free micellar solution. This effect is 
attributed to the action of more hydrophobic cosurfactants intercalating into the more 
hydrophilic surfactant interfacial monolayer.  




The PIT of NE prepared using Tween 80 and H2O in the absence or presence of 
Dermosoft GMCY exhibited different patterns in the variation in the PIT depending 
upon the nature (including molecular volume) and concentration of the incorporated oil. 
Due to the very low aqueous solubility of the oils studied, it is assumed that the added 
oil will be present within the NE droplets. 
Regardless of the surfactant/combination of surfactants used, when the relatively low 
molar volume oil (Vm = 600 Å
3) 98hEO was incorporated into a NE, the PIT of the NE 
decreased with increasing oil content. This pattern of behaviour is consistent with the 
relationship predicted between the site of incorporation of the oil in an aggregate and 
the concentration of added oil, such that at low concentrations of added oil, it is more 
likely that the oil penetrates the hydrophobic region of the surfactant monolayer 
(Nagarajan, 1997). Surprisingly, TD25 NE containing higher amounts of 98hEO, 
exhibited, instead of the anticipated increase, a decrease in PIT which was the opposite 
trend to that seen in Brij O10 NE upon increasing amount of 98hEO (section 3.2.3.1, 
Malcolmson et al., 1998; Warisnoicharoen et al., 2000a). This result could be explained 
that it is reasonable to assume that the mixed micelles formed by Tween 80:Dermosoft 
GMCY (Km 3:1) are slightly asymmetrical rather than spherical, therefore any oil 
penetrating the hydrophobic region of the surfactant monolayer would be expected to 
accentuate the asymmetrical aggregate shape, thus further lowering the PIT of the NE, 
possibly even below that of the corresponding micelles. As a consequence of the results 
obtained here, it can be concluded that 98hEO did penetrate the interfacial surfactant 
monolayer. 
In contrast, the relatively large molecular volume oil (Vm = 1563 Å
3) hSBO, produced 
only an increase in the PIT, regardless of the about of hSBO added, although the PIT for 
Tween 80 NE-containing hSBO could not be determined due to the limited area over 
which NE containing hSBO could be produced. It could be explained by the hypothesis 
that hSBO, which because of its bulky structure and large molecular volume, would not 
be expected to penetrate the interfacial monolayer, preferring instead to reside within 
the droplet core forming spherical NE droplets. Indeed, hSBO-containing ME have been 
previously reported to show an increase in the PIT with increasing oil concentration 
(Malcolmson et al., 1998).  
 




4.2.4 Light scattering investigations by photon correlation spectroscopy 
The particle size of diluted T20, TD25 and TDL25 micelles and NE containing different 
concentrations of either hSBO or 98hEO were measured using PCS at a scattering angle 
of 90° is shown in Table 4.7.  
 
Table 4.7 The variation in the apparent hydrodynamic size of micelles and nanoemulsions 
containing either 20 %w/w Tween 80, 25 %w/w Tween 80:Dermosoft GMCY (3:1) or 25 
%w/w Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) with hSBO or 98hEO content at 25 °C. 
 











- means that samples were not performed the light scattering investigation. 
 
It was clear that, over a month, the apparent hydrodynamic size of all Tween 80-
stabilised micelles and NE was unchanged, therefore the preparations were stable over 
this period. In the present study, the measured hydrodynamic size of T20 micelles was ~ 
10 nm, slightly larger than the size of Tween 80 of 8.7 nm reported by Jawhari (1999) 




which was determined by extrapolation to zero surfactant concentration and is therefore 
a more accurate measurement of the size of the Tween 80 micelles. Although some of 
this observed difference in Tween 80 particle size could be explained by the batch-to-
batch variation of POE surfactant.  
On the other hand, the apparent hydrodynamic size of the mixed surfactant/surfactant: 
cosurfactant micellar solutions, i.e. TD25 and TDL25, was larger than that determined 
for T20 micelles. Specifically the micelle size recorded for T20 was 10 nm, whereas the 
sizes determined for micelles TD25 and TDL25 micelles were 13 and 20 nm, 
respectively. Satra et al. (1998) suggested the addition of Dermosoft GMCY to Tween 
80 micelles changed the intermicellar forces for Tween 80 micelles from repulsive to 
attractive which is related to the change in shape of aggregates occurring in the presence 
of cosurfactant, leading to enhanced intermicellar interactions due to a lower interaction 
between the POE chains of the surfactant and water. Attractive intermicellar 
interactions increase for nonionic POE surfactants as the experimental temperature 
approaches the CP/PIT of the micellar solutions/NE (Aveyard et al., 1989). The addition 
of lecithin to Triton X-100 micelles resulted in the transformation of spherical micelles 
of Triton X-100 micelles to non-spherical mixed micelles of Triton X-100 and lecithin 
while NMR self-diffusion studies showed a decrease in the inter- and intramicellar 
repulsion in the mixed micelle system (Sadaghiania and Khan, 1991). However, it is not 
always easy to predict the effect of adding a second surface active compound will have 
on the micellar properties of the mixed aggregates because the effect will be dependent 
on the ability of the second surface active agent to partition into the micelles. For 
example, n-propanol, a short chain alcohol, will partition between the micellar and 
aqueous phase, lowering the hydrophilicity of the aqueous phase and therefore, 
indirectly influencing the micellar microstructure by altering the effective HLB of 
surfactant. Conversely, hexanol, an intermediate chain alcohol, will exert its effect by 
primarily locating itself at the micellar interface, changing the packing of the surfactant 
and causing the interfacial layer to expand (Muller and Muller, 1984). 
In conclusion, the addition of Dermosoft GMCY to Tween 80 micelles results in an 
increase in the apparent hydrodynamic size of the micelles. It is likely that this increase 
in size is caused by an expansion of the interfacial layer because Dermosoft GMCY is 
expected to sit preferentially at the interface of the micelles. Note that due to its high 
lipophilicity, Dermosoft GMCY, is not expected to partition into the aqueous phase. 




The effect of oil on the apparent hydrodynamic particle size of the T20, TD25 and 
TDL25 NE is shown in Table 4.7. It was clear that the apparent hydrodynamic particle 
size of the NE increased as the amount of oil, either hSBO or 98hEO, incorporated into 
the NE increased. Interestingly, the particle size of TDL25-hSBO NE exhibited first a 
decrease upon the addition of a small amount of hSBO, thereafter size increased upon 
the addition of further hSBO. From comparison with other studies on ME prepared 
using either ionic or nonionic surfactants (Hoffmann and Ulbright, 1989), the variation 
in the size of the TDL25 aggregates upon addition of the hSBO, it is suggested that the 
initial shape of the micelles and the NE containing a very small amount of hSBO were 
asymmetrical and that upon addition of more oil, the shape of the NE transformed into a 
more spherical shape. 
Micelles formed by POE-containing surfactants are expected to show a phase separation 
at and above the PIT due to the dehydration of the POE head group (Mitchell et al., 
1983; Corti et al., 1984). The changes in hydration taking place upon approach to the 
PIT generally result in an increase in the particle size of the micelle, with the aggregate 
shape becoming less highly curved and tending towards an ellipsoidal shape (Zulauf et 
al., 1985; Conroy et al., 1990). However, at a temperature far below the CP (i.e. more 
than 20-30 °C below the CP), the particle size of the micelle is constant and unaltered 
with any change in temperature. For example, the size of the C8E5 and C12E8 micelles 
were constant over the temperature range of 30-60 °C at a surfactant concentration 
range of 0-35 %w/w (Zulauf et al., 1985). In the present study, most of the systems 
investigated had a much higher CP than the temperature at which the PCS studies were 
performed. For example, the CP of T20 micellar solution was around 90 °C, although 
the addition of Dermosoft GMCY or lecithin lowered the CP to ~ 60 °C. Despite this 
lowering, the CP for all systems examined in the present study was still above the 
experiment temperature of 25 °C and therefore no complication arising from the 
proximity of the CP was expected to influence the results.  
 
4.3 Micelle and nanoemulsion in the presence of hydrophobic 
drugs 
4.3.1 The incorporation of testosterone propionate 
The water-insoluble, hydrophobic steroid (0.0009 ± 0.002 %w/w, log Poct 4.78 (Craig, 
1990)), testosterone propionate (TP), was selected as a drug to investigate the 




incorporation of drug in a NE (Craig, 1990; Malcolmson et al., 1998). On the basis of 
its solubility, it was anticipated that TP would be partially located at the interface 
between the hydrophobic and hydrophilic regions of the surfactant. While it has been 
reported that Brij 96 microemulsions containing SBO are unaffected by the presence of 
an excess of TP (Malcolmson, 1992), it has also been reported that some drugs do 
significantly affect the particle size of NE with some drugs causing precipitation upon 
dilution of the NE (Borhade et al., 2008). The effect of the addition of TP on NE 
containing varying amounts of oil was investigated in the present study by saturating 
with TP NE prepared using 25 %w/w Tween 80:Dermosoft GMCY (3:1) (TD25) and 
containing the oil 98hEO. Excess drug was removed from the NE after 7, 10 and 14 
days by centrifugation. Other reasons why TP was selected for study include the fact 
that several studies have shown that it is possible to increase its apparent aqueous 
solubility by its formulation in a ME (Satra et al., 1998, Malcolmson et al., 1998). The 
solubility of TP in TD25 micelles and in NE containing 98hEO was measured, and the 
effect of TP on the area of NE existence, the apparent hydrodynamic size and phase 
inversion temperature of the NE determined. 
 
4.3.1.1 Effect of testosterone propionate on the area of NE existence 
TD25-98hEO samples within the o/w NE region prepared in the absence of a saturation 
amount of drug are shown in Table 4.2 (section 4.2.1). Encouragingly, NE that where 
within Region A, in the absence of TP, remained completely clear in the presence of a 
saturation amount of drug and remained stable for at least 2 months. Furthermore, there 
was no visible change in the area of NE existence in the presence of saturation levels of 
TP. The high stability of the TP-containing TD25-98hEO NE, coupled with the large 
NE region they produced suggested that the TD25-98hEO NE offered considerable 
potential as drug delivery vehicles. 
 
4.3.1.2 Effect of testosterone propionate on cloud point and phase inversion 
temperature 
The cloud point (CP) and phase inversion temperature (PIT) of both drug-loaded and 
drug-free micelles and NE are recorded in Figure 4.2. It was clear that both the CP and 
PIT of TP-saturated samples were reduced in comparison to the corresponding TP-free 
samples suggesting that TP were partly located at the boundary between the 




hydrophobic and hydrophilic portions of the surfactant (p<0.05). Interestingly, the PIT 
of TD25-98hEO8 and TD25-98hEO9 NE after saturation with TP for 7 days was much 
higher than that measured for samples after 10- or 14-days saturation with TP (p<0.05) 
(Figure 4.2). This result suggests that TD25-98hEO8 and TD25-98hEO9 NE saturated 
with TP for 7 days contained less TP than those saturated for 10- or 14-days, a result in 
agreement with the solubilisation studies which suggested that equilibrium 
solubilisation was achieved by 10-days. 
Oil concentration (%w/w)




























TD25-98hEO NE in H2O   
TD25-98hEO NE with TP 7 days  
TD25-98hEO NE with TP 10 days
TD25-98hEO NE with TP 14 days 
 
Figure 4.2: Variation in mean cloud point of micelles prepared at 25 %w/w Tween 
80:Dermosoft GMCY at a Km of 3:1 and the phase inversion temperature of nanoemulsions 
containing 98hEO and stabilised by 25 %w/w Tween 80:Dermosoft GMCY at a Km of 3:1 in 
H2O and in the absence and presence of testosterone propionate (TP). The data are the mean ± 
S.D. of triplicate measurements. Error bars in some cases contained within the symbols. 
 
At day 7 of the TP equilibration, the difference in the PIT of TD25-98hEO8 and TD25-
98hEO9 NE saturated with TP compared to the corresponding drug free samples was ~ 
5 ºC - equivalent to the difference between the CP of the TP-free and the TP-loaded 
micelles. These findings suggest that the amount of TP solubilised in the TD25-
98hEO8-TP and TD25-98hEO9-TP NE is similar to the amount of TP solubilised in the 
TD25-TP micelles. However, the decrease in the PIT of the TP-containing TD25-
98hEO10 NE was greater than the differences recorded between the CP of the TP-free 
and TP-loaded micelles, suggesting that the amount of TP solubilised in the TD25-
98hEO10 NE was greater than that solubilised in the TD25 micelles.  
At days 10 and 14 of TP equilibration (i.e. the time by which TP saturation was 
reached), the decrease in the PIT of the TP-containing TD25-98hEO was much greater 
than the difference in the CP of the TP-free and TP-loaded micellar solutions. This 
observation suggested that the amount of TP was solubilised in the TD25-98hEO-TP 
NE was greater than that solubilised in the TD25-TP micelles.  




4.3.1.3 Effect of testosterone propionate on the size of the micelle and 
nanoemulsions 
Light scattering investigations by photon correlation spectroscopy (PCS) were 
performed on micelles prepared using a total of 25 %w/w Tween 80:Dermosoft GMCY 
at a Km of 3:1 as well as the corresponding NE containing 98hEO and in which excess 
TP had been added in order to examine the effect of the addition of a saturation amount 
of TP on the apparent hydrodynamic size of TD25-98hEO NE. PCS investigations on 
the equivalent drug-free NE had previously been performed over a period of 1 month. 
Light scattering analysis of TDL25-98hEO-TP NE where also carried out 7, 10 and 14 
days after the addition of TP, with the excess TP removed by centrifugation. 
The variation in the apparent hydrodynamic size of NE saturated with TP for either 7, 
10 or 14 days, assessed by PCS, plotted as a function of oil concentration is shown in 
Figure 4.3. As can be seen the apparent hydrodynamic size of TP-containing TD25-
98hEO NE increased with increasing concentration of 98hEO. Furthermore, no 
difference was observable in the size of TP-containing NE measured at different days of 
TP saturation (p>0.05) (Figure 4.3). Indeed, when comparing all the Region A NE 
studied, it is clear that the apparent hydrodynamic size of NE with TP was the same size 
as that of TP-free NE.  
 
Figure 4.3: Variation in the mean apparent hydrodynamic size (as assessed using Brookhaven 
ZetaPlus particle sizer) of the nanoemulsions stabilised by 25 %w/w Tween 80:Dermosoft 
GMCY at a Km of 3:1 and containing different concentrations of 98hEO in the absence and 
presence of testosterone propionate (TP) at 25 °C. The data are the mean ± S.D. of triplicate 
measurements. Error bars in some cases contained within the symbols. 
 




4.3.1.4 The solubility of testosterone propionate in micelle and nanoemulsions 
The level of TP incorporation in TD25 micelles and TD25-98hEO NE containing 
different concentrations of oil was determined (Figure 4.4). Clearly, TP solubilisation 
in TD25 micelles and in TD25-98hEO10 NE reached maximal levels by 7-day. In 
contrast, maximal TP solubilisation in NE containing 8 and 9 %w/w hEO (TD25-
98hEO8 and TD25-98hEO9) was not achieved until after 10-day TP equilibration. 
These results suggest that in order for NE containing 8 and 9 %w/w 98hEO to be 
saturated with TP at least 10 days is required. These TP solubilisation results are in 
agreement with the results of the CP and the PIT studies of the micelle and NE which 
indicated that the amount of TP incorporated into the TD25-98hEO8 and TD25-98hEO9 
NE after 7 days incubation was lower than that achieved at 10 days (Figure 4.2). This 
behaviour may be a consequence of the high viscosity of the NE causing a reduced rate 
of drug solubilisation, meaning that longer time was required to reach maximal TP 
solubilisation. However, the equilibrium solubility of TP in either Brij 97 or sodium 
dodecyl sulphate micelles and NE/ME was typically reached within 6 h for micelles and 
24 h for NE/ME (Luangwitchajaroen, 2017). Finally, the results showed that there was a 
significant increase in the amount of TP solubilised in the TD25-98hEO NE when 
compared to corresponding micelles.  
 
Figure 4.4: Variation in solubilisation of testosterone propionate in micelles and nanoemulsions 
prepared using 25 %w/w Tween 80:Dermosoft GMCY at a Km of 3:1 and containing different 
amounts of 98hEO at 25 °C. The data are the mean ± S.D. of triplicate measurements. Error 
bars in some cases contained within the symbols. 
 
It has been reported that the difference in the location of solubilised steroid molecules in 
surfactant micelles depends upon the polarity of the drug (Tomida et al., 1978; 
Lundberg et al., 1979). It has also been suggested that TP is more generally associated 
98hEO concentration (%w/w)






















TD25-98hEO NE with TP 7 days
TD25-98hEO NE with TP 10 days
TD25-98hEO NE with TP 14 days




with the head group region of an ethoxylated nonionic surfactant rather than with the 
surfactant’s hydrophobic chains (Thakkar and Hall, 1967; Thakkar and Kuehn, 1968) 
and, in particular, is associated with the least hydrated polyoxyethylene region closest to 
the hydrocarbon core (Barry and El Eini, 1976). In the present study, it is suggested 
that, in the TD25 micelles, the TP is predominately solubilised in the dehydrated 
polyoxyethylene region of the surfactant, closet to the micelle core.  
As can be seen, a significant increase in TP solubilisation with increasing oil 
concentration was seen for NE in Region A. The solubility of TP in NE containing a 
high amount of oil was enough to cause a significant increase in the amount of TP in the 
NE over the corresponding micelles. It is anticipated that NE in Region A would exhibit 
an increase in TP solubilisation due to their high oil loading and larger apparent 
hydrodynamic size, as assessed by PCS. According to the generally held view, oils with 
large molecular volumes form a core in the centre of the droplet. (Evans et al., 1986). It 
would be anticipated therefore, that an oil with a higher molecular volume would 
increase the PIT by forming a core in the centre of the NE which would be expected to 
provide an additional site for drug solubilisation.  
Moreover, the comparison of the experimentally measured TP solubilisation with that 
predicted from that calculated by the addition of TP solubilisation in the corresponding 
micelles with the solubility of TP in the amount of oil incorporated in the NE is shown 
in Table 4.8. The comparison in Table 4.8 shows that the experimental TP 
solubilisation in NE was higher than the predicted TP solubilisation, showing the 
advantage of NE to improve the apparent solubility of drug in water. This observation 













Table 4.8 Comparison of experimentally determined and expected TP solubilisation in TD25 
micelles and NE and after saturation with TP for 10 days at 25 °C. 
 
Sample Region Experimental TP solubilisation (%w/v) Expected TP solubilisation (%w/v) a 
TD25 - 0.43 ± 0.05 - 
TD25-98hEO8 
A 
1.49 ± 0.10 0.89 
TD25-98hEO9 1.42 ± 0.08 0.95 
TD25-98hEO10 1.11 ± 0.09 1.01 
 
a calculated from the experimental TP solubilisation in micelle and oil according to amount of oil in the NE samples. 
The solubility of TP in 25 %w/w Tween 80:Dermosoft GMCY was 0.43 ± 0.05 %w/v at 25 ⁰C while the solubility of 
TP in 98hEO was 5.79 ± 0.40 %w/v at 25 ⁰C (Malcolmson et al., 1992; Malcolmson et al., 1998).  
 
4.3.2 The incorporation of curcumin 
A water insoluble, anticancer drug, curcumin (log Poct 2.23 (Singh et al., 2010)), was 
selected as a second drug to investigate the incorporation of hydrophobic drug into NE 
systems. The effect of the addition of CUR on the stability of the NE containing varying 
amounts of oil was investigated in the present study by saturating either T20, TD25 or 
TDL25 NE with CUR. Excess drug was removed from the NE after 5 or 7, 10 and 14 
days by centrifugation.  
4.3.2.1 Effect of curcumin on the area of NE existence 
Clear, Region A NE, T20-hSBO, T20-98hEO, TD25-98hEO and TDL25-hSBO NE 
were saturated with CUR (Table 4.1, 4.2 and 4.4). The area of all NE existence found 
with in the presence of CUR was identical to that found in its absence, suggesting that a 
saturation amount of CUR could be incorporated without any visible change on the area 
of existence. Furthermore, the CUR-saturated NE where stable for at least 2 months, 
longer periods were not observed. From visual observation, it is worth noting that no 
precipitation was seen in any NE after centrifugation, either in the absence or presence 
of CUR, further suggesting that the NE were stable. The stability of the Tween 80-
containing NE in the presence of a saturation amount of CUR suggested that the NE 
offer potential as drug delivery vehicles. 
 
4.3.2.2 Effect of the presence of curcumin on the cloud point and phase inversion 
temperature of Tween 80 containing nanoemulsions 
The cloud point (CP) and phase inversion temperature (PIT) of CUR-loaded and CUR-
free micelles and nanoemulsions prepared using Tween 80 and containing either SBO 




and EO (i.e. T20-hSBO or T20-98hEO NE) are shown in Figure 4.5. It was clear that 
both the CP and most of the PIT were unchanged in the presence of a saturation amount 
of CUR. Such a lack of an effect may suggest that CUR is predominately located in the 
core of the Tween 80 micelles and their corresponding NE, although it should be noted 
that due to the low solubility of CUR in hSBO (0.18 %w/v) and 98hEO (0.14 %w/v) 
only a small amount of CUR would be expected to be located in the core. This result 
implies that if any of the CUR is in the head group region it does not alter the hydration 
of the polyoxyethylene chains. Only the PIT of T20-hSBO1-CUR was lower than the 
corresponding CUR-free NE (p<0.05)  suggesting that in this case, sufficient CUR sits 
in the shell, thereby lowering the PIT of T20-hSBO1.  
a) b)  
Figure 4.5: The variation in cloud point and the phase inversion temperature of micelles and 
nanoemulsion prepared using 20 %w/w Tween 80 and containing either a) hSBO or b) 98hEO 
in the absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in some cases 
contained within the symbols. 
 
The cloud point (CP) and phase inversion temperature (PIT) of CUR-loaded and CUR-
free TD25 micelles and TD25-98hEO NE are shown in Figure 4.6. It was clear that CP 
of CUR-saturated micelle was little lower than the corresponding CUR-free micelles. 
This result suggests that CUR sits in the interfacial surfactant/cosurfactant region. 
However, no difference was seen in the PIT of TD25-98hEO8 in the absence and 
presence of CUR. Surprisingly, the PIT of CUR-saturated TD25-98hEO9 and TD25-
98hEO10 NE was much higher than that of the corresponding CUR-free NE (p<0.05). 
Furthermore, this difference increased with increasing 98hEO concentration. This 
observation is thought to be a consequence of the penetration of Dermosoft GMCY into 
the surfactant interfacial resulting causing an increase the area of surfactant head group, 
an increase in the hydration and hydrophilicity of head group. In addition, the shape of 




the CUR-containing TD25-98hEO NE at 9 and 10 %w/w 98hEO is expected to become 
more spherical upon increasing oil concentration.   
 
Figure 4.6: The variation in cloud point and the phase inversion temperature of micelles and 
nanoemulsion prepared using 20 %w/w Tween 80:Dermosoft GMCY (3:1) and containing 
98hEO in the absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in some cases 
contained within the symbols. 
 
 
Figure 4.7: Variation in cloud point and the phase inversion temperature of micelles and 
nanoemulsions prepared using 20 %w/w Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) and 
containing hSBO in the absence and presence of curcumin (CUR) (mean ± S.D.). Error bars in 
some cases contained within the symbols. 
 
The cloud point (CP) and phase inversion temperature (PIT) of both CUR-loaded and 
CUR-free TDL25 micelles and TDL25-hSBO NE are shown in Figure 4.7. It was clear 
that the CP/PIT of the CUR-saturated samples is lower than the CUR-free samples 
(p<0.05). This suggests that CUR sits in the interfacial region of the 
surfactant/cosurfactant mixture and increases the hydrophobicity of surfactant. Note that 
although the log P of CUR was 2.23 (Singh et al., 2010) and its aqueous solubility was 
0.00006 %w/v (Kurien et al., 2007), the solubility of CUR in octanol was low at only 
0.00013 %w/v. The solubility of CUR in PEG 400 was 7 %w/v (Sood et al., 2014). 




Based on these solubilities, it is suggested that CUR prefers sitting in the surfactant 
shell and in particular the dehydrated part close to the hydrocarbon core (Barry and El 
Eini, 1976). Furthermore, the fact that the difference in the PIT between the absence and 
presence of CUR decreased as the hSBO concentration increased suggests that the 
ability of the CUR to be solubilised in the core increases so that less of the drug sits in 
the interfacial boundary region between the hydrophobic and hydrophilic portions of the 
surfactant. 
 
4.3.2.3 Effect of curcumin on the particle size of Tween 80-containing micelles and 
nanoemulsions 
The apparent hydrodynamic size (Dh) of T20 micelles and T20-hSBO and T20-98hEO 
NE in the absence and presence of CUR, measured using the Brookhaven ZetaPlus 
particle sizer, is shown in Figure 4.8. The Dh of the T20 micelles and the T20-hSBO 
NE exhibited an increase in the CUR-containing micelles and NE with increasing hSBO 
concentration (Figure 4.8a). In contrast, the Dh of the T20-98hEO1 and T20-98hEO1-
CUR where of comparable similar size (Figure 4.8b). 
a) b)  
Figure 4.8: Variation in the mean hydrodynamic size (as assessed by the Brookhaven ZetaPlus 
particle sizer) of Tween 80 micelles and nanoemulsions prepared using 20 %w/w and 
containing either a) hSBO or b) 98hEO in the absence and presence of curcumin (CUR) (mean 
± S.D.) at 25 °C. Error bars in some cases contained within the symbols. 
 
The apparent hydrodynamic size (Dh) of TD25 micelles and TD25-98hEO NE in the 
absence and presence of curcumin is shown in Figure 4.9. While the Dh of the TD25 
micelles and the TD25-98hEO8 NE, regardless of 98hEO concentration, showed an 
increase in size of the CUR-containing micelles and NE, the Dh of TD25-98hEO9-CUR 




and TD25-98hEO10-CUR, in contrast, were of comparable size to the corresponding 
CUR-free NE. 
 
Figure 4.9: Variation in the mean hydrodynamic size (as assessed by the Brookhaven ZetaPlus 
particle sizer) of micelles and nanoemulsions prepared using 25 %w/w Tween80:Dermosoft 
GMCY (3:1) and containing 98hEO in the absence and presence of curcumin (CUR) (mean ± 
S.D.) at 25 °C. Error bars in some cases contained within the symbols. 
 
The apparent hydrodynamic size (Dh) of TDL25 micelles and TDL25-hSBO NE in the 
absence and presence of curcumin is shown in Figure 4.10. The Dh of the TDL25 
micelles and TDL25-hSBO NE, regardless of hSBO, showed a significant increase in 
size in the CUR-containing micelles and NE in comparison when compared to the 
corresponding CUR-free NE. 
a)   
Figure 4.10: Variation in the mean hydrodynamic size (as assessed by the Brookhaven ZetaPlus 
particle sizer) of micelles and nanoemulsions prepared using 25 %w/w Tween80:Dermosoft 
GMCY:lecithin (7.5:2.5:1) and containing varying amounts of hSBO in the absence and 
presence of curcumin (CUR) (mean ± S.D.) at 25 °C. Error bars in some cases contained within 
the symbols. 
 
4.3.2.4 The solubility of curcumin in micelle and nanoemulsions 
The incorporation of CUR into T20, TD25 and TDL25 micelles and T20-hSBO, T20-
98hEO, TD25-98hEO and TDL25-hSBO NE as a function of oil concentration was 




investigated (Table 4.9). Clearly, CUR solubilisation had reached equilibration by 5-
day in T20 micelles, T20-hSBO and T20-98hEO NE, whereas CUR solubilisation in 
TD25 micelles, TD25-98hEO NE, TDL25 micelles and TDL25-hSBO NE only reached 
saturation after 10-days equilibration. Surprisingly, the amount of CUR incorporated 
into the NE did not increase over the corresponding micellar solution. This observation 
could be explained by the low solubility of CUR in either hSBO or 98hEO. 
 
Table 4.9 Solubilisation of curcumin in micelles and nanoemulsions prepared using either 20 
%w/w Tween 80, 25 %w/w Tween 80:Dermosoft GMCY (3:1) or 25 %w/w Tween 
80:Dermosoft GMCY:lecithin (7.5:2.5:1) and containing different concentrations of either 
hSBO or 98hEO (mean ± S.D.) at 25 °C. 
 
Sample Drug Solubilisation (%w/v) 
5 days 7 days 10 days 14 days 
T20-CUR in H2O 0.33 ± 0.01 0.33 ± 0.02 0.31 ± 0.01 0.31 ± 0.01 
T20-hSBO1-CUR in H2O 0.30 ± 0.01 0.33 ± 0.02 - 0.31 ± 0.02 
T20-hSBO2-CUR in H2O 0.33 ± 0.03 0.34 ± 0.03 - 0.32 ± 0.02 
T20-98hEO1-CUR in H2O 0.35 ± 0.03 0.32 ± 0.03 - 0.34 ± 0.01 
TD25-CUR in H2O 0.17 ± 0.02 - 0.21 ± 0.03 0.22 ± 0.02 
TD25-98hEO8-CUR in H2O 0.19 ± 0.03 - 0.22 ± 0.02 0.22 ± 0.02 
TD25-98hEO9-CUR in H2O 0.18 ± 0.01 - 0.19 ± 0.03 0.20 ± 0.02 
TD25-98hEO10-CUR in H2O 0.20 ± 0.02 - 0.20 ± 0.03 0.23 ± 0.03 
TDL25-CUR in H2O 0.18 ± 0.01 - 0.21 ± 0.02 0.20 ± 0.04 
TDL25-hSBO2-CUR in H2O  0.17 ± 0.01 - 0.17 ± 0.01 0.18 ± 0.01 
TDL25-hSBO3-CUR in H2O 0.16 ± 0.01 - 0.16 ± 0.01 0.19 ± 0.00 
TDL25-hSBO4-CUR in H2O 0.16 ± 0.01 - 0.18 ± 0.01 0.21 ± 0.01 
 
Interestingly, the level of CUR solubilisation in T20 micelles and NE was higher than 
that obtained in TD25 and TDL25 micelles and NE (Table 4.9). The low amount of 
CUR solubilised in the cosurfactant-containing micelles and NE suggested that both 
Dermosoft GMCY and lecithin could affect the formation of micelles and NE causing a 
decrease in CUR solubilisation. 
A comparison of the experimentally obtained CUR solubilisation and the expected CUR 
solubilisation in the various NE is shown in Table 4.10. The anticipated CUR 
solubilisation was calculated from the measured solubilisation of CUR in micelles and 
in oil. This comparison showed that, regardless of oil, the experimentally measured 
CUR solubilisation in T20 and TD25 NE was similar to the expected CUR 




solubilisation in both NE while the experimentally determined CUR solubilisation in 
the TDL25 NE containing an amount of oil was less than the expected level of 
solubilisation. These results indicated that the NE do not possess an advantage over 
micelles in respect to solubilisation of CUR, which suggests that the oil was either 
incorporated into the NE in such a way as to not improve drug solubilisation and/or the 
solubilisation of CUR in oils was too low. In order to understand the effect of structure 
on solubilisation, small angle neutron scattering studies where undertaken. 
 
Table 4.10 Comparison of experimentally determined and predicted CUR solubilisation in 
Tween 80-containing micelles and nanoemulsions at 25 °C. 
 
Sample Experimental CUR solubilisation in 
samples (%w/v) 
Expected CUR solubilisation  
in samples (%w/v) a 
T20-CUR in H2O (7 days) 0.33 ± 0.02 - 
T20-hSBO1-CUR in H2O (7 days) 0.33 ± 0.02 0.31 
T20-hSBO2-CUR in H2O (7 days) 0.34 ± 0.03 0.31 
T20-98hEO1-CUR in H2O (7 days) 0.32 ± 0.03 0.31 
TD25-CUR in H2O (10 days) 0.21 ± 0.03 - 
TD25-98hEO8-CUR in H2O (10 days) 0.22 ± 0.02 0.22 
TD25-98hEO9-CUR in H2O (10 days) 0.19 ± 0.03 0.22 
TD25-98hEO10-CUR in H2O (10 days) 0.20 ± 0.03 0.22 
TDL25-CUR in H2O (10 days) 0.21 ± 0.02 - 
TDL25-hSBO2-CUR in H2O (10 days) 0.17 ± 0.01 0.21 
TDL25-hSBO3-CUR in H2O (10 days) 0.16 ± 0.01 0.22 
TDL25-hSBO4-CUR in H2O (10 days) 0.18 ± 0.01 0.22 
 
a calculated from the experimental CUR solubilisation in micelle and oil according to amount of oil in NE samples. 
The solubility of CUR in T20, TD25 and TDL25 was 0.33 ± 0.02, 0.21 ± 0.03 and 0.21 ± 0.02 %w/v at 25⁰C while 
the solubility of CUR in hSBO and 98hEO was 0.18 ± 0.03 and 0.14 ± 0.03 %w/v at 25 ⁰C (Table 3.4).   
 
4.3.3 The incorporation of curcumin and testosterone propionate 
Curcumin (CUR) and testosterone propionate (TP) were selected as hydrophobic drugs 
to investigate the effect of the incorporation of two drugs into the same NE. The effect 
of the addition of both CUR and TP on the stability of the TD25-98hEO NE containing 
varying amounts of 98hEO was investigated by saturating TD25-98hEO with CUR and 
TP. Excess drug was removed from the NE after either 7, 10 or 14 days by 
centrifugation. The effect of the incorporation of both drugs on the area of NE existence 
for TD25-98hEO and the phase inversion temperature and particle size of the NE 




droplets was determined, as well as the solubility of CUR and TP in TD25 micelles and 
TD25-98hEO-CUR-TP NE. 
4.3.3.1 Effect of curcumin and testosterone propionate on the area of NE existence 
Clear, Region A TD25-98hEO NE (Table 4.2) were used to study the effect on the area 
of existence on the incorporation of a saturation amount of both drugs. It was 
established that the area of NE existence was unchanged in the presence of saturation 
amounts of both drugs. Furthermore the drug-saturated NE, prepared with 98hEO, 
where all stable for at least 2 months. It is important to note that there was no evidence 
of the centrifugation precipitating in any of the NE, regardless of the absence or 
presence of CUR and TP. The high stability of the TD25-98hEO-CUR-TP NE and the 
relatively large NE region they exhibited suggests that the NE offer potential as drug 
delivery vehicles. 
 
4.3.3.2 Effect of curcumin and testosterone propionate on cloud point and phase 
inversion temperature 
The cloud point (CP) and phase inversion temperature (PIT) of CUR and TP-loaded and 
CUR and TP-free TD25 micelles and TD25-98hEO NE are shown in Figure 4.11. It 
was clear that both the CP and PIT of CUR-TP-saturated micelles and NE were lower 
than that of the corresponding CUR-TP-free samples (p<0.05). The lower recorded CP 
and PIT suggests that the CUR and/or TP sit in the surfactant interfacial region which is 
likely to increase the hydrophobicity of system leading to the observed decrease in CP 
and PIT of the CUR-TP-containing samples. 
 
Figure 4.11: The cloud point and phase inversion temperature of micelles and nanoemulsions 
prepared using 25 %w/w Tween 80:Dermosoft GMCY (3:1) and containing 98hEO in the 
absence and presence of curcumin (CUR) and testosterone propionate (TP) (mean ± S.D.). Error 
bars in some cases contained within the symbols. 




4.3.3.3 Effect of curcumin and testosterone propionate on the particle size of 
micelle and nanoemulsions 
The apparent hydrodynamic size (Dh) of 25 %w/w Tween 80:Dermosoft GMCY (3:1) 
micelle and NE containing different concentration of 98hEO in the absence and 
presence of CUR and TP was measured using both the Brookhaven ZetaPlus particle 
sizer and Malvern Nano ZS Zetasizer (Figure 4.12). The measured Dh of the hSBO NE, 
obtained using the Brookhaven ZetaPlus particle sizer, showed a significant increase in 
size of the TD25-CUR-TP and TD25-98hEO8-CUR-TP NE, although apparently 
random fluctuations in Dh of CUR-TP-containing NE at 9 and 10 %w/w 98hEO were 
observed, even though the diluted samples containing CUR and TP were completely 
clear (Figure 4.12a). The laser in the Brookhaven was checked to ensure it did not blur 
after passing through the yellow sample, which it did not. Moreover, when the clear, 4-
sided and 10-mm path length disposable polystyrene cuvette, normally used for PCS 
measurements, were exchanged for a 1-cm path length quartz cuvette normally used for 
fluorescent measurement to ensure that no chemical reaction occurred between samples 
and container - the particle size of the NE droplets still exhibited seemingly random 
fluctuations.  
 
a) b)  
Figure 4.12: Variation in the mean hydrodynamic size of micelles and nanoemulsions prepared 
using 25 %w/w Tween80:Dermosoft GMCY (3:1) and Tween80:Dermosoft GMCY:lecithin 
(7.5:2.5:1) and containing varying amounts of 98hEO in the absence and presence of curcumin 
(CUR) and testosterone propionate (TP) using a) Brookhaven ZetaPlus particle sizer and b) 
Malvern Nano ZS Zetasizer (mean ± S.D.) at 25 °C. Error bars in some cases contained within 
the symbols. 
 
When the particle size measurement of TD25 and TD25-98hEO in the absence and 
presence of CUR and TP was performed using Malvern Nano ZS Zetasizer (Figure 




4.12b), the Dh of TD25-CUR-TP and TD25-98hEO-CUR-TP did not show an increase. 
Again small angle neutron scattering studies will be performed in TD25-98hEO-CUR-
TP NE in order to probe the internal structure of NE. 
 
4.3.3.4 Solubility of curcumin and testosterone propionate in micelle and 
nanoemulsions 
The analysis of CUR and TP using UV-vis spectroscopy is shown in section 3.3.3.4. 
The solubilisation of CUR and TP in TD25-98hEO NE after incubation with both drugs 
for 7, 10 and 14 days are shown in Figure 4.13. The results showed that while CUR 
was equilibrated in all samples by 7 days, TP reached equilibration levels between 7-10 
days. Figure 4.14 shows the solubility of (a) CUR and (b) TP in TD25-98hEO-CUR 
NE in the absence and presence of either CUR or TP after incubation with drug for 14 
days. It was clear that TD25-98hEO-CUR-TP NE could incorporate a slightly higher 
amount of CUR than the TD25-98hEO-CUR NE (i.e. TP-free NE). In contrast, far less 
TP was solubilisation was observed in TD25-98hEO-CUR-TP NE than in TD25-
98hEO-TP NE. Interestingly, the level of TP solubilisation was lower in TD25-98hEO-
CUR-TP NE than in TD25-98hEO-TP NE. These results suggest that the presence of 
CUR could affect TP solubilisation in NE. 
 
a) b)  
Figure 4.13: Solubilisation of a) curcumin (CUR) and b) testosterone propionate (TP) in 98hEO 
NE prepared using 25 %w/w Tween 80:Dermosoft GMCY (3:1) containing varying amounts of 
98hEO and saturated with curcumin and testosterone propionate for 14 days (mean ± S.D.) at 25 
°C. Error bars in some cases contained within the symbols. 
 




a) b)  
Figure 4.14: Solubilisation of a) curcumin (CUR) and b) testosterone propionate (TP) in 98hEO 
NE prepared using 25 %w/w Tween 80:Dermosoft GMCY (3:1) and saturated with curcumin 
and testosterone propionate and compared with CUR solubilisation in TD25-98hEO-CUR and 
TP solubilisation in TD25-98hEO-TP after 14 days saturation (mean ± S.D.) at 25 °C. Error 
bars in some cases contained within the symbols. 
 
A comparison between the expected and experimentally determined TP and CUR 
solubilisation is shown in Table 4.11. The expected TP and CUR solubilisation was 
calculated using a knowledge of the solubilisation of TP or CUR in TD25 micelles and 
in the relevant bulk oils. This comparison showed that the experimentally measured 
CUR solubilisation in TD25-98hEO-CUR-TP NE was similar to that predicted but was 
not significantly different than that achieved in the corresponding micelles. This result 
demonstrated that NE did not possess any advantage over micelles in respect to CUR 
solubilisation - a result undoubtedly attributable to the poor solubility of CUR in hSBO. 
On the other hand, the experimentally measured solubilisation of TP in TD25-98hEO-
CUR-TP NE was higher than the predicted TP solubilisation. These results showed that 
formulation of TP in a NE improves its solubilisation. Small angle neutron scattering 













Table 4.11 Comparison of predicted curcumin and testosterone propionate solubilisation in 










  solubilisation in  
TD25-98hEO- 
CUR-TP (%w/v) a 
Experimental TP 




  solubilisation in  
TD25-98hEO- 
CUR-TP (%w/v) b 
0 0.23 ± 0.01 - 0.76 ± 0.02 - 
8 0.25 ± 0.01 0.22 1.12 ± 0.06 0.89 
9 0.24 ± 0.03 0.22 1.09 ± 0.06 0.95 
10 0.24 ± 0.02 0.22 1.16 ± 0.03 1.01 
 
a calculated from the experimental CUR solubilisation in micelle and oil according to amount of oil in NE samples. 
The solubility of CUR in 25% Tween 80:Dermosoft GMCY was 0.21 ± 0.03 %w/v at 25⁰C while the solubility of 
CUR in 98hEO was 0.14 ± 0.03 %w/v at 25 ⁰C (Table 3.4).   
b calculated from the experimental TP solubilisation in micelle and oil according to amount of oil in NE samples. The 
solubility of TP in 25% Tween 80:Dermosoft GMCY was 0.43 ± 0.05 %w/v at 25⁰C while the solubility of TP in 
98hEO was 5.79 ± 0.40 %w/v at 25 ⁰C (Malcolmson et al., 1992; Malcolmson et al., 1998). 
 
4.3.4 The incorporation of docetaxel into micelles and nanoemulsions 
The water insoluble anticancer drug, docetaxel (DTX), log Poct 4.1 (Tang et al., 2015), 
was selected as a drug to investigate the incorporation of another hydrophobic drug into 
NE. The effect of the addition of DTX on the stability of the NE containing varying 
amounts of oil was investigated by saturating micelles prepared using 25 %w/w Tween 
80:Dermosoft GMCY:lecithin (7.5:2.5:1) (TDL25) and NE varying amounts of 98hEO 
with DTX (TDL25-98hEO). Excess drug was removed from the NE after 7, 10 and 14 
days by centrifugation.  
 
4.3.4.1 Effect of docetaxel on the area of NE existence 
DTX-saturated TDL25-hSBO NE containing varying amounts of hSBO from Region A 
are shown in Table 4.4. As can be seen the DTX-containing NE from Region A were 
clear, suggesting that there was no visible change in the area of existence. As previously 
reported, centrifugation either in the absence or presence of DTX, produced no evidence 
of precipitation. Furthermore, the DTX-saturated NE, prepared with hSBO, was stable 
for at least 2 months. The high stability of the TDL25-hSBO-DTX NE suggested that 
the TDL25-hSBO NE offer potential as drug delivery vehicles for hydrophobic drugs 
such as DTX. 
 




4.3.4.2 Effect of docetaxel on cloud point and phase inversion temperature 
The cloud point (CP) and phase inversion temperature (PIT) of DTX-saturated and 
DTX-free micelles and NE are shown in Figure 4.15. It was clear that both the CP and 
the PIT of DTX-saturated samples were reduced in comparison with the corresponding 
DTX-free samples (p<0.05), suggesting that DTX were located at the boundary between 
the hydrophobic and hydrophilic portions of the surfactant.  
 
 
Figure 4.15: Cloud point and phase inversion temperature of micelles and nanoemulsions 
prepared using 25 %w/w Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) and containing 
98hEO in the absence and presence of docetaxel (DTX) (mean ± S.D.). Error bars in some cases 
contained within the symbols. 
 
4.3.4.3 Effect of docetaxel on the particle size of micelle and nanoemulsions 
Light scattering investigations using photon correlation spectroscopy (PCS) were 
performed on 25 %w/w Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) micelles and 
the corresponding 98hEO NE in which DTX has been added to examine the effect of 
the addition of DTX on the apparent hydrodynamic size of TDL25-hSBO NE. PCS 
investigations of the equivalent drug-free NE had already been performed. Light 
scattering analysis of the TDL25-hSBO-DTX NE were performed after 7, 10 and 14 
days incubation with excess DTX, which was removed by centrifugation. The apparent 
hydrodynamic sizes of the micelles and NE with and without DTX were investigated by 
PCS and the results plotted as a function of oil concentration (Figure 4.16). No 
difference in the size of the DTX-containing NE at each of the different drug incubation 
times was observed. In all compositions studied, the apparent hydrodynamic size of the 




micelles and the NE in the presence of DTX was the same size as the DTX-free 
micelles and NE.  
 
 
Figure 4.16: Variation in the mean hydrodynamic size of micelles and nanoemulsions prepared 
using 25 %w/w Tween80:Dermosoft GMCY:lecithin (7.5:2.5:1) and containing varying 
amounts of 98hEO in the absence and presence of docetaxel (DTX) at 25 °C. Error bars in some 
cases contained within the symbols. 
 
4.3.4.4 The solubility of docetaxel in micelle and nanoemulsions 
 
Figure 4.17: Solubilisation of docetaxel (DTX) in micelles and nanoemulsions prepared using 
25 %w/w Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) and containing different 
concentrations of hSBO after 7, 10 and 14 days saturation (mean ± S.D.) at 25 °C. Error bars in 
some cases contained within the symbols. 
 
The incorporation of DTX in TDL25 micelles and TDL25-hSBO3 NE is shown in 
Figure 4.17. DTX solubilisation in TDL25 micelles had reached equilibrium by 7-day 
incubation. Equilibration in the TDL25-hSBO3 NE was much more variable but as the 




data showed not clear no trend with incubation time, it is assumed here that saturation in 
the NE was also obtained by day 7. Taking a mean of the level of DTX incorporation 
achieved, suggested that there was no increase in DTX solubilisation in the TDL25-
hSBO NE system when compared to the corresponding micelles. This result suggests 
that DTX is most likely preferentially associated with the interfacial surfactant layer, 
most probably in the dehydrated region close to the core, rather than with the oil.  
A comparison between the experimentally determined DTX solubilisation and the 
calculated DTX solubilisation is shown in Table 4.12. The expected/calculated DTX 
solubilisation was obtained from a knowledge of the solubilisation of DTX in TDL25 
micelles and the solubility of DTX in hSBO. This comparison showed that the 
experimentally measured level of DTX solubilisation in TDL25-hSBO-DTX NE was 
similar to that expected, indicating that there was not advantage formulating DTX in the 
NE under study. 
 
Table 4.12 Comparison of the experimentally measured and expected/calculated docetaxel 
solubilisation in TDL25-hSBO-DTX nanoemulsions after incubation with excess drug for 14 




Experimental DTX solubilisation  
in TDL25-hSBO-DTX (%w/v) 
Expected CUR solubilisation  
in TDL25-hSBO-DTX  (%w/v) a 
0 0.20 ± 0.06 - 
3 0.29 ± 0.05 0.26 
 
a calculated from the experimental DTX solubilisation in micelle and oil according to amount of oil and surfactant in 
the samples. The solubility of DTX in 25% Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) was 0.20 ± 0.06 %w/v at 
25⁰C while the solubility of DTX in hSBO was 1.94 ± 0.37 %w/v at 25 ⁰C (Yao et al., 2012).   
 
4.4 Small angle neutron scattering data 
Analysis of the SANS data gave an excellent estimation of the shape of micelles and NE 
particles using different form factor P(Q) (i.e. a sphere, an oblate or a prolate ellipsoid 
(Figure 4.18). In analysis of the SANS data, the interparticulate structure factor was 
modelled as hard-sphere interactions using the Percus-Yevick approximation. 
Furthermore, it was assumed that the micelles and NE monodisperse, exhibiting a 
constant scattering length density (SLD) to analysis the SANS data.  
 




a) b) c)  
 
Figure 4. 18: Schematic representation of a) sphere, b) oblate ellipsoid and c) prolate ellipsoid. 
 
In order to analyse the SANS data for the micelles, it was assumed that a core-shell 
particle of micelles contained 2 parts: a core composed of the hydrocarbon chains of 
Tween 80 surfactant (and the hydrocarbon chains of cosurfactants either Dermosoft 
GMCY or lecithin if micelles contain cosurfactants) and a shell containing the 
surfactant/cosurfactants polar head groups with some solvent molecules. On the other 
hand, the model used for the NE, where only drop contrast was available, was different 
and assuming that the core of the NE consisted only of the oil, and the shell consisted of 
the whole surfactant molecule (and whole cosurfactant molecule if cosurfactants 
present) and solvent molecule.  
A preliminary fitting of SANS data, it showed that the SANS data could not be fitted 
using the simple spherical form factor, although it could be reasonably well fitted using 
an oblate ellipsoid for T2d micelles and a prolate ellipsoid for TD2d and TDL2d 
micelles. It is clear that the ellipsoid model was the best model to be used to fit SANS 
data. As a consequence therefore, a core-shell ellipsoid model was chosen to analyse 
SANS data in the present study due to the fact that it provided better fits to the 
experimentally obtained SANS data and yielded statistically better results were obtained 
in comparison with the sphere model.  
 
4.4.1 SANS studies of Tween 80 micelle in the presence and absence of 
cosurfactant or drugs 
A series of best fits were obtained assuming a core-shell ellipsoid shape for Tween 80-
containing micelles as shown in Figure 4.19 while Table 4.13 gives the parameters 
obtained from the best fit to the Tween 80-containing micelles, namely, the core 
equatorial radius, the major and minor radii, and the shell thickness. Note that Q and 
I(Q) are the scattering vector and the intensity of the scattered neutron radiation, 




respectively. The absence of an interaction peak in the SANS curves suggested that the 
Tween 80-containing micelles possessed no charge as expected. Furthermore, when a 
structure factor was used to explore the presence of interparticulate interactions in the 
samples at 2 %w/w surfactant concentration, it was found that there was no change to 
the fit suggesting that, at these concentrations, there were no interparticulate 
interactions. 
 
Figure 4.19: Drop contrast of SANS data and ‘best’ fits for 2 %w/w Tween 80, 2 %w/w Tween 
80:Dermosoft GMCY (weight ratio 3:1) and 2 %w/w Tween 80:Dermosoft GMCY:lecithin 
(weight ratio 7.5:2.5:1) micelles in D2O at 25 ˚C using a core-shell ellipsoid model together 
with a hard sphere model for interactions. 
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Table 4.13 Parameters obtained for the best fit to the SANS data for 2 %w/w Tween 80, 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and 2 %w/w 
Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) micelles in the absence of drugs at 25 °C using a core-shell ellipsoid model together with a hard sphere 
structure factor S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
sample core  
equatorial 



































T2d 32.0 0.4 13.4 14.7 46.7 28.2 0.6 257343 50.0 15 112 74 5272 
TD2d 17.8 5.4 95.4 12.4 30.2 107.8 3.6 410801 115.8 15 401 42 4231 
TDL2d 17.0 11.0 186.8 19.5 36.4 206.3 5.7 1147142 225.2 60 630 49 1857 
 
Estimated uncertainty for R1 were ± 0.15 for T2d, ± 0.1 for TD2d or ± 0.07 for TDL2d, respectively.  
Estimated uncertainty for x were ± 0.01 for T2d and TD2d or ± 0.1 for TDL2d. 
 




It was clear that the T2d micelles were oblate ellipsoid as indicated by the core axial 
ratio of less than 1. The core equatorial radius of 32.0 Å determined for T2d was, as 
expected, was bigger the 16.5 Å estimated for Tween 20 (Saaka, 2016), partially as a 
consequence of the elongation of the hydrophobic alkyl chain (Tanford et al., 1977). 
Moreover, Tween 80 has been shown to form the largest aggregates within the Tween 
series of surfactant (Atwood et al., 1992). The thickness of T2d shell was 14.7 Å which 
was thinner than that reported for 2 %w/w Tween 20 (a surfactant containing same 
number of ethylene oxide groups attached to the sorbitan head group as Tween 80) 
which was 19.1 Å (Saaka, 2016). The aggregation number (Nagg) of Tween 80 was 112, 
which was double that determined by Jawhari (1999) using static light scattering. The 
surface area of the Tween 80 micelles was calculated to be 74 Å2, smaller than the value 
of 81.1 Å2, established using TILS and 86.5 Å2 using surface tension measurements 
(Jawhari, 1999) and was similar to the value of 72 Å2 determined by Yang et al. (2013) 
from surface tension experiments. The variation in the shell thickness, aggregation 
number and area per Tween 80 molecule could be explained by variation in the degree 
of ethoxylation (Penfold et al., 2015). 
In this study, the effect of the addition of the cosurfactant, Dermosoft GMCY and the 
second (hydrophobic) surfactant, lecithin on the size and shape of the micelle is given in 
Figure 4.19. Clearly, the inclusion of either a cosurfactant or a cosurfactant and second 
(hydrophobic) surfactant had an effect on the shape of micelles which transformed from 
oblate ellipsoid, for T2d, to prolate ellipsoid for TD2d and TDL2d, respectively as 
shown by their possession of a core axial ratio greater than 1. The inclusion of a 
cosurfactant/second hydrophobic surfactant in a NE is known to have an influence on 
the size and shape of their aggregates. The core equatorial radius decreased from 32 Å 
for T2d to 17.8 Å for TD2d and 17.0 Å for TDL2d. Correspondingly, the micelle 
volume increased from 257 nm3 for T2d to 410 nm3 for TD2d and 1147 nm3 for 
TDL2d. This result of the formation of larger aggregates after adding a cosurfactant or a 
cosurfactant/second hydrophobic surfactant is in agreement with the apparent 
hydrodynamic size (Dh) of micelles measured in this study using PCS which showed a 
slight increase in the Dh for TD25 micelles and a much larger increase in Dh of TDL25 
micelle when compared to the site of the T20 micelles. When compared to T2d 
micelles, the Nagg of TD2d and TDL2d micelle was 4 and 6 times higher, respectively.  
The increase in Nagg due to the presence of cosurfactant or cosurfactant/second 
hydrophobic surfactant was the same trend in Nagg as that observed by Jawhari (1999) 




upon adding Imwittor 308 (at a weight mixing ratio of 3:1 - 5:1) to Tween 80 micelles. 
Table 4.14 shows the total aggregation number (Nagg), Tween 80 aggregation number 
(NT), Dermosoft GMCY aggregation number (ND) and lecithin aggregation number 
(NL) in Tween 80-stabilised micelles in the absence and presence of either Dermosoft 
GMCY or Dermosoft GMCY and lecithin. In the presence of drug, it was clear that the 
increase in the Nagg of TD2d micelles occurred due to an mainly increase in the 
Dermosoft GMCY aggregation number (ND) with a small increase in Tween 80 
aggregation number (NT) while the increase in Nagg of TDL2d occurred due to the major 
increase in Dermosoft GMCY aggregation number (ND) with the a small increase in the 
NT and lecithin aggregation number (NL). Figure 4.20 gives a schematic representation 
of the Tween 80 micelles in the absence and presence of cosurfactant.  
 
Table 4.14 Number of surfactant and cosurfactant monomers comprising Tween 80 micelles in 
the presence of either Dermosoft GMCY or Dermosoft GMCY in combination with lecithin at 
25 ˚C. 
Composition Ratio of surfactant: cosurfactant Aggregate parameter 
Weight ratio Molar ratio Nagg NT ND NL 
T2d 0 0 112 112 0 0 
TD2d 
3:1 1:2 
401 134 267 0 
TD2d-CUR 433 148 295 0 
TD2d-CUR-TP 586 195 391 0 
TDL2d 
7.5:2.5:1 4.4:8.8:1 
630 195 390 45 
TDL2d-CUR 769 238 477 54 
TDL2d-CUR-TP 1068 331 662 75 
 
Nagg, NT, ND and NL are the total aggregation number, Tween 80, Dermosoft GMCY and lecithin aggregation number 
respectively. 
 
a) b) c)  
 
Figure 4.20: Schematic representation of the ellipsoidal a) 2 %w/w Tween 80 micelle, b) 
2%w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) micelle and c)  2%w/w Tween 
80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) micelle.  




The SANS data for the Tween 80 micelles with cosurfactant or surfactant/second 
hydrophobic surfactant in the absence and presence of drug is shown in Figure 4.21. 
Saturation of TD2d and TDL2d with either CUR or CUR and TP resulted in a change in 
the intensity of scattering I(Q). For TD2d micelles (Figure 4.21a and Table 4.15), the 
presence of a saturated amount of CUR slightly increased the core axial ratio from 5.4 
for TD2d to 6.1 for TD2d-CUR with no change in the core equatorial radius (17.6-17.8 
Å) or shell thickness (~12.4 Å). There was a small increase in the Nagg of the surfactant 
from 401 in TD2d micelles to 443 in the mixed TD2d-CUR micelles, although the 
surface area calculated for the surfactant remained constant at 42 Å2. Moreover, the 
addition of a saturation amount of both CUR and TP dramatically increased the core 
axial ratio from 5.4 for TD2d micelles to 7.5 for the mixed TD2d-CUR-TP micelles, 
along with a very small change in the core equatorial radius from 17.8 Å to 18.1 Å for 
TD2d and TD2d-CUR-TP micelles, respectively. A small increase in the shell thickness 
to 13.0 Å was seen for TD2d-CUR-TP micelles along with a large increase in Nagg to 
586, although the surface area in the presence of drug/drugs remains the same at ~ 41 
Å2. Interestingly, the presence of drugs resulted in the increase in the surfactant and 
cosurfactant aggregation number for TD2d system (Table 4.13).  
 
 
a) b)  
Figure 4.21: SANS curve and ‘best’ fit to the data obtained for drop contrast of mixed micelles 
of 2 %w/w of a) Tween 80:Dermosoft GMCY (weight ratio 3:1) and b) Tween 80:Dermosoft 
GMCY:lecithin (weight ratio 7.5:2.5:1) in the absence and presence of drugs at 25 ˚C. 
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Table 4.15 Parameters obtained for the ‘best’ fit to the SANS data for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and Tween 80:Dermosoft 
GMCY:lecithin (weight ratio 7.5:2.5:1) micelles in the presence of drugs at 25 °C using a core-shell ellipsoid model together with a hard sphere structure factor 
S(Q). The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
sample core  
equatorial 




































TD2d-CUR 17.6 6.1 107.4 12.4 30.1 119.8 4.0 453691 124.1 15 443 42 4834 
TD2d-CUR-TP 18.1 7.5 135.4 13.0 31.1 148.5 4.8 600891 154.3 15 586 41 3638 
TDL2d-CUR 16.9 13.6 229.9 19.7 36.6 249.6 6.8 1399298 263.4 60 769 50 1410 
TDL2d-CUR-TP 17.1 18.2 311.2 20.3 37.4 331.5 8.9 1943646 356.2 60 1068 49 774 
 
Estimated uncertainty for R1 of micelles in the presence of drug were ± 0.1 for TD2d and ± 0.5 for TDL2d, respectively.  
Estimated uncertainty for x was ± 0.1. 




The variation of the parameters obtained for the ‘best’ fit to the TDL2d system after the 
addition of either CUR or CUR and TP is shown in Figure 4.21b and Table 4.15. The 
core axial ratio of the mixed micelles of TDL2d-CUR increased from 11.0 Å for the 
TDL2d micelles to 13.6 Å in the presence of CUR with no change in the core equatorial 
radius, which remained constant at ~ 16.9-17.0 Å while the shell thickness was ~ 19.5-
19.7 Å. An increase in the Nagg of surfactant and cosurfactant from 630 for TDL2d 
micelles to 769 for CUR-containing TDL2d micelles whereas the surface area of the 
surfactant remained constant at 50 Å2. In addition, the addition of saturation amount of 
CUR and TP dramatically increased the core axial ratio from 11.0 for ‘empty’ TDL2d 
micelles to 18.2 for CUR and TP-containing TDL2d micelles with no difference in the 
core equatorial radius of either TDL2d or TDL2d-CUR-TP micelles, remaining constant 
at 17.1 Å for. In contrast, the shell thickness changed from 19.5 Å for TDL2d micelles 
to 20.3 Å for TDL2d-CUR-TP micelles with a corresponding large increase in Nagg to 
1068, although the surface area of the surfactant of remained unchanged at 49 Å2. 
Similar to the TD2d system, the presence of drug resulted in an increase in the NT, ND 
and NL compared to empty micelles (Table 4.13). Schematic representations of the 
ellipsoid Tween 80 micelles, with and without cosurfactant, in the presence of drug are 
shown in Figure 4.22. 
 
a) b) c) d)  
 
Figure 4.22: Schematic representation of the ellipsoidal 2 %w/w Tween 80:Dermosoft GMCY 
(weight ratio 3:1) micelle with either a) CUR or b) CUR and TP, and 2 %w/w Tween 
80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) micelle with either c) CUR or d) CUR 
and TP.  
 




4.4.2 SANS studies of Tween 80 nanoemulsions containing triglyceride or ethyl 
ester and cosurfactant in the presence and absence of or drugs 
A range of models was used to fit the drop contrast of TD2-98hEO NE at different 
concentrations of 98hEO in both the absence and presence of drugs. The resulting 
SANS data, along with the ‘best’ fits for the TD2-98hEO NE, fitted with core-shell 
ellipsoid model are shown in Figure 4.23, while Table 4.16 shows the parameters 
obtained for the ‘best’ fits of SANS data.  
a) b)  
c)  
Figure 4.23: SANS data and ‘best’ fits using the oblate ellipsoid model for the drop contrast of 
NE prepared using 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and containing 
various concentrations of 98hEO from a) 0.6 %w/w, b) 0.72 %w/w and c) 0.8 %w/w in the 
absence and presence of drugs at 25 ˚C. Note that the best fits of TD2-98hEO0.72d and TD2-
98hEO0.8d in the absence and presence of drug were not well fitted to SANS data at low Q.   
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Table 4.16 Individual SANS best fits results for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and ethyl oleate nanoemulsions in the absence and 
presence of drug at 25 °C using a core-shell ellipsoid model together with a hard sphere structure factor S(Q). The data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TD2-98hEO0.64d 63.0 0.3 21.6 23.9 86.9 45.4 0.5 1438156 95.9 15 999 50 85158 
TD2-98hEO0.64d-CUR 60.6 0.4 23.0 24.1 84.7 47.2 0.6 1418259 92.4 15 985 49 63537 
TD2-98hEO0.64d-CUR-TP 60.3 0.4 22.6 23.9 84.2 46.5 0.6 1381917 97.9 15 960 50 26343 
TD2-98hEO0.72d 67.1 0.3 23.0 23.4 90.5 46.4 0.5 1589625 106.9 15 1070 52 375790 
TD2-98hEO0.72d-CUR 67.4 0.3 22.3 23.1 90.5 45.4 0.5 1555576 105.0 15 1048 53 276400 
TD2-98hEO0.72d-CUR-TP 67.7 0.3 22.6 23.3 91.0 45.9 0.5 1590893 105.2 15 1071 52 143490 
TD2-98hEO0.8d 74.8 0.3 23.8 23.3 98.0 47.1 0.5 1897101 113.0 15 1240 52 222250 
TD2-98hEO0.8d-CUR 75.8 0.3 23.8 23.4 99.2 47.2 0.5 1947306 116.4 15 1273 52 869860 
TD2-98hEO0.8d-CUR-TP 75.7 0.3 25.0 24.0 99.7 49.0 0.5 2039364 116.0 15 1333 50 743900 
 
Estimated uncertainty for R1 of either 0.64, 0.72 or 0.8 %w/w 98hEO NE were ± 0.5, ± 1.5 or ± 2.0, respectively.  
Estimated uncertainty for x were ± 0.02. 
 




The results suggest that, as expected, no strong interaction exist between the droplets in 
the diluted NE system. It is worth noting, however, that the ‘best’ fits for TD2-
98hEO0.72d and TD2-98hEO0.8d in the absence and presence of drug did not well fit 
to the SANS data at low Q. As expected, the core equatorial radius increased with 
increasing 98hEO content - being 63.0 Å for TD2-98hEO0.64d NE and 74.8 Å for 
TD2-98hEO0.8d NE. The increase in the core equatorial radius showed a similar trend 
to that seen for the hydrodynamic size assessed using PCS (Table 4.7 in section 4.2.4) 
and is also in the agreement with that reported in the literature on the effect of oil on the 
aggregation properties of surfactant micelles. Similar trends have been previously 
reported by other researchers for both o/w and w/o ME (Baker et al., 1984; Attwood et 
al., 1992; Saint Ruth et al., 1995). After fitting SANS data for each NE with varying 
levels of shell hydration, a shell hydration of 15 % was found to fit TD2-98hEOd NE 
best. The thickness of the shell obtained from the best fits for the NE were in the range 
23.1-24.1 Å. It was clear that the shape which provided the best fit to the SANS data 
was an ellipsoid. The axial ratio of the core suggested that the shape of TD2-98hEO NE 
was an oblate ellipsoid because the calculated core axial ratio was in the range 0.3-0.4. 
The shape of the NE droplets did not change as the oil content increased as indicated by 
the droplet axial ratio. This observation was not the trend suggested by the PIT result 
(Table 4.6 in section 4.2.3) where the shape of TD25-98hEO NE droplets become more 
asymmetric with increasing 98hEO content. The increase in Nagg with increasing oil 
content probably encompass the increasing size of the oil core and this increase in Nagg 














Table 4.17 Number of surfactant and cosurfactant monomers comprising Tween 80 
nanoemulsions in water in the presence of Dermosoft GMCY and/ or lecithin at 25 ˚C. 
 
Composition Ratio of surfactant: cosurfactant Aggregate parameter 
Weight ratio Molar ratio Nagg NT ND NL 
TD2-98hEO0.64d 
3:1 1:2 
999 333 666 0 
TD2-98hEO0.64d-CUR 985 328 657 0 
TD2-98hEO0.64d-CUR-TP 960 320 640 0 
TD2-98hEO0.72d 1070 357 713 0 
TD2-98hEO0.72d-CUR 1048 349 699 0 
TD2-98hEO0.72d-CUR-TP 1071 357 714 0 
TD2-98hEO0.8d 1240 413 827 0 
TD2-98hEO0.8d-CUR 1273 424 849 0 
TD2-98hEO0.8d-CUR-TP 1333 444 889 0 
TDL2-hSBO0.24d 
7.5:2.5:1 4.4:8.8:1 
369 114 229 26 
TDL2-hSBO0.24d-CUR 368 114 228 26 
TDL2-hSBO0.24d-CUR-TP 440 136 273 31 
 
Nagg, NT, ND and NL are the total aggregation number, Tween 80, Dermosoft GMCY and lecithin aggregation number 
respectively. 
 
In the presence of a saturation amount of drug, either CUR or CUR and TP, it was clear 
that the size and shape of TD2-98hEO NE did not change. The observation from the 
SANS data that there was no change in the size of the TD2-98hEO-CUR NE droplets 
was not in the agreement with the PCS data which indicated that TD25-98hEO8-CUR 
NE were larger than TD25-98hEO8 NE (Figure 4.9). The PIT results suggested the 
TD25-98hEO-CUR NE droplets became more spherical as the amount of 98hEO 
incorporated increased, however the SANS data did not show the same trend (Figure 
4.6 and 4.11). Moreover, no change in the Nagg, NT or ND was seen (Table 4.17) while 
the fitting results for drug-saturated NE imply that the level of solubilisation of CUR or 
CUR and TP was not enough to cause the change in head group region - believed to be 
the main locus of solubilisation leading to no change in the size, shape and aggregation 
number of NE. Schematic representations of the, Region A, TD2-98hEO NE, in the 
absence and presence of drug, is shown in Figure 4.24. 




a) b) c)  
 
Figure 4.24: Schematic of the ellipsoidal 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 
3:1) NE containing 0.64 %w/w 98hEO with a) no drug, b) CUR and c) CUR and TP in D2O. 
 
After a range of shapes were used to fit the drop contrast of TDL2-hSBO0.24 NE in the 
absence and presence of drugs, the SANS data and best fits to the SANS data for TDL2-
hSBO0.24 NE using a core-shell ellipsoid model are shown in Figure 4.25 and Table 
4.18. The results suggest that, as expected, no strong interaction existed between the 
droplets in the diluted NE system. It is worth noting that the SANS data was not well 
fitted at low Q. The core equatorial radius of 32.2 Å was for TDL2-hSBO0.24d NE and 
the axial ratio of the core of 0.3 suggested that the shape of TDL2-hSBO0.24d NE were 
oblate ellipsoid. After fitting the SANS data using various levels of shell hydration for 
each NE sample, a shell hydration of 25% for the TDL2-hSBO0.24d NE was found to 
produce the best fit to SANS data. The thickness of the shell under these conditions was 
found to be 25.7 Å. It was clear that the model which provided the best fit to the SANS 
data was that of an ellipsoid.  
 
Figure 4.25: SANS data and ‘best’ fits using the oblate ellipsoid model for the drop contrast of 
2 %w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) NE containing the upper 
limit of hSBO incorporated into Region A in the absence and presence of drugs at 25 °C. Note 
that the best fits of TDL2-hSBO0.24d in the absence and presence of drug were not well fitted 
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Table 4.18 Individual SANS best fits results for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and soybean oil nanoemulsions in the absence and 
presence of drug at 25 °C using a core-shell ellipsoid model together with a hard sphere structure factor S(Q). The data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TDL2-hSBO0.24d 32.2 0.3 10.7 25.7 57.9 36.3 0.6 510430 65.9 25 369 50 1074 
TDL2-hSBO0.24d-CUR 32.3 0.3 10.6 25.6 57.9 36.2 0.6 508375 66.4 25 368 50 957 
TDL2-hSBO0.24d-CUR-TP 35.7 0.3 10.4 26.8 62.5 37.2 0.6 607910 65.0 25 440 47 1463 
 
Estimated uncertainty for R1 and x were ± 0.2 and ± 0.01, respectively 
 




In the presence of a saturation amount of drug, either CUR or CUR and TP, it was clear 
that neither the size, shape, Nagg, NT, ND nor NL of the TDL2-hSBO0.24d-CUR NE 
changed. In contrast, those of TDL2-hSBO0.24d-CUR-TP NE because larger with an 
increase in the core equatorial from 32.2 Å for TDL2-hSBO0.24d NE to 35.7 Å for 
TDL2-hSBO0.24d-CUR-TP NE (Table 4.17 and 4.18). This SANS result suggests that 
the solubilisation of a saturation amount of CUR and TP caused the increase in size and 
aggregation of NE. A schematic representation of the Region A, TDL2-hSBO0.24d NE 
in the absence and presence of drugs is shown in Figure 4.26. 
 
a) b)  
c)  
Figure 4.26: Schematic of the ellipsoidal 2 %w/w Tween 80:Dermosoft GMCY:lecithin 
(weight ratio 7.5:2.5:1) NE containing 0.24 %w/w hSBO with a) no drug, b) CUR and c) CUR 
and TP.  
 
4.4.3 Effect of temperature on Tween 80 nanoemulsions in the present of 
cosurfactant and in the absence and presence of drug 
It is essential to understand the effect of temperature and in particular the temperature 
of 37 °C (i.e. body temperature and the temperature of the cytotoxicity experiment) on 
the structure of NE containing hSBO or 98hEO as the disperse phase and the nonionic 
surfactant, Tween 80 alone or in the presence of cosurfactant with or without a second 
surfactant in order to successfully use the NE as vehicles for the delivery of drugs such 
as anticancer agents as well as being able to test their cytotoxicity using cell culture. 
Zielinski et al. (1995) reported that no change occurred in the structure of nonionic 
surfactant micelles formed by C12E6 over the temperature range of 25-31 °C when 
examined by SANS. In contrast, there was a 10% decrease in the size of SDS anionic 
micelles and a 10% increase in size of the C12E10, nonionic micelles over the 




temperature range 30 to 75 °C when measured by SANS. The SANS data of C12E10 
exhibited a weak correlation peak, which shifted to smaller Q values in conjunction 
with an increase in the scattering cross-section upon increasing the temperature (Aswal 
and Wagh, 2008). Therefore, it is worth performing a SANS experiment to determine 
the effect of temperature on the physico-chemical properties of the Brij O10 NE. The 
insight provided by such a study should provide a better understanding of the potential 
of Tween 80-stabilised NE in the absence and presence of cosurfactant as vehicles for 
drug delivery. 
A range of models (form factors) were used to attempt to fit the drop contrast of TD2d 
and TDL2d micelles in the absence and presence of drugs at 37 °C. The SANS data 
along with the ‘best’ fits obtained for the TD2d and TDL2d micelles using a core-shell 
ellipsoid model are shown in Figures 4.27-4.28 while Table 4.19 shows the parameters 
used to obtain the best fits to SANS data.  
 
a)  b)  
 
c)  
Figure 4.27: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY (weight ratio of 3:1) micelles with and without the presence of drug at 25 and 37 ˚C. 
 






Figure 4.28: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY:lecithin (weight ratio of 7.5:2.5:1) micelles with and without the presence of drug at 25 
and 37 ˚C. 
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Table 4.19 Parameters used for the best fits to the individual SANS data for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and Tween 80:Dermosoft 
GMCY:lecithin (weight ratio 7.5:2.5:1) micelles in the absence and presence of drug using a core-shell ellipsoid model together with a hard sphere structure factor 


































Nagg surfaces  







TD2d-37C 18.1 7.0 126.1 12.9 31.0 139.1 4.5 560233 159.2 15 547 41 6309 
TD2d-CUR-37C 18.0 8.2 147.2 13.1 31.1 160.3 5.2 647791 168.3 15 632 41 7313 
TD2d-CUR-TP-37C 18.5 10.5 194.8 13.7 32.3 208.5 6.5 910367 215.6 15 888 40 10821 
TDL2d-37C 17.3 21.4 369.8 20.7 38.0 390.5 10.3 2357829 400.1 60 1295 48 4122 
TDL2d-CUR-37C 17.1 30.3 517.3 20.7 37.8 538.0 14.2 3221874 540.5 60 1770 49 5915 
TDL2d-CUR-TP-37C 17.5 51.6 900.7 21.5 38.9 922.1 23.7 5859295 930.2 60 3219 48 5978 
 
Estimated uncertainty for R1 were ± 0.1.  














As can be seen from the parameters used to fit the micelles, there were only small 
differences in both the core equatorial radius and shell thickness but large differences in 
the shape of micelle at temperatures of 25 and 37 °C in both drug-free and drug-
containing micelles. For example, the axial ratio of TD2d micelles was 5.4 at 25 ˚C but 
increased to 7.0 at 37 ˚C. Moreover, the change in the shape of the micelle in the 
presence of cosurfactant or cosurfactant and a second surfactant at 37 ˚C was due to an 
increase in the Nagg of micelle was due to an increase in both NT and ND for TD2d 
micelles and NT, ND and NL for TDL2d micelles (Table 4.20).  
 
Table 4.20 Number of surfactant and cosurfactant monomers comprising Tween 80 micelles in 
the presence of Dermosoft GMCY or Dermosoft GMCY and lecithin at 37 ˚C. 
 
Composition Ratio of surfactant: cosurfactant Aggregate parameter 
Weight ratio Molar ratio Nagg NT ND NL 
TD2d-37C 
3:1 1:2 
547 182 365 0 
TD2d-CUR-37C 632 211 421 0 
TD2d-CUR-TP-37C 888 296 592 0 
TDL2d-37C 
7.5:2.5:1 4.4:8.8:1 
1295 401 803 91 
TDL2d-CUR-37C 1770 548 1097 125 
TDL2d-CUR-TP-37C 3219 997 1994 227 
 




This change in the shape of the TD2d and TDL2d micelles is in line with the decrease in 
the CP of the TD2d and TDL2d micelles. Fortunately the CP of the TD2d and TDL2d 
micelles were around 60 ˚C, ~ 30 ˚C higher than body temperature. The micelles in the 
presence of CUR and TP at 37 ˚C exhibited the biggest change in the shape of the 
micelles because the lowering in CP of micelles. For example, the CP of TD2d-CUR-
TP at 25 ˚C was around 55 ˚C which was the lower CP than TD2d micelle in the 
absence and presence of CUR which occurred the CP at 60 ˚C (Table 4.6, Figures 4.6 
and 4.11). Unfortunately, the CP of TDL2d-CUR-TP was not performed but it was 








When fitting the SANS data for TD2d NE, a range of models were explored to 
individually fit the drop contrast of TD2-98hEO NE at either 0.64 or 0.8 %w/w 98hEO 
in the absence and presence of drugs at 37 °C. The best fits to the SANS data for TD2-
98hEO where obtained when fitted using a core-shell ellipsoid model (shown in 
Figures 4.29-4.30).  
 
a) b)  
c)  
Figure 4.29: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY (weight ratio 3:1) containing 0.64 %w/w 98hEO with and without the presence of drug 
at 25 and 37 ˚C. 
 
 






Figure 4.30: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY (weight ratio 3:1) containing 0.8 %w/w 98hEO with and without the presence of drug at 
25 and 37 ˚C. 
 
Table 4.21 shows the parameters used for the best fits. It was clear from the fitting 
parameters that no difference in shape and/or size of TD2-98hEO0.64d-37C NE was 
observed in the absence and presence of drug at either 25 or 37 °C or even when the NE 
was stored at 37 °C for 10 hours, correspondingly the Nagg of TD2-98hEO0.64d-37C 
without drug and with drugs did not change (Table 4.22).  
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Table 4.21 Parameters used for the best fits to the individual SANS data for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and 98hEO nanoemulsions in 
the absence and presence of drug using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 ˚C. The modelling of the SANS data was 
constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TD2-98hEO0.64d-37C-t0 61.5 0.4 22.4 24.0 85.5 46.4 0.5 1423209 99.8 15 988 49 16158 
TD2-98hEO0.64d-37C-10h 61.4 0.4 22.8 24.2 85.6 47.0 0.5 1443940 93.9 15 1003 49 13918 
TD2-98hEO0.64d-CUR-37C-t0 61.1 0.4 23.2 24.3 85.4 47.5 0.6 1451671 94.4 15 1008 48 11423 
TD2-98hEO0.64d-CUR-37C-10h 61.1 0.4 23.3 24.4 85.4 47.7 0.6 1458163 92.3 15 1013 48 11859 
TD2-98hEO0.64d-CUR-TP-37C-t0 62.3 0.4 23.1 24.5 86.8 47.6 0.5 1503500 97.5 15 1044 48 14657 
TD2-98hEO0.64d-CUR-TP-37C-10h 61.5 0.4 23.6 24.6 86.1 48.2 0.6 1496906 99.2 15 1039 48 14110 
TD2-98hEO0.8d-37C-t0 74.4 0.3 25.8 24.2 98.6 49.9 0.5 2034913 111.4 15 1330 49 29339 
TD2-98hEO0.8d-37C-10h 74.3 0.4 26.4 24.4 98.8 50.8 0.5 2077701 117.7 15 1358 48 28479 
TD2-98hEO0.8d-CUR-37C-t0 76.5 0.3 24.9 24.1 100.5 49.0 0.5 2074395 115.9 15 1356 50 56207 
TD2-98hEO0.8d-CUR-37C-10h 74.7 0.3 25.8 24.2 99.0 50.0 0.5 2054002 113.3 15 1343 49 36880 
TD2-98hEO0.8d-CUR-TP-37C-t0 76.7 0.3 25.8 24.6 101.3 50.4 0.5 2167841 119.1 15 1417 48 37524 
TD2-98hEO0.8d-CUR-TP-37C-10h 76.3 0.3 26.4 24.8 101.0 51.1 0.5 2186670 113.1 15 1429 48 31077 
 








Table 4.22 Number of surfactant and cosurfactant monomers comprising Tween 80 micelles in 
water in the presence of Dermosoft GMCY and/ or lecithin at 37 ˚C. 
 
Composition Ratio of surfactant: cosurfactant Aggregate parameter 
Weight ratio Molar ratio Nagg NT ND NL 
TD2-98hEO0.64d-37C-t0 
3:1 1:2 
988 329 659 0 
TD2-98hEO0.64d-37C-10h 1003 334 669 0 
TD2-98hEO0.64d-CUR-37C-t0 1008 336 672 0 
TD2-98hEO0.64d-CUR-37C-10h 1013 338 675 0 
TD2-98hEO0.64d-CUR-TP-37C-t0 1044 348 696 0 
TD2-98hEO0.64d-CUR-TP-37C-10h 1039 346 693 0 
TD2-98hEO0.64d-CUR-TP-DM-37C-t0 984 328 656 0 
TD2-98hEO0.64d-CUR-TP-DM-37C-2.5h 990 330 660 0 
TD2-98hEO0.64d-CUR-TP-DM-37C-6h 1021 340 681 0 
TD2-98hEO0.64d-CUR-TP-DM-37C-12h 1023 341 682 0 
TD2-98hEO0.8d-37C-t0 1330 443 887 0 
TD2-98hEO0.8d-37C-10h 1358 453 905 0 
TD2-98hEO0.8d-CUR-37C-t0 1356 452 904 0 
TD2-98hEO0.8d-CUR-37C-10h 1343 448 895 0 
TD2-98hEO0.8d-CUR-TP-37C-t0 1417 472 945 0 
TD2-98hEO0.8d-CUR-TP-37C-10h 1429 476 953 0 
TDL2-hSBO0.24d-37C 
7.5:2.5:1 4.4:8.8:1 
385 119 239 27 
TDL2-hSBO0.24d-CUR-37C 399 124 247 28 
TDL2-hSBO0.24d-CUR-TP-37C 465 144 288 33 
 
Nagg, NT, ND and NL are the total aggregation number, Tween 80, Dermosoft GMCY and lecithin aggregation 
number, respectively. 
 
On the other hand, a lower intensity of scattering was observed for TD2-98hEO0.8d-
37C at both time zero and ten hours of storage at 37 °C, regardless of the absence or 
presence of drug (Figure 4.30). Interestingly however, the values of the parameters 
used for fitting did not show any change in the size and shape of the NE (Tables 4.16 
and 4.21), largely because the SANS data of samples at 25 °C were not well fitted at 
low Q. Interestingly, the Nagg of TD2-98hEO0.8d-37C without and with drugs (Table 
4.22) increase compared to TD2-98hEO0.8d in the absence and presence of drugs at 25 
°C (Table 4.17) which can be explained that the TD2-98hEO0.8d NE were on the 
boundary of Region A which tended to be easily altered.  




As with the other NE studies, a range of models were used to fit the SANS data for the 
drop contrast of TDL2-hSBO0.24d NE in the absence and presence of drug at 37 °C. 
The ‘best fit’ to the SANS data of TDL2-hSBO0.24d NE at 25 and 37 °C were obtained 
using a core-shell ellipsoid model (Figure 4.31). Table 4.23 gives the parameters used 
to obtain these best fits. From these results it was clear that there was no difference in 
shape and/or size of the TDL2-hSO0.24d-37C NE in the absence and presence of drug 
either at 25 or 37 °C, or even 10 hours storage of the samples at 37 °C. This result 
suggests that all of TDL2-hSBO0.24d NE system were stable on change in temperature. 
Note however the Nagg of TDL2-hSBO0.24d-37C NE slightly increased compared to 
TDL2-hSBO0.24d in the absence and presence of drugs due to an increase in ND 
(Tables 4.17 and 4.20). In the absence of drug, Nagg of TDL2-hSBO0.24d-37C NE 




a)  b)  
c)  
Figure 4.31: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY:lecithin (weight ratio 7.5:2.5:1) containing 0.24 %w/w hSBO with and without the 
presence of drugs at 25 and 37 ˚C. 
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Table 4.23 Parameters used for the best fits to the individual SANS data for 2 %w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) and hSBO 
nanoemulsions in the absence and presence of drug using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 ˚C. The modelling of 
the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TDL2-hSBO0.24d-37C 34.0 0.3 10.0 25.7 59.7 35.7 0.6 532524 63.4 25 385 50 1321 
TDL2-hSBO0.24d-CUR-37C 35.5 0.3 9.5 25.7 61.2 35.2 0.6 551666 64.5 25 399 51 1966 
TDL2-hSBO0.24d-CUR-TP-37C 37.7 0.3 9.8 26.9 64.6 36.7 0.6 642982 66.9 25 465 47 2197 
 
Estimated uncertainty for R1 and x were ± 0.25 and ± 0.01, respectively. 




4.4.4 Effect of cell culture media on Tween 80 nanoemulsions in the presence of 
cosurfactant in the absence and presence of drug 
It is essential to understand the effect of plasma proteins, which are present in the 
bloodstream and cell culture media, on the structure of the NE, in order to best use the 
TD2-98hEO NE and TDL2-hSBO NE as vehicles for the delivery of therapeutic agents 
including anticancer agents and to test their cytotoxicity in cell culture. For example, the 
addition of either the anionic surfactant SDS or the cationic surfactant CTAB to the 
protein, bovine serum albumin (BSA) has been shown to result in its binding to the 
protein, causing a change in the size and structure of protein (Chodankar et al., 2007; 
Gull et al., 2008; Gull et al., 2009).   
Although using light scattering to observe any changes in the physical properties of the 
NE in the presence of electrolyte and plasma proteins is theoretically possible, the 
wavelength of light (~ 500 nm) compared to the size (< 20 nm) of the NE droplets 
means that it will only be possible to detect changes in the whole system without being 
able to attribute these changes are due to changes in shape and/or size of the NE (and/or 
protein). Moreover, the light scattering experiments are more complicated in the 
presence of plasma proteins, which themselves scatter light, resulting in serious 
complications in the analysis of particle size. It is therefore essential to determine the 
effect of serum on the NE using SANS if the NE are to be used successfully as delivery 
vehicles intended for the intravenous administration. The aim of this part of the study 
was therefore to use SANS to determine the influence of the presence of plasma 
proteins on the physico-chemical properties of the TD2-98hEO and TDL2-hSBO NE. 
Significantly, it is possible to design a SANS study using contrast variation to make the 
proteins ‘invisible’ to the neutrons allowing only the behaviour of the NE to be 
observed. Fortunately in the present study, however, the cell culture media did not 
exhibit any scattering above that of it as a solvent, so it was not necessary to perform a 
contrast match study. Such a study should provide a better knowledge of the potential of 
cosurfactant-stabilised Tween 80 NE as vehicles for drug delivery. 
A range of models were used in order to try and fit the drop contrast of TD2-
98hEO0.64d and TD2-98hEO0.8d NE alone or with drugs in the presence of cell culture 
media at 37 °C overtime. The SANS data for the TD2-98hEO0.64d and TD2-
98hEO0.8d NE, along with the best fits to the data, which were obtained using the core-
shell ellipsoid model, are shown in Figures 4.32-4.33.  




a) b)  
c)  
Figure 4.32: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY (weight ratio 3:1) containing 0.64 %w/w 98hEO with and without drugs in the absence 














a) b)  
c)  
Figure 4.33: SANS data and best fits to the drop contrast for 2 %w/w Tween 80:Dermosoft 
GMCY (weight ratio 3:1) containing 0.8 %w/w 98hEO with and without drugs in the absence 
and presence of cell culture media (1:1 volume ratio) at 37 ˚C.  
 
Tables 4.24-4.25 show the parameters obtained from the best fits to the SANS data. As 
can be seen from the fitting parameters, the SANS results obtained for the TD2-98hEO-
DM-37C NE exhibited a lower scattering intensity than the NE dispersed in D2O, due to 
the fact that cell culture media-added samples contained H2O, which has a lower 
scattering density than D2O and therefore reduces the overall scattering of the NE. Note 
that the intensity of scattering is a function of the square of the difference in the SLD 
between the scattering particles and the solvent.  
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Table 4.24 Parameters used for the best fits to the individual SANS data for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and 0.64 %w/w 98hEO 
nanoemulsions in the absence and presence of drug and cell culture media using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 
ºC. The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TD2-98hEO0.64d-DM-37C-t0 60.4 0.4 22.4 23.8 84.1 46.1 0.5 1368160 94.3 15 950 50 797 
TD2-98hEO0.64d-DM-37C-2.5h 60.9 0.4 21.8 23.6 84.5 45.4 0.5 1359423 92.6 15 944 51 577 
TD2-98hEO0.64d-DM-37C-6h 60.7 0.4 22.0 23.6 84.4 45.7 0.5 1362515 96.1 15 946 51 472 
TD2-98hEO0.64d-DM-37C-12h 59.5 0.4 22.9 23.8 83.4 46.7 0.6 1360527 95.9 15 945 50 267 
TD2-98hEO0.64d-CUR-DM-37C-t0 59.8 0.4 22.7 23.8 83.5 46.5 0.6 1358969 88.4 15 944 50 400 
TD2-98hEO0.64d-CUR-DM-37C-2.5h 60.6 0.4 22.8 24.0 84.6 46.8 0.6 1401722 88.3 15 973 49 536 
TD2-98hEO0.64d-CUR-DM-37C-6h 60.6 0.4 22.4 23.8 84.4 46.2 0.5 1377242 89.6 15 956 50 413 
TD2-98hEO0.64d-CUR-DM-37C-12h 60.9 0.4 22.6 24.0 84.8 46.6 0.5 1406532 88.7 15 977 49 318 
TD2-98hEO0.64d-CUR-TP-DM-37C-t0 60.1 0.4 23.3 24.2 84.3 47.5 0.6 1416760 96.4 15 984 49 593 
TD2-98hEO0.64d-CUR-TP-DM-37C-2.5h 60.1 0.4 23.5 24.3 84.4 47.7 0.6 1425143 93.4 15 990 48 567 
TD2-98hEO0.64d-CUR-TP-DM-37C-6h 63.1 0.3 22.0 24.1 87.2 46.1 0.5 1469705 97.8 15 1021 49 684 
TD2-98hEO0.64d-CUR-TP-DM-37C-12h 62.1 0.4 22.8 24.3 86.4 47.1 0.5 1472745 91.0 15 1023 49 467 
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Table 4.25 Parameters used for the best fits to the individual SANS data for 2 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and 0.8 %w/w 98hEO 
nanoemulsions in the absence and presence of drug and cell culture media using a core-shell ellipsoid model together with a hard sphere structure factor S(Q) at 37 
ºC. The modelling of the SANS data was constrained using Vshell(dry)/Vcore. 
 
































Nagg surfaces  







TD2-98hEO0.8d-DM-37C-t0 76.0 0.3 25.6 24.3 100.3 49.9 0.5 2105431 113.7 15 1376 49 992 
TD2-98hEO0.8d-DM-37C-3.5h 72.4 0.3 24.6 23.3 95.7 47.9 0.5 1836991 102.0 15 1201 52 7543 
TD2-98hEO0.8d-DM-37C-6h 73.1 0.3 23.5 22.9 95.9 46.3 0.5 1786846 109.0 15 1168 53 9935 
TD2-98hEO0.8d-DM-37C-12h 71.5 0.3 23.8 22.8 94.3 46.6 0.5 1733362 100.6 15 1133 54 9219 
TD2-98hEO0.8d-CUR-DM-37C-t0 73.8 0.3 25.2 23.8 97.6 49.0 0.5 1953677 113.3 15 1277 50 1338 
TD2-98hEO0.8d-CUR-DM-37C-3.5h 73.4 0.3 25.5 23.9 97.3 49.4 0.5 1961504 108.4 15 1282 50 1212 
TD2-98hEO0.8d-CUR-DM-37C-6h 72.7 0.3 25.3 23.7 96.4 49.0 0.5 1906928 104.7 15 1246 50 1605 
TD2-98hEO0.8d-CUR-DM-37C-12h 71.9 0.3 25.1 23.5 95.3 48.6 0.5 1849918 111.4 15 1209 51 2187 
TD2-98hEO0.8d-CUR-TP-DM-37C-t0 74.8 0.4 26.2 24.5 99.3 50.7 0.5 2093803 114.6 15 1369 48 943 
TD2-98hEO0.8d-CUR-TP-DM-37C-3.5h 74.5 0.4 26.3 24.4 98.9 50.7 0.5 2080192 119.3 15 1360 48 1151 
TD2-98hEO0.8d-CUR-TP-DM-37C-6h 74.2 0.4 26.2 24.4 98.5 50.6 0.5 2059141 106.3 15 1346 49 1557 
TD2-98hEO0.8d-CUR-TP-DM-37C-12h 73.4 0.4 25.9 24.1 97.5 49.9 0.5 1989546 111.7 15 1300 49 2078 
 
Estimated uncertainty for R1 and x were ± 1.0 and ± 0.01, respectively. 
 




Clearly, the neutron scattering intensity, I(Q), at low Q for TD2-98hEO0.64d-DM-37C 
NE did not show any significant change, while in contrast, that of TD2-98hEO0.8d-
DM-37C kept increasing overtime suggesting that the presence of the cell culture media 
in TD2-98hEO0.8d-DM-37C resulted in an increase in size of the NE. 
As can be seen from the fitting parameters, neither the size nor shape of TD2-
98hEO0.64d-DM-37C NE droplets of the drug-free and drug-containing NE changed 
over 12 hours when compared to that of TD2-98hEO0.64d NE at 25 °C. In contrast, 
both drug-free and drug-containing TD2-98hEO0.8d-DM-37C NE demonstrated a 
decrease in the core equatorial radius over time when compared to the corresponding 
TD2-98hEO0.8d NE at 25 °C. As anticipated, the core equatorial radius of the TD2-
98hEOd-37C NE increased with the concentration of 98hEO, a trend which was similar 
to that seen for TD2-98hEO NE at 25 °C. After fitting the SANS data using varying 
levels of shell hydration, the shell hydration of TD2-98hEO-DM-37C was found to be 
constant at 15% for NE containing either 0.64 or 0.8 %w/w 98hEO, regardless of the 
presence of drugs. The thickness of the shell obtained from the fits was in the range 
22.0-26.2 Å. As with the other NE examined in the present study, it was clear that the 
model that provided the best fit to the SANS data was an oblate ellipsoid.  
The effect of amount of oil and the presence of drug on the SANS results of micelles 
and NE is summarised in Table 4.26, while the effect of temperature and the presence 
of cell culture media on the SANS results of TD-98hEO and TDL-hSBO NE are shown 
in Table 4.27. 
 
Table 4.26 SANS results of micelles and NE in the absence and presence of drugs at 25 °C. 
 
Sample Appearance of droplet 
T2d Oblate ellipsoid 
TD2d Prolate ellipsoid 
TD2d-CUR Prolate ellipsoid 
TD2d-CUR showed the slight difference in shape and size compared 
to drug-free TD2d. 
TD2d-CUR-TP Prolate ellipsoid 
TD2d-CUR-TP showed a change in shape compared to drug-free 
TD2d due to an increase in axial ratio. 
TDL2d Prolate ellipsoid 
 
 




Table 4.26 SANS results of micelles and NE in the absence and presence of drugs at 25 °C. 
 
Sample Appearance of droplet 
TDL2d-CUR Prolate ellipsoid 
TDL2d-CUR showed a slight difference in shape and size compared 
to drug-free TDL2d. 
TDL2d-CUR-TP Prolate ellipsoid 
TDL2d-CUR-TP showed a dramatic change in shape compared to 
drug-free TDL2d due to an increase in axial ratio. 
TD2-98hEOd Oblate ellipsoid 
As the oil content increases, the size of NE become larger with no 
change in the shape of NE being noted.  
Note that the best fits obtained for both TD2-98hEO0.72d and TD2-
98hEO0.8d did not fit the SANS data well. 
TD2-98hEOd-CUR Oblate ellipsoid 
No difference in the size and shape of NE droplets was noted in the 
presence of drug. 
Note that the best fits of TD2-98hEO0.72d and TD2-98hEO0.8d in 
the presence of either CUR or CUR-TP did not fit the SANS data 
well. 
TD2-98hEOd-CUR-TP 
TDL2-hSBO0.24d Oblate ellipsoid 
TDL2-hSBO0.24d-CUR Oblate ellipsoid 
TDL2d-hSBO0.24d-CUR no difference was seen in size compared to 
drug-free TDL2-hSBO0.24d. 
TDL2-hSBO0.24d-CUR-TP Oblate ellipsoid 
TDL2d-hSBO0.24d-CUR-TP showed a slight difference in size 

























Table 4.27 SANS results of micelles and NE at 37 °C in the absence and presence of cell 
culture media.  
 
Sample Appearance of droplet 
TD2d-37C 
Prolate ellipsoid 
The large difference observed in the size and shape of NE droplets 













No difference in the size and shape of NE droplets at 37 °C. 
TDL2-hSBO0.24d-CUR-37C 
TDL2-hSBO0.24d-CUR-TP-37C 
TD2-98hEOd-DM-37C Oblate ellipsoid 
No change in the shape and size of TD2-98hEO0.64d-DM-37C 
NE of at 37 °C while the TD2-98hEO0.8d-DM-37C NE showed 
change in shape with the increasing neutron scattering intensity, 
I(Q) overtime. 
 
4.5 Chapter summary 
Clearly, the addition of the cosurfactant, Dermosoft GMCY in the absence or presence 
of a second hydrophobic surfactant, namely lecithin, to Tween 80 NE lead to an 
increase in the area of NE existence, the formation of larger aggregates and a 
transformation of aggregate shape when to compared to NE prepared using solely 
Tween 80 NE as determined by PIT, PCS and SANS studies. The presence of a 
cosurfactant and second surfactant in NE has an effect on the dilutability of the NE 
which needs to be considered before continuing the further studies to exploit the NE for 
the purposes of drug delivery. The PIT experiments, particle size studies and SANS 
experiments suggested that Tween 80-containing NE in the absence and presence of 
cosurfactant contain a distinct oil core.  
To examine the application of Tween 80 containing NE as drug delivery system, TP, 
CUR and DTX were chosen to be as poorly water soluble drugs. The solubility of TP in 
TD25-98hEO NE increased as the amount of oil present increased. On the other hand, 




while T20, TD25-98hEO and TDL25-hSBO could solubilise a good level of CUR, the 
solubility of CUR did not increase as the amount of oil increased. In addition, the 
solubility of TP decreased in the presence of CUR. Furthermore, no improvement in 
DTX solubilisation was seen in TDL25-hSBO NE. Although it is hard to evaluate the 
advantage of NE over micelle in respect to DTX solubilisation due to the limited 
amount of hSBO incorporated in TDL25-hSBO NE.    
In order to determine the cytotoxicity of the micelles and NE in the absence and 
presence of the anticancer drugs, CUR and DTX, T20-CUR, TD25-CUR, TDL25-CUR, 
TDL25-DTX micelles and T20-hSBO-CUR, TD25-98hEO-CUR, TDL25-hSBO-CUR 
and TDL25-hSBO-DTX NE were tested with CT26 and HeLa cell lines and the 




















Chapter 5                              
Toxicological evaluation of nonionic 




5.1.1 In vitro cytotoxicity 
The use of in vitro cell culture systems for the evaluation of cytotoxicity is very 
attractive, particularly as an alternative to the use of animals, i.e. in vivo, testing (Doke 
and Dhawale, 2015). In vitro cytotoxicity tests are generally more reliable, accurate, 
practical, environmentally friendly and economical than the use of animals (Ranganatha 
and Kuppast, 2012). Further, since cellular toxicity testing based on quantitative 
colourimetric assays has been widely used from about the mid 1990’s so that the 
understanding of the methodology is good. Generally, the colourimetric assays provide 
information about some aspect of cellular metabolic function, and include resazurin 
(alamar blue) assay, neutral red incorporation (NRI) assay, adenosine triphosphate 
(ATP) content assay and tetrazolium-based assays (Bunel et al., 2014). Resazurin, for 
example, which is reduced to resorufin, is used to determine cell survival and 
proliferation, while the NRI assay measures the uptake and accumulation of neutral red 
(3-amino-m-dimethylamino-2-methyl-phenazine) in the lysosome. The ATP assay 
allows an estimate of the number of living cells (and by implication the number of the 
unviable cells) by measuring the production of adenosine triphosphate. The tetrazolium-
based assays use a range of tetrazolium salts, including MTT, XTT, MTS or WST-1, as 
redox sensors that can only be reduced by metabolically active cells into formazan 
derivatives (Petty et al., 1995; Arechabala et al., 1999; Bunel et al., 2014).  
Other assays which provide information about cell viability are based on plasma 
membrane integrity and include lactase dehydrogenase (LDH), trypan blue exclusion 
and fluorescence staining. The LDH assay measures lactase dehydrogenase (LDH) 
leakage from injured cells, while the trypan blue exclusion measures the penetration of 
trepan blue stain into the cytoplasm of dead cells and fluorescent staining measures the 
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extent of a fluorescent dye crossing the cell membrane of dying/dead cells and binds to 
DNA and/or RNA (Bunel et al., 2014).  
 
5.1.1.1 MTT assay  
As the NE formulated in this study are intended for intravenous administration for the 
treatment of cancer, the cytotoxicity of the formulations was examined in two cancer 
cell lines, namely the CT26 and HeLa cells lines, murine colon carcinoma and folate-
expressing cervical-tumour-derived cells, respectively, using the MTT assay to assess 
their acute toxicity. The MTT assay, which was first described by Mosmann in 1983 has 
been modified by over the intervening years in order to improve its sensitivity and 
reproducibility, for example by using different tetrazolium salts (Wan et al., 1994; 
Goodwin et al., 1995). In the present study, the modified MTT protocol proposed by 
Klippstein et al. (2015) has been used. 
The MTT assay (or thiazolyl blue assay) examines the reduction of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), a yellow and water soluble dye 
by mitochondrial succinic dehydrogenase present in viable cells, to form a purple, water 
insoluble product, formazan (Mosmann, 1983). The cleavage of the heterocyclic 
tetrazolium ring, by succinate-dehydrogenase enzymes present in viable cells, results in 
the production of the insoluble formazan (Stockert et al., 2012) (Figure 5.1). 
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5.1.2 Interaction of surfactants with biological membrane 
Cell membranes are comprised of a lipid bilayer, mainly composed of phospholipids 
possessing a heterogeneity of acyl chain lengths and head groups. Depending upon the 
particular cell membrane, these lipids frequently include: phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, glycolipids 
(glucosylceramide and galactosylceramide) and cholesterol (Swenson and Curatolo, 
1992). In addition, cell membranes also contain molecules of protein imbedded in the 
lipid bilayer, while their external surface is covered by a polysaccharide-protein 
glycocalyx (Ratner, 1995). 
A surfactant molecule can permeate across cell membrane in a variety of different ways. 
Possible routes of surfactant passage include the paracellular pathway (low 
concentrations of surfactant are thought to affect the integrity of the tight junctions 
between cells), the transcellular pathway, and ‘gaps’ in a (leaky) cell membrane caused 
by the denudation of cells at high surfactant concentrations (Anderberg et al., 1992). 
Due to the fact that surfactant molecules can directly affect the proteins and 
phospholipids of the cell membrane, they are sometimes used in pharmaceutical 
formulations as penetration enhancers of drugs (Swenson and Curatolo, 1992). Indeed, 
there is evidence of a correlation between enhanced permeability and cell damage. The 
study of Dimitrijevic et al. (2000) examined the effect of a range of nonionic surfactant, 
namely polysorbate 20, polysorbate 60, polysorbate 85 and Solulan C24, as absorption 
enhancers for the drug, metformin, by assessing transepithelial electrical resistance 
(TEER) and the viability of Caco-2 cells. The results showed an increase in TEER and 
in the permeability of metformin across the Caco-2 cell monolayer corresponding to a 
decrease in cell viability. In another study, Aungst (2012) showed that although sodium 
N-[8-(2-hydroxylbenzoyl)amino] caprylate increased the absorption of cromolyn across 
Caco-2 cell monolayers, a range of cytotoxicity assays, including lactate 
dehydrogenase, mitochondrial dehydrogenase activity, trypan blue exclusion, and 
neutral red binding, indicated that the molecule damage the membrane. 
In general, the mechanism by which a surfactant can interact with a cell membrane 
depends upon the concentration of surfactant. At low concentrations of surfactant, the 
surfactant monomer may partition into the lipid bilayer. At higher surfactant 
concentrations, the formation of phospholipid-surfactant mixed micelles may be 
observed (Helenius and Simons, 1975; Lasch, 1995). The solubilisation of the 
phospholipid vesicles by surfactants has been widely studied for a better understanding 
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of the interaction between a surfactant and a biological membrane (Lichtenberg et al., 
1983; Lasch, 1995; Heerklotz, 2008). Figure 5.2 shows the transition of a lipid vesicle 
(A) to a swollen mixed vesicle (B) by the addition of surfactant. The addition of further 
surfactant can lead to the formation of small regions of local curvature (termed ‘hump-
backed’ vesicles) (C) which can then ‘bud off’ to form sheets of mixed bilayer (D). It 
has been found that the complete transformation of vesicles to mixed micelles may 
occur when the effective molar ratio of surfactant to lipid in the bilayer exceeds the 
range 0.5 to 3.0 - the precise value being dependent upon the surfactant/lipid system of 
interest (Lichtenberg et al., 1983). The results of Pantaler et al. (2000) and Ahyayauch 
et al. (2010) confirmed the insertion of surfactant in the bilayer, supporting the proposed 
mechanism of Lichtenberg et al. (1983). 
 
 
Figure 5.2: Schematic diagram of the solubilisation of a lipid vesicle by surfactants and 
transformation of lipid vesicles to mixed micelles: ( ) phospholipid, ( ) surfactant; (A) lipid 
vesicles, (B) swollen mixed bilayers, (C) humpbacked vesicles with surfactant at region of high 
curvature and (D) mixed bilayer sheets. In the steps of C to D, open flat bilayers and cylindrical 
mixed micelles form. (Reproduced from Lasch, 1995). 
 
The interaction of the nonionic surfactant, Triton X-100, and the ionic surfactant, 
sodium dodecyl sulphate (SDS), with the Semliki Forest virus membrane glycoprotein 
have been studied (Helenius and Simons, 1975). These workers found that the 
disruption of the nucleocapsides and virus membrane was caused by the binding 
surfactant to the viral cell membrane followed by the formation of surfactant-lipid 
mixed micelles and surfactant-protein complexes.  Recently, Mattei et al. (2017) 
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showed that the permeability of Triton X-100 to the vesicle was dependent on the lipid 
composition of the membrane. The membranes studied were composed of either of two 
phospholipids, namely palmitoyl oleoyl phosphatidylcholine (POPC) or sphingomyelin 
(SM), with and without 30 mol% of the steroid, cholesterol (chol). A fluorescence 
quenching assay showed that membranes composed of either POPC or SM alone, were 
completely solubilised by Triton X-100, whereas the presence of chol decreased the 
solubilisation of the lipid membranes by Triton X-100. In the case of POPC/chol 
membranes, the membrane was only partially solubilised by Triton X-100 whereas the 
membrane composed of SM/chol was virtually insoluble. In the case of erythrocytes, 
the penetration of surfactant molecules into the cell membrane induces the change its 
molecular organisation, its permeability and osmotic equilibrium, resulting in the 
eventual leakage of haemoglobin (Helenius and Simons, 1975; Manaargadoo-Catin et 
al., 2016). 
The interaction of surfactants with the cell membrane has been proposed by Balgavy 
and Deveinsky (1996) to follow a free volume mechanism in which surfactant initially 
interacts with the cell membrane by means of its polar group interacting with the polar 
head group of phospholipid bilayer and the hydrocarbon chain of the surfactant 
inserting into the hydrophobic region of the phospholipid bilayer. Any mismatch 
between the hydrophobic parts of the surfactant and phospholipids results in the 
formation of free volume within the hydrophobic region of the bilayer which can only 
be eliminated by the trans-gauche isomerisation, the bending, or the hydrocarbon chain 
interdigitation of the hydrophobic chains of the bilayer. The effect of these interventions 
lead to a changes in the thickness and fluidity of the bilayer which are subsequently 
thought to result in the changes in cell membrane and cell function.  
The possible mechanism of surfactant-induced bilayer to micelle transition depends on 
the solubilisation of phospholipid by the surfactants, which mainly depends on the 
trans-membrane motion of surfactant or “flip-flop” (Lichtenberg et al., 2013). The 
mechanism by which solubilisation occurs is different depending upon the fast and slow 
flipping of the surfactant. If the flipping of the surfactant to the inner monolayer is fast, 
solubilisation is rapid, whereas if the flipping of the surfactant is slow, solubilisation is 
slow. Figure 5.3 shows the mechanism of the fast solubilisation of bilayers occurs by 
the trans-bilayer mechanism and the insertion of monomeric surfactant molecules into 
both the outer and inner membrane (Kragh-Hansen et al., 1998) resulting in the 
formation of open vesicles (Stuart and Boekema, 2007). In contrast, figure 5.4 shows 
that the slow solubilisation results from either (a) the binding of micelles to the bilayers 
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(Kragh-Hansen et al., 1998) and the subsequent extraction of the membrane components 
from the outer bilayer into the surfactant micelles (Stuart and Boekema, 2007) or (b) 
vesicle-to-micelle transformation by the fragmentation of the closed phospholipid-
surfactant mixed vesicles to form either thread-like, cylindrical or spherical micelles 




Figure 5.3: Schematic diagram of fast solubilisation of lipid membrane by surfactant ( ) 
phospholipid, ( ) surfactant by trans-bilayer mechanism (Reproduced from Kragh-Hansen et 
al., 1998).  
 
 (a) (b)  
 
 
Figure 5.4: Schematic diagram of slow solubilisation of lipid membrane by surfactant ( ) 
phospholipid, ( ) surfactant and ( ) phospholipid extracted from bilayer into a micelle by 
(a) the extraction of phospholipid from the outer bilayer into surfactant micelles and (b) vesicle-
to-micelle transformation (Reproduced from Kragh-Hansen et al., 1998; Elsayed and Cevc, 
2011).   
 
In conclusion, the factors affecting the toxicity of the surfactants towards cells include 
the physicochemical properties of surfactants and/or the membrane properties of the 
cells themselves. It may be anticipated that the properties of the surfactants may be 
related to the value of their hydrophile-lipophile balance (HLB) and their critical 
micelle concentration (cmc) (Hofland et al., 1992).  
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5.2 Aim 
The aim of this chapter is to investigate the cytotoxicity, using the MTT assay, of the 
o/w NE prepared using either Brij O10 or Tween 80 in the absence/presence of a 
cosurfactant (Dermosoft GMCY or lecithin). All the NE were examined in both in the 
absence and presence of the anticancer drugs, curcumin (CUR) and docetaxel (DTX), 
using one of two types of cancer cell lines, namely the CT26 and HeLa cells from 
murine colon carcinoma and folate-expressing cervical-tumour-derived cells, 
respectively.  
 
5.3 Cytotoxicity of nonionic surfactant micellar solutions 
The viability of CT26 and HeLa cells in the presence of Brij O10 (B), Tween 80 (T), 
Tween 80:Dermosoft GMCY at a 3:1 weight ratio (3:1) (TD) and Tween 80:Dermosoft 
GMCY:lecithin (7.5:2.5:1) (TDL) micelles was assessed with the MTT assay in the 
absence and presence of a saturation amount of either CUR or DTX, with CUR present 
at a concentration within the range 0.01 - 100 µM and DTX present at a concentration 
in the range 0.00001 - 100 µM (Figure 5.5 and 5.6). The drug-free micelles containing 
the same amount of surfactant as the drug-saturated micellar samples were tested in 
order to examine the cytotoxicity of drug-free and drug-containing formulations to both 
cell lines. It is worth noting that, due to the difference in the level of solubilisation of 
CUR and DTX in the micelles, the amount of either T, TD or TDL in the CUR-
saturated micelles and the amount of TDL in the DTX-saturated TDL micelles were 
different (see section 4.3.2.4 for the solubilisation of CUR in T-CUR, TD-CUR and 
TDL-CUR and section 4.3.4.4 for the solubilisation of DTX in TDL-DTX). Regardless 
of the nonionic surfactant and cell line studied, a dose-dependent reduction in cell 
viability was seen. Due to the high toxicity of Brij O10 micelles, the B-CUR samples 
were not tested the cytotoxicity in the CT26 and HeLa cell lines. Unfortunately, 
however, no significant difference was seen in the viability of cells incubated for 72 
hours with either CUR-free and CUR-saturated TD micelles (p>0.05). Only the 
cytotoxicity of T20-CUR micelles (at 2.4 x 10-1 and 2.4 %w/w T in CT26 cells) and 
TDL25-CUR micelles (at 5.2 %w/w TDL in HeLa cells) was significantly higher than 
that of CUR-free T20 and TDL25, respectively (p<0.05) suggesting that at high 
surfactant concentrations, the CUR containing systems exhibited a higher toxicity due 
to its presence. This experiment was repeated twice and the results showed the same 
trend. Surprisingly, the proliferation of cell lines in the presence of some CUR-
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containing systems, namely T20 and TDL25 such as T20-CUR (at 2.4 %w/w T in HeLa 
cells) and TDL25-CUR (at 5.2 x 10-1 %w/w TDL in CT26 cells) was higher than in the 
corresponding CUR-free systems, namely T and TDL micelles (p<0.05). The reason for 
this proliferation is not known. 
In contrast, it was clear that at the same time point of 72 hours, the viability of both the 
CT26 and HeLa cell lines in the presence of DTX-saturated TDL micelles at 10-2, 10-1 
and 10 %w/w TDL in CT26 cells and at 10-3, 10-2 and 10-1 %w/w TDL in HeLa cells 
was significantly much lower than seen in the DTX-free TDL micelles (p<0.05). These 
results showed that the DTX was more potent against both the CT26 and HeLa cell lines 
than CUR, a result which is in agreement with a previous study showing that the IC50 of 
DTX (4.26 ± 0.51 nM) was much lower than that of CUR (10.25 ± 1.03 µM) in A549 
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B20 CT26 72 hr
Surfactant concentration (%w/w) b)  
c)  d)  
e)  
Figure 5.5: Viability of CT26 cells at 72 hours incubation in the presence of micelles: either a) 
Brij O10, b) Tween 80, c) Tween 80:Dermosoft GMCY (3:1) or d) Tween 80:Dermosoft 
GMCY:lecithin (7.5:2.5:1) in the absence and presence of a saturation amount of CUR and e) 
Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) in the absence and presence of a saturation 
amount of DTX expressed as a percentage of control ‘untreated’ cells determined by MTT assay 
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B20 HeLa 72 hr
Surfactant concentration (%w/w)  b)  
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Figure 5.6: Viability of HeLa cells at 72 hours incubation in the presence of micelles: either a) 
Brij O10, b) Tween 80, c) Tween 80:Dermosoft GMCY (3:1) or d) Tween 80:Dermosoft 
GMCY:lecithin (7.5:2.5:1) in the absence and presence of a saturation amount of CUR and e) 
Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) in the absence and presence of a saturation 
amount of DTX expressed as a percentage of control ‘untreated’ cells determined by MTT assay 
(mean ± S.D.; n=5; * p<0.05). 
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Figure 5.7: The surfactant concentration (%w/w) in the micellar solutions and oil-in-water 
nanoemulsions in the absence and presence of drug in the concentration range of 0.01-100 µM 
for CUR-saturated samples and 0.00001-100 µM for DTX-saturated samples. 
 
At a surfactant concentration of 0.01 %w/w, the concentration of drug present in the 
micelles was 0.1 µM DTX and 0.2 µM CUR in TDL, 0.2 µM CUR in TD, 0.5 µM CUR 
in T and 1 µM CUR in B (Figure 5.7, see section 3.3.2.4 for solubilisation of CUR in 
B-CUR, section 4.3.2.4 for solubilisation of CUR in T-CUR, TD-CUR and TDL-CUR 
and section 4.3.4.4 for solubilisation of DTX in TDL-DTX). At the same amount of 
surfactant, the drug-free Tween 80 micelles were seen to be less toxic to both types of 
cells than the corresponding Brij O10 micelles. This result is in agreement with that of 
Ohnishi and Sagitani (1993) when examining the haemolytic activity of Brij O10 and 
Tween 80.  
As the HLB value of a surfactant is thought to be important in determining its toxicity, 
the relationship between the HLB of the surfactants and toxicity was examined 
(Hofland et al., 1992). Note that the HLB of Tween 80 and Brij O10, two surfactants 
used in the present study, is 15.0 and 12.4, respectively (Helenius and Simons, 1975). 
The haemolysis of POE-type nonionic surfactants (POE(n) oleyl ether and POE(n) 
monostrearate) was studied by Ohnishi and Sagitani (1993) who showed that 
haemolysis decreased as the HLB of surfactant increased. It has been reported that the 
ability of a surfactant to partition into a cell membrane is related to its hydrophobicity. 
A surfactant with a very high hydrophilicity will only poorly, if at all, partition into the 
lipid bilayer and therefore would be only expected to slightly, if at all, disrupt the cell 
membrane whereas a more hydrophobic surfactant will partition into the lipid bilayer 
causing damage to the membrane (Helenius and Simons, 1975). However, polyethylene 
glycol ester surfactants, such as polysorbate 20, polysorbate 60 and polysorbate 80 
which posses a higher HLB exhibit a higher toxicity than the propylene glycol ester 
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surfactants, namely Capryol 90, Capryol PGMC and Lauroglycol 90 which posses a low 
HLB (Ujhelyi et al., 2012). This result indicates that the HLB of a surfactant is not a 
good parameter to indicate the toxicity. 
The critical micelle concentration (cmc) of a surfactant is also considered to be an 
important parameter in determining membrane solubilisation power since the cmc is 
directly related, not only to the chemical potential of the surfactants, but also the 
thermodynamics of micelle formation (Tanford, 1972). The free energy of micelle 
formation (∆G) can be expressed as ∆G = RT ln (cmc) where R is the gas constant and 
T is the temperature (K) (Tanford, 1972). However, in the presence of biological 
membranes, there is also competition between micelle formation and surfactant 
partitioning into the lipid bilayer of a cell membrane. If the free energy of partitioning is 
greater than that of micelle formation, the surfactant prefers to partition into the 
membrane rather than form micelles (Becker et al., 1975). In addition, the binding of 
surfactant monomer to the membrane delays/prevents the formation of pure surfactant 
micelles as the concentration of free surfactant monomer is reduced (Helenius and 
Simons, 1975). The mixed micelles will only be formed when the free monomeric 
surfactant has reached its cmc. 
If the surfactant exerts its toxicity by the interaction of the monomeric surfactant with 
the cell membrane, any membrane toxicity should occur at below the cmc of the 
surfactant. As a consequence therefore surfactants possessing a lower cmc should 
exhibit a lower toxicity due to the fact that less free surfactant monomer will be 
available to insert in the cell membrane (Singer et al., 1995). In the present study, the 
cmc of Brij 97 was 0.002 %w/w (Warisnoicharoen et al., 2003) while that of Tween 80 
was 0.0128 %v/v (Ujhelyi et al., 2012). Based on the experimentally measured cmc of 
the surfactants, the expected relationship between the cytotoxicity and the cmc of 
surfactants was not observed.  Hofland et al. (1991) found no correlation between either 
the HLB or the cmc of the polyoxyethylene surfactant vesicles containing cholesterol 
and either their ciliotoxicity or their effect on the proliferation of human keratinocytes. 
Indeed it was surprising that while the increase in the length of alkyl chain (from 12 to 
18) or the decrease in the number of POE units (from 7 to 3) reduced ciliotoxicity, it 
had no effect on cellular proliferation. In addition, the bond by which the head group 
was linked to the alkyl chain exerted a very strong effect on toxicity in that the oleyl-
EO5 ester surfactant was 10 times less toxic than oleyl-EO5 ether surfactant. This result 
may be a consequence of the fact that the oleyl-EO5 ester surfactant degrades at a much 
quicker rate than its ether counterpart. On the other hand, a linear relationship between 
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cmc and the solubilisation of protein released by the lysis of gill epithelial cells has been 
noted for several homologous series of surfactants, namely the n-alkyl sulphates, single 
and double chain tri/dimethylammonium bromides, cholates as well as the nonionic 
surfactants, n-octylglucoside and Trition X-100 (Partearroyo et al., 1991). 
Unexpectedly in the present study, the addition of a small amount of lecithin into TD 
micelles did not significantly affect the cytotoxicity of CT26 and HeLa cell lines 
towards TDL micelles. This observation was not in agreement with previous studies by 
others, specifically Gould et al. (1994) and Trotta et al. (1996). For example studies by 
Gould et al. (1994) showed a decrease in haemolysis upon the addition of egg PC to 
Brij 96 micelles at egg PC:Brij 96 molar ratios between 0.1 and 2.0 while Trotta et al. 
(1996) noted that the addition of 5 mM lecithin to monoalkylphosphates, ranging from 
120 mM hexylphosphate to 5 mM decylphosphate, and 15-80 mM polysorbate 60 also 
resulted in a decrease in haemolysis. 
 
5.4 Cytotoxicity of nonionic nanoemulsions 
Brij O10 NE systems 
B20-98hEO NE in the presence of curcumin 
CT26 and HeLa cell viability of B20-98hEO NE was assessed using the MTT assay in 
the absence and presence of CUR (Figures 5.8 and 5.9). The range of CUR present in 
this samples was 0.01 to 100 µM. The drug-free NE samples containing the same 
amount of surfactant as drug-saturated NE were tested in order to examine the 
cytotoxicity of comparable drug-free and drug-containing formulations to both cell 
lines. A dose-dependent reduction in cell viability was seen in both cell lines. 
Unfortunately, after 72 hours, there was no significant difference in cell viability 
between the CUR-free and the CUR-saturated NE (p>0.05). Only some of the CUR-
containing B20-98hEO NE showed a significantly higher toxicity than CUR-free B20-
98hEO NE (p<0.05), such as B20-98hEO1-CUR (observed at 1.3 x 10-1 %w/w B in 
CT26 and at 1.3 x 10-1 and 1.3 %w/w B in HeLa cells), B20-98hEO2-CUR (observed at 
1.3 %w/w B in CT26 and at 1.3 x 10-1 and 1.3 %w/w B in HeLa cells), B20-98hEO4-
CUR (observed at 1.3 x 10-4, 1.3 x 10-1 and 1.3 %w/w B in HeLa cells) and B20-
98hEO6-CUR (observed at 1.3 x 10-1 and 1.3 %w/w B in HeLa cells). Surprisingly, the 
proliferation of the cell lines when incubated with B20-98hEO-CUR NE was higher 
than that seen in the corresponding CUR-free B20-98hEO NE (p<0.05), for example 
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some CUR-containing B20-98hEO-CUR NE such as B20-98hEO1-CUR (seen at 1.3 x 
10-2 %w/w B in CT26 cells and at 1.3 x 10-3 and 1.3 x 10-2 %w/w B in HeLa cells), B20-
98hEO2-CUR (seen at 1.3 x 10-4 and 1.3 x 10-2 %w/w B in HeLa cells), B20-98hEO6-
CUR (seen at 1.3 x 10-3, 1.3 x 10-2, 1.3 x 10-1 and 1.3 %w/w B in CT26 cells). In 
addition, due to the level of CUR solubilisation in the B20-98hEO-CUR NE as a 
function of 98hEO content being comparable, it is possible to test the various B20-
98hEO-CUR NE at similar Brij O10 concentrations (see section 3.3.2.4). Surprisingly, 
the NE incorporating 98hEO did not reduce the toxicity towards the CT26 and HeLa 
cells when compared to the corresponding micelles (Figures 5.5 and 5.6). This 
observation is contrary to a previous cytotoxicity study performed on human bronchial 
(16-HBE14o-) epithelium cells (Warisnoicharoen et al., 2003) where C18:1E10 NE 
containing various amounts of large molar volume oils, such as soybean oil, ethyl oleate 
and Miglyol 812 exhibited lower cytotoxicity toward 16-HBE14o- cells than the 
corresponding surfactant micelles (Warisnoicharoen et al., 2003).  
a)  b)  
Figure 5.8: Viability of CT26 cells at 72 hours incubation of Brij O10 NE at the difference 
concentrations of 98hEO, a) 1-2 %w/w 98hEO and b) 4-6 %w/w 98hEO, expressed as a 
percentage of control ‘untreated’ cells in the absence and presence of curcumin determined by 
the MTT assay (mean ± S.D.; n=5; * p<0.05). 
 
a)  b)  
Figure 5.9: Viability of HeLa cells at 72 hours incubation of Brij O10 NE at the difference 
concentrations of 98hEO, a) 1-2 %w/w 98hEO and b) 4-6 %w/w 98hEO, expressed as a 
percentage of control ‘untreated’ cells in the absence and presence of curcumin determined by 
the MTT assay (mean ± S.D.; n=5; * p<0.05). 
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B20-hSBO NE in the presence of curcumin 
The viability of CT26 and HeLa cells after incubation with B20-hSBO NE was assessed 
by the MTT assay in the absence and presence of CUR (Figure 5.10). The 
concentration of CUR in these samples was in the range of 0.01 to 100 µM. The drug-
free NE samples containing the same amount of surfactant as the drug-saturated NE 
were tested in order to examine the cytotoxicity of the two types of formulation to both 
cell lines. A dose-dependent reduction in cell viability was seen in both cell lines. 
Unfortunately, no significant differences in cell viability between the CUR-free and 
CUR-saturated NE was observed at 72 hours (p>0.05). This experiment was repeated 3 
times and each time the results showed the same trend. However, an increase in cell 
proliferation was seen after the incubation with some of the B20-hSBO-CUR NE. For 
example, proliferation was observed in cell lines incubated with B20-hSBO9-CUR (in 
CT26 cells NE containing either 1.3 x 10-1 or 1.3 %w/w B and in HeLa cells NE 
containing 1.3 %w/w B and was higher than in the cell lines incubated with CUR-free 
B20-hSBO9 NE (p<0.05). 
 
a) b)  
Figure 5.10: Viability of a) CT26 and b) HeLa cells at 72 hours incubation of Brij O10 NE at a 
concentration of 1 %w/w hSBO, expressed as a percentage of control ‘untreated’ cells in the 
absence and presence of curcumin determined by the MTT assay (mean ± S.D.; n=5; * p<0.05). 
 
It is assumed the fact that was no difference in the toxicity of Brij O10 NE in the 
absence and presence of CUR was due to the quite high toxicity of Brij O10. As a 
consequence further studies used Tween 80 as the nonionic surfactant.  
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Tween 80 NE systems 
T20-hSBO NE in the presence of curcumin 
The viability of CT26 and HeLa cells in the presence of T20-hSBO1 NE was assessed 
using the MTT assay, both in the absence and presence of CUR (Figure 5.11). The 
concentration range of CUR used in these studies was 0.01 to 100 µM. The drug-free 
NE samples containing the same amount of surfactant as drug-saturated NE were also 
tested in order to examine the cytotoxicity of both types of formulation towards both 
cell lines. Notably a large reduction in cell viability was seen in both cell lines at the 
highest concentration of Tween 80 studied. Unfortunately, after 72 hours incubation, 
there was no significant difference in cell viability after incubation with CUR-free T NE 
and with CUR-saturated T NE, the latter of which contained 100 µM of CUR (p>0.05).  
 
a) b)  
Figure 5.11: Viability of a) CT26 and b) HeLa cells at 72 hours incubation of Tween 80 NE 
containing 1 %w/w hSBO, expressed as a percentage of control ‘untreated’ cells in the absence 
and presence of curcumin determined by the MTT (mean ± S.D.; n=5; * p<0.05). 
 
TD25-98hEO NE in the presence of curcumin 
Due to the fact that Tween 80 alone could only incorporate a very small amount of oil, 
the cosurfactant, Dermosoft GMCY, was added in an attempt to increase the amount of 
oil incorporated into the Tween 80-containing NE. It is noteworthy that while Tween 
80-containing NE in the presence of Dermosoft GMCY could increase the amount of 
98hEO present, they could not increase the amount of hSBO incorporated and still form 
clear NE. As a consequence, the viability of CT26 and HeLa cells after incubation of 
98hEO containing NE (i.e. TD25-98hEO NE) was assessed using the MTT assay in the 
absence and presence of CUR (Figure 5.12). The concentration of CUR used in this 
part of the study was in the range of 0.01 to 100 µM. The drug-free NE samples 
containing the same amount of surfactant as drug-saturated NE were tested in order to 
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examine the cytotoxicity of both types of formulation towards both cell lines. A dose-
dependent reduction in cell viability was seen in both cell lines with a great reduction in 
viability between observed 10 and 100 µM of CUR, with the NE containing 100 µM 
CUR being prepared using the highest concentration of Tween 80. Unfortunately, no 
significant difference in cell viability between the CUR-free TD NE and CUR-saturated 
TD NE was seen at 72 hours incubation (p>0.05). Only the cytotoxicity of TD25-
98hEO10-CUR (seen at 100 µM CUR in CT26 cells) was significantly higher than that 
of CUR-free TD25-98hEO NE (p<0.05). This experiment was repeated twice and each 
time the results showed the same trend. Surprisingly, the proliferation of cell lines in the 
presence of TD25-98hEO8-CUR (seen at 4.6 x 10-1 %w/w TD in HeLa cells) and 
TD25-98hEO10-CUR (observed at 4.6 x 10-1 and 4.6 %w/w TD in HeLa cells) was 
higher than that seen in the corresponding CUR-free TD25-98hEO NE (p<0.05). 
 
a) b)  
Figure 5.12: Viability of a) CT26 and b) HeLa cells at 72 hours incubation of Tween 
80:Dermosoft GMCY (3:1) NE containing 8 and 10 %w/w 98hEO, expressed as a percentage of 
control ‘untreated’ cells in the absence and presence of curcumin determined by the MTT (mean 
± S.D.; n=5; * p<0.05). 
 
TDL25-hSBO NE in the presence of curcumin 
The ‘safer’ surfactant, lecithin, was added to TD NE in an attempt to decrease the 
cytotoxicity of the NE. However, it was found that only a small amount of lecithin 
could be added for clear TDL NE be formed. Interestingly, a higher amount of hSBO 
could be incorporated into TDL NE than 98hEO. As a consequence therefore the 
viability of CT26 and HeLa cells was determined at by the MTT assay after incubation 
with TDL25-hSBO NE was assessed in the absence and presence of CUR (Figures 5.13 
and 5.14). The concentration of CUR used in the study was in the range of 0.01 to 100 
µM. Drug-free NE containing the same amount of surfactant as the drug-saturated NE 
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were tested to examine the cytotoxicity of both formulations in both cell lines. A 
reduction in cell viability was seen in both cells lines, with the reduction being more 
significant at 72 hours incubation compared to 24 hours incubation. Unfortunately, no 
significant differences in cell viability were observed between the CUR-free TDL-
hSBO NE and the CUR-saturated TDL-hSBO NE at 24 and 72 hours (p>0.05). Only the 
cytotoxicity of TDL25-hSBO3-CUR (seen at 5.2 x 10-4 %w/w TDL in CT26 cells at 24 
hours incubation) was significantly higher than that of the CUR-free TDL25-hSBO3 
NE (p<0.05). Surprisingly, the proliferation of cell lines in the presence of TDL25-
hSBO3-CUR (observed at 5.2 x 10-1 %w/w TD in both CT26 and HeLa cells at 72 
hours incubation) was higher than that seen in CUR-free TDL25-hSBO3 NE (p<0.05). 
It is generally noted that the cytotoxicity of a surfactant depends on exposure time, i.e. 
whether it is acute or prolonged exposure. For example, an increase in the cytotoxicity 
of surfactant towards human skin fibroblasts was seen at longer incubation times 
(Cornelis et al., 1991). Moreover, it was found that the IC50 value decreased upon 
increasing exposure time from 1 to 24 hours when using the LDH leakage test (Grant et 
al., 1992). Interestingly, however, there was no significant difference in the IC50 value 
observed after 1 and 24 hours when using either the NRI or the MTT assay (Grant et al., 
1992). This apparent discrepancy is possibly due to the fact that the NRI and MTT tests 
require between 1-3 hours to complete after completion of the treatment of the cells 
with surfactant. During that period of time, the surfactant is still able to destroy the cells 
and consequently the toxicity observed (IC50) in such cases is often considered to be 
representative of longer exposure times (Grant et al., 1992). 
A clear reduction in cell viability was seen in both cell lines at the highest concentration 
of TDL, regardless of the presence of 100 µM CUR. Unfortunately, no significant 
difference in cell viability was seen after incubation with either CUR-free or CUR-
saturated NE after 24 and 72 hours incubation (p>0.05).  
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a) b)  
Figure 5.13: Viability of a) CT26 and b) HeLa cells at 24 hours incubation of Tween 
80:Dermosoft GMCY:lecithin (7.5:2.5:1) NE containing 3 %w/w hSBO, expressed as a 
percentage of control ‘untreated’ cells in the absence and presence of curcumin determined by 
the MTT (mean ± S.D.; n=5; * p<0.05). 
 
a)  b)  
Figure 5.14: Viability of a) CT26 and b) HeLa cells at 72 hours incubation of Tween 
80:Dermosoft GMCY:lecithin (7.5:2.5:1) NE containing 3 %w/w hSBO, expressed as a 
percentage of control ‘untreated’ cells in the absence and presence of curcumin determined by 
the MTT (mean ± S.D.; n=5; * p<0.05).  
 
TDL25-hSBO NE in the presence of docetaxel 
Another anticancer drug, DTX, was added at saturation levels to TDL NE in order to 
see whether it was possible to increase the cytotoxicity of the drug containing NE as it 
was felt that CUR was not toxic enough to allow a differentiation between the toxicity 
of the CUR-containing and the CUR-free NE. Such a differentiation was however seen 
for TDL-hSBO3 NE containing CUR (Figure 5.14) and TDL-hSBO3 NE containing 
DTX (Figure 5.15). The viability of CT26 and HeLa cells after TDL25-hSBO3 NE 
incubation was assessed using the MTT assay in the absence and presence of a 
saturation amount of DTX. The concentration range of DTX used in this part of the 
study was between 0.00001 and 100 µM. The drug-free NE samples containing the 
same amount of surfactant as the drug-saturated NE were tested in order to examine the 
cytotoxicity of both formulation types to both cell lines. The nonionic surfactants 
examined in the present study exhibited a clear dose-dependent cytotoxicity in both cell 
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lines in that a decrease in the number of viable cells was found with increasing 
surfactant concentration. Fortunately, however, a significant difference in cell viability 
was seen between the DTX-free and DTX-saturated NE at 72 hours. The cytotoxicity of 
TDL25-hSBO3-DTX (observed at 10-3-10-1 %w/w TDL in CT26 cells and at 10-5-1 
%w/w TDL in HeLa cells) was significantly higher than that of DTX-free TDL-hSBO3 







Figure 5.15: Viability of a) CT26 and b) HeLa cells at 72 hours incubation of Tween 
80:Dermosoft GMCY:lecithin (7.5:2.5:1) NE containing 3 %w/w hSBO, expressed as a 
percentage of control ‘untreated’ cells in the absence and presence of docetaxel determined by 
the MTT (mean ± S.D.; n=5; * p<0.05). 
 
It is noteworthy that a similar decrease in toxicity attributable to a surfactant when 
formulated as an integral part of another type of aggregate has also been recorded by 
other workers. For example, the toxicity of the surfactant Solulan C24 (Cholesteryl 
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poly(24)oxyethylene ether) was decreased when formulated as a niosome compared to a 
micellar solution (Dimitrijevic et al., 1997). The components of the niosome were 
Solulan C24, cholesterol and sorbitan monostrearate (Span 80). Similarly, the 
haemolytic activity of monoalkylphosphate or polysorbate solutions were reduced when 
prepared in the presence of 5 mM lecithin (Trotta et al., 1996). Moreover, the addition 
of egg PC to Brij 96 and C12E10 micelles (Gould et al., 1994) and the addition of 
Epikuron 200 (soy lecithin) in NE solubilising ethyl butyrate and ethyl oleate (Satra, 
1998) resulted in a decrease in the haemolytic effect of these preparations. In the latter 
case, the lower critical aggregation concentration of NE in the presence of Epikuron 200 
tends to suggest that there was less free monomeric surfactant to cause haemolysis 
(Satra, 1998). In contrast however, lecithin showed no effect in reducing the toxicity of 
NE containing polysorbate (Tween) 60 (Trotta et al., 1996). 
The IC50 values determined at 72 hours for incubation of micelles and NE with CT26 
and HeLa cells are shown in Tables 5.1 and 5.2, respectively. Clearly, Brij O10-
containing micelles and NE exhibited the lowest IC50 for both CT26 and HeLa cell 
lines. No difference in IC50 were seen either CUR-free and CUR-saturated micelles and 
NE, whereas the IC50 in the presence of DTX-saturated micelles and NE on both CT26 
and HeLa cell lines were much lower than were seen for the DTX-free micelle and NE. 
 
Table 5.1 IC50 Values of the micelles with CT26 and HeLa cell lines 
 
Samples Time (hours) IC50 (%w/w) 
CT26 HeLa 
B20 72 7.2 x 10-3 2.0 x 10-2 
T20 72 1.7 1.7 
T20-CUR 72 0.7 1.8 
TD25 72 9.4 x 10-1 8.7 x 10-1 
TD25-CUR 72 7.6 x 10-1 2.9 x 10-1 
TDL25 72 6.0 x 10-1 9.2 x 10-1 
TDL25-CUR 72 5.5 x 10-1 8.9 x 10-1 
TDL25-DTX 72 1.2 x 10-2 5.1 x 10-4 
TD25-98hEO10-CUR 72 2.9 x 10-1 1.5 
TDL25-hSBO3 72 2.2 x 10-1 8.6 x 10-1 
TDL25-hSBO3-CUR 72 2.2 3.8 
TDL25-hSBO3-DTX 72 5.9 x 10-3 6.4 x 10-5 
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Table 5.2 IC50 Values of the nanoemulsions with CT26 and HeLa cell lines 
 
Samples Time (hours) IC50 (%w/w) 
CT26 HeLa 
B20-98hEO1 72 3.6 x 10-3 6.9 x 10-3 
B20-98hEO1-CUR 72 4.3 x 10-3 2.4 x 10-2 
B20-98hEO2 72 5.1 x 10-3 8.8 x 10-3 
B20-98hEO2-CUR 72 3.8 x 10-3 2.3 x 10-2 
B20-98hEO4 72 4.1 x 10-3 1.6 x 10-2 
B20-98hEO4-CUR 72 4.2 x 10-3 2.3 x 10-2 
B20-98hEO6 72 3.1 x 10-3 1.4 x 10-2 
B20-98hEO6-CUR 72 4.9 x 10-3 2.3 x 10-2 
B20-hSBO9 72 6.7 x 10-3 2.2 x 10-2 
B20-hSBO9-CUR 72 7.4 x 10-3 1.8 x 10-2 
T20-hSBO1 72 1.8 1.8 
T20-hSBO1-CUR 72 1.7 1.8 
TD25-98hEO8 72 1.3 7.3 x 10-1 
TD25-98hEO8-CUR 72 1.4 1.1 
TD25-98hEO10 72 8.7 x 10-1 8.5 x 10-1 
TD25-98hEO10-CUR 72 2.9 x 10-1 1.5 
TDL25-hSBO3 72 2.2 x 10-1 8.6 x 10-1 
TDL25-hSBO3-CUR 72 2.2 3.8 
TDL25-hSBO3-DTX 72 5.9 x 10-3 6.4 x 10-5 
 
5.5 Chapter summary 
The cytotoxicity of all nonionic surfactant NE in HeLa (folate-expressing cervical-
tumour-derived cells) and CT26 (murine colon carcinoma cells) suggested that drug-
free B20-hSBO and B20-98hEO NE were toxic while drug-free T20-hSBO, TD25-
98hEO and TDL20-hSBO NE were far less toxic. Furthermore, TD NE containing 
98hEO and TDL NE containing hSBO did not exhibit any difference in toxicity of the 
NE in the absence and presence of CUR (a high-dose anticancer agent). On the other 
hand, TDL NE containing hSBO in the presence of DTX (a low-dose anticancer agent) 
exhibited a significant difference in cytotoxicity in both CT26 and HeLa cell lines when 





Chapter 6                                       
Synthesis of folate derived Brij O10 
 
6.1 Introduction 
Various ligands for tumour-cell-specific receptors have been immobilised on the surface of 
nanoparticle systems in an attempt to direct ‘target’ the delivery vehicles to the desired cell 
type, where it is intended to deliver its payload. Folate receptor (FR)-derived drugs or 
delivery vehicles, in particular have shown considerable promise for the uptake, into target 
cells, of anticancer agents (Lee and Low, 1994; Lee and Low, 1995; Gabizon et al., 1995; 
Anderson et al., 2001), gene therapy products (Lee and Huang, 1996; Wang et al., 1995), and 
radiopharmaceuticals (Mathias et al., 1996) amongst other things. In order to achieve the 
selective targeting of the drug or drug carrier towards FR-positive tumour cells, folic acid is 
directly linked to the drug or drug carrier/vehicle. Such derivatized drugs/drug delivery 
systems frequently show FR-dependent cellular uptake and internalisation into FR-positive 
cells by the mechanism of endocytosis. The preparation of FR-derived liposomes has been 
previously reported. The covalent attachment of a folate moiety to anticancer drugs and 
liposomes has been previously used to target drug against tumours (Lee and Low, 1994; Lee 
and Low, 1995; Guo et al., 2000; Lu and Low, 2002). This targeting was achieved the linkage 
of folate to phospholipid or cholesterol using a polyethyleneglycol (PEG) spacer (Lu and 
Low, 2002; Lee and Low, 1995; Lee and Low, 1994; Guo et al., 2000). In vitro experiments 
using folate derived liposomes containing doxorubicin have shown that KB and HeLa cells, 
which highly overexpress the FR, significantly take-up the drug, whereas WI-38 fibroblast 
cells, which do not express the FR, showed minimal drug uptake (Lee and Low, 1995). 
 
6.2 Aim of study 
In the present study, folate derived Brij O10 was synthesised. The main objective of this part 
of the study was to synthesis a folate derived Brij O10 which could be incorporated into the 
NE in order to directly target to folate receptor embedded in the membrane of cancer cells. 
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During these studies the combined use of UV/vis spectroscopy, ninhydrin assay and 1H NMR 
analysis was used employed to confirm the structure of the intermediates and final product. 
 
6.3 The design folate targeting group 
To selectively deliver anticancer drug to solid tumours expressing folate receptor, folate 
derived Brij O10 has been synthesised. Figure 6.1 shows the design and the process of the 
preparation of the folate derived Brij O10. 
 
 
Figure 6.1: Design and the process of the preparation of folate derived Brij O10. 
 
The first step is the preparation of PEG bis(3-aminopropyl) terminated-folate. The second 
step is the synthesis of tresylated-Brij O10. Lastly, folate derived Brij O10 was prepared by 
reacting PEG bis(3-aminopropyl) terminated-folate with the tresylated-Brij O10. A wide 
range of techniques, namely UV/vis spectroscopy, ninhydrin assay and 1H NMR, were used 
to confirm the structure of the products in each step of the synthesis. 
 
6.4 The synthesis of PEG bis(3-aminopropyl) terminated-folate 
6.4.1 The preparation of PEG bis(3-aminopropyl) terminated-folate 
The synthesis of PEG bis(3-aminopropyl) terminated-folate is outlined in Figure 6.2. Bis(3-
aminopropyl) terminated PEG was reacted with folic acid in the presence of a coupling 
reagent (i.e. dicyclohexylcarbodiimide (DCC)), dimethylsulfoxide (DMSO) and pyridine to 
yield PEG bis(3-aminopropyl) terminated-folate. 
1. Tresylated Brij O10 
 
2. PEG bis(3-aminopropyl) 
terminated-folate 
 
3. Folate derived Brij O10 
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Folic acid   Bis(3-aminopropyl) terminated PEG           PEG bis(3-aminopropyl) terminated-folate 
Figure 6.2: Synthesis of PEG bis(3-aminopropyl) terminated-folate. 
 
The folate molecule (Figure 6.3) has two potentially reactive carboxyl groups, namely the α 
and γ carboxyl groups, which can be activated in the presence of DCC (Vortherms et al., 
2008). As the α carboxyl group is more sterically hindered due to its position in the middle 
of the folic acid molecule, it is possible to select the experimental conditions to limit reaction 
at this site. In contrast, the (terminal) γ carboxylic acid group being more accessible and 
therefore more reactive can be selectively activated using DCC (Kim et al., 2007) before 
being reacted with the primary amine group of bis(3-aminopropyl) terminated PEG. 
 
Figure 6.3: Structure of folic acid (modified from Vortherms et al., 2008). 
 
Then water was added to the reaction mixture. Dicyclohexylurea, the by-product formed 
when using DCC, was insoluble in the organic solvent and water and precipitated out from 
the reaction mixture so this was removed by the filtration through a microfiber filter. The 
filtrate was evaporated to remove the solvent, however due to the high volume of filtrate, this 
filtrate was divided into 6 parts (each of about 10-15 mL). The purification of the remaining, 
crude PEG bis(3-aminopropyl) terminated-folate was achieved via size exclusion 
chromatography using Sephadex G-25. When each part of the filtrate was eluted through the 
Sephadex G-25 column it was called a separation. Finally, after the 6 parts of the filtrate had 
been passed through the column, separations 1 to 6 of products were called “the first 
separation” to “the sixth separation”. Such a separation was possible because of the increased 
molecular weight (MW) of the product. In fact, the MW of the PEG bis(3-aminopropyl) 
terminated-folate (MW = 1923) was sufficiently high to allow it to be separated from the low 
MW folate (MW = 441) and from the intermediate MW bis(3-aminopropyl) terminated PEG 
(MW = 1500). At this stage of the synthesis, the product, bis(3-aminopropyl) terminated 
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PEG-folate was more water soluble than folic acid, due to it being conjugated to the long 
PEG chain. 
 
6.4.2 The analysis of PEG bis(3-aminopropyl) terminated-folate 
After the crude PEG bis(3-aminopropyl) terminated-folate was eluted with water, the 10 mL 
fractions were collected from the first which contained a yellow material. This generally 
occurred at around fractions 15-16 (i.e. 150-160 mL of eluent). Collection of elute continued 
until all of the yellow colour had disappeared from the aliquots being collected, which 
generally occurred at around fractions 29-30 (i.e. 290-300 mL of eluent). Figure 6.4 shows 
a schematic representation of the analysis of the PEG bis(3-aminopropyl) terminated-folate. 
As can be seen a combination of UV/vis spectroscopy, ninhydrin assay and 1H NMR was 
used for characterisation. The folate content and -NH2 content of each fraction were analysed 
by determining the UV absorbance at 364 nm (for folate content) and by ninhydrin (for -NH2 
content). The fractions which were positive for both folate and -NH2 were pooled and 
evaporated using a rotary evaporator. In Figure 6.4, the dry product of first eluted fractions 
containing folate but no -NH2 (i.e. negative to ninhydrin) are denoted as “1-A”, while dry 
product of fractions containing both folate and -NH2 was named as “1-B”. Finally the dry 
product of fractions containing folate but no -NH2 (i.e. negative to ninhydrin) but which were 
collected after the fractions which were positive to ninhydrin are described as “1-C”. The 
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Figure 6.4: Flow diagram showing the process of analysis of the crude PEG bis(3-aminopropyl) 
terminated folate product using UV/vis spectroscopy, ninhydrin and proton nuclear magnetic 
resonance spectroscopy (1H NMR). 
 
6.4.2.1 Analysis of PEG bis(3-aminopropyl) terminated-folate using UV/vis 
spectroscopy 
After elution of the filtrate of crude PEG bis(3-aminopropyl) terminated-folate obtained from 
the preparation of PEG bis(3-aminopropyl) terminated-folate through a Sephadex G-25, the 
amount of folic acid in each of the ‘yellow’ fractions from each separation was determined 
(Figure 6.5). It is clear that all the ‘yellow’ coloured fractions contained folate in some form. 
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Figure 6.5: Amount of folic acid in the 10 mL ‘yellow’ coloured fractions eluted from the Sephadex 
G-25 column in the first separation to the sixth separation of PEG bis(3-aminopropyl) terminated-
folate determined by the UV/vis spectroscopy using the absorbance at the wavelength of 364 nm.  
 
6.4.2.2 Analysis of PEG bis(3-aminopropyl) terminated-folate using ninhydrin reaction 
In the ninhydrin test, bis(3-aminopropyl) terminated PEG and folic acid were used as positive 
and negative controls, respectively. The bis(3-aminopropyl) terminated PEG reacted with 
ninhydrin to produce a purple coloured solution upon heating. On the other hand, when folic 
acid is reacted with ninhydrin the solution remains yellow in colour after heating. The 
reaction of each of the yellow coloured eluates with ninhydrin to produce a purple colour (or 
otherwise) upon heating was used to establish the presence (or otherwise) of -NH2 in each of 
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Table 6.1 Reaction of each fraction in the synthesis of PEG bis(3-aminopropyl) terminated-folate to 
ninhydrin solution. 
 
Sample Order of separation 
First Second Third Forth Fifth Sixth 
Bis(3-aminopropyl) terminated PEG (positive control) Purple Purple Purple Purple Purple Purple 
Folic acid (negative control) Yellow Yellow Yellow Yellow Yellow Yellow 
Fraction 1 at 150 - 160 ml Yellow Yellow Yellow Yellow Yellow Yellow 
Fraction 2 at 160 - 170 ml Yellow Yellow Yellow Yellow Yellow Yellow 
Fraction 3 at 170 - 180 ml Yellow Yellow Yellow Purple Purple Yellow 
Fraction 4 at 180 - 190 ml Yellow Purple Yellow Purple Purple Purple 
Fraction 5 at 190 - 200 ml Purple Purple Yellow Purple Purple Purple 
Fraction 6 at 200 - 210 ml Purple Purple Yellow Purple Purple Purple 
Fraction 7 at 210 - 220 ml Purple Purple Yellow Purple Purple Purple 
Fraction 8 at 220 - 230 ml Purple Purple Purple Purple Purple Purple 
Fraction 9 at 230 - 240 ml Purple Purple Purple Purple Purple Purple 
Fraction 10 at 240 - 250 ml Purple Purple Purple Purple Purple Purple 
Fraction 11 at 250 - 260 ml Yellow Yellow Purple Yellow Purple Purple 
Fraction 12 at 260 - 270 ml Yellow Yellow Purple Yellow Yellow Yellow 
Fraction 13 at 270 - 280 ml Yellow Yellow Purple Yellow Yellow Yellow 
Fraction 14 at 280 - 290 ml Yellow Yellow Yellow Yellow Yellow Yellow 
Fraction 15 at 290 - 300 ml Yellow Yellow Yellow Yellow Yellow Yellow 
 
From the results of the UV/vis spectroscopy and ninhydrin assays, fractions 1-4 (first 
separation), fractions 1-3 (second separation), fractions 1-7 (third separation), fractions 1-2 
(forth separation), fractions 1-2 (fifth separation), and fractions 1-3 (sixth separation) were 
found to contain folate but no -NH2 (i.e. were negative in the ninhydrin assay) and were 
therefore pooled and the solvent evaporated using the rotary evaporation to obtain a dry 
product which was described  as “1-A” (Figure 6.4). 
In contrast, fractions 5-10 (first separation), fractions 4-10 (second separation), fractions 8-
13 (third separation), fractions 3-10 (forth separation), fractions 3-11 (fifth separation), and 
fractions 4-11 (sixth separation) were found to contain folate and were positive in the 
ninhydrin assay (i.e. contained -NH2) so these fractions were pooled together and evaporated 
using the rotary evaporation to obtain dry product which was denoted as “1-B” (Figure 6.4). 
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Finally, fractions 11-15 (first separation), fractions 11-15 (second separation), fractions 14-
15 (third separation), fractions 11-15 (forth separation), fractions 12-15 (fifth separation), 
and fractions 12-15 (sixth separation) were also found to contain folate but no -NH2 (i.e. were 
negative in the ninhydrin assay). As a consequence these fractions were pooled together and 
evaporated using the rotary evaporation to obtain dry product which was denoted as “1-C” 
(Figure 6.4). 
Subsequently, the dry products, namely 1-A, 1-B and 1-C, were dissolved either in D2O or 
DMSO in order to determine the chemical structure of each dry product using a 400 MHz 1H 
NMR. 
 
6.4.2.3 Analysis of PEG bis(3-aminopropyl) terminated-folate using proton nuclear 
magnetic resonance spectroscopy (1H NMR) 
All three dry products, namely 1-A, 1-B and 1-C were characterized by 1H NMR 
spectroscopy to determine the structure of product (Figures 6.6-6.8). 
Dry product 1-A 
The 1H NMR spectrum of the dry product, 1-A, which had previously showed an absorbance 
due to folate but was negative to ninhydrin solution, exhibited hydrogen resonances due to 
folate and bis(3-aminopropyl) terminated PEG (Figure 6.6). In particular the 1H NMR 
spectrum exhibited a signal at 3.47 ppm (position l, m, n, o) corresponding to a methyl proton 
in the oxyethylene region of bis(3-aminopropyl) terminated PEG molecule while the signals 
at 2.80 ppm (position j, q), and 1.81 ppm (position k, p) were assigned to methylene of bis(3-
aminopropyl) terminated PEG. In contrast, the signals at 6.63 ppm (position c, d) and 7.48 
ppm (position e, f) corresponded to the para-aminobenzoic acid (PABA) of the folate, while 
the signal at 8.42 ppm (position a) corresponded to the protons in the pteridine moiety of the 
folate. Furthermore, the signal at 4.09 ppm (position b, g), and 2.05 ppm (position h, i) were 
assigned to the methylene of the folate. 
In addition, the 1H NMR results also indicated that the conjugation of folate and bis(3-
aminopropyl) terminated PEG were present in a 2:1 ratio as determined from the ratio of the 
hydrogen peaks from the folate moiety and the bis(3-aminopropyl) terminated PEG and 
suggested the structure was folate-PEG bis(3-aminopropyl) terminated-folate (MW = 2346). 
This result was also supported by the time taken to elute the products from the Sephadex G-
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25 column, in that fractions containing 1-A eluted first and before the fractions of the 
believed to contain the product 1-B, PEG bis(3-aminopropyl) terminated-folate, which is of 
a lower molecular weight (MW = 1923) than folate-PEG bis(3-aminopropyl) terminated-
folate of fractions of product 1-A, folate-PEG bis(3-aminopropyl) terminated-folate, (MW = 
2346). Moreover, product 1-A was not soluble in water and required a mixture of D2O and 
DMSO (5:1) to prepare a clear solution for structure determination using 1H NMR. The 
integral of the peaks attributed to the folate and bis(3-aminopropyl) terminated PEG of 
product 1-A indicate that product 1-A had higher amount of folate than product 1-B.  
 
 
Figure 6.6: 1H NMR spectrum of dry product 1-A (400 MHz, D2O: DMSO (5:1)): δ 8.42, 7.48, 6.63, 
4.09, 3.47, 2.80, 2.05, and 1.81 ppm.  
 
Dry product 1-B 
It is clear that the 1H NMR spectrum of dry product 1-B which was positive to both folate 
and positive to ninhydrin solution, indicating the presence of -NH2 exhibited 
1H NMR signals 
originating from both folic acid and the bis(3-aminopropyl) terminated PEG (Figure 6.7). 
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The 1H NMR spectra exhibited a signal at 3.59 ppm (position l, m, n, o) corresponding to the 
methyl protons in the oxyethylene moieties of bis(3-aminopropyl) terminated PEG molecule 
while the signals at 3.00 ppm (position j, q), and 1.93 ppm (position k, p) could be assigned 
to the methylene of bis(3-aminopropyl) terminated PEG. In contrast, the signals at 6.56 ppm 
(position c, d) and 7.51 ppm (position e, f) corresponded to the para-aminobenzoic acid 
(PABA) moiety of the folate, while the signal at 8.57 ppm (position a) corresponds to the 
protons of the pteridine moiety of the folate. Finally, the signal at 4.22-4.39 ppm (position b, 
g), and 2.21 ppm (position h, i) was assigned to the methylene of the folate. The integrals of 
each hydrogen peak of the 1H NMR spectra confirmed that both folate and bis(3-
aminopropyl) terminated PEG were present and that they were associated in a 1:1 ratio. The 
percentage yield of product 1-B, PEG bis(3-aminopropyl) terminated-folate, was 40 %. 
The human metabolome database (HMDB, http://www.hmdb.ca) showed that the 1H NMR 
spectra of folic acid exhibited signals at 2.1 ppm (position h), 2.3 (position i), 4.3 (position 
g), 6.2 ppm (position c, d), 7.4 ppm (position e, f) and 8.4 (position a). This illustrated that 
the coupling of folic acid and bis(3-aminopropyl) terminated PEG affected the chemical shift 
of position i causing it to move upfield.  In addition, mass spectral analyses (e.g. MALDI-
TOF) could have been used in the analysis of PEG bis(3-aminopropyl) terminated-folate. 
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Figure 6.7: 1H NMR spectrum of dry product 1-B (400 MHz, D2O): δ 8.57, 7.51, 6.56, 4.39, 4.22, 
3.59, 3.00, 2.21 and 1.93 ppm. 
 
Dry product 1-C 
The 1H NMR spectrum of dry product 1-C (Figure 6.8), which was positive to folate but was 
negative to ninhydrin, suggests that the product 1-C was in fact folic acid. The 1H NMR 
result showed signals at 6.51 ppm (position c, d) and 7.42 ppm (position e, f) corresponding 
to the para-aminobenzoic acid (PABA) moiety of folate, while the signals at 8.29 ppm 
(position a) corresponded to the protons of the pteridine moiety of the folate. Finally, the 
signals at 4.00-4.27 ppm (position b, g) and 1.46 ppm (position h, i) were assigned to 
methylene of folate. Surprisingly, the spectra indicated that bis(3-aminopropyl) terminated 
PEG was present as the signal at 3.29 ppm (position l, m, n, o), and 3.00 ppm (position j, q) 
and 1.10 ppm (position k, p) was assigned to the methylene of bis(3-aminopropyl) terminated 
PEG. So, despite the fact that qualitative analysis using ninhydrin assay had been negative 
result to the presence of -NH2, 
1H NMR spectroscopy suggested the presence of a very small 
amount of bis(3-aminopropyl) terminated PEG in product 1-C. While 1H NMR spectroscopy 
supported the presence of folate as the major product in dry product 1-C, size exclusion 
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spectroscopy also supported its presence due to the elution time – it would be expected to be 
more slowly eluted than the other possible products of the reaction. This is a consequence of 
the low MW of folic acid (MW = 441) when compared to bis(3-aminopropyl) terminated 
PEG (MW = 1500) and PEG bis(3-aminopropyl) terminated-folate (MW = 1923). In 
addition, the product 1-C was not soluble in water and so DMSO was used as a solvent to 
prepare the clear solution for structural determination of dry product 1-C using 1H NMR.  
 
 
Figure 6.8: 1H NMR spectrum of dry product 1-C (400 MHz, DMSO): δ 8.29, 7.42, 6.51, 4.27, 4.00, 
3.29, 3.00, 1.46, and 1.10 ppm. 
 
In previous study, it has been reported that in the 1H NMR spectra of the folic acid conjugated 
to poly(ethylene glycol) (PEG)-modified dendrimers, the aromatic folate proton peaks could 
be observed at δ 6.65, 7.67, and 8.63 ppm, while the PEG protons were present at δ 3.58 
ppm. (Chang, 2013). It was also reported that the 1H NMR spectrum of folate-poly (PEG-
cyanoacrylateco-cholesteryl cyanoacrylate) (FA-PEG-PCHL) exhibited a signal at 3.51 ppm 
which could be assigned to the methylene protons of the PEG backbone. In additions, signals 
at 2.00-2.40 ppm and 4.50 ppm were attributed to the methylene of folate. Finally the signals 
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at 6.61 ppm, 7.41 ppm, and 8.66 ppm were attributed to the protons of the aromatic ring of 
folate (Li et al., 2011). 
 
6.4.2.4 The analysis of PEG bis(3-aminopropyl) terminated-folate for ratio of folate 
content and -NH2 content 
The folate content and -NH2 content of product 1-B were assessed and used to calculate the 
molar ratio of folate and bis(3-aminopropyl) terminated PEG in its structure. In addition, the 
amount of folic acid present in product 1-B was also determined using UV/vis spectroscopy. 
The absorbance of the product 1-B, PEG bis(3-aminopropyl) terminated-folate, at a 
concentration of 0.368 mg/mL at a wavelength of 364 nm was determined to be 0.45. 
Therefore, the amount of folic acid in this sample was determined to be 0.032 mg.  
The bis(3-aminopropyl) terminated PEG content was determined by preparing a 1.014 
mg/mL stock solution of the PEG derivative which was then diluted with ethanol to yield 
working solutions of PEG derivative concentrations ranging from 0.043 to 0.145 mg/mL. 
The absorbance at 570 nm of each concentration of bis(3-aminopropyl) terminated PEG was 
plotted against concentration to get a standard curve.  
Ninhydrin assay of bis(3-aminopropyl) terminated PEG (Standard curve) 
 
4 x ninhydrin + bis(3-aminopropyl) terminated PEG  (ninhydrin)4-bis(3-aminopropyl) terminated PEG 
 
Ninhydrin assay of bis(3-aminopropyl) terminated PEG-folate  
 
2 x ninhydrin + bis(3-aminopropyl) terminated PEG-folate  (ninhydrin)2-bis(3-aminopropyl) terminated PEG-folate 
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In order to compare the amount of bis(3-aminopropyl) terminated PEG and bis(3-
aminopropyl) terminated PEG-folate, the chemical reaction of ninhydrin assay with bis(3-
aminopropyl) terminated PEG-folate should be multiplied with 2 in order that both reactions 
have used the same number of mole of ninhydrin. 
 
4 x ninhydrin + 2 x bis(3-aminopropyl) terminated PEG-folate  (ninhydrin)4-bis(3-aminopropyl) terminated PEG-folate 
 
As the same number of mole of ninhydrin (i.e. 4 mole) was used in both reactions; therefore, 
1 mole of bis(3-aminopropyl) terminated PEG-folate is equivalent to 2 moles of bis(3-
aminopropyl) terminated PEG-folate. The absorbance of a 0.368 mg/mL PEG bis(3-
aminopropyl) terminated-folate solution at a wavelength of 570 nm was 0.25 which 
equivalent to 0.059 mg of bis(3-aminopropyl) terminated PEG obtained using the standard 
curve.  
H2N-(CH2)3-(CH2CH2O)n-(CH2)3-NH2  = 2   
MW = 1500     MW=1923 
if X is weight of bis(3-aminopropyl) terminated PEG-folate 
0.059/1500    = (2X)/1923 
X     =  0.037 mg 
Therefore, the amount of bis(3-aminopropyl) terminated PEG-folate was 0.037 mg. 
Consequently, the UV/vis spectrophotometric results of folate and -NH2 content verified both 
the presence of folate and -NH2 in sample and indicated that the folate and -NH2 were 
associated in the desired 1:1 ratio. 
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6.5 The synthesis of tresylated Brij O10 
6.5.1 The preparation of tresylated Brij O10 
In the preparation of tresylated Brij O10 (Figure 6.9), tresyl chloride (2,2,2-
trifluoroethanesulfonyl chloride), an organic sulfonyl chloride, was reacted with Brij O10 
dissolved in anhydrous dichloromethane. The synthesis of tresylated Brij O10 was performed 
in an anhydrous solvent in order to avoid the hydrolysis of the sulfonyl chloride (-SO2Cl) in 
the tresyl chloride. Pyridine was added to neutralise the acidity of the reaction due to the HCl 
produced in the reaction. It is also known that Brij O10 has one terminal hydroxyl (OH) 
group. The terminal OH can then be activated with tresyl chloride. Tresyl chloride can then 
be coupled with the amine group of bis(3-aminopropyl) terminated PEG during the 
preparation in folate derived Brij O10. From this reaction, tresylated Brij O10, a white and 
waxy product, was produced. The percent yield of tresylated Brij O10 was 22%. 
 
            Brij O10       Tresyl chloride          Tresylated Brij O10 
Figure 6.9: Synthesis of tresylated Brij O10 
  
In previous studies, a skilful method was developed for the activation of hydroxyl expressing 
supports such as agarose, cellulose, diol-silica, glycophase-glass or hydroxyethyl 
methacrylate using tresyl chloride such that a coupling reaction of proteins with a tresylated 
OH group was developed (Nilsson and Mosbach, 1981; Nilsson and Mosbach, 1984). In this 
method, tresyl chloride was used to convert a hydroxyl (OH) group to a sulfonate (RSO3
-) - 
a good leaving group - which allowed the formation of linkages between the nucleophile and 
the hydroxyl group-carrying carbon. The activation and coupling of the ligand to the support 
involved the following steps: 
Activation:  support-CH2OH  + R-SO2CI         support-CH2OSO2-R 
Coupling:    support-CH2OSO2-R + H2N-ligand  support-CH2-NH-ligand + HOSO2-R 
Analogous to this methodology both Brij 78 and Brij 700 have been reacted with tresyl 
chloride to prepare tresylated Brij 78 and tresylated Brij 700, respectively which were 
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subsequently conjugated to horseradish peroxidase to prepare solid lipid nanoparticles (Jain 
et al., 2010). 
 
6.6 The synthesis of folate derived Brij O10 
6.6.1 The preparation of folate derived Brij O10  
The synthesis of folate derived Brij O10 is shown in Figure 6.10. Tresylated Brij O10 was 
prepared by the conversion OH group of Brij O10 into a sulfonate - a good leaving group - 
which allowed the formation of linkage between the nucleophile and the hydroxyl group-
carrying carbon (Nilsson and Mosbach, 1981; Nilsson and Mosbach, 1984).  
In the present study the support-CH2OSO2-R is the tresylated Brij O10, while the H2N-ligand 
represents bis(3-aminopropyl) terminated PEG. Furthermore, the support-CH2-NH-ligand is 
folate derived Brij O10. From this coupling reaction, it would be anticipated that PEG bis(3-
aminopropyl) terminated-folate was coupled with tresylated Brij O10 to form folate derived 
Brij O10. The solvent was removed from the reaction mixture using rotary evaporation and 
the resulting dry product dissolved in water. 
 
Figure 6.10: Synthesis of folate derived Brij O10 
 
Due to the high amount of product used in the preparation of folate derived Brij O10, the 
product was divided into 3 separations. After that, each product solution was eluted through 
Sephadex G-25 to separate folate derived Brij O10 molecule from the uncoupled PEG bis(3-
aminopropyl) terminated-folate according to their difference in molecular weight. The 
compound with higher molecular weight, namely the folate derived Brij O10 (MW = 2615) 
was eluted more quickly than the lower molecular weight parent molecule, namely PEG 
bis(3-aminopropyl) terminated-folate (MW = 1923) and tresylated Brij O10 (MW = 855). 





Folate derived Brij O10 
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The difference in molecular weight between the folate derived Brij O10 and the PEG bis(3-
aminopropyl) terminated-folate and tresylated Brij O10 was enough to separate them. 
 
6.6.2 The analysis of folate derived Brij O10 
Figure 6.11 gives a schematic diagram of the analysis of folate derived Brij O10. The folate 
and -NH2 content of each 10 mL fraction eluted through a Sephadex G-25 column were 
determined using UV absorbance at 364 nm and by the ninhydrin assay, respectively. 
  
Figure 6.11: Diagram shows the process of the analysis of all fractions obtained from the preparation 
of folate derived Brij O10 by using UV/vis spectroscopy, ninhydrin reaction and proton nuclear 
magnetic resonance spectroscopy (1H NMR). 
 
The first yellow 10 mL fraction were collected starting at about 150-160 mL (fractions 15-
16) and continued until the last yellow fraction, which eluted at ~ 300-310 mL (fractions 30-
31). UV/vis spectroscopy and ninhydrin reaction were used to analyse all fractions obtained 
from the preparation of folate derived Brij O10 (Figure 6.11). 10 mL fractions which 
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exhibited the same result for the folate analysis and the ninhydrin reaction were pooled 
together and the solvent removed using a rotary evaporator. The dry product of fractions 
which contained folate but were negative to ninhydrin were denoted as “3-A”, while the dry 
product of fractions positive to both folate and ninhydrin were described as “3-B”. The 
chemical structures of dry product of 3-A and 3-B were separately determined using 1H NMR 
spectroscopy.  
 
6.6.2.1 The analysis of folate derived Brij O10 using UV/vis spectroscopy  
All yellow coloured elutes from the Sephadex G-25 column were analysed using UV/vis 
spectroscopy to determine the amount of folic acid (Figure 6.12). 
 
a) b)  
c)  
Figure 6.12: The amount of folic acid in the yellow 10 mL fractions eluted from Sephadex G-25 in 
the (a) first, (b) second and (c) third separation of the preparation of folate derived Brij O10 
determined by the UV/vis spectroscopy using the absorbance at the wavelength of 364 nm. 
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6.6.2.2 The analysis of folate derived Brij O10 using ninhydrin reaction 
Each fraction of yellow coloured elutes was analysed for the presence of -NH2 group using 
the ninhydrin assay. In the ninhydrin assay, bis(3-aminopropyl) terminated PEG and folic 
acid were the positive and negative controls, respectively. The positive control, bis(3-
aminopropyl) terminated PEG was mixed with ninhydrin and upon heating the colour of the 
mixture become purple. On the other hand, when the negative control, folic acid, was reacted 
with ninhydrin, the colour of the mixture remained yellow after heating. The result of 
ninhydrin assay performed on each yellow fraction is shown in Table 6.2. 
 
Table 6.2 The reaction of each fraction in the synthesis of folate derived Brij O10 to ninhydrin 
solution 
 
Sample Order of separation 
First Second Third 
Bis(3-aminopropyl) terminated PEG (positive control) Purple Purple Purple 
Folic acid (negative control) Yellow Yellow Yellow 
Fraction 1 at 150 - 160 ml Yellow Yellow Yellow 
Fraction 2 at 160 - 170 ml Yellow Yellow Yellow 
Fraction 3 at 170 - 180 ml Yellow Yellow Yellow 
Fraction 4 at 180 - 190 ml Yellow Yellow Yellow 
Fraction 5 at 190 - 200 ml Yellow Yellow Yellow 
Fraction 6 at 200 - 210 ml Yellow Yellow Yellow 
Fraction 7 at 210 - 220 ml Yellow Yellow Yellow 
Fraction 8 at 220 - 230 ml Yellow Yellow Yellow 
Fraction 9 at 230 - 240 ml Purple Yellow Yellow 
Fraction 10 at 240 - 250 ml Purple Yellow Purple 
Fraction 11 at 250 - 260 ml Purple Yellow Purple 
Fraction 12 at 260 - 270 ml Yellow Purple Purple 
Fraction 13 at 270 - 280 ml Yellow Purple Purple 
Fraction 14 at 280 - 290 ml Yellow Purple Yellow 
Fraction 15 at 290 - 300 ml Yellow Purple Yellow 
Fraction 16 at 300 - 310 ml Yellow Yellow Yellow 
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According to the results of the UV/vis spectroscopy and the ninhydrin assay, fractions 1-8 
(first separation), fractions 1-11 (second separation) and fractions 1-9 (third separation) 
contained folate but were negative to ninhydrin assay (i.e. the fractions did not contain a -
NH2 group). Consequently these fractions were pooled together and evaporated using the 
rotary evaporation to obtain dry product which was called “3-A” (Figure 6.11). 
On the other hand, fractions 9-11 (first separation), fractions 12-15 (second separation) and 
fractions 10-13 (third separation) all contained folate and were positive to ninhydrin 
indicating that these fractions contained -NH2 group. Thus all these fractions were pooled 
together and evaporated using a rotary evaporator to obtain dry product which was called “3-
B” (Figure 6.11). 
According to the order of elution, it can be assumed that the structure of the compound 
contained in fractions 1-8 (first separation), fractions 1-11 (second separation) and fractions 
1-9 (third separation) was likely to be folate derived Brij O10, whereas the compound present 
in fractions 9-11 (first separation), fractions 12-15 (second separation) and fractions 10-13 
(third separation) was considered to be PEG bis(3-aminopropyl) terminated-folate. In order 
to confirm the structures contained in the dry products 3-A and 3-B, 400 MHz 1H NMR 
spectroscopy was used. 
 
6.6.2.3 Proton nuclear magnetic resonance spectroscopy (1H NMR) 
The molecular weight of folate derived Brij O10 and PEG bis(3-aminopropyl) terminated-
folate were respectively, 2615 and 1923. The results of the UV/vis spectroscopy (Figure 
6.12) and ninhydrin assays (Table 6.2) suggested that the dry product 3-A (the first peak in 
the three separations) was the desired product, the folate derived Brij O10, because of the 
absence of a -NH2 group coupled with the fact that folate derived Brij O10 possess a higher 
molecular weight than bis(3-aminopropyl) terminated PEG as so will be expected to be eluted 
much quicker. The production of the desired conjugation product was confirmed by 1H NMR 
spectroscopy as shown in Figure 6.13.  
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Figure 6.13: 1H NMR spectrum of fraction 1-8 (first separation) (400 MHz, D2O): δ 8.78, 8.64, 8.49, 
8.00, 7.61, 6.73, 5.26, 4.23, 3.96, 3.56, 2.23, 1.97, 1.50, 1.22, and 0.82 ppm. (a*, c*, d*, e* and f* 
were protons of folate of folate derived Brij O10 while a, c, d, e and f were protons of folate of bis(3-
aminopropyl) terminated PEG). 
 
It is clear that the 1H NMR spectrum of the folate derived Brij O10 contained signals arising 
from folic acid, bis(3-aminopropyl) terminated PEG and Brij O10. 1H NMR results of the 
dry product 3-A showed the signal at 3.56-3.96 ppm (position l, m, n, o, r, s) corresponded 
to the methylene protons present in the PEG region of bis(3-aminopropyl) terminated PEG 
and the PEG in Brij O10 molecule. The signals at 8.00 ppm (position c*, d*) and 8.78 ppm 
(position e*, f*) corresponded to the para-aminobenzoic acid (PABA), and the signal at 8.64 
ppm (position a*) corresponded to the pteridine moiety proton from the folate of folate 
derived Brij O10. The signal at 4.23 ppm (position b, g), and 2.23 ppm (position h, i) was 
assigned to the methylene of folate. The signal at 1.97 ppm (position k, p) was assigned to 
the methylene of bis(3-aminopropyl) terminated PEG. The signal at 5.26 ppm (position t, u) 
was belonged to double bond of Brij O10, and the signal at 0.82 ppm (position v) was 
assigned to methylene group of Brij O10. Consequently, 1H NMR results confirmed the 
conjugation of PEG bis(3-aminopropyl) terminated-folate and tresylated Brij O10 to yield 
the desired product. The percentage yield of folate derived Brij O10 was 89%. However, the 
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signals at 6.73 ppm (position c, d) and 7.61 ppm (position e, f) corresponded to the para-
aminobenzoic acid (PABA) in the folate of bis(3-aminopropyl) terminated PEG, while the 
signal at 8.66 ppm (position a) corresponded to protons from the pteridine moiety present in 
the folate of bis(3-aminopropyl) terminated PEG which suggested that this product contained 
a very small amount of bis(3-aminopropyl) terminated PEG. 
On the other hand, the second peak of dry product 3-B in the preparation of folate derived 
Brij O10 was considered to be PEG bis(3-aminopropyl) terminated-folate because the 
fractions contained molecules possessing a -NH2 group (i.e. they were positive to ninhydrin). 
This result is supported by the 1H NMR results which indicate that there is no signal 
attributable to a double bond nor any methylene group of Brij O10 (Figure 6.14).  
 
Figure 6.14: 1H NMR spectrum of fraction 9-11 (first separation) (400 MHz, D2O): δ 8.63, 7.55, 
6.66, 4.47, 4.22, 3.60, 3.05, 1.88 and 1.20 ppm.  
 
The product 3-B showed the signals originating from both the folic acid and the bis(3-
aminopropyl) terminated PEG. The 1H NMR results showed the signals at 3.60 ppm (position 
l, m, n, o) corresponded to the methylene protons in the bis(3-aminopropyl) terminated PEG 
molecule, while the signals at 6.66 ppm (position c, d) and 7.55 ppm (position e, f) 
corresponded to the para-aminobenzoic acid (PABA) from the folate, and the signal at 8.63 
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ppm (position a) to the protons of the pteridine moiety of the folate. The signals at 4.22-4.47 
ppm (position b, g), and 1.88 ppm (position h, i) were assigned to methylene of the folate. 
The signals at 3.05 ppm (position j, q), and 1.20 ppm (position k, p) were assigned to 
methylene of bis(3-aminopropyl) terminated PEG. Moreover, mass spectral analyses (e.g. 
MALDI-TOF) could have been used in the analysis of folate derived Brij O10. 
In addition, a comparison of the UV absorbance of the various fractions eluted from 
Sephadex G-25 column showed that folate derived Brij O10 eluted more quickly than the 
PEG bis(3-aminopropyl) terminated-folate because of the higher molecular weight of folate 
derived Brij O10 (Figure 6.15). The molecular weight of folate derived Brij O10 was 2615, 
while that of PEG bis(3-aminopropyl) terminated-folate was 1923. This observation also 
supported the hypothesis that the first peak eluted (i.e. product 3-A) was folate derived Brij 
O10, while the second peak eluted (i.e. product 3-B) was PEG bis(3-aminopropyl) 
terminated-folate. 
  
Figure 6.15: A comparison of the UV absorbance at the wavelength of 364 nm of fractions obtained 
from the synthesis of bis(3-aminopropyl) terminated-PEG folate and the synthesis of folate derived 
Brij O10.  
 
6.7 Chapter summary 
In order to selectively deliver anticancer drugs such as CUR and DTX to solid tumours 
expressing folate receptor, folate derived Brij O10 has been synthesised. Firstly, PEG bis(3-
aminopropyl) terminated-folate was prepared by reacting bis(3-aminopropyl) terminated 
PEG with folic acid in dimethylsulfoxide containing dicyclohexylcarbodiimide and pyridine 
overnight in the dark. Secondly, tresylated-Brij O10 was prepared by dropwise addition at 
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0oC of tresyl chloride in pyridine to Brij O10 in dichloromethane, after which the mixture 
was stirred under nitrogen. Finally, folate derived Brij O10 was prepared by reacting PEG 
bis(3-aminopropyl) terminated-folate in anhydrous dimethylformamide with tresylated-Brij 
O10 overnight. UV/vis spectroscopy, ninhydrin assay and 1H NMR analysis were employed 
to confirm the structure of the intermediates and final product.  
A ninhydrin assay and UV/vis spectroscopy showed that the product of the first reaction 
contained folate and an -NH2 group while 
1H NMR confirmed the coupling of folate with 
bis(3-aminopropyl) terminated PEG. The white and waxy tresylated Brij O10 was 
synthesised. In the third step, the results of ninhydrin assay, UV/vis spectroscopy and 1H 
NMR investigations showed that the product of third step was folate derived Brij O10 group 
while 1H NMR confirmed the coupling of folate with bis(3-aminopropyl) terminated PEG. 
Therefore, it can be concluded that folate derived Brij O10 has been successfully synthesised 
and characterised. In addition, the mass spectral analyses (e.g. MALDI-TOF) could have 




Chapter 7                                
Conclusion and Future Work 
 
7.1 Conclusion 
7.1.1 The preparation, characterisation and cytotoxicity of Brij O10 NE  
Brij O10 NE was studied for the preparation of NE containing either a high molecular 
volume triglyceride or ethyl ester oil. The phase behaviour of Brij O10 NE showed the 
effect of the purity and the presence of saturation levels of oils on the extent of the area 
of NE existence. The PIT experiments, particle size determination and SANS studies 
suggest that Brij O10 NE forms a distinct core of oil in the NE. 
To investigate the ability of Brij O10 NE to solubilise poorly water soluble drugs, TP and 
CUR, were chosen as drugs. The TP solubilisation suggested that the level of TP 
solubilisation in Brij O10 NE was noticeably higher than that observed in the Brij O10 
micelles which indicated that the NE are suitable as drug delivery vehicles for TP. In 
particular, TP solubilisation exhibited an increase in TP solubility in the clear/transparent, 
Region A NE. However, TP solubilisation levelled off in bluish/translucent, Region B 
NE and dramatically decreased in the cloudy/milky, Region C NE. This levelling off and 
decrease in TP solubilisation was unexpected as it was anticipated that TP solubilisation 
in these regions would increase due to the high oil content. This unexpected solubilisation 
behaviour was explained by the SANS studies which indicated the transformation in the 
morphology of the aggregates upon increasing oil content from an oblate ellipsoid to a 
more elongated ellipsoid, which results in a decrease in the solubility of TP in the 
cloudy/milky, Region C NE. In addition, CUR solubilisation suggested that Brij O10 NE 
are suitable to deliver CUR as they exhibited a high level of CUR solubilisation. 
However, the solubilisation of CUR did not show the anticipated increase in CUR 
solubilisation in the clear/transparent, Region A NE as the amount of oil increased. This 
observation could be explained by a small amount of CUR solubilised in both hSBO and 
98hEO. Moreover, the CUR and TP solubilisation in B20-hSBO NE showed an increase 
in CUR solubilisation and a decrease in TP solubilisation compared to the level of 
solubilisation obtained for a single drug in the corresponding NE, suggesting that the 
presence of CUR affected the level of TP solubilisation in NE. Taken together the results 
of the characterisation and solubilisation studies suggest that the ability of Brij O10 NE 
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to solubilise drug(s) depends on the nature of drug, the amount of oil in NE, the 
morphology of NE and the absence or presence of a second drug. 
Unfortunately, the MTT assay showed the high level of cytotoxicity of the Brij O10 NEs 
towards HeLa (folate-expressing cervical-tumour-derived cell line) and CT26 (murine 
colon carcinoma) cells, suggesting that the pharmaceutical application of the Brij O10 
NE was limited. 
 
7.1.2 The preparation, characterisation and cytotoxicity of Tween 80 NE in the 
absence and presence of cosurfactant 
Among the various nonionic surfactant NE systems that were studied, Tween 80 NE were 
seen to incorporate the highest amount of oil, which indicated that these NE were worthy 
of further study. However, relative to the Brij O10 NE, the Tween 80 NE (T20) could 
incorporate only small amounts of oil and were therefore not expected to exhibit a high 
level of drug solubilisation. Consequently, the addition of the cosurfactant, Dermosoft 
GMCY and the second surfactant, lecithin were considered for further studies. It was 
clear that the addition of Dermosoft GMCY and lecithin, in T20 NE resulted in a bigger 
area of NE existence as well as the formation of larger aggregates of TD25 and TDL25 
NE as determined by PIT, PCS and SANS studies. Understanding the dilutability of the 
NE in the presence of the cosurfactant, Dermosoft GMCY, was important before 
performing any further studies as it is well known that the presence of cosurfactant could 
affect the stability of the diluted NE. The PIT experiments, the particle size studies and 
the SANS measurements suggested that, regardless of the presence of cosurfactant, the 
oil in the Tween 80-containing NE contained a distinct core of oil. 
To examine the ability of the Tween 80 containing NE as drug delivery systems for the 
poorly water soluble drugs, TP, CUR and DTX were selected as poorly water soluble 
drugs. Clearly, T20-hSBO, T20-98hEO, TD25-98hEO and TDL25-hSBO NE could 
solubilise good levels of TP or CUR. The solubility of TP in TD25-98hEO NE showed 
an increase in TP solubilisation with the increasing oil content. In contrast, the solubility 
of CUR did not exhibit an increase in CUR solubilisation with increasing oil content. In 
addition, the presence of CUR in an NE was observed to decrease the solubility of TP in 
the NE. Surprisingly, no improvement in DTX solubilisation was observed in TDL25-
hSBO NE. It is hard, however, to evaluate the advantage of NE over the corresponding 
micelles on DTX solubilisation because of the limited amount of hSBO (3 %w/w) 
incorporated into the TDL25-hSBO NE.    
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The cytotoxicity of T20-hSBO, TD25-98hEO and TDL25-hSBO NE towards the HeLa 
and CT26 cell lines suggested that ‘drug-free’ T20-hSBO, TD25-98hEO and TDL25-
hSBO NE were far less toxic than the ‘drug-free’ B20-hSBO and B20-98hEO NE. 
Unfortunately, the NE containing CUR did not show any difference in cytotoxicity from 
the blank NE which suggested that the presence of CUR in NE did not enhance the 
cytotoxicity of NE in both cancer cell lines. On the other hand, the presence of DTX in 
TDL25-hSBO-DTX NE exhibited a significant enhancement in the cytotoxicity of NE in 
both CT26 and HeLa cell lines when compared to the ‘drug-free’ TDL25-hSBO NE, 
suggesting that the NE were potentially suitable delivery vehicles.  
In order to selectively deliver NE containing DTX to solid tumours expressing the folate 
receptor, folate derived Brij O10 was synthesised. Folate derived Brij O10 was prepared 
by reacting PEG bis(3-aminopropyl) terminated-folate with tresylated Brij O10. UV/vis 
spectroscopy, a ninhydrin assay and 1H NMR analysis were employed to confirm the 
structure of the intermediates of the synthesis as well as the final product. From the range 
of analytical techniques it was concluded that the folate derived Brij O10 was successfully 
synthesised. 
 
7.2 Future work 
The folate derivative, Brij O10 (FA-PEG-Brij) which contains a folate targeting group 
and is attached to Brij O10 via a short polyoxyethylene glycol chain is an attractive 
molecule to incorporate into the TDL25-hSBO3 NE to see if it is possible to specifically 
target cancer cells expressing folate receptors on their cell surface. However, before the 
ability of DTX containing NE incorporating the folate derived Brij O10 (FA-PEG-Brij-
TDL25-hSBO3) to target to cancer cells is determined, the cytotoxicity of FA-PEG-Brij-
TDL25-hSBO3 and FA-PEG-Brij-TDL25-hSBO3-DTX needs to be studied. Although 
the cytotoxicity studies of NE prepared from Brij O10 in CT26 and HeLa cells indicated 
that Brij O10 was quite toxic, the concentration of folate derived Brij O10 to be added to 
the TDL25-hSBO3-DTX NE to achieve targeting is likely to be very low. From Figures 
5.5, 5.6 and 5.7, it can be seen that a concentration of 0.001 %w/w Brij O10 did not 
exhibit toxicity towards the CT26 and HeLa cell lines suggesting a concentration of 0.001 
%w/w or less in the formulation would be satisfactory. NE formulations to be tested 
containing the Brij O10 derived folate targeting group are: (a) FA-PEG-Brij-TDL25-
hSBO3; and (b) FA-PEG-Brij-TDL25-hSBO3-DTX. The cytotoxicity of these 
formulations will be compared to the cytotoxicity results obtained for TDL25-hSBO3 and 
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TDL25-hSBO3-DTX NE in the absence of targeting group, which is recorded in Chapter 
5. It is anticipated that significant differences would be obtained between the targeted and 
nontargeted NE formulations when tested in HeLa cells, a positive cell line in this study, 
whereas the murine Colon Cancer CT26 cells, a negative cell line in this study, would be 
expected not to show a difference in the cytotoxicity obtained when treated with NE in 
the presence or absence of FA. These results are expected to confirm the benefit of the 
NE containing the FA-PEG-Brij targeting molecule. Figure 7.1 gives a schematic of what 
the TDL25-hSBO NE may look like in the absence and presence of folate derived Brij 
O10. 
a) b)  













Figure 7.1: Schematic representative of a) Tween 80, b) Dermosoft GMCY, c) lecithin, d) folate 
derived Brij O10 and e) TDL25-hSBO NE in the absence and presence of folate derived Brij O10. 
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Moreover, to understand the mechanism behind the enhanced cytotoxicity of FA-PEG-
Brij-TDL25-hSBO3 NE in comparison with blank TDL25-hSBO3 NE, the uptake of NE 
inside HeLa cell will be performed in NE labelled by incorporating the lipid soluble 
fluorescent dye, 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate 
(Dil) in the oil core of NE. The concentration of dye in the NE will be optimised so that 
the lowest concentration that can be detected will be present in the cell lysate. When the 
optimisation has been satisfactorily achieved, HeLa cells will be incubated with drug-free 
NE. In addition, the intracellular delivery to HeLa cells of the folate targeted NE will be 
studied by confocal laser scanning microscopy (CLSM). HeLa cells will be fixed and 
stained for F-actin (green) before examination by CLSM. The uptake of the NE will be 
further confirmed by the presence of red fluorescence of Dil inside the cells.  
Finally, TDL25-hSBO3 NE in the absence and presence of FA-PEG-Brij will be 
examined by animal studies. In particular NE uptake by tumours in in vivo experiments 
will be established using hydrophobic fluorescent markers such as DiR (1,1’-
Dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine iodide) incorporated into the oil 
phase of the NE. Dil will be exchanged with DiR for the in vivo studies as it absorbs light 
in the near-infrared (NIR) region, thus allowing for better tissue penetration and a better 
signal-to-noise ratio. Female Athymic nude and SHrN mice aged-4-6 weeks (Harlan) will 
be used for the in vivo studies and inoculated subcutaneously with HeLa cells (5 x 106 
cells in 0.1 mL PBS) in their lower flanks. When the tumours reach an appropriate size 
(600 mm3), the mice will be maintained on a folate free diet (Test Diet) for one week 
prior to, and for the duration of the in vivo studies. Mice (n = 3) will be intravenously 
injected with the DiR-labelled TDL25-hSBO3 NE in the absence and presence of FA-
PEG-Brij and the animals scanned at 1, 4, and 24 hours post injection. Animals will be 
anesthetized to maintain sedation during imaging. Ex vivo imaging will be performed 
immediately afterward by imaging excised major organs (heart, lung, liver, spleen and 
kidney) including the tumours. The tumours in the HeLa-bearing mice which were 
injected with Dil-labelled NE will be snap-frozen at 24 h post IV injection prior to 









Appendix A: Composition of stock 
micelle and nanoemulsion solutions for 
small-angle neutron scattering 
experiments 
 
Usually 15 μA were accumulated during the scattering measurement for Brij O10 NE 
samples containing hSBO, 85hTPN and 99hTPN (namely B2-hSBO, B2-85hTPN, B2-
99hTPN) in D2O and 20 μA and 25 μA were accumulated during the scattering 
measurement for Brij O10 NE containing dTPN (i.e. B2-dTPN) in D2O and H2O, 
respectively. 10 μA was accumulated during the scattering measurement for Brij O10 
micelles (B micelle) and Brij O10 NE containing 65hGTO, 99hGTO, dGTO, 99hGTS 
and 98hEO (namely B2-65hGTO, B2-99hGTO, B2-dGTO, B2-99hGTS, B2-98hEO) in 
D2O or H2O. 20 μA was accumulated during the scattering measurement for Tween 80 
micelles (T micelle) in D2O while 10 μA was accumulated during the scattering 
measurement for Tween 80:Dermosoft GMCY micelles (TD micelle) in D2O. 5 μA was 
accumulated during the scattering measurements made for Tween 80:Dermosoft GMCY 
NE containing 98hEO (i.e. TD2-98hEO), Tween 80:Dermosoft GMCY:lecithin micelles 
(TDL micelle) and Tween 80:Dermosoft GMCY:lecithin NE containing hSBO (TDL-
hSBO) in D2O. Similarly, 5 μA was accumulated for Brij O10 NE containing hSBO, TD 
micelles and NE containing 98hEO and TDL micelles and NE containing hSBO (namely 
B2-hSBO-37C, TD2-37C, TD2-98hEO-37C, TDL2-37C and TDL2-hSBO-37C) 
prepared in D2O and measured at 37 ºC and for Brij O10 NE containing hSBO and TD 
NE containing 98hEO samples (namely B2-hSBO-DM-37C and TD2-98hEO-DM-37C)  
prepared in a mixture of D2O and complete media at 37 ºC. The compositions of stock 
micelle and nanoemulsion formulations are given in Table A.1. 
  Appendix  
342 
Table A.1 Composition of stock micelle and nanoemulsions 
A.1a) Brij O10 micelles (B micelles) 
Micelle composition (%w/w) B0.1 B0.2 B0.5 B1 B1.5 B2 B5 B10 B15 B20 
Brij O10 (B) (%w/w) 0.1 0.2 0.5 1 1.5 2 5 10 15 20 
Aqueous phase (%w/w) 99.9 99.8 99.5 99 98.5 98 95 90 85 80 
 
A.1b) Brij O10 and soybean oil nanoemulsions (B-SBO NE) 
NE composition (%w/w) B20-SBO2 B20-SBO4 B20-SBO6 B20-SBO8 B20-SBO9 B20-SBO10 B20-SBO12 B20-SBO14 B20-SBO16 
Brij O10 (B) (%w/w) 20 20 20 20 20 20 20 20 20 
Soybean oil (SBO) (%w/w) 2 4 6 8 9 10 12 14 16 
Aqueous phase (%w/w) 78 76 74 72 71 70 68 66 64 
Weight ratio of surfactant/oil 10:1 5:1 3.3:1 2.5:1 2.2:1 2:1 1.7:1 1.4:1 1.25:1 
The maximum level of incorporation of hSBO in the clear, Region A, bluish/translucent, Region B and cloudy/milky, C NE was 9, 14 and 16 %w/w, respectively. 
 
A.1c) Brij O10 and triolein nanoemulsions (B-GTO NE) 
NE composition (% w/w) B20-GTO0.5 B20-GTO1 B20-GTO2 B20-GTO4 B20-GTO6 B20-GTO8 B20-GTO10 B20-GTO12 B20-GTO15 
Brij O10 (B) (%w/w) 20 20 20 20 20 20 20 20 20 
Triolein (GTO)a (%w/w) 0.5 1 2 4 6 8 10 12 15 
Aqueous phase (%w/w) 79.5 79 78 76 74 72 70 68 65 
Weight ratio of surfactant/oil 40:1 20:1 10:1 5:1 3.3:1 2.5:1 2:1 1.7:1 1.3:1 
a According to the ternary phase diagram of B20-65hGTO and B20-99hGTO NE, B20-65hGTO NE were prepared at oil concentrations of 0.5 and 1 %, while B20-99hGTO NE were prepared at oil 
concentrations of 0.5, 1, 2, 4, 6, 8, 10, 12 and 15%. 
 
The maximum level of incorporation of 65hGTO in the clear, Region A and bluish/translucent, Region B NE was 1 and 2 %w/w, respectively while 8 and 15 %w/w of the 99hGTO, respectively was 
incorporated into the corresponding A and B Regions. 
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A.1d) Brij O10 and tripalmitin nanoemulsions (B-TPN NE) 
NE composition (%w/w) B20-TPN2 B20-TPN4 B20-TPN6 B20-TPN8 B20-TPN10 B20-TPN12 B20-TPN14 B20-TPN16 
Brij O10 (B) (%w/w) 20 20 20 20 20 20 20 20 
Tripalmitin (TPN) (%w/w) 2 4 6 8 10 12 14 16 
Aqueous phase (%w/w) 78 76 74 72 70 68 66 64 
Weight ratio of surfactant/oil 10:1 5:1 3.3:1 2.5:1 2:1 1.7:1 1.4:1 1.25:1 
The maximum level of incorporation of 85hTPN in the clear, Region A, bluish/translucent, Region B and cloudy/milky, C NE was 6, 11 and 18 %w/w, respectively while 0.5, 1 and 18 %w/w of the 99hTPN, 
respectively was incorporated into the corresponding A, B and C Regions. 
A.1e) Brij O10 and ethyl oleate nanoemulsions (B-EO NE) 
NE composition (%w/w) B20-EO2 B20-EO4 B20-EO6 B20-EO8 B20-EO9 
Brij O10 (B) (%w/w) 20 20 20 20 20 
Ethyl oleate (98hEO) (%w/w) 2 4 6 8 9 
Aqueous phase (%w/w) 78 76 74 72 71 
Weight ratio of surfactant/oil 10:1 5:1 3.3:1 2.5:1 2.2:1 
The maximum level of incorporation of 60hEO in the clear, Region A and cloudy/milky, C NE was 7 and 8 %w/w, respectively while 6 and 8 %w/w of the 98hEO, respectively was incorporated into the 
corresponding A and B Regions. 
 
A.1f) Brij O10 and tristearin nanoemulsion (B-GTS NE) 
NE composition (%w/w) B20-GTS1 B20-GTS2 B20-GTS4 B20-GTS6 B20-GTS8 B20-GTS10 B20-GTS12 B20-GTS13 
Brij O10 (B) (%w/w) 20 20 20 20 20 20 20 20 
Tristearin (99hGTS) (%w/w) 1 2 4 6 8 10 12 13 
Aqueous phase (%w/w) 79 78 76 74 72 70 68 67 
Weight ratio of surfactant/oil 20:1 10:1 5:1 3.3:1 2.5:1 2:1 1.7:1 1.5:1 
The maximum level of incorporation of 60hGTS in the bluish/translucent, Region B NE was 1 %w/w while 11 and 13 %w/w of the 99hGTS, respectively was incorporated into the corresponding B and C Regions. 
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A.1g) Tween 80 (T micelle), Tween 80:Dermosoft GMCY micelles (3:1) (TD micelles), and Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) (TDL micelle) 
Micelle composition (%w/w) T20 TD25 (3:1) TDL25 (7.5: 2.5: 1) 
Tween 80 (T) (%w/w) 20 18.75 17.05 
Dermosoft GMCY (D) (%w/w) - 6.25 5.68 
Lecithin (L) (%w/w) - - 2.27 
Aqueous phase 80 75 75 
 
A.1h) Tween 80:Dermosoft GMCY (3:1) and ethyl oleate nanoemulsions (TD-EO NE) and Tween 80:Dermosoft GMCY:lecithin (7.5:2.5:1) and soybean oil nanoemulsion (TDL-
SBO NE) 
NE composition (%w/w) TD25-EO8 TD25-EO9 TD25-EO10 TDL25-SBO3 
Tween 80 (T) (%w/w) 18.75 18.75 18.75 17.05 
Dermosoft GMCY (D) (%w/w) 6.25 6.25 6.25 5.68 
Lecithin (L) (%w/w) - - - 2.27 
Ethyl oleate (EO) (%w/w) 8 9 10 - 
Soybean oil (SBO) (%w/w) - - - 3 
Aqueous phase (%w/w) 67 66 65 - 
Weight ratio of surfactantb/oil 3.1:1 2.8:1 2.5:1 8.3:1 
 
b The surfactant and cosurfactant contained in TD25-EO8, TD25-EO9 and TD25-EO10 are Tween 80 and Dermosoft GMCY respectively, while TDL25-SBO3 contains the second surfactant lecithin. 
The maximum level of incorporation of 98hEO in the clear, Region A NE was 10 %w/w for TD25-98hEO NE while 3 %w/w of hSBO was incorporated into the corresponding A Regions for TDL25-hSBO NE. 
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Appendix B: The results for the 
preparation of Brij O10 nanoemulsions 
 
The structure of all oils was measured using 1H NMR by diluting the oil in deutero- 
chloroform (Figure B.1 – B.10). 
 
Figure B.1: 1H NMR spectrum of hSBO (400 MHz, CDCl3): δ 5.34, 4.29, 4.14, 2.77, 2.31, 2.16, 




Figure B.2: 1H NMR spectrum of 65hGTO (400 MHz, CDCl3): δ 5.35, 5.08, 4.23, 4.16, 3.74, 
3.49, 2.76, 2.48, 2.32, 2.00, 1.61, 1.28, and 0.88 ppm.  
 
 
Figure B.3: 1H NMR spectrum of 99hGTO (400 MHz, CDCl3): δ 5.32, 4.29, 4.14, 3.49, 2.31, 




Figure B.4: 1H NMR spectrum of 85hTPN (400 MHz, CDCl3): δ 5.27, 4.29, 4.14, 3.49, 2.44, 
2.31, 1.61, 1.25, and 0.87 ppm. 
 
 
Figure B.5: 1H NMR spectrum of 99hTPN (400 MHz, CDCl3): δ 5.27, 4.29, 4.14, 2.31, 1.60, 




Figure B.6: 1H NMR spectrum of 60hGTS (400 MHz, CDCl3): δ 5.27, 4.29, 4.15, 2.31, 1.60, 
1.25, and 0.88 ppm. 
 
 
Figure B.7: 1H NMR spectrum of 99hGTS (400 MHz, CDCl3): δ 5.27, 4.29, 4.14, 3.49, 2.31, 




Figure B.8: 1H NMR spectrum of 60hEO (400 MHz, CDCl3): δ 5.34, 4.12, 2.77, 2.29, 2.01, 1.60, 
1.27, and 0.88 ppm. 
 
 
Figure B.9: 1H NMR spectrum of 98hEO (400 MHz, CDCl3): δ 5.34, 4.12, 3.49, 2.29, 2.01, 1.60, 








Table B.1 Variation in the cloud point of Brij O10 micelles prepared using either 1, 2, 5, 10, 15, 
20 or 25 %w/w Brij O10 (mean ± S.D., n = 3). 
 
Micelles Cloud point (°C) 
B1 in H2O 58.6 ± 0.7 
B2 in H2O 59.1 ± 0.3 
B5 in H2O 61.7 ± 0.5 
B10 in H2O 64.4 ± 0.6 
B15 in H2O 67.4 ± 0.5 
B20 in H2O 69.3 ± 0.8 









Table B.2 Variation in the phase inversion temperature of nanoemulsions prepared using 20 





Phase inversion temperature (°C) 
B20- 
hSBO  






























NE in  
H2O  
1 month 
0.5 - 64.1 ± 0.4 68.6 ± 0.5 - - - - 
1 63.8 ± 0.4 53.0 ± 0.4 68.4 ± 0.6 62.3 ± 0.7 51.5 ± 0.5 53.8 ± 0.3 53.7 ± 0.3  
2 61.9 ± 0.4 - 67.3 ± 0 .5 63.8 ± 0.6 40.8 ± 0.4 42.9 ± 0.2 - 
4 66.4 ± 0.4 - 73.7 ± 0.6 68.2 ± 0.5 36.4 ± 0.8 38.8 ± 0.8 - 
6 69.2 ± 0.4 - 78.5 ± 0.5 72.3 ± 0.4 38.0 ± 0.9 43.1 ± 0.3 - 
8 72.9  ± 0.5 - 81.0 ± 0.3 - 40.3 ± 0.8 - - 




Table B.3 Variation in the apparent hydrodynamic size of Brij O10 micelles prepared using either 
1, 5, 10, 15, 20 or 25 %w/w Brij O10 after 1-month preparation. All samples were diluted to 1 
%w/w of Brij O10 (mean ± S.D., n = 3). 
 
Micelles 
Hydrodynamic droplet size (nm) 
H2O 1 month 
B1 in H2O 14.2 ± 0.6 
B5 in H2O 13.8 ± 0.6 
B10 in H2O 13.2 ± 0.4 
B15 in H2O 14.2 ± 0.8 
B20 in H2O 14.8 ± 0.8 













Table B.4 Variation in the apparent hydrodynamic size of nanoemulsions prepared using 20 
%w/w Brij O10 and containing varying amounts of oil 1-month after preparation. All samples 





Hydrodynamic droplet size (nm) 
B20- 
hSBO        








NE in H2O  
1 month 
B20- 
85hTPN   
NE in H2O  
1 month 
B20- 
99hTPN   
NE in H2O  
1 month 
B20- 
99hGTS   
NE in H2O  
1 month 
B20- 
98hEO     
NE in H2O  
1 month 
0.5 - 14.2 ± 0.2 11.7 ± 0.4 - -  - 
1 10.5 ± 0.3 11.1 ± 0.3 10.2 ± 0.5 10.9 ± 0.5 - 328.7 ± 1.9 10.9 ± 0.2 
2 12.1 ± 0.4 11.0 ± 0.1 11.5 ± 0.4 12.6 ± 0.3 17.5 ± 1.3 27.3 ± 2.5 11.8 ± 0.5 
4 13.5 ± 0.4 - 13.1 ± 0.2 14.5 ± 0.3 - 21.2 ± 0.1 - 
5 - - - - -  13.8 ± 0.2 
6 15.4 ± 0.3 - - 16.5 ± 1.5 20.7 ± 3.0  14.5 ± 0.1 
8 17.9 ± 0.2 - 18.1 ± 0.6 18.0 ± 0.1 -  96.4 ± 9.7 
9 19.6 ± 0.9 - - - -  - 
10 - - - 22.8 ± 2.9 22.6 ± 0.8  - 
12 27.2 ± 0.6 - 26.4 ± 0.4 23.5 ± 0.1 - 43.1 ± 2.6 - 
13      72.7 ± 11.2  
14 - - - 30.0 ± 0.1 -  - 
15 50.6 ± 1.3 - 54.0 ± 3.7 - -  - 
16 - - - 37.7 ± 4.0 34.6 ± 3.1  - 
 
Table B.5 Variation in cloud point of Brij O10 micelle prepared using 20 %w/w Brij O10 in the 
presence of testosterone propionate after 7-days saturation (mean ± S.D., n = 3). 
 
Micelles Cloud point (°C) 
B20 with TP in H2O 7 days 63.5 ± 1.0  
 













Table B.6 Variation in phase inversion temperature of nanoemulsions prepared using 20 %w/w 
Brij O10 and containing varying amounts of oil in the presence of testosterone propionate after 





Phase inversion temperature (°C) 
B20-hSBO  
NE with TP  
in H2O 7 days 
B20-65hGTO  
NE with TP  
in H2O 7 days 
B20-99hGTO  
NE with TP  
in H2O 7 days 
B20-85hTPN  
NE with TP  
in H2O 7 days 
B20-98hEO  
NE with TP  
in H2O 7 days 
0.5 - 54.3 ± 0.5 59.7 ± 0.5 - - 
1 58.0 ± 0.5 46.4 ± 0.6 58.6 ± 0.4 55.4 ± 0.7 45.6 ± 0.6 
2 57.3 ± 0.5 - 59.1 ± 0.3 58.8 ± 0.5 36.3 ± 0.5  
4 61.0 ± 0.4 - 63.4 ± 0.4 60.3 ± 1.0 33.6 ± 0.4 
6 64.6 ± 0.6 - 67.1 ± 0.7 64.2 ± 0.6 38.3 ± 0.5 
8 67.9 ± 0.4 - 70.9 ± 0.6 - - 
9 69.9 ± 0.6 - - - - 
 
The PIT of TP-saturated NE was significant lower than the PIT of TP-free NE (p<0.05).  
 
Table B.7 Variation in the apparent hydrodynamic size of Brij O10 micelle prepared using 20 
%w/w Brij O10 in the presence of testosterone propionate after 7-days saturation. All samples 
were diluted to 1 %w/w of Brij O10 (mean ± S.D., n = 3). 
 
Micelles Hydrodynamic droplet size (nm) 
B20 with TP in H2O 15.5 ± 0.2 
 
Table B.8 Variation in the apparent hydrodynamic size of nanoemulsions prepared using 20 
%w/w Brij O10 and containing varying amounts of oil in the presence of testosterone propionate 





Hydrodynamic droplet size (nm) 
B20-hSBO  
NE with TP  
in H2O  
7 days 
B20-65hGTO  
NE with TP  
in H2O  
7 days 
B20-99hGTO  
NE with TP  
in H2O  
7 days 
B20-85hTPN  
NE with TP  
in H2O  
7 days 
B20-99hTPN  
NE with TP  
in H2O  
7 days 
B20-98hEO  
NE with TP  
in H2O  
7 days 
0.5 - 15.6 ± 0.2 * 10.4 ± 0.5 - - - 
1 10.6 ± 0.2 10.7 ± 0.2 * 10.6 ± 0.1 11.1 ± 0.2 14.1 ± 0.7 12.3 ± 0.2 * 
2 11.7 ± 0.2 11.3 ± 0.3 12.0 ± 0.6 12.4 ± 0.7 16.1 ± 0.3 10.6 ± 0.6 
4 15.6 ± 0.7 - 13.8 ± 0.1 * 13.7 ± 0.1 19.9 ± 1.6 12.6 ± 0.3 
6 19.4 ± 1.0 * - 17.5 ± 0.2 14.8 ± 0.3 24.1 ± 2.4 * 14.3 ± 0.3 
8 20.1 ± 0.9 * - 18.5 ± 0.2 20.7 ± 0.6 22.0 ± 1.6 155.5 ± 35.0 
9 22.0 ± 1.0 - - - - - 
10 24.9 ± 3.1 - 24.2 ± 2.1 21.4 ± 1.0 28.3 ± 7.7 - 
12 36.8 ± 6.0 - 30.6 ± 4.7 23.6 ± 0.5 35.4 ± 3.5 - 
14 51.8 ± 2.9 - - 31.5 ± 0.3 34.0 ± 3.4 - 
15 - - 140.3 ± 8.6 * - - - 
16 138.4 ± 7.6 - - 57.6 ± 2.9 * 60.8 ± 15.1 - 
 
* The particle size of TP-saturated NE was larger than that of TP-free NE (p<0.05). 
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Table B.9 Solubilisation of testosterone propionate in micelles and nanoemulsions stabilised 
using 20 %w/w Brij O10 and containing varying amounts of oil at room temperature (mean ± 





TP solubilisation (%w/v) 
B20-hSBO  
NE with TP  
in H2O  
7 days 
B20-65hGTO  
NE with TP  
in H2O  
7 days 
B20-99hGTO  
NE with TP  
in H2O  
7 days 
B20-85hTPN  
NE with TP  
in H2O  
7 days 
B20-99hTPN  
NE with TP  
in H2O  
7 days 
B20-98hEO  
NE with TP  
in H2O  
7 days 
0 0.48 ± 0.03 0.48 ± 0.03 0.48 ± 0.03 0.48 ± 0.03 0.48 ± 0.03 0.48 ± 0.03 
0.5 - 0.51 ± 0.03 0.60 ± 0.05 - - - 
1 0.50 ± 0.05 0.52 ± 0.05 0.60 ± 0.03 0.53 ± 0.03 0.71 ± 0.05 0.55 ± 0.04 
2 0.72 ± 0.04 0.46 ± 0.03 0.68 ± 0.03 0.60 ± 0.04 0.72 ± 0.03 0.65 ± 0.03 
4 0.88 ± 0.04 - 0.83 ± 0.02 0.64 ± 0.02 0.72 ± 0.04 0.79 ± 0.04 
6 0.90 ± 0.08 - 0.96 ± 0.03 0.70 ± 0.04 0.67 ± 0.03 0.92 ± 0.05 
8 1.10 ± 0.11 - 1.06 ± 0.05 0.84 ± 0.04 0.66 ± 0.03 1.09 ± 0.06 
9 1.17 ± 0.08 - - - - - 
10 1.08 ± 0.10 - 1.13 ± 0.05 0.83 ± 0.10 0.70 ± 0.03 - 
12 1.12 ± 0.08 - 1.12 ± 0.04 0.86 ± 0.11 0.70 ± 0.05 - 
14 1.07 ± 0.07 - - 0.69 ± 0.06 0.66 ± 0.05 - 
15 - - 1.10 ± 0.05 - - - 
16 0.74 ± 0.08 - - 0.54 ± 0.06 0.46 ± 0.06 - 
 
 
Table B.10 Solubilisation of curcumin in micelles and nanoemulsions stabilised using 20 %w/w 
Brij O10 and containing varying amounts of hSBO at room temperature (after 7-days saturation 
with curcumin and testosterone propionate (mean ± S.D., n = 3). 
 
Oil concentration (%w/w) Curcumin solubilisation (%w/v) 
B20-hSBO NE with CUR and TP in H2O 7 days 
0 0.61 ± 0.03 
2 0.58 ± 0.04 
4 0.65 ± 0.03 
6 0.61 ± 0.05 
8 0.62 ± 0.03 










Table B.11 Solubilisation of testosterone propionate in micelles and nanoemulsions stabilised 
using 20 %w/w Brij O10 and containing varying amounts of hSBO at room temperature after 7-
days saturation with curcumin and testosterone propionate mean ± S.D., n = 3). 
 
Oil concentration (%w/w) TP solubilisation (%w/v) 
B20-hSBO NE with CUR and TP in H2O 7 days 
0 0.48 ± 0.08 
2 0.66 ± 0.11 
4 0.90 ± 0.08 
6 0.59 ± 0.08 
8 0.59 ± 0.03 
9 0.53 ± 0.08 
 
 
Table B.12 Variation in cloud point of Brij O10 micelles prepared using either 1, 5, 10, 15, 20 or 
25 %w/w Brij O10 in D2O (mean ± S.D., n = 3). 
 
Sample Cloud point (°C) 
B1 in D2O 55.8 ± 0.3 
B5 in D2O 59.0 ± 0.7 
B10 in D2O 60.9 ± 0.9 
B15 in D2O 64.2 ± 0.5 
B20 in D2O  65.4 ± 0.6 
B25 in D2O  70.1 ± 0.5 
 
The PIT of B20 micelle in D2O was significant lower than the PIT of B20 micelle in H2O (p<0.05).  
 
 
Table B.13 Variation in phase inversion temperature of nanoemulsions prepared using 20 %w/w 
















0.5 - 60.8 ± 0.5 64.4 ± 0.3 - - 
1 60.3 ± 0.3 50.8 ± 0.5 64.5 ± 0.3 61.3 ± 0.6 50.1 ± 0.6 
2 59.1 ± 0.5 - 63.7 ± 0.5 60.7 ± 0.4 38.1 ± 0.5 
4 64.6 ± 0.5 - 68.6 ± 0.6 65.1 ± 0.4 33.9 ± 0.4 
6 68.3 ± 0.3 - 74.2 ± 0.3 68.2 ± 0.9 38.2 ± 0.5 
8 70.9 ± 0.6 - 78.4 ± 0.7 - - 
9 73.4 ± 0.4 - - - - 
 




Table B.14 Variation in the apparent hydrodynamic size of Brij O10 micelles prepared using 20 
%w/w Brij O10 in D2O after 1-month preparation. All samples were diluted to 1 %w/w Brij O10 
for measurement (mean ± S.D., n = 3). 
 
Sample Hydrodynamic droplet size (nm) 
B1 in D2O 1 month 15.8 ± 0.4 
B5 in D2O 1 month 15.0 ± 0.5 
B10 in D2O 1 month 15.6 ± 0.8 
B15 in D2O 1 month 14.4 ± 0.4 
B20 in D2O 1 month 15.6 ± 0.6 
B25 in D2O 1 month 15.4 ± 0.5 
 
 
Table B.15 Variation in the apparent hydrodynamic size of nanoemulsions prepared using 20 
%w/w Brij O10 and containing varying amounts of oil in D2O after 1-month after preparation. 





Hydrodynamic droplet size (nm) 
B20-hSBO  
NE in D2O 
1 month 
B20-65hGTO  
NE in D2O 
1 month 
B20-99hGTO  
NE in D2O 
1 month 
B20-85hTPN  
NE in D2O 
1 month 
B20-98hEO  
NE in D2O 
1 month 0.5 - 15.3 ± 0.5 1 .5 ± 0.4 - - 
1 11.1 ± 0.2 11.4 ± 0.2 10.5 ± 0.1 * 12.3 ± 0.1 11.5 ± 0.1 
2 11.8 ± 0.1 12.0 ± 0.2 * 11.7 ± 0.2 14.1 ± 0.7 * 11.5 ± 0.1 
4 13.4 ± 0.3 - 14.3 ± 0.3 * 16.9 ± 1.7 - 
5 - - - - 13.8 ± 0.3 
6 18.2 ± 0.7 * - - 17.4 ± 0.5 14.6 ± 0.1 
8 21.9 ± 0.9 * - 20.2 ± 0.8 * - 100.1 ± 11.2 
9 22.9 ± 0.6 - - - - 
10 - - - 20.7 ± 0.9 - 
12 25.8 ± 1.4 - 27.0 ± 0.4 - - 
14 - - - - - 
15 50.8 ± 1.6 - 47.2 ± 1.5 * - - 
16 - - - 32.2 ± 2.1 - 
 








a) b)  
 
Figure B.11: Drop contrast of SANS data and ‘best’ fits for Brij O10 micelle droplets with 
increasing surfactant concentration from a) 0.1 to 5 %w/w and b) 10 to 20 %w/w at 25 ˚C using 
a core-shell ellipsoid model together with a hard sphere model for interactions. 
 
a) b)  
 
 
Figure B.12: SANS curves obtained for drop contrast of 2 %w/w Brij O10 micelles a) in the 
absence and presence of TP, b) in the presence of either CUR or CUR-TP, along with the ‘best’ 

















a) b)  
c)  
 
Figure B.13: SANS data and ‘best’ fits using the oblate ellipsoid model for the drop contrast of 
NE prepared using 2 %w/w Brij O10 and containing various concentration of hSBO from a) 0.2 
- 0.6 %w/w, b) 0.8 - 1.0 %w/w and c) 1.2-1.6 %w/w in the absence of drug. SANS data of NE 
performed on SANS2D with the rear detector positioned at 8 m showed a wider Q range than that 
of NE performed on SANS2D with the rear detector positioned at 4 m. 
 
a)  b)  
c)  
Figure B.14: SANS data and corresponding ‘best’ fits to the drop contrast of 2 %w/w Brij O10 
and hSBO nanoemulsions with increasing hSBO content from a) 0.2 - 0.6 %w/w, b) 0.8 - 1.0 
%w/w and b) 1.2 - 1.6 %w/w in the presence of TP.  
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Figure B.15: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 




Figure B.16: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 
O10 and hSBO nanoemulsions with increasing hSBO content from 0.2 - 0.9 %w/w in the presence 
of CUR and TP. 
 
 
Figure B.17: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 
O10 and hSBO nanoemulsions with increasing hSBO content from 0.2 – 1.6 %w/w in the absence 






Figure B.17: SANS data and the corresponding ‘best’ fits to the drop contrast for 2 %w/w Brij 
O10 and hSBO nanoemulsions with increasing hSBO content from 0.2 – 1.6 %w/w in the absence 











Figure B.18: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 







Figure B.19: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 

































Figure B.20: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 
either 0.6 or 0.9 %w/w hSBO with and without drugs in the absence and presence of cell culture 










Figure B.21: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing 
varying amounts of 65hGTO in the absence of drug. Shell contrast for 2 %w/w Brij O10 NE 
containing 98dGTO was multiplied by the factor of 10. 
 
  
Figure B.22: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing 
varying amounts of 99hGTO in the absence of drug. The shell contrast for 2 %w/w Brij O10 NE 
containing 98dGTO was multiplied by the factor of 10. Note that the best fits to the shell contrast 
for 2 %w/w Brij O10 NE containing 0.8 %w/w 98dGTO and higher concentrations of 98dGTO 











Figure B.22: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing 
varying amounts of 99hGTO in the absence of drug. The shell contrast for 2 %w/w Brij O10 NE 
containing 98dGTO was multiplied by the factor of 10. Note that the best fits to the shell contrast 
for 2 %w/w Brij O10 NE containing 0.8 %w/w 98dGTO and higher concentrations of 98dGTO 





Figure B.23: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 




Figure B.24: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 







Figure B.25: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 


























Figure B.26: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing 
varying amounts of 85hTPN in the absence of drug. The shell contrast for NE containing 
98.6dTPN was multiplied by the factor of 10. Note that the best fits to the shell contrast for 2 
%w/w Brij O10 NE containing 0.4 %w/w 98.6dTPN and higher concentrations of 98.6dTPN were 
not well fitted to SANS data and the best fits to the core contrast for 2 %w/w Brij O10 NE 









Figure B.27: SANS data and best fits to three contrasts for 2 %w/w Brij O10 NE containing 
varying amounts of 99hTPN in the absence of drug. The shell contrast for NE containing 
98.6dTPN was multiplied by the factor of 10. Note that the best fits to the shell contrast for 2 
%w/w Brij O10 NE containing 0.4 %w/w 98.6dTPN and higher concentrations of 98.6dTPN were 
not well fitted to SANS data and the best fits to core contrast for 2 %w/w Brij O10 NE containing 








Figure B.28: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 






Figure B.29: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE containing 







Figure B.30: SANS data and best fits to the core contrast for 2 %w/w Brij O10 NE containing 
varying amounts of 98.6dTPN in the presence and absence of TP. The best fits to the core contrast 
for 2 %w/w Brij O10 NE containing 0.8 %w/w 98.6dTPN and higher concentrations of 98.6dTPN 







Figure B.31: SANS data and best fits to the shell contrast for 2 %w/w Brij O10 NE containing 
varying amounts of 98.6dTPN in the presence and absence of TP. The shell contrast for NE 
containing 98.6dTPN was multiplied by the factor of 10. Note that the best fits to the shell contrast 
for 2 %w/w Brij O10 NE containing 0.4 %w/w 98.6dTPN and higher concentrations of 98.6dTPN 





Figure B.32: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 
increasing concentration of 99hGTS from a) 0.1-0.6 %w/w and b) 0.8-1.3 %w/w. 
 
 
Figure B.33: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 
increasing concentration of 98hEO from 0.2-0.8 %w/w. 
 
Figure B.34: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 






Figure B.35: SANS data and best fits to the drop contrast for 2 %w/w Brij O10 NE upon 

















Appendix C: The results for the 
preparation of nanoemulsions with 
other nonionic surfactants in the 
absence and presence of cosurfactant 
 
Table C.1 Variation in the cloud point of 20 %w/w Tween 80, 25 %w/w Tween 80:Dermosoft 
GMCY (weight ratio 3:1) and 25 %w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 
7.5:2.5:1) micelle and the phase inversion temperature NE containing varying amounts of either 





Cloud point and phase inversion temperature (°C) 
T20-hSBO NE 
in H2O  
1 month 
T20-98hEO NE 
in H2O  
1 month 
TD25-98hEO NE 
in H2O  
1 month 
TDL25-hSBO NE 
in H2O  
1 month 
0 87.8 ± 0.4 87.8 ± 0.4 60.9 ± 0.3 62.8 ± 0.5 
1 95.0 ± 0.0 86.4 ± 0.5 - - 
2 95.0 ± 0.0 - - 66.0 ± 0.7 
3 - - - 70.4 ± 0.4 
4 - - - 71.8 ± 0.4 
8 - - 60.0 ± 0.4 - 
9 - - 58.1 ± 0.4 - 
10 - - 56.0 ± 0.3 - 
 
Table C.2 Variation in the apparent hydrodynamic size of micelle and nanoemulsions stabilised 
by either 20 %w/w Tween 80, 25 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) or 25 
%w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) and containing varying 
amounts of either hSBO or 98hEO after 1-month after preparation. All samples were diluted to 1 





Hydrodynamic droplet size (nm) 
T20-hSBO NE 
in H2O  
1 month 
T20-98hEO NE 
in H2O  
1 month 
TD25-98hEO NE 
in H2O  
1 month 
TDL25-hSBO NE 
in H2O  
1 month 
0 10.8 ± 0.4 10.8 ± 0.4 12.7 ± 0.1 23.5 ± 0.3 
1 12.4 ± 0.2 12.6 ± 0.4 - - 
2 13.7 ± 0.4 - - 13.9± 0.8 
3 - - - 15.0 ± 0.1 
4 - - - 16.2 ± 0.3 
8 - - 19.6 ± 0.4 - 
9 - - 20.8 ± 0.3 - 
10 - - 22.0 ± 0.6 - 
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Table C.3 Variation in the cloud point of 20 %w/w Tween 80, 25 %w/w Tween 80:Dermosoft GMCY (weight ratio 3:1) and 25 %w/w Tween 80:Dermosoft 
GMCY:lecithin (weight ratio 7.5:2.5:1) micelle and the phase inversion temperature of nanoemulsions stabilised by 20 %w/w Tween 80, 25 %w/w Tween 
80:Dermosoft GMCY (weight ratio 3:1) and 25 %w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) and containing varying amount of either 98hEO 





Cloud point and phase Inversion Temperature (°C) 
TD25-98hEO NE 






NE with CUR 
in H2O 
TD25-98hEO 
NE with CUR  
in H2O 
TDL25-hSBO 
NE with CUR  
in H2O 
TD25-98hEO 
NE with CUR 
and TP  
in H2O 
TDL25-hSBO 
NE with DTX 
in H2O 
7 days 10 days 14 days 7, 10 and 14 days 
0 55.3 ± 0.4 * 54.8 ± 0.4 * 55.2 ± 0.3 * 87.6 ± 0.4 87.6 ± 0.4 59.7 ± 0.6 57.7 ± 0.5 * 55.0 ± 0.7 * 56.5 ± 0.7 * 
1 - - - 87.4 ± 0.5 * 85.8 ± 0.4 - - - - 
2 - - - 96.0 ± 0.0 * - - 63.4 ± 0.6 * - - 
3 - - - - - - 67.8 ± 0.5 * - 66.4 ± 0.6 * 
4 - - - - - - 69.8 ± 0.6 * - - 
8 55.2 ± 2.0 * 27.6 ± 0.6 * 29.0 ± 0.3 * - - 59.8 ± 0.3 - 33.5 ± 0.9 * - 
9 54.3 ± 0.5 * 31.1 ± 0.4 * 32.4 ± 0.4 * - - 61.7 ± 0.6 a - 32.6 ± 0.6 * - 
10 44.3 ± 0.5 * 44.0 ± 0.8 * 43.3 ± 1.4 * - - 63.3 ± 0.4 a - 38.5 ± 0.6 * - 
 
* The CP or PIT of drug-saturated micelles or NE was significant lower than the CP or PIT of drug-free micelle or NE (p<0.05).  





Table C.4 The drug solubilisation in 20 %w/w Tween 80, 25 %w/w Tween 80:Dermosoft GMCY 
(weight ratio 3:1) and 25 %w/w Tween 80:Dermosoft GMCY:lecithin (weight ratio 7.5:2.5:1) 
micelles and nanoemulsions containing varying amounts of either 98hEO or hSBO in H2O and in 
the presence of either testosterone propionate (TP), curcumin (CUR) or docetaxel (DTX) (mean 
± S.D., n = 3).  
 
Sample Drug Solubilisation (%w/v) 
7 days 10 days 14 days 
TD25 with TP 0.45 ± 0.05 0.43 ± 0.05 0.45 ± 0.05 
TD25-98hEO8 NE with TP 0.71 ± 0.03 1.49 ± 0.10 1.32 ± 0.09 
TD25-98hEO9 NE with TP 0.73 ± 0.07 1.42 ± 0.08 1.46 ± 0.20 
TD25-98hEO10 NE with TP 1.28 ± 0.15 1.11 ± 0.09 1.27 ± 0.18 
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